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 Abstract 
Osteomodulin (OMD) and Proline/arginine-rich and Leucine-rich Repeat protein 
(PRELP) belong to the small leucine-rich repeat proteoglycan (SLRP) family and as 
extracellular matrix components have the ability to influence various cellular 
functions, including cell growth, migration and proliferation, while their mutation or 
aberrant expression can cause developmental disorders and cancer. This thesis 
extends previous work in further understanding the roles of OMD and PRELP in 
cancer and also during mouse development. 
 In the current project OMD and PRELP are overexpressed in a bladder cancer 
cell line where they are found to alter cell morphology, reduce cell invasion and 
anchorage-independent growth, while they also inhibit tumour growth in xenograft 
mouse models. Additionally, we show that OMD and PRELP mediate their effects 
by cross-regulating different signalling pathways and also by affecting tight junction 
formation.   
Furthermore, novel knock-out mouse models of OMD and PRELP were 
generated, where a Lac-Z cassette has been inserted in the coding regions of the two 
genes, allowing us to follow their expression under X-gal staining. Therefore a 
detailed analysis of expression patterns was initially conducted. OMD and PRELP 
were both expressed in skeletal elements during mouse development, while in adult 
mice they were differentially expressed in neurons and epithelia of the brain and the 
eye, and in the urothelium of the bladder. Finally, the novel knock-out mice were 
used to assess any cancer-related aberrant phenotypes arising from OMD and PRELP 
deficiency. The bladders of the knock-out mice presented with early stages of 
urothelial papillary formations, where the junctional complexes were also disrupted, 
suggesting that lack of OMD and/or PRELP is permissive for cancer initiation.  
Overall, with our current findings we hope to improve the understanding of 
SLRP biology in carcinogenesis, and we would like to propose OMD and PRELP as 
potential targets for the development of cancer therapies. 
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1.1 Preface to the Introduction 
The current project interrogates the novel proposition that two small leucine-rich 
repeat proteoglycan (SLRP) family members, osteomodulin/osteoadherin (OMD) 
and proline/arginine-rich and leucine-rich repeat protein (PRELP) are involved in 
cancer. So far, there are no published literature reports associating these two 
molecules to cancer, but there are many studies of other SLRP members showing 
their relation to tumour formation and their potential as anti-cancer agents. In 
addition, the spatio-temporal expression of the two proteins is studied using novel 
knock-out mice models, providing important information. Following a brief 
description of the cancer disease, the SLRP protein family and the project aims are 
extensively presented below. 
1.2 Cancer 
Cancer can be defined as a large group of diseases, medically known as 
malignant neoplasms, where cells divide and grow uncontrollably forming malignant 
tumours, and thus disrupting the normal functions of the affected organ. In some 
cases, tumour cancer cells acquire the ability to penetrate and infiltrate adjacent 
normal tissues, where a new tumour can be formed, a processed named as local 
metastasis. In other cases, cancer cells can penetrate the blood vessels, becoming 
circulating tumour cells, whereby they can metastasize to more distant organs or 
tissues of the body.  
Approximately 14.1 million cancer cases and 8.2 million cancer deaths are 
estimated to have occurred in 2012 worldwide (Globocan 2012, IARC-International 
Agency for Research on Cancer).  Cancer accounts for around 13% of all deaths 
annually, with lung cancer being the most common type followed by liver, stomach, 
colorectal and then breast cancer (World Health Organisation, 2014). Today, cancer 
constitutes the leading cause of death among adults aged between 40 and 80 years 
old, followed by heart disease (Siegel et al., 2014). The majority of cancer cases are 
attributed to environmental factors (e.g. smoking, nutrition, infections, radiation), 
while a small percentage, around 5-10% of cancers, are caused by genetic factors 
(Anand et al., 2008). In the genetic context, development and progression of human 
tumours involves the accumulation of multiple alterations, such as activation of 
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oncogenes and inactivation of tumour-suppressor genes (TSG), which often can rise 
through the aforementioned environmental factors. An exception constitutes the 
group of hereditary cancers, which are caused by an inherited genetic defect, 
accounting for less than 10% of the total cancers (Roukos, 2009). The most striking 
examples are mutations in the BRCA1 and BRCA2 genes leading to a very high risk 
of breast and ovarian cancer and the hereditary non-polyposis colorectal cancer 
(HNPCC) syndrome, which is present in about 3% of people with colorectal cancer 
(Cunningham et al., 2010). 
1.2.1 Molecular basis of cancer – Oncogenes and tumour-suppressor genes 
Already by the mid-1980s two main types of cancer-causing genes were 
identified, i.e. oncogenes and tumour-suppressor genes, emerging from various 
genomic alterations, including nucleotide mutations, chromosomal aberrations, DNA 
rearrangements, gene amplifications, etc. (Macconaill and Garraway, 2010). Today 
the basic principle in cancer research is that tumour development is a multistage 
process extending over decades, and which is driven by progressive accumulation of 
mutations, as well as epigenetic abnormalities, in genes that have variable and 
multiple functions  (Stratton et al., 2009; Weinstein, 2002; Weinstein and Joe, 2006). 
In other words, a single genetic change is rarely sufficient for the development of a 
malignant tumour and the knowledge gathered so far points to a process of multiple 
steps with sequential alterations in several, often many, oncogenes, TSGs, or 
microRNA genes (Croce, 2008). In addition, mutations involved in cancer 
progression can be classified as drivers, conferring growth advantage on the cells 
carrying them and therefore being positively selected during the evolution of cancer, 
and as passengers, which do participate in cancer development (Stratton et al., 2009). 
Usually, driver mutations are activating in dominant genes, i.e. mutation in only one 
allele is sufficient to contribute to tumour development (oncogenes), and account for 
almost 90% of the cancer-related genes, whereas the remaining 10% include tumour-
suppressor genes which act in a recessive manner and mutations in both alleles are 
needed to nullify the protein function (Stratton et al., 2009). Therefore, identification 
of the driver mutations and the genes that encompass them, and further distinction 
from other passenger events that simply accumulate during cell growth, is important 
for the advancement of more efficient therapies. 
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I.B. Weinstein firstly used the term "oncogene addiction" to describe the 
phenomenon where some cancers are dependent on one or few genes in order to 
maintain their malignant phenotype (Weinstein, 2000).     
1.2.1.1 Oncogenes 
 Proto-oncogenes are genes coding for proteins that control cell proliferation, 
differentiation and apoptosis, and upon activation they become tumour-inducing 
agents (oncogenes) (Todd and Wong, 1999). There are three ways of oncogene 
activation including mutations, chromosomal translocation, e.g. by juxtaposition 
close to enhancer elements, and amplification/duplication, and their products can be 
classified in six broad groups: chromatin remodelers, growth factors, growth factor 
receptors, transcription factors, signal transducers and apoptosis regulators (Croce, 
2008).  
In some tumours, for example, the Fos and Jun proteins form the AP1 
transcription factor, which regulates cell proliferation and survival (Shaulian and 
Karin, 2001). In prostate carcinomas the TMPR552 gene fuses with and activates 
ERG1 or ETV1, genes which belong to the ETS family of transcription regulators, 
and leads to increased proliferation and inhibited apoptosis of prostate gland cells 
(Tomlins et al., 2005). In addition, the WNT family of proteins inhibits 
phosphorylation of β-catenin resulting in cell proliferation and invasion (Giles et al., 
2003). Mutations occurring in protein kinases, like the epidermal growth factor 
receptor (EGFR) or the fibroblast growth factor receptor (FGFR) families, including 
genes such as EGFR, ERBB2/ERBB3/ERBB4, FGFR1/FGFR2/FGFR3 deregulate 
signalling in many pathways and often are found in lung and breast cancer and 
gastrointestinal tumours (Johnson and Lapadat, 2002; Paez et al., 2004; Stephens et 
al., 2004). One of the most common oncogene in human cancer is the RAS set of 
genes (including KRAS, HRAS and NRAS), which encode for small GTPases 
involved in cellular signal transduction. RAS mutations result in permanently 
activated protein products, which in turn continuously transduce signals that induce 
unceasing cell growth and proliferation (Goodsell, 1999). Another well-known 
oncogene often found mutated in many cancers is the MYC gene, which as a 
transcription factor is again capable of regulating cell growth and proliferation 
(through binding on Enhancer Box sequences (E-boxes) and recruiting histone 
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acetyltransferases) (Oster et al., 2002). Apart from the oncogenes explained briefly 
here, there are many more genes involved in cancer initiation and progression.  
1.2.1.2 Tumour-suppressor genes 
 Tumour-suppressor genes code for proteins that usually have a repressive effect 
on the regulation of the cell cycle, preventing unrestrained cellular growth, while 
they promote DNA repair and cell cycle checkpoint activation. Because their cancer-
preventative effects usually require the presence of only one single functional allele, 
tumour-suppressor genes are considered recessive following the “two-hit” 
hypothesis, as it was proposed by A.G. Knudson for retinoblastoma cases (Knudson, 
1971).  
The first “classic” tumour suppressor gene identified is the retinoblastoma 
tumour susceptibility gene (RB1). Loss of pRB function has been implicated in the 
development of numerous cancers, while pRB-deficient cells have altered regulation 
of G1 checkpoints, changes in the control of cell cycle exit (differentiation, 
senescence, quiescence), and altered levels of autophagy, apoptosis, angiogenesis, 
and metastatic potential (Burkhart and Sage, 2008). The RB family proteins 
physically interact with transcription factors, best characterized of which are the 
E2Fs (Sherr, 2004). Another important tumour suppressor is the p53 suppressor 
protein encoded by the TP53 gene, which is recognized as the most frequently 
inactivated gene in human cancers (Kandoth et al., 2013). The INK4 family of Cdk 
inhibitors, and especially the founding member p16INK4a as well as p14ARF interfere 
with RB and p53 respectively, forming part of a signalling network that monitors cell 
cycle and restrains aberrant growth-promoting signals (Sharpless and DePinho, 1999; 
Sherr, 2001). Other well-studied TSGs are for example the APC gene, involved in 
the WNT and β-catenin signalling cascade, being responsible for familial 
adenomatous polyposis and some colorectal cancers (Morin et al., 1997; Rubinfeld et 
al., 1993), the PTEN gene, which participates in phosphoinositide metabolism 
inhibiting the AKT signalling pathway, and is often mutated in glioblastoma, 
endometrial and advanced prostate cancers (Sulis and Parsons, 2003); the MSH2 and 
MLH1 DNA mismatch repair genes; the  BRCA1 and BRCA2 genes associated with 
familial breast and ovarian cancer, and many other genes that are not mentioned here. 
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1.2.2 Extracellular matrix and tumour microenvironment  
The extracellular matrix (ECM) constitutes a three-dimensional structure that 
surrounds the cells and defines the cellular microenvironment (Aumailley and 
Gayraud, 1998). The main ECM components are different types of collagens, 
elastins, laminins, fibronectins (fibrous components) and proteoglycans (including 
hyaluronic acid and chondroitin/heparan/keratan sulphate) (Frantz et al., 2010). 
Although in the beginning ECM was considered to have a purely supporting role for 
cells within the tissue, now it is recognized as an important regulator of cell and 
tissue behaviour via transmembrane signalling, thereby contributing to 
differentiation, proliferation, survival, polarity and migration of cells (Hynes, 2009; 
Radisky and Bissell, 2004).  
During tumour formation, the malignant cells have been found to create their 
own tumour microenvironment, which in turn essentially affects the malignant cells 
themselves but also the other surrounding cells of the ECM (Fang and Declerck, 
2013; Lu et al., 2012). The tumour microenvironment is composed of endothelial 
cells (ECs), pericytes, invading inflammatory cells and leucocytes, fibroblasts and 
multiple ECM components, forming the so-called tumour stroma (Hanahan and 
Weinberg, 2011; Hanna et al., 2009).  
The importance of the tumour stroma in cancer growth, invasion and metastasis 
has been amplified the last years, as many recent studies have demonstrated that the 
tumour stroma does not have a passive support structure, but rather plays an active 
role in cancer progression (Bissell and Hines, 2011; Blavier et al., 2006; Derynck et 
al., 2001; Gilkes et al., 2014; Radisky and Bissell, 2004; Sainio, 2014; Shekhar et al., 
2001). The architecture of tumour-associated ECM is fundamentally different from 
normal tissue stroma and these morphological changes can promote cell 
transformation, tumour growth, motility and invasion, enable metastatic 
dissemination and facilitate establishment of secondary tumours at distant sites 
(Clarijs et al., 2003; Ruiter et al., 2002). Important mediators in these procedures are 
the matrix metalloproteinases (MMPs), which represent the most prominent family 
of proteinases associated with tumorigenesis.  
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MMPs have multiple roles, regulating the extracellular matrix turnover and 
cancer cell migration, while they can also affect signalling pathways that control cell 
growth, inflammation, or angiogenesis (Kessenbrock et al., 2010). For example, 
MMP-1 derived from tumour-infiltrating fibroblasts has been shown to play a critical 
role in the cleavage of PAR-1 (proteinase activated receptor-1), which appears to 
drive cancer cell migration and invasive behaviour of the tumour (Boire et al., 2005), 
highlighting the important roles of stroma-derived proteinases in the progression of 
tumorigenesis. Additionally, a number of ECM degrading proteolytic enzymes, such 
as MMP-2, -13, and -14 have been implicated in ECM remodelling, while MMP-14 
(MT1-MMP) may be critical and rate limiting in collagen turnover, potently 
patterning the tissue to facilitate single-cell and finally collective-cell migration and 
invasion (Friedl and Wolf, 2008; Itoh and Seiki, 2006; Sabeh et al., 2009; Sabeh et 
al., 2004; Zarrabi et al., 2011). In a different context, MMP-9 appears to be critical 
for the formation of the metastatic niche, which is most likely linked with its ability 
to liberate VEGF and thereby support angiogenesis (Bergers et al., 2000; Kaplan et 
al., 2005).  
Thus, it is becoming obvious that the tumour ECM is a dynamical structure 
surrounding the malignant cancer cells, which can fundamentally affect tumour 
growth and metastasis. Therefore, combination therapies that target components of 
the tumour microenvironment may be a key strategy to overcome compensatory 
mechanisms that tumours usually rely on to survive and also achieve more 
permanent and efficient therapies (Blansfield et al., 2008; Mangiameli et al., 2007). 
1.3 Small leucine rich repeat proteoglycans 
1.3.1 Structural biology 
The small leucine-rich repeat proteoglycans (SLRPs) are a group of proteins 
sharing various structural and functional similarities that have multiple roles in the 
organization of the extracellular matrix and on cell behaviour (Hocking et al., 1998). 
Being part of the leucine-rich repeat (LRR) superfamily of proteins, SLRPs are 
characterized by a central LRR domain flanked by conserved cysteine motifs on their 
N- and C- terminal sides (McEwan et al., 2006). Today, the SLRP family is 
composed of 17 members, which are sub-divided into five classes based on their 
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homology, chromosomal organization and the spacing between their N-terminal Cys-
rich clusters (Fig. 1.1) (Dellett et al., 2012; Schaefer and Iozzo, 2008), while two 
recent studies have included one extra member in the first class (Nastase et al., 2014; 
Ni et al., 2014).    
Structural analysis has shown that SLRPs consist of 2 main structural 
components, a conserved protein core which has a role in protein-protein 
interactions, and several different types and numbers of glycosaminoglycan (GAG) 
side chains, which form chondroitin (CS), keratan (KS) or dermatan sulphate (DS) 
(Hocking et al., 1998; Iozzo, 1997; Iozzo, 1998). More specifically, the core proteins 
contain a number of leucine-rich repeats (LRRs), which contain a consensus 
sequence LXXLXLXXNXL, where X is any amino-acid, L is leucine, isoleucine or 
valine, N is asparagine, cysteine or threonine. The total number of LRRs varies 
between the different members, with typical LRRs expanding from 20 to 29 residues, 
Figure 1.1: Phylogenetic analysis of the SLRP family and structural organization. 
Dendrogram displaying the phylogeny and the five distinct classes of the growing SLRP protein 
family. Generated by multiple sequence alignment using ClustalW2 from the European 
Bioinformatics Institute (http://www.ebi.ac.uk/Tools/msa/clustalw2/). 
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while the most common length is 24 amino acids (McEwan et al., 2006). However, 
as mentioned before, all SLRPs contain additional N- and C-terminal domains.  
The N-terminal cluster usually contains four cysteines, with their internal 
spacing varying between the five classes (exceptions are ECM2 with 2 cysteines, 
Tsukushi with 5 and Podocan with 6).  In class I the cysteines are spaced in a 
Cx3CxCx6C configuration, where C = cysteine and x = any other amino acid. In class 
II, they are arranged as Cx3CxCx9C, in class III as Cx2CxCx6C, in class IV as 
CX3CXCX6-17C and in class V as CX3-4CXCX9C (see Table 1.1) (Schaefer and Iozzo, 
2008). Taking into account the structure of decorin, the most well characterized 
member, it can be speculated that this N-terminal cluster is probably a capping motif 
common to all SLRPs, irrelative of the spacing and number of cysteines (McEwan et 
al., 2006; Scott et al., 2004). Furthermore, these four N-terminal cysteines form a 
disulphide knot between the first LRR (LRR-I) and a β-hairpin, while the variation in 
the number of residues between cysteines provides variety in the length of the β-
hairpin (McEwan et al., 2006). Such cysteine N-terminal capping motifs are also 
found in other LRRs besides the SLRPs, like the Nogo receptor ectodomain and the 
glycoprotein GPIba (He et al., 2003; Huizinga et al., 2002; Uff et al., 2002). 
McEwan et al. also determined the relatively new C-terminal motif specific to 
SLRPs, which basically consists of the penultimate LRR, usually being the longest 
repeat of the protein, named as “ear repeat” (McEwan et al., 2006). Ear repeats can 
vary in length and sequence between different SLRP members, with classes I and III 
having 30 residues, while class II members range from 31 residues (fibromodulin, 
osteomodulin and lumican) to notably “long ears” of keratocan and PRELP, with 38 
and 39 residues respectively (Fig. 1.2) (McEwan et al., 2006). So far no such motifs 
have been identified in classes IV and V.  
Instead, proteins such as chondroadherin and nyctalopic seem to adopt a 
different kind of C-terminal cap including four C-terminal cysteines linked to form 
two disulphide bonds, a motif often found in other eukaryotic LRR proteins (like 
GPIba and Nogo), whilst on the other hand, podocan has 12 C-terminal glutamate 
residues (Ross et al., 2003; McEwan et al., 2006). 
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Table 1.1: Structure of SLRP family members 
SLRP member 
Number 
of LRR 
N-terminal 
Cys-rich 
cluster 
Ear 
repeat 
GAG 
type/Member 
Reference 
Biglycan 
Decorin 
Asporin† 
ECM2 
Class I 12* CX3CXCX6C Yes 
CS/DS 
(DKN, BGN) 
(Iozzo, 1999; 
Matsushima et al., 2000) 
(Dammer et al., 1995; 
Schaefer and Schaefer, 
2010) 
Fibromodulin 
Lumican 
PRELP† 
Keratocan 
Osteomodulin 
Class II 12 CX3CXCX9C Yes KS 
(Sommarin et al., 1998) 
(Vogel, 1994) 
(Blochberger et al., 1992; 
Corpuz et al., 1996) 
(Plaas and Wong-Palms, 
1993) 
(Bengtsson et al., 1995) 
 
Epiphycan 
Opticin† 
Osteoglycin 
Class III 8 CX2CXCX6C Yes 
DS (EPYC) 
KS (OGN) 
O-linked 
oligosaccharides 
(OPTC/EPYC) 
(Reardon et al., 2000) 
(Funderburgh et al., 
1997; Johnson et al., 
1997) 
Chondroadherin 
Nyctalopin 
Tsukushi 
Class IV 12 
CX3CXCX6-
17C 
No 
Potential sites for 
glycosylation  
(Ohta et al., 2004) 
(Neame et al., 1994) 
Podocan 
Podocan-like 1 
protein 
Class V 20* 
CX3-
4CXCX9C 
No 
Potential sites for 
glycosylation 
(Ross et al., 2003) 
(Mochida et al., 2011) 
*ECM2 has 15 LRRs, Podocan-like protein 1 has 21 LLRs; †Asporin, PRELP and Opticin have no 
GAG chains, but have potential sites for substitution by N or O-linked oligosaccharides (Grover and 
Roughley, 2001; Iozzo, 1999). C=cysteine, X=any other residue, CS=Chondroitin sulfate, 
DS=Dermatan sulfate, KS=Keratan sulfate. 
 
 
 
Figure 1.2: Structural organization of OMD and PRELP. Each circle represents a LLR with the number of 
residues written inside it, while the circles are shaded according to their length. The red LRR named E is the 
extended Ear repeat having 30 residues in OMD and 38 in PRELP (by V.Papadaki). 
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Most SLRPs are synthesized as proteoglycans containing CS, DS or KS sulphate 
side chains, while some appear as glycoproteins containing N-linked 
oligosaccharides (see Table 1.1). Class I proteins decorin and biglycan bind 
chondroitin and dermatan sulphate side chains, whilst asporin instead of a GAG 
chain contains a stretch of aspartic acid residues in its N-terminus (Iozzo 1997; 
Henry et al., 2001; Lorenzo et al., 2001). Class II fibromodulin, lumican, keratocan 
and OMD all bind keratan sulphate side chains, whereas PRELP often exists as a 
glycoprotein lacking a GAG attachment, but has four potential N-linked 
glycosylation sites (Blochberger et al., 1992; Plaas & Wong-Palms, 1993; Vogel, 
1994; Bengtsson et al., 1995; Corpuz et al., 1996; Sommarin et al., 1998). In 
addition, PRELP can bind heparin and heparan sulphate through its 22 amino-acid N-
terminal region, which contains two threonine residues to which they may attach, 
whereas the presence of KS in bovine PRELP has also been suggested, due to a shift 
in the electrophoretic mobility following keratanase digestion (Bengtsson et al., 
2000; Bengtsson et al., 1995). Class III epiphycan and osteoglycin contain DS and 
KS respectively, while opticin has potential sites for substitution by O-linked 
oligosaccharides (Johnson et al., 1997; Funderburgh et al., 1997; Reardon et al., 
2000). Class IV and V proteins have not been found to bear any GAG side chains but 
have many potential sites for glycosylation (Neame et al., 1994; Ross et al., 2003; 
Ohta et al., 2004; Mochida et al., 2011).  
1.3.2 SLRPs expression, functions and signalling pathways  
 Due to their proteoglycan structure, SLRPs tend to localize in the extracellular 
matrix (ECM) and after secretion can interact with a variety of many other ECM 
proteins. Initially SLRPs were thought to act exclusively as structural components 
modulating synthesis, assembly and degradation of collagen fibrils, but today are 
also recognised as important regulators of cell-matrix crosstalk, influencing a variety 
of biological processes such as cell proliferation, differentiation, survival, adhesion, 
inflammation, angiogenesis and tumorigenesis (Merline et al., 2009). Thus, SLRPs 
are justifiably defined as matricellular proteins. In addition, although they have 
similar structure and some common functions, their expression is dynamic and 
varies, presenting different spatio-temporal patterns during development and adult 
life. Since one of the main subjects examined in this project is the murine expression 
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patterns of OMD and PRELP, the differential expression of SLRPs will be described 
in detail at the introductions of the relative chapters (Chapters 4&5). Alternatively, 
SLRP cellular functions and affected signalling pathways will be presented below. 
1.3.2.1 Structure and adhesion 
As mentioned before, SLRPs are active components of the ECM and through 
their multipotent binding abilities can regulate matrix and more specifically collagen 
fibril assembly. Most of the SLRPs that modulate fibrillogenesis belong to class I 
and class II. Firstly, decorin, which is the archetypal and best-characterized SLRP, 
was named after its ability to “decorate” collagen fibrils (Pogany and Vogel, 1992). 
It binds to collagen type I, II, III, V, VI, XII and XIV (Bidanset et al., 1992; Douglas 
et al., 2006; Ehnis et al., 1997; Font et al., 1996; Whinna et al., 1993) while it 
participates in collagen fibril growth and regulation of fibril diameter in vitro (Fig. 
1.3) (Danielson et al., 1997). Furthermore, Elefteriou et al. demonstrated that the 
GAG chain of decorin binds to tenascin-X mediating its interaction with collagen 
fibrils and thus contributing to extracellular matrix integrity (Elefteriou et al., 2001). 
The in vivo function of decorin in regulating collagen fibrillogenesis was established 
by the use of knock-out mice, which showed abnormal skin fragility due to loosely 
packed networks of collagen fibres and increased fibril diameter (Danielson et al., 
1997; Reed and Iozzo, 2002).  
Biglycan follows as the second most-studied SLRP and was found to bind to 
collagen type I, II, III and IV in vitro, though without influencing fibril diameter or 
fibrillar kinetics (Douglas et al., 2006; Schonherr et al., 1995; Wiberg et al., 2002). 
Biglycan null mice show an osteoporosis-like phenotype with thin dermis and 
reduced bone mass due to larger, irregular fibrils (Corsi et al., 2002; Xu et al., 1998). 
Fibromodulin, a class II KS SLRP, binds to collagen type I and II and also regulates 
Figure 1.3: SLRPs and collagen assembly. SLRPs have a curved shape and bind to collagen 
fibrils through their core protein, thereby participating in the formation and spacing of the fibrils 
(by Theocharis et al., 2010) 
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fibrillogenesis, especially in the peripheral cornea, where the sclera and corneal 
stromas are integrated during development (Chen et al., 2010), while fibromodulin-
deficient animals have an abnormal tendon phenotype with impaired collagen fibrils 
(Kalamajski and Oldberg, 2009; Svensson et al., 1999; Viola et al., 2007).  Similarly, 
lumican binds to collagen type I and participates in fibrillar assembly in tendons and 
cornea, which is further supported by the fact that lumican knock-out mice 
demonstrated increased skin fragility and also bilateral corneal opacity (Chakravarti 
et al., 1998; Chakravarti et al., 2000; Ezura et al., 2000).  
PRELP binds collagen type I and II (Bengtsson et al., 2002), while OMD binds 
the non-collagenous domain 4 of collagen type IX and αvβ3 integrin (Lucchini et al., 
2004; Tillgren et al., 2009). The core protein of PRELP has been demonstrated to 
interact with collagen fibrils and thus it was suggested that it may play a role in 
linking basement membranes or cells to the adjacent extracellular matrix, something 
that could be further supported by the fact that PRELP also binds perlecan through 
its 22 amino acid N-terminal region and in that way can function as a basement 
membrane anchor (Bengtsson et al., 2000; Bengtsson et al., 2002).  So far there are 
no studies about OMD or PRELP null mice. However, considering their structural 
similarities with the other SLRP members mentioned above we can speculate that 
they may have additional roles in cell-cell/cell-matrix adhesion processes and in 
extracellular matrix organization. 
In addition, it was demonstrated that decorin and biglycan together can co-
ordinate in regulating collagen fibril assembly in tendons (Zhang et al., 2006) and in 
the cornea (Zhang et al., 2009). Finally, it was shown that in tendon, lumican was 
increased in the absence of fibromodulin, suggesting that they can co-operate and 
maybe function as a pair like decorin and biglycan (Svensson et al., 1999; 
Chakravarti et al., 2003). 
1.3.2.2 Signalling pathways and other biological functions 
Apart from the roles SLRPs have in ECM structure they participate in many 
important cellular processes through interactions with multiple signalling pathways, 
as described extensively in reviews by Dellett et al., Merline et al. and Schaefer & 
Schaefer (Dellett et al., 2012; Merline et al., 2009; Schaefer and Schaefer, 2010), 
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while the most studied pathways and relative SLRP members will be briefly 
described here. To start with, decorin binds to and sequesters transforming growth 
factor beta, TGF-β, inhibiting the TGF signalling pathway, modulating in that way 
cell proliferation (Li et al., 2008; Yamaguchi et al., 1990). In addition, decorin can 
act as modulator of programmed cell death, due to its interaction with the insulin-like 
growth factor receptor by binding to the IGF-IR and signalling via the PI3K/Akt 
pathway, thus having an anti-apoptotic effect of tubular epithelial and endothelial 
cells, affecting fibrosis and angiogenesis (Nastase et al., 2014; Schaefer et al., 2007; 
Schonherr et al., 2005; Schonherr et al., 2004). Furthermore, decorin interacts with 
ErbB receptors (Csordas et al., 2000; Iozzo et al., 1999b), epidermal growth factor 
receptor EGFR (Santra et al., 2000), lipoprotein-receptor related protein LRP-1 
(Brandan et al., 2006; Cabello-Verrugio and Brandan, 2007) and the Met receptor 
(Goldoni et al., 2009), thus acting through many signalling pathways (further details 
on some of these pathways which are involved in cancer will be discussed in the next 
section). 
Biglycan has been shown to decrease caspace-3 activity in mesangial cell 
protecting them from apoptosis (Schaefer et al., 2003), while on the contrary, 
lumican mediates Fas and FasL-related apoptosis by inducing Fas in mouse 
embryonic fibroblasts (Vij et al., 2005). Biglycan and decorin interact with WISP-1 
in fibroblasts and osteogenic cells (Desnoyers et al., 2001; Inkson et al., 2009), while 
both proteins can also bind TNFα, thus having roles in inflammation (Tufvesson and 
Westergren-Thorsson, 2002). In addition, soluble biglycan can act as endogenous 
ligand of TLR4 and TLR2 in macrophages, further affecting downstream signalling 
via p38, p42/44 and NFκB (Schaefer et al., 2005). Additional multifunctional 
inflammatory signalling properties of decorin and biglycan are described in a recent 
review by Moreth et al. (Moreth et al., 2012). 
Tsukushi (TSK) can regulate embryonic development in the Xenopus embryo by 
modulating several growth factors. For example, TSK binds to Vg1, and potentiates 
its activity in promoting axis formation (Ohta et al., 2006), functions as a Wnt 
signalling inhibitor regulating peripheral eye formation (Ohta et al., 2011), while it 
also binds to bone morphogenetic protein 4 (BMP4) ablating its activity in inhibiting 
axis formation (Ohta et al., 2004). Moreover, in the Xenopus embryo TSK regulates 
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endoderm formation by binding and activating Xenopus nodal-related protein-2 
(Xnr2) and by binding and inhibiting FGF8b (Morris et al., 2007). In the same 
context, biglycan promotes axis formation by binding to and inhibiting BMP4 
(Moreno et al., 2005), while in osteoblasts it is essential for BMP-4 and Wnt signal 
transduction in the stimulation of cellular differentiation (Berendsen et al., 2011; 
Chen et al., 2004). Also, study by Tillgren et al. showed that osteomodulin binds and 
fibromodulin binds bFGF in cell-free systems, but did not explore the functional 
significance of these interactions (Tillgren et al., 2009). Additionally, lumican-
mediated induction of corneal epithelial cell migration has been shown to be 
dependent on ERK1/2 signalling (Seomun and Joo, 2008). Finally, expression of 
OMD is down-regulated by TGF-β1 and up-regulated by BMP-2 during bone 
development (Rehn et al., 2006), while the protein can bind osteoblasts via ανβ3 
integrin, an interaction mentioned previously (Lucchini et al., 2004). 
 At present, it has also been established that various SLRPs actively participate 
in bone development and homeostasis, and are further involved in cell proliferation, 
matrix and mineral deposition, and bone remodelling (Nikitovic et al., 2012). More 
details on the roles of SLRPs in bone pathophysiology will be presented in Chapter 
6, where the effects of OMD and PRELP on bone development are examined. 
1.3.3 SLRPs in Cancer 
During the process of carcinogenesis many growth factors are secreted from the 
malignant cells that further stimulate cell growth but also enhance the surrounding 
stromal cells to secrete more molecules that in turn increase permissiveness in 
tumour growth.  The extracellular matrix integrity is crucial to maintain normal 
homeostasis and prevent invasion and metastasis of cancer cells, and both tumour 
and stromal cells are involved in the re-organisation of the ECM to promote tumour 
growth, invasion and migration.  In that context, as SLRPs are important regulators 
of the extracellular matrix structure, their expression is markedly altered in the 
tumour microenvironment. Modified expression of SLRPs, and more generally of 
matrix-accumulated proteoglycans, in stromal cell membranes can affect survival, 
signalling, growth, adhesion and migration of cancer cells. No less than 8 SLRPs 
have been found to be implicated in cancer so far and again the most well studied 
members will be discussed below.  
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1.3.3.1 Expression patterns and clinical significance 
The expression levels of SLRPs do not show a stable pattern but fluctuate 
between different cancer types. To start with, decorin is found overexpressed in 
pancreatic cancer (Crnogorac-Jurcevic et al., 2001; Koninger et al., 2004), in breast 
cancer (Leygue et al., 2000), in leukaemia (Campo et al., 2006), in chondrosarcoma 
(Soderstrom et al., 2002), and in squamous cell laryngeal carcinoma (Stylianou et al., 
2008). On the contrary, decorin expression was found downregulated in 2 types of 
non-small cell lung cancer, adenocarcinoma and squamous cell carcinoma 
(McDoniels-Silvers et al., 2002), in colorectal cancer (Mlakar et al., 2009), in thyroid 
tumours (Arnaldi et al., 2005), in ovarian tumours (Nash et al., 2002) and in a variety 
of cancer cell lines (Santra et al., 1997). Of note is the fact that, while in normal 
tissues the ratio of CS and DS decorin side chains is balanced, in tumour tissue, and 
specifically in pancreatic cancer (Skandalis et al., 2006), colorectal cancer 
(Theocharis, 2002), ovarian cancer (Nash et al., 2002) and gastric cancer (Skandalis 
et al., 2005), the chondroitin sulphate chains become predominant. Due to the fact 
that DS is chemically more complex than CS and requires additional enzymes to be 
synthesized, it was proposed that synthesis of a chemically simpler CS is favoured in 
tumour tissue (Goldoni and Iozzo, 2008; Theocharis et al., 2010). In line with this 
concept, CS side chains have been proposed to be more permissive to cell migration 
favouring tumour aggressiveness (Merle et al., 1999).  
 There are not many studies analysing the prognostic significance of decorin 
expression levels in terms of patience survival. However, high expression of decorin 
in patients with advance ovarian cancer was associated with poor response to 
treatment and a greater incidence of relapse for the patients that initially responded 
(Newton et al., 2006). In addition, decreased amounts of decorin were associated 
with poor prognosis in node-negative invasive breast cancer (Troup et al., 2003) and 
some types of soft tissue tumours (Matsumine et al., 2007). 
The other two class I SLRPs, biglycan and asporin, were overexpressed in 
various types of cancer.  For example, asporin was overexpressed in breast cancer 
(Turashvili et al., 2007), while biglycan was overexpressed in salivary gland 
carcinoma (Leivo et al., 2005), in colorectal cancer (Galamb et al., 2009), in 
intrahepatic cholangiocellular carcinoma (Nishino et al., 2008), in pancreatic cancer 
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(Weber et al., 2001) and pancreatic cancer cell lines (Chen et al., 2002), and in the 
stroma of basal cell carcinoma (Hunzelmann et al., 1995).   
Lumican, a class II SLRP, was found overexpressed in breast cancer (Leygue et 
al., 1998) and in melanomas (Sifaki et al., 2006), whilst there was altered expression 
in various types of human malignancies like osteosarcomas (Nikitovic et al., 2008) 
and pulmonary (Matsuda et al., 2008), pancreatic (Ishiwata et al., 2007) and colon 
carcinomas (Lu et al., 2002). Similarly to decorin, there are not constant reports 
regarding the role of lumican as prognostic indicator or patience survival, but 
lumican overexpression was associated with poor prognosis in advanced colorectal 
and pancreatic cancers (Ishiwata et al., 2007), as well as in lung adenocarcinomas 
and squamous cell carcinomas (Matsuda et al., 2008). Also, low lumican expression 
in breast tumours was correlated with large tumour size, increased host inflammatory 
response, slower time to progression and poorer survival (Troup et al., 2003), while 
rectal tumours expressing higher levels of lumican were more sensitive to pre-
operative radiotherapy (Watanabe et al., 2006). Another class II SLRP, fibromodulin, 
was found overexpressed in leiomyoma (Levens et al., 2005), B-cell chronic 
lymphocytic leukaemia and mantle cell lymphoma (Mayr et al., 2005; Mikaelsson et 
al., 2005). 
Finally, one of our two proteins of interest, PRELP, was described as one of four 
genes comprising a genetic signature that allows discrimination of two types of brain 
tumour, glioblastoma multiforme and meningothelial meningioma (Castells et al., 
2009). However, this study did not explore the functional significance that PRELP 
could have in the diagnostic procedure. 
1.3.3.2 Knockout mice and functions related to cancer 
Among the several SLRP knockouts that have been established only decorin 
deficient mice show susceptibility to cancer. Around 30% of decorin null mice 
develop spontaneous intestinal tumours (Bi et al., 2008), while double-knockout 
mice of decorin and the tumour suppressor p53 together showed a faster rate of 
tumour emergence which leads to earlier mortality (mice succumbed very early with 
a mean survival of ≈ 4 months versus 6 months for the p53 null mice alone) (Iozzo et 
al., 1999). Collectively, these studies could represent genetic evidence that lack of 
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decorin is “permissive” for tumour development (Goldoni and Iozzo, 2008; Iozzo 
and Sanderson, 2011). 
Several functional studies have demonstrated that some SLRPs can regulate 
hallmark activities, like proliferation and migration, of cancer cells. In this context, 
ectopic decorin suppressed the proliferation of colorectal, ovarian, gastrointestinal, 
genital, skeletal, cutaneous, and bone marrow cancer cell lines (Goldoni and Iozzo, 
2008). Following the evidence that decorin has a potency to act as an inhibitor of 
tumour cell proliferation in vitro, many of the recent studies have focused on the 
antitumor therapeutic effect decorin may have in vivo. Adenoviral-mediated delivery 
of decorin inhibits the in vivo tumorigenicity of lung, squamous and colon carcinoma 
tumour xenografts in immunocompromised mice (Reed et al., 2002; Tralhao et al., 
2003), arrests mammary adenocarcinoma growth and prevents metastatic spreading 
to the lungs (by reducing ErbB2 receptor levels) (Reed et al., 2005; Theocharis, 
2002). In addition, ectopic decorin expression in a rat glioma model prolongs the 
animal’s lifespan, whilst the size of the tumour is directly proportional to the 
concentration and time point that decorin is expressed (Biglari et al., 2004). On the 
contrary, in a mouse osteosarcoma model decorin expression did not affect the 
primary tumour volumes, but inhibited metastasis to the lung (Shintani et al., 2008). 
Seidler et al. were the first group to demonstrate that decorin can be 
administered as a therapeutic agent against cancer. Specifically, these researchers 
used the A431 squamous carcinoma model, where they showed that systemic 
injection of decorin protein core localises within the tumour, antagonizes EGFR 
activity and induces apoptosis of the tumour cells (Seidler et al., 2006). Another 
report from the same group proved that again systemic injection of decorin can 
reduce breast tumour growth and metabolism and halt metastatic spread to the lungs 
(Goldoni et al., 2008). In addition, ectopic decorin expression can revert the 
malignant phenotype in several cell lines of various histogenetic origins (Santra et 
al., 1997; Santra et al., 1995).  
Lumican is another SLRP what was implicated in cancer in several studies. To 
start with, stable expression of lumican in B16F1 mouse melanoma cells reduced 
anchorage-independent growth and xenograft tumour formation, increased apoptosis 
and suppressed migration (Vuillermoz et al., 2004). In addition, other studies showed 
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that lumican regulates vertical growth and binds to β1-containing integrin receptors 
on melanoma cells, thereby inhibiting their migration by disrupting focal adhesion 
complexes (Brezillon et al., 2009; Brezillon et al., 2007; D'Onofrio et al., 2008). 
Furthermore, Zelts et al. identified that this inhibitory ability was mediated through 
the lumican protein core, and specifically the 9th LRR named as lumcorin (Zeltz et 
al., 2009), while knockdown of lumican in HEK293 cells increased cellular 
proliferation (Ishiwata et al., 2004). Finally, another SLRP, osteoglycin, inhibited 
migration of hepatocellular carcinoma cells in vitro, and also suppressed their ability 
to metastasize, when xenografted into mice (Cui et al., 2008). 
 Collectively, all these findings about SLRP’s involvement in cancer progression 
and the fact that decorin and lumican can indeed antagonize primary tumour growth 
and metastases in vivo further show the potential that these molecules have in clinical 
application as anti-cancer agents. 
1.3.3.3 Mechanisms of action 
So far the mechanisms of SLRP activity in cancer are poorly characterised and 
most of the published studies are focused only on few representative members of the 
gene family, such as decorin, biglycan and lumican, with research on other SLRPs 
lagging far behind. However, there has been some significant progress in 
understanding the way extracellular matrix proteoglycans work against 
tumorigenesis and the most important findings will be described below. 
 Initially, decorin was found to supress tumour cell growth by directly binding 
the epidermal growth factor receptor (Iozzo et al., 1999b; Moscatello et al., 1998). 
The EGFR region that decorin binds to is partially overlapping but distinct from the 
EGF (natural ligand of EGFR) binding domain and this interaction between the 
SLRP and the receptor leads to autophosphorylation, and a sustained downregulation 
of EGFR, as well as other EGFR-like receptors, such as ErbB4 and ErbB2 (Csordas 
et al., 2000; Santra et al., 2000; Santra et al., 2002). This in turn triggers prolonged 
activation of the mitogen-activated protein kinase (MAPK) pathway – activation of 
ERK1/2, Ca2+ influx, induction of the cyclin-dependent kinase (CDK) p21WAF1/CIP1 
and growth arrest (as shown in the same studies), while decorin-bound EGFR is 
further internalised and degraded leading to consequent reduction of receptor number 
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(Fig. 1.4) (Zhu et al., 2005). In addition, in glioma cells exposed to oxygen and 
glucose deprivation, ectopic decorin protects cells from apoptosis by inducing 
expression of p21WAF1/CIP1, p27Kip1, PI3K and Ras (Santra et al., 2006), whilst in 
prostate cancer cells decorin binds androgen receptors as well as EGFR, with a 
downstream suppression of the PI3K pathway (Hu et al., 2009).  
Apart from EGFR and ErbB4/ErbB2 decorin appears to interact with other 
RTKs as well. A more recent study by Goldoni et al., demonstrated that exogenous 
decorin binds to Met, the hepatocyte growth factor (HGF), leading to receptor 
downregulation and thus attenuating the Met signalling pathway (Goldoni et al., 
2009). Notably, several biological activities mediated by the Met signalling cascade, 
like cell scatter, evasion and migration, were blocked by decorin through a 
downregulation of non-canonical β-catenin levels (Fig. 1.4) (Iozzo et al., 2011). 
Additionally, Myc, which is a downstream target of Wnt or RTK pathways (EGFR or 
Met), was markedly downregulated by decorin accompanied by an induction of 
phosphorylation at Thr58, further leading to proteasomal degradation of Myc and 
suppression of cell motility, migration and tumour growth both in vitro and in vivo 
(Buraschi et al., 2010). In the same study by Buraschi et al., it was also shown that 
systemic delivery of decorin in three tumour xenograft models caused 
downregulation of Met and a concurrent suppression of β-catenin and Myc levels. 
Overall, by antagonistically binding to multiple tyrosine kinase receptors, decorin 
participates in reduction of primary tumour growth and metastatic spreading. 
In addition, in a recent study by Neill et al., decorin inhibited pro-angiogenic 
factors such as HIF-1α and VEGFA via the Met receptor (Neill et al., 2012), while in 
an alternative mechanism decorin directly interacted with VEGFR2 leading to rapid 
phosphorylation of AMPK and increased levels of the paternally expressed gene 3 
(Peg3) and other Peg3-dependent autophagy-related genes, thereby leading to 
autophagy and angiostasis (Buraschi et al., 2013; Goyal et al., 2014).  Moreover, 
another mechanism was proposed linking inflammation and cancer growth, where 
decorin binds to TLR2/4 thereby activating MAPKs and NF-κB, inducing the 
transcription of TNF, interleukin 12B and 10 (IL-12B, IL10), and the programmed 
cell death protein 4-PDCD4-gene (Merline et al., 2011). This decorin-induced 
expression of PDCD4 further leads to translational repression of IL-10, which is an 
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anti-inflammatory cytokine, and therefore an enhanced inflammatory response is 
mediated. At the same time, when decorin was overexpressed in tumor xenografts an 
induced pro-inflammatory immune response through inhibition of TGF-β1, 
subsequent downregulation of the oncogenic microRNA-21 (miR-21) and an 
increased PDCD4 abundance was noted (Merline et al., 2011). The latter findings 
were also independently confirmed in a different study by Soria-Valles et al., thereby 
emphasizing the relation of decorin with TGF-β1 and miR-21 (Soria-Valles et al., 
2013). Finally, decorin is also able to bind to the insulin growth factor receptor and 
its ligand, IGF-IR and IGF-I respectively, and thus attenuate the IGF-I-induced Akt 
and ERK1/2 pathways, further leading to inhibition of downstream ribosomal s6 
kinases and resulting in decreased migration and invasion of bladder cancer cells 
(Iozzo et al., 2011). All the above mechanisms are also shown in Figure 1.4, 
summarizing all the possible ways that have been discovered so far, through which 
decorin acts against tumorigenesis (Nastase et al., 2014).    
The other two SLRPs that have been studied in detail so far are biglycan and 
lumican, and their cancer-related signaling pathways will be shortly described here. 
Briefly, in pancreatic tumour cells biglycan overexpression caused inhibition of cell 
proliferation by G1 arrest, an effect associated with upregulation of the p27 CDK 
inhibitor and downregulation of cyclin A and proliferating cell nuclear antigen 
(PCNA), as well as with attenuated activation of Ras and Erk (Weber et al., 2001). In 
addition, biglycan inhibited oncogenic properties of HER-2/neu-transformed 
fibroblasts and this effect was dependent on protein kinase C (PKC) and the cAMP 
response element binding protein (CREB) (Recktenwald et al., 2012), while another 
study showed that biglycan can act as  a  pro-angiogenic  factor  in  murine  tumour  
endothelial  cells, via interactions with the TLR2/4 receptors, and thus influence their 
migration and morphology (Yamamoto et al., 2012).   
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 Figure 1.4: Decorin signalling in cancer. Decorin binds to IGF-IR and also its ligand IGF-I at different binding 
sites and decreases both IGF-I-induced MAPK and Akt activation leading to lower levels of ribosomal s6 kinases. 
Through binding to EGFR, decorin leads to receptor internalization and its lysosomal degradation, while after EGFR 
phosphorylation Erk1/2 are activated, leading to the transcription of the CDKN1A gene corresponding to cyclin-
dependent kinase inhibitor 1, p21WAF1. When decorin activates Met, the HGF receptor, phosphorylation at 
Threonine 58 follows, which causes Myc and β-catenin to be phosphorylated for proteasomal degradation, thereby 
inhibiting translocation of these two molecules in the nucleus, negatively affecting cell evasion and migration. In 
addition, through Met, decorin inhibits pro-angiogenic factors such as HIF-1α. Alternatively, decorin interacts with 
VEGFR2 thereby leading to rapid phosphorylation of AMPK and increased levels of Peg3, causing autophagy and 
angiostasis. Moreover, decorin binds to TLR2/4 thereby activating MAPKs and NF-κB, linking inflammation and 
cancer growth. By inhibiting TGF-β signalling, decorin decreases the abundance of oncogenicmicroRNA-21 (miR-
21) and prevents the miR-21-dependent translational repression of PDCD4 and thus reduces the levels of IL-10 
protein. For more information see the main text. Abbreviations: AMPK, 5′ adenosine monophosphate-activated 
protein kinase; AP4, activating enhancer-binding protein; BECN1, Beclin1; CDKN1A, cyclin-dependent kinase 
inhibitor 1; EGFR, epidermal growth factor receptor; Erk, extracellular-signal-regulated kinase; HGF, hepatocyte 
growth factor; HIF-1α, hypoxia inducible factor-1α; IGF-I, insulin growth factor type I; IGF-IR, insulin-like growth 
factor type I receptor; IL, interleukin; MAP1LC3a,microtubule-associated protein 1 light chain 3 alpha; 
MAPK,mitogen-activated protein kinase; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; 
PDCD4, programmed cell death 4; Peg3, paternally expressed gene 3; TCF/LEF, lymphoid enhancer-binding 
factor/T-cell-specific factor; TNF-α, tumour necrosis factor; TGF-β, transforming growth factor-β; VEGFR2, 
vascular endothelial growth factor receptor. Adopted by Nastase et al., 2014.  
 
42 
 
  In analogy to decorin, lumican inhibits colony formation in soft agar (a 
hallmark of malignant transformation) of a variety of cell types including 
fibrosarcoma, carcinoma and normal embryonic cells, and this effect is mediated 
through increased expression of the cyclin-dependent kinase inhibitor p21WAF1 (Li et 
al., 2004). However, it appears that the underlying mechanism is different compared 
to decorin, as in lumican expressing cells upregulation of p21 happens in a p53-
dependent manner with a subsequent decrease in cyclins A, D1 and E (Vij et al., 
2004). Furthermore, lumican reduces anchorage-independent growth and in vivo 
tumorigenicity in immunocompromised mice of cells transformed by the v-K-ras and 
v-src oncogenes, which suggests that lumican might be selectively inhibiting 
transformation caused by these 2 viral oncogenes and thus play a role in the 
development of some human cancers (Iozzo and Sanderson, 2011; Yoshioka et al., 
2000).  
Finally, there have been some studies linking the activity of SLRP’s with matrix 
metalloproteinases, demonstrating how ECM and proteoglycan degradation can play 
a major role in the control of tumour progression. More specifically, it was shown 
that membrane-type matrix metalloproteinase-1 (MT1-MMP or MMP-14) can cleave 
lumican, leading to abrogation of its activity to supress tumour cell colony formation 
in soft agar (Li et al., 2004), while it can also cleave decorin inhibiting its anti-
vascularisation effect in the cornea (Mimura et al., 2011). In contrast, another two 
studies showed that lumican regulates bone marrow mesenchymal stem cell (MSC) 
functions and migration via mechanisms that involve a decrease of MMP-14 
expression and activity, while via the same mechanism lumican also inhibits 
angiogenesis in in vivo Matrigel plug assays (Malinowski et al., 2012; Niewiarowska 
et al., 2011).  
In conclusion, the roles of SLRPs in cancer initiation and progression are quite 
complex and additional research is required to support their potential as valid 
therapeutic agents against cancer. However, as studies on SLRPs are constantly 
increasing, there is a novel emerging concept that this cancer-repressive activity 
functions wholly within the extracellular matrix and therefore a "basically inert" 
matrix component can turn into a tumour suppressor or pro-inflammatory agent 
(Schaefer and Iozzo, 2012), offering novel perspectives in the fight against cancer. 
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1.3.4 OMD and PRELP in cancer 
So far there are no published studies involving osteomodulin in any cancer-
related field, while PRELP has only been linked to cancer once, as one of four genes 
comprising a genetic signature for diagnosis of a brain tumour type (Castells et al., 
2009). In collaboration with Dr. R. Hamamoto and Dr. T. Tamura, we previously 
discovered by microarray analysis that expression of OMD and PRELP is reduced in 
a number of cancers. The largest differences in expression were seen with bladder 
cancer, so downregulation of OMD and PRELP in urological cancers was 
reconfirmed by RT-PCR.  A significant reduction in OMD and PRELP expression 
was seen in urothelial cell carcinoma and renal cell carcinoma (Fig. 1.5). More 
reductions in expression were seen in high stage and grade bladder tumours, and in 
bladder tumours that metastasized.  
Further study of the effect of OMD and PRELP overexpression in a bladder 
cancer cell line was conducted by a previous lab member, Dr. Julie Watson, who 
found that both genes affected cell cycle progression, increased susceptibility of cells 
to mitomycin C-mediated apoptosis, abolished anchorage-independent growth of 
cancer cells and affected their morphology and migration capability. In search of 
signalling pathways involved, she found several signalling molecules to be 
differentially phosphorylated or expressed in OMD- and/or PRELP-transfectants, 
including EGFR, p38 MAPK, c-Jun, Akt, β-catenin and Smad2, suggesting that 
OMD and PRELP regulate networks of genes centred on the kinases, ERK, JNK, 
PI3K and p38 MAPK, and affect gene transcription through the HNF transcription 
factors. Collectively, from data generated previously in our lab and from 
collaborators, we have identified OMD and PRELP as candidate regulators of 
carcinogenesis, which may have the potential to alter the activities of cancer cells 
and/or affect cancer progression or initiation through a variety of mechanisms. More 
details on the previous data collected so far are presented in Chapter 3 and in the 
Appendix at the end of this thesis. 
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1.4   Project hypothesis and aims 
The small leucine-rich proteoglycans are important extracellular regulators of 
matrix architecture and of signalling into the cell. Disruption of the normal 
expression, or mutation, of various family members leads to a spectrum of 
musculoskeletal and optical disorders, while an emerging body of evidence suggests 
that SLRPs are also involved in carcinogenesis. While OMD and PRELP still remain 
two-little studied members of the SLRP family, our lab (with additional help from 
Figure 1.5: Expression of OMD and PRELP in urothelial cell carcinoma and renal cell 
carcinoma. Quantitative RT-PCR of a cohort of tumours and normal samples.  Tissue was snap-
frozen and sectioned.  Epithelial cells were isolated by laser-capture microdissection, and RT-PCR 
was carried out.  Data was normalized to GAPDH expression.  126 bladder tumours and 31 normal 
bladder samples were examined for expression of (a) OMD and (b) PRELP.  78 renal cell carcinomas 
and 15 normal kidney samples were examined for expression of (c) OMD and (d) PRELP. Graphs and 
data are kindly provided by Dr. Hamamoto and Dr. Watson.   
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our collaborators) has managed to collect a respectable amount of data demonstrating 
the involvement of OMD and PRELP genes in cancer.  Initially, the fact that these 
two genes were found significantly downregulated in urothelial cell carcinoma and 
renal cell carcinoma, while their expression was also correlated with disease 
progression in urothelial cell carcinoma, was our starting point. In addition, 
overexpression of OMD and PRELP in the EJ28 bladder cancer cell line lead to 
inhibition of cell cycle progression and proliferation, and to enhancement of 
apoptosis and drug susceptibility (unpublished data, acquired by Dr. Watson), further 
supporting the involvement of the two genes in cancer. Hence, we began this project 
under the hypothesis that OMD and PRELP act as tumour-suppressor genes and can 
regulate functions involved in carcinogenesis. 
The test our hypothesis the present study has the following aims: 
• To determine the roles of OMD and PRELP in cellular functions 
involved in carcinogenesis and specifically in bladder cancer, and 
elucidate their mechanisms of action. 
• To establish the spatial-temporal pattern of OMD and PRELP expression 
in the mouse. 
• To characterise the phenotypes of neonatal and adult OMD and PRELP 
knock-out mice. 
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2.1 Materials 
2.1.1 Standard Solutions 
Table 2.1: Standard solutions used throughout this project 
Solution Composition/Methods 
Ampicillin stock 
solution 50μg/ml 
Mix 1.10g Ampicillin Sodium Salt (Sigma, UK) + 22ml dH2O 
(1100mg / 50(mg/ml)), filter with 0.22 μm syringe filter 
(Anachem, UK), 1ml aliquots, store at -20°C 
Phosphate Buffer Saline 
(PBS) 
Add 137mM NaCl, 2.7mM KCl, 100mM Na2HPO4, 20mM 
KH2PO4 in 800ml dH2O, stir to dissolve, top up water to 1L, 
autoclave 
50X TAE buffer Provided ready in 1L bottles 
1X TAE buffer for gel 
electrophoresis 
For 1L: use 20ml of 50X TAE into 980ml dH2O 
Luria-Bertani (LB) 
Broth 
25g LB Broth powder (Fisher Scientific, UK) in 1L dH2O, 
autoclave 
LB-agar 
40g LB-agar powder (Fisher Scientific, UK) in 1L dH2O, 
autoclave 
Agarose (for soft agar 
assay) 
Seaplaque Agarose   (Lonza,UK). Make 1.4%, 1.2%, 0.7% and 
0.6% in 50ml dH2O, autoclave 
Blocking Buffer 
(ICH/IF) 
PBS with 10% goat serum (Sigma, UK) + 0.3% Triton-X 100 
(Sigma, UK) + 0.1% sodium azide (Sigma, UK), filter sterilize, 
store at 4°C for 1 month 
Transfer Buffer (WB) 
Tobwin transfer buffer: Dissolve 3.03g Tris-base (Sigma, UK), 
14.4g Glycine (Sigma, UK) in 600ml PBS, add 200ml Methanol 
(Sigma, UK), stir and top up with PBS to 1L 
Blocking Buffer (WB) PBS with 5% non-fat milk + 0.1% Triton-X 100 
Wash buffer (WB) 1L PBS with 0.1% Triton-X 100 
Paraformaldehyde 
(PFA) 4% 
 
Freshly prepared using 32% PFA (Electronic Microscopy 
Sciences, USA). Mix 7 parts dH2O and 1 part of 32% PFA 
1x Trypsin 100ml bottles of 1X Tripsin-EDTA (PAA, UK) kept at 4°C 
Doxycycline stock 
solution 
Dissolve 0.1g Doxycycline hyclate (Sigma, UK) in 10ml dH2O 
(final concentration of 10mg/ml), filter with 0.22 μm syringe 
filter, 1ml aliquots, store at -20°C 
Crystal violet 
For 100% stock solution, add 5mg crystal violet powder (Sigma, 
UK) to 5ml dH2O, store at room temperature 
Stripping buffer (WB) 
Use Restore Plus Western blot Stripping buffer (Thermo 
Scientific, UK, Prod #46430) 
X-gal (stock solution) 
Dissolve 0.1g of X-gal (Melford, UK) in 5 ml 
dimethylformamide-DMF  (Sigma, UK), store in the dark, -20°C 
X-gal staining solution 
Dissolve 5.35mM K3Fe(CN)6, 5.35mM K4Fe(CN)63H2O, 1.2mM 
MgCl2, 0.01% Sodium deoxycolate, 0.02% NP40, in 100ml PBS 
(all chemicals are from Sigma, UK), store in the dark, at RT 
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 2.1.2 Cell lines and media 
Table 2.2: Cell lines and media used throughout this project 
 
 
 
Ammonium Persulfate 
(APS 10%) 
Freshly prepared, dissolve 0.2g APS (Sigma, UK) in 2ml  dH2O 
100% (w/v) 
Trichloroacetic acid 
(TCA) 
Dissolve 500g TCA (as shipped) into 350 ml dH2O, store at RT 
0.03% Alcian blue 
Dissolve 0.015g of alcian blue (Sigma, UK) in 10ml 100% 
ethanol and 10ml acetic acid, store at RT 
0.1% Alizarin red 
Dissolve 100mg alizarin red (Sigma, UK) in 100ml dH2O, add 
1% KOH 
Methylene Blue solution 
Dissolve 0.3g of methlylene blue (Sigma, UK) in 30ml 
ethanol/100ml dH2O, 0.1% KOH 
Basic fuchsin solution 
Dissolve 1g of basic fuchsin (Sigma, UK) in 100ml 50% ETOH 
in dH2O 
Citrate buffer pH 6.0 for 
antigen retrieval 
Dissolve 10mM citric acid (Sigma, UK), 0.05%  Tween (Sigma, 
UK), pH 6.0, store at RT for 3 months 
Tris-EDTA buffer pH 
9.0 for antigen retrieval 
Dissolve 10mM Tris (Fisher Scientific, UK), 1mM EDTA, .05%  
Tween (Sigma, UK), pH 9.0, store at RT for 3 months 
Cell lines/Media Origin/Composition 
EJ28 cell line 
Epithelial bladder, urinary carcinoma cell line, grown in 
complete DMEM,  CLS #300172 
HEK 293T cells 
Epithelial human kidney cells that  constitutively express 
the simian virus 40 (SV40) large T antigen, cultured in 
complete DMEM,  CRL#11268 
Complete DMEM medium 
Dulbecco’s Modified Eagle Media (Gibco, Invitrogen, 
UK,#31885-049) + 10% FBS (Fetal Bovine 
Serum)(Biosera, UK) + 100 U/ml Penicillin/Streptomycin 
(Sigma, UK) 
2X DMEM 
Dissolve 3.35g powder DMEM (Gibco, #31600), 0.92g 
NaHCO3 and 0.44g HEPES in 100ml dH2O, pH to 7.4, 
filter-sterilize, add 25ml FBS and 2.5ml P/S 
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2.2  Methods 
2.2.1 DNA/RNA Methods 
2.2.1.1 Vectors 
All the vectors (plasmids as well as viral vectors) that were used throughout the 
project are described below: 
a) pIRES2-EGFP-OMD/mtOMD: plasmid coding for the human OMD cDNA or 
the myc-tagged OMD cDNA and the GFP protein. Original vector from 
Clontech. OMD/mtOMD cDNA was cloned into the vector by Dr. Watson 
b) pIRES2-EGFP-PRELP/mtPRELP: plasmid coding for the human PRELP or the 
myc-tagged PRELP cDNA and the GFP protein. Original vector from 
Clontech. PRELP/mtPRELP cDNA was cloned into the vector by Dr. Watson  
c) pLenti.TRE/CMVmin-KGF.IRES-eGFP.hPGK-rtTA2S-M2: Lentiviral “all-in-
one” expression vector utilizing the Tet on system, coding for the KGF gene 
under an inducible GFP promoter, followed by the IRES-eGFP element and the 
hPGK promoter coding for the transactivator protein rtTA2S-M2. Kindly 
provided by Prof. Sam Janes (UCL) 
d) pLenti.TRE/CMVmin.IRES-eGFP.hPGK-rtTA2S-M2: Lentiviral expression 
“all-in-one” vector utilizing the Tet on system, with no gene under the 
inducible TRE/CMVmin promoter, acting as a control for the previous vector. 
Kindly provided by Prof. Sam Janes (UCL) 
Vectors a-b were used for creation of stable cell lines overexpressing OMD and 
PRELP, and also served as template to amplify OMD/mtOMD and 
PRELP/mtPRELP cDNAs for cloning into the lentivector; vectors c & d were used to 
create an inducible system for OMD/PRELP. 
2.2.1.2 Plasmids transformation and selection 
Prior to transformation water bath was balanced to exactly 42°C and a vial of 
SOC media (Invitrogen, UK) was prewarmed to 37°C. Plasmids (lab stocks stored at 
-20°C) mentioned above as well as vials of competent E.coli cells (DH5a-100μl) 
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where thawed on ice. 100μl of DH5a cells were used for each transformation. 1μl of 
each plasmid DNA was added into each vial of competent cells and these were 
mixed by tapping the tube gently. The tubes were subsequently incubated on ice for 
30 minutes and then heat-shocked for exactly 45 seconds in the 42°C waterbath. 
After that the tubes were put again on ice and 900μl of SOC medium was added 
under sterile conditions. This mixture was incubated at 37°C for 1 hour in a shaking 
incubator at 250 rpm. 10-200μl of the transformed cells were then spread on pre-
warmed LB agar + ampicillin (50μg/mL) 10cm plates. The plates were then inverted 
and incubated overnight at 37°C. 
After 12-16 hours bacterial colonies had formed on the LB-agar plates which 
contained plasmids conferring ampicillin resistance. In order to have a starter culture 
of the bacteria carrying our plasmids of interest, from plates where well-separated 
colonies had developed a single colony of transformed bacteria was picked and 
transferred into 5ml LB containing 50μg/mL ampicillin. This starter culture was then 
incubated at 37°C in a shaking incubator at 250 rpm, in order to proceed with the 
next step which was plasmid DNA extraction from the bacteria. 
2.2.1.3 DNA purification – Mini preps – Maxi preps 
Mini-preps and maxi-preps were performed to extract the plasmid DNA from the 
bacterial cells using the corresponding Endofree plasmid purification kit (Qiagen, 
UK) continuing from our starter cultures (as mentioned above) exactly as described 
in the Qiagen kit handbooks. Determination of DNA concentration and purity was 
done using the Nanodrop ND-1000 spectrophotometer. 
2.2.1.4 Gel electrophoresis 
For all the procedures involving gel electrophoresis 1% and 2% agarose gels 
were used. 1g or 2g of agarose powder (Fisher Scientific, UK) were dissolved in 
100ml 1x TAE buffer (table 2.1) by microwaving with hand stirring every 30 
seconds. After the mix was completely dissolved, agarose was slightly cooled under 
cold tap running water, and 10μl of SYBR Safe DNA gel stain (Life technologies, 
UK) was added. The agarose was mixed by swirling and poured into a gel former 
with the appropriate size comb and was left to set. Once the gel was ready it was 
transferred (along with the former) to the suitable size gel tank and was submerged 
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into 1x TAE buffer. The combs where removed just before the samples were loaded. 
A final volume of 20μl (with loading dye) of each sample was loaded into each well 
along with a ladder marker.  Gels were run at 80V until the dye front was almost at 
~85% of the distance down the gel and gel images were captured using a UVP 
transilluminator. 
2.2.1.5 Restriction enzyme digestion 
Restriction enzyme digestion was performed either to confirm the propagated 
plasmid’s identities or to prepare vectors and inserts for ligation (will be explained in 
detail in the next section) during cloning procedures. Unless stated otherwise, all 
single digests were carried out with 2μl DNA (in a concentration of ~400ng of 
DNA), 2μl of buffer (NEB, UK), 2μl BSA 10X (NEB, UK 10μg/ml), 13.5μl of water 
and lastly 0.5μl restriction enzyme into a 1.5ml Eppendorf tube. For the double 
digest the quantity of the water was readjusted to have a final volume of 20μl. 
Reactions were incubated in 37°C for 1.5 hours (time and temperature always 
depending on the restriction enzyme). After the incubation 4μl of loading dye (NEB, 
6x concentration) was added to each tube and the samples were analysed by gel 
electrophoresis. Undigested DNA (control samples) was always run alongside the 
digested ones, while a DNA 1kb Ladder (Roche/Invitrogen, UK) was used. The 
restriction enzymes used as well as the conditions of the reactions are listed beneath: 
Table 2.3: Restriction digestion enzymes used in this project 
Restriction 
enzyme Buffer BSA needed 
T/Incubation 
time Manufacturer 
EcoRV-HF 
NEB Buff. 3 
(B7003S) 
Yes 37°C / 1.5h NEB, R3195L 
MluI 
NEB Buff. 2 
(B7002S) 
Yes 37°C / 1.5h NEB, R0198L 
NheI NEB Buffer 2 Yes 37°C / 1.5h NEB, R0131L 
 
2.2.1.6 Ligation 
Inserts and vector were prepared by PCR/gel purification and restriction enzyme 
digestion, followed by phosphatase treatment of the vector to avoid self-ligation 
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(Calf intestinal alkaline phosphatase-CIAP, Promega, UK). Around 40μl of vector 
(up to 10pmol of 5’-ends), 5μl CIAP 10x reaction buffer and diluted CIAP (0.01u/μl) 
were mixed and incubated at 37°C for 30 minutes. Another aliquot of diluted CIAP 
(of the same quantity as before) was added to the mixture and another incubation for 
30 minutes at 37°C followed. Next, DNA purification was performed (Macherey-
Nagel kit, UK) and the vector was ready for ligation. For the ligation, insert(s) and 
vector were mixed in an eppendorf tube in a ratio of 3:1 (insert:vector). To calculate 
this ratio 2μl of each insert and vector were run on an agarose gel and according to 
the band intensities and the length of each fragment the values for the ligation were 
calculated using the following formula: 
 
,where v=vector and i=insert, so Sv is size of vector, Si is size of insert, lv and li are 
the relative intensities of the bands on the gel (the weaker band is given the value of 
1), Vv and Vi are the volumes loaded on the gel (usually are equal), and the volume 
of the vector that will be used for the ligation is Lv. According to that formula the 
volume of the insert to be used for the ligation, Li, is calculated. 5μl of 10X ligation 
buffer (NEB) and 1μl of T4 DNA ligase (NEB) were included to the mix and water 
was added to a final volume of 20μl. The reaction mix was left at 16ºC overnight. 5μl 
of the ligation was then used for subsequent transformation and plating of E.coli 
competent cells (DH5a). DNA from the derived colonies was mini-prepped and 
screened for the insert with restriction enzyme digestions. Successful clones were 
sent for sequencing to confirm the result. 
2.2.1.7 Quantitative RT-PCR 
RNA was collected using the RNeasy Purification Kit (Qiagen, UK).  Three 
biological replicates of each sample were collected.  Concentration of RNA was 
checked on a Nanodrop spectrophotometer.  Reverse transcription was carried out on 
2µg of each sample in a volume of 20µl, using 5x First strand buffer, 0.1M DTT, 
500ng random primers (Promega), 2.5mM each of dNTPs (Promega) and 200 units 
Superscript reverse transcriptase II (Invitrogen).  A negative water control was 
always included, as were reactions for every sample but without the addition of 
reverse transcriptase, to act as negative control for the reaction and to make sure that 
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during PCR amplification was only due to the cDNA and not due to genomic DNA. 
Tubes were then incubated at 25ºC for 10 minutes, at 42ºC for 50 minutes, at 70ºC 
for 15 minutes and then cooled on ice. Also treatment with RNaseH (Invitrogen) 
followed at 37 ºC for 30 minutes (for more detailed protocol, check the online 
manual for Superscript Reverse Transcriptase II, Invitrogen).  20ng of cDNA was 
then loaded into each well of a 96-well dish.  Triplicate samples of each cDNA were 
included for each primer set.  Primers against OMD and/or PRELP and GAPDH 
were used.  200nM of each forward and reverse primers, and 1x Fast SYBR-green 
master mix (Applied Biosystems) were then added to each sample, to make a final 
volume of 20µl in each well.   Plates were then loaded onto 7900HT Real-time PCR 
machine (Applied Biosystems) and run on the standard programme.  Ct data was 
linearized, normalized to GAPDH.  Means of each set of three technical replicates 
were taken, and then means and standard deviations of each set of three biological 
replicates were calculated, while analysis was conducted using the Pfaffle method 
(Pfaffle M.W., 2001). This method entails the relative quantification of a target gene 
transcript in comparison to a reference gene transcript. The relative expression ratio 
is calculated from the real-time PCR efficiencies and the crossing point deviation of 
an unknown sample versus a control. Sequences of primers were as follows: 
OMD Forward: 5’-TCTTCCCAACATTGTAGAACTCAG-3’ 
OMD Reverse: 5’-ATTGTTTGACCATTAGTGCTTCGT-3’ 
PRELP Forward: 5’-CTGTCCCACAACAGGATCAGCAG-3’ 
PRELP Reverse: 5’-CAGGTCCGAGGAGAAGTCATGG-3’ 
GAPDH Forward: 5’-CCCCACCACACTGAATCTCC-3’ 
GAPDH Reverse: 5’-GGTACTTTATTGATGGTACATGACAAG-3’ 
Additionally, qPCR using the Taqman method was done for PRELP expression. 
50ng of cDNA in 2µl volume were used and 10µl of TaqMan Gene Expression 
Master Mix 2X (Applied Biosystems), 1µl of TaqMan Gene Expression for PRELP 
(Applied Biosystems, #Hs00160431_m1) or TaqMan Gene Expression for GAPDH 
(Applied Biosystems, #Hs99999905_m1) were added topped up with water to a final 
volume of 20 µl. Plates were again loaded onto 7900HT Real-time PCR machine and 
run on the standard programme indicated for the Taqman assay, and data were 
analysed in the same way. 
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2.2.2 Cell culture Methods 
2.2.2.1  Cell culture 
The EJ28 cell line was cultured in complete DMEM medium (see table 2.2 for 
complete medium compositions) in T75cm2 flasks (PAA, UK). Cell passaging was 
always done under sterile conditions inside a hood (Microflow II Biological cabinet) 
using the same type of flasks usually every 2-3 days, after the cells had reached 80-
90% confluency, to avoid cell death. The procedure involves splitting the cells and 
re-plating them into new flasks. Firstly, the medium was removed from each flask, 
followed by rinsing with 5ml 1X PBS (PAA, UK). PBS was removed and 2ml of 1X 
trypsin (PAA, UK), promoting disruption of the cells adhesion, (prewarmed in 37°C 
waterbath) was added per flask. After 2-3 minutes when cells were completely 
detached, 10.5ml fresh medium (prewarmed in 37°C waterbath) was added to stop 
the reaction and the resulting mix was transferred to a 50ml Falcon tube. From that, 
usually 1 or 2ml (depending on the time we wanted to re-split the cells) were plated 
into new T75 flasks and fresh complete medium was added to a final volume of 20ml 
per flask. In cases where we needed to count the cells in order to use a specific 
amount, cells were diluted in Trypan Blue 0.4% solution (Sigma, UK) and the 
hematocytometer was used. Flasks were always kept in a 37°C incubator with 5% 
CO2 supply (Sanyo, MCO-18AIC, Japan). 
When needed, cell freezing was done in early passages to keep a stock of the 
cells. Approximately one million cells in a volume of 1ml of complete medium plus 
5% DMSO (Sigma, UK) was aliquoted in each cryo-tube (PAA, UK), and cells were 
frozen overnight in a Nalgene Mr. Frosty Cryo 1°C Freezing container. The next day 
tubes were transferred in a liquid nitrogen tank, to be kept for long-term storage. 
2.2.2.2 Lentiviral transfections/transductions 
Cells were seeded in a 48-well plate one day prior to transfection, in a cell 
density of 2x104 cells/well in 500μl medium. After 24 hours, when cells were around 
70% confluent, their medium was removed, and the appropriate amount of lentivirus 
to give an MOI of 5 was mixed with 300μl fresh complete cell medium (in the 
presence of 8μg/ml Hexadimethrine bromide, Sigma, UK), which was then added to 
the cells, followed by a swirling of the plate. Cells were incubated in a 37°C 
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incubator with 5% CO2 supply for 24 hours. Then, the virus-containing medium was 
removed and fresh medium was added. After another 24 hours the medium was 
changed again and cells were cultured normally from this point onwards. All the 
experiments involving lentiviruses were conducted in a category II safety hood and 
room. 
2.2.2.3 Anchorage independent growth assay (or soft agar assay) 
 Autoclaved, sterile solutions of 1.2% Seaplaque agarose were microwaved until 
liquidified, and then cooled to 40ºC in a water bath.  2x DMEM was made up and 
filtered-sterilised.  Twice the usual amount of serum and antibiotics was added to 
these solutions. The media were then mixed with the 1.2% agarose solution to yield a 
final solution of 1x growth medium + 0.6% agarose solution. The solution was 
quickly poured into 6-well plates, before hardening.  1ml of solution was added per 
well.  Plates were then incubated at 4ºC overnight to allow the agarose to set 
thoroughly (bottom gel).  For the top gel, sterile solution of 0.6% Seaplaque agarose 
was microwaved and cooled to 40ºC in a water bath.  This solution was then mixed 
with the aforementioned 2x growth medium to yield 1x growth medium + 0.3% 
agarose.  A suspension of 5000 cells in 200µl 1x growth medium was then added to a 
2ml aliquot of the 1x growth medium + 0.3% agarose solution, and the resultant 
mixture was plated out on the top of the bottom gel.  Once the top layer had cooled 
and hardened, 1ml of growth medium was added on top of the agarose, to keep it 
moist. Triplicate samples of each cell line were prepared in this way.  Then, plates 
were incubated for 3 to 4 weeks in a 37°C incubator with 5% CO2 supply, until 
visible colonies appeared.  Colonies were then stained with 1% Crystal Violet 
(Sigma, UK) and the whole well was imaged with a stereoscope. Pictures of all the 
wells were imported into a computer and colonies were counted using the Image J 
software (open source, developed by National Institutes of Health, USA).  
2.2.2.4  3D Matrigel morphogenesis assay 
For 3D morphogenesis, EJ28 and EJ28-OMD/PRELP transfected cells were 
plated on top of a layer of growth factor–reduced Matrigel (BD Bioscience, 
#356231). In brief, 8-well multi chamber coverslips were covered with 100 µl 
Matrigel and left to gel for 45 min at 37°C. 10,000 cells in 200 µl of Matrigel were 
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then plated and cultured in complete DMEM. The medium was replaced with fresh 
medium twice a week. After 7 days, 3D morphogenesis was assessed by light 
microscopy. 
2.2.2.5  Matrigel invasion assay 
Assay insert plates (BD Bioscience, #354480) were prepared by rehydrating the 
Matrigel™ coating with PBS for 2 hours at 37°. The rehydration solution was 
carefully removed, 0.75 ml DMEM containing 10% fetal bovine serum was added to 
the plate well as a chemoattractant, and 0.5 ml of cell suspension (2.5x10^4 cells) in 
DMEM containing 0.1% FBS was added to each insert well. The assay insert plates 
were incubated for 48 hours at 37°C. Following incubation, the medium was 
removed from the upper chamber and the insert membrane was stained with 
hematoxylin using Hemacolor® (MERCH, HX093929). After staining, cells attached 
to the top of membrane were wiped off and the dye staining cells under the 
membrane was eluted with 0.1M citric acid (unbuffered) and absorbance was read at 
630 nm. 
2.2.2.6 Cdc42 activation assay 
Cells were seeded at 1 x 105 cells/well in 10% FBS containing DMEM in 24 
well plate and after 24 h, cells were harvested and analysed for levels of active 
Cdc42 using the G-LISA assay kits (Cytoskeleton; #BK127). 
2.2.2.7 Transwell co-culture assay 
1x105 cells/well of EJ28 cells were seeded on the bottom of 6-well plates, while 
5x104 cells of each EJ28/ EJ28-OMD/mtOMD/PRELP/mtPRELP were seeded on 
transwells with 0.4μm pores (VWR, UK #29442-104). Both the lower compartment 
and the transwell were filled with complete DMEM. Cells were co-cultured like this 
for 72 hours, after which brightfield images of both the cell layer on the transwell 
and the bottom of the wells were captured. Living cells were counted after 
thrypsinisation and trypan blue staining. 
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2.2.2.8  Xenograft 
EJ28 and EJ28-OMD/PRELP transfected cells were used for the xenograft 
experiments. Xenografts were initiated by subcutaneous implantation of 5×106 cells, 
suspended in 100μl of MATRIGEL (Becton Dickinson, USA) solution, into the right 
flank of nude mice in accordance with UK Home Office regulations and allowed to 
develop to measurable size. Two weeks after inoculation, tumour measurements 
were started. Tumour volume was assessed using digital callipers. The volume was 
calculated using the following formula: tumour volume (mm3) = (a) x (b)2 / 2, where 
(a) is longer diameter, (b) is shorter diameter. 
2.2.2.9 Lentiviral production 
Viral production was conducted by a 3-plasmid co-transfection of HEK 293T 
cells and the JetPEI (Polyplus transfection, USA) system. For a full viral preparation 
16-18x106 cells were seeded in 9 T175 flasks in complete DMEM. The next day the 
transfection mixture was performed for each flask, where: 20μg of the mtOMD or 
GFP expressing lentivector (vectors c and d from section 2.2.1.1), 7μg pMD.G2 and 
13μg pCMV-dR8.74 plasmids were added to 1ml 150Mm NaCl, mixed by hand and 
passed through a 0.22μl filter. 80μl of JetPEI were added to 1ml 150Mm NaCl and 
the mixture was vortexed for 10 seconds. Then the NaCl/PEI solution was added to 
the NaCl/DNA solution, was mixed by hand, and was left to incubate at room 
temperature for 30 minutes. After the incubation the NaCl/PEI/DNA solution was 
added to 13ml of complete DMEM. The old medium was removed from each flask 
of 293T cells and the medium with the transfection mix was added (a total of 
15ml/flask), and cells were left for 4hours at 37ºC, after which the medium was 
replaced with fresh complete DMEM. The next day the medium was replaced again 
with fresh DMEM. The fourth day, the virus-containing medium was removed from 
the flasks and was centrifuged at 300g for 10 minutes at 4 ºC. In the meantime fresh 
medium was added to the flasks, which were put back to the incubator until the 
following day. The supernatant from the centrifugation was filtered through 0.45μm 
filters and was transferred into clean, dry Beckman centrifuge tubes, which were in 
turn ultracentrifuged at 17,000 rpm for 2hours at 4ºC. After the centrifuge the 
supernatant was discarded and the tubes with the virus pellet were covered in 
parafilm and left to incubate on ice for 30 minutes. Afterwards, the pellet was 
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thoroughly resuspended with the few drops of medium that were left on the walls of 
the tubes, using a P10 pipette. The virus was aliquoted into 20μl aliquots and stored 
at -80ºC until use. The following day the same procedure was performed with the 
medium that was now present in the flasks, after which the cells were discarded. All 
the work involving viral preparation was performed in a class II safety hood. All the 
above procedures were conducted in the UCL-Ryan Building, in Professor Sam 
Jane’s laboratory.  
2.2.2.10 Lentiviral titration 
For viral titration HEK 293T cells were seeded in a 12-well plate with a density 
of 50,000/well in 1.5ml complete DMEM. The next day the medium was exchanged 
with 1.5ml fresh DMEM containing 1.5μl polybrene (4μg/ml) (Sigma, UK) per well, 
and was left at room temperature for 5 minutes. Next, the medium was exchanged 
again for a mix of media/polybrene/virus with a final volume of 1.5ml/well. A serial 
dilution of the mixture was performed, where 20μl of the virus (day 4 or 5) were 
added in 2ml of DMEM/polybrene (first well) and then 500μl of this mix were added 
to the next well containing 1.5ml DMEM/polybrene, was mixed again, and again 
500μl were removed to be added to the next well, and so on. Four serial dilutions 
were performed in this way. One well served as negative control with no virus. The 
next day the medium was exchanged with fresh DMEM containing 10μg/ml 
doxycycline (Sigma, UK), to allow for expression of the genes under the inducible 
promoter, and the cells were incubated for another 48hours. The fifth day the cells 
were harvested by trypsinisation, and after centrifugation at 3000 rpm for 3 minutes 
were resuspended in 0.5ml PBS. This solution was then passed through a FACS 
analyser (BD Biosciences, USA), operated by Grazyna Galatowicz, where the 
percentage of the GFP positive cells was calculated. The viral titer was calculated by 
the formula: Viral titer = (proportion of GFP positive cells x number of seeded 
cells)/Volume of virus (in ml), where the volume of the virus that results in no more 
that 20% of positive cells is used. This method gives the number of viral transduction 
units (TU) per ml. All the experiments involving lentiviruses were conducted in a 
category II safety hood and room. 
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2.2.3 Protein methods 
2.2.3.1 SDS/PAGE electrophoresis 
Cell lysates were obtained using RIPA protein extraction buffer (50mM Tris-
HCl, pH 8.0, 150mM NaCl, 1% NP-40, 0.5% Sodium deoxycholate, 0.1% SDS, 
Sigma, UK), supplemented with “Complete EDTA-free” protease inhibitors (Roche) 
and phophatase inhibitors (Roche).  The amount of protein in each sample was 
determined using a BCA assay kit (Thermo scientific).  Laemmli sample buffer 
(62.5mM Tris, pH 6.8, 20% glycerol, 2% SDS, 0.01% bromophenol blue, Biorad, 
UK) was added to samples, which were heated to 95ºC for 5min in a heatblock for 
the purpose of protein denaturation. SDS-PAGE gels were poured, with a 
concentration of 10% acrylamide.  30µg of each protein sample was run out on the 
gel, alongside a molecular weight marker (All Blue Marker, Biorad, UK). 
Electrophoresis was performed with the Mini-Protean III system (Biorad), at 70V for 
the stacking gel and 100V for the running gel, in 1X running buffer.  Proteins were 
transferred onto nitrocellulose membranes (GE healthcare), using the BioRad wet 
transfer system at 25V for 20 min.  Protein integrity was checked using Ponceau 
stain (Sigma, UK).  Membranes were then blocked in PBS/0.1% Triton-X + 5% non-
fat milk for 30 minutes at room temperature, and incubated overnight with the 
primary antibody according to the manufacturer’s instructions.  Membranes were 
then washed thrice in PBS/0.1% Triton-X for ten minutes per wash, and incubated in 
a 1:2000 dilution of secondary HRP-conjugated antibody in the same buffer that the 
primary antibody was diluted in, for 1h at room temperature.  Membranes were 
washed thrice in PBS/0.1% Triton-X, for 10 minutes per wash.  ECL reagents (GE 
Healthcare) were applied for 5 minutes in dark conditions.  Membranes were then 
wrapped in cling film and exposed to autoradiography film (Kodak, UK). 
When needed, membranes were stripped in stripping buffer (Biorad, UK) for 15 
minutes, and were subsequently washed thrice in PBS/0.1% Triton-X for 10 minutes 
per wash. This was particular useful to detect levels of the protein of interest in 
relation to a loading control. All the antibodies used in the western blots are 
summarised in the table below: 
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Table 2.4: List of antibodies used in Western blotting  
Antibody Manufacturer  Host species Dilution 
Anti-OMD Abgent, #AP7474b Rabbit polyclonal 1:250 
Anti-OMD Abnova, #H00004958-M01 Mouse monoclonal 1:250 
Anti-PRELP Abnova, #H00005549-B01P Mouse polyclonal 1:250 
Anti-PRELP Abgent, #AP6665b Rabbit polyclonal 1:250 
Anti-β actin Cell Signaling, #3700 Mouse monoclonal 1:1000 
Anti-GFP Invitrogen, #A-11122 Rabbit polyclonal 1:1000 
Anti-myc Cell Signaling, #2276   Mouse monoclonal 1:1000 
Anti-p-Akt Cell Signaling, #4060 Rabbit polyclonal 1:2000 
Anti-p-ERK1/2 Cell Signaling, #4370 Rabbit polyclonal 1:2000 
Anti-pEGFR Cell Signaling, #3777 Rabbit polyclonal 1:1000 
Anti-EGFR Cell Signaling, #4267 Rabbit polyclonal 1:1000 
Anti-p-IGF-1R Cell Signaling, #3918 Rabbit polyclonal 1:1000 
Anti-IGF-1R Cell Signaling, #9750 Rabbit polyclonal 1:1000 
Mouse IgG HRP-
conjugated  
GE Healthcare, #NXA931 
Sheep 
1:2000 
Rabbit IgG HRP-
conjugated 
GE Healthcare, # NA934 Donkey 1:2000 
 
When needed, protein concentration was performed before running the sample 
through the SDS/PAGE gel. Briefly, 1 volume of 100% TCA stock solution was 
added to 4 volumes of protein sample and the mixture was incubated at 4°C for 10 
minutes. Centrifugation at 14K rpm for 15 minutes followed, after which the 
supernatant was removed leaving the protein pellet intact. The pellet was washed 
with 200μl of cold acetone and was centrifuged again under the same conditions. The 
last steps were repeated two more times and finally the protein pellet was dried by 
placing the tubes in 95°C heat block for 5-10 min to drive off the acetone. For SDS-
PAGE, add sample buffer (with or without β-ME) was added and after boiling the 
samples for 5 minutes at 95°C they were ready to load onto the polyacrylamide gel. 
Alternatively, Millipore amicon ultra-centrifugal filter units were occasional used 
(Millipore, #UFC503024), following the manufacturer’s’ instructions.  
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When needed commercially available recombinant human EGF ligand (R&D 
Systems, UK, #236-EG), IGF ligand (R&D Systems, UK, #291-G1) and TGF-β 
ligand (Sigma, UK,  #T7039) were used. 
2.2.3.2 Co-immunoprecipitation 
Co-immunoprecipitation was performed using the commercially available kit 
ProFound c-Myc Tag IP/Co-IP Kit (Thermo Scientific, UK, #23620) according to the 
manufacturer’s instructions. 
2.2.3.3 Immunocytochemistry (ICH) 
Cells were seeded at the desired density in 8-well slide-chambers (Tissue culture 
Lab Tek II, Thermo Scientific Nunc, UK) in 400μl medium. When cells had reached 
the confluency we wanted, they were washed twice with PBS and then fixed with the 
addition of 100μl 4% PFA (see table 2.1) or ice-cold methanol for 10 minutes at 
37°C or at -20°C respectively. The immunofluorescence procedure started with 
addition of 100μl per well of blocking buffer (table 2.1) for 15 minutes (200μl/well). 
Then, the primary antibody was diluted (at desired concentration) in blocking buffer 
and was added to the wells (200μl/well), incubating for 24 hours at 4°C, after which 
the wells were washed 3 times x 10 minutes with PBS. Secondary antibodies 
(fluorescent) were also diluted in blocking buffer and were added to the cells, which 
were then left to incubate for 1 hour in the dark at room temperature. The 8-well 
chamber slide was then washed 3x10 minutes with PBS and finally, after the plastic 
compartment forming the chambers was removed, a drop of mounting medium 
Prolong Gold anti-fade with DAPI (Invitrogen, UK) was added to all the cells, 
covered-up by a cover slip. All slides were stored at 4°C after mounting. Images 
were captured using a 3-filter fluorescent microscope (Carl Zeiss Axioskop 2 Plus) 
with the QICAM 12-bit Color Fast 1394 (Qimaging) and the Openlab 5.5.0 
(Improvision) software. Softwares used for imaging process were Adobe Photoshop 
CS6 (Adobe Systems Incorporated, Eastern Europe) and Image J.  
2.2.3.4 Immunofluorescence (IF) 
Frozen sections were thawed at room temperature and were post-fixed for 10 
minutes in 4% PFA. Following 3 times, 5 minutes rinses in 1X PBS the slides were 
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incubated for 1 hour in blocking buffer (see Table 2.1) and were subsequently 
incubated with primary antibody in blocking buffer  in the appropriate dilution 
overnight at 4°C. The next day slides were washed with 1x PBS 5 times for 8 
minutes each and were incubated with the secondary fluorescent antibody diluted in 
blocking buffer for 1h in the dark. Slides were washed again afterwards with 1x PBS 
5 times for 8 minutes each, and were mounted using Prolong Gold anti-fade with 
DAPI. All slides were stored at 4°C after mounting. Images were captured using a 3-
filter fluorescent microscope (Carl Zeiss Axioskop 2 Plus) with the QICAM 12-bit 
Color Fast 1394 (Qimaging) and the Openlab software or a confocal Zeiss LSM 710 
microscope and the LSM software. Softwares used for imaging process were Adobe 
Photoshop CS6 (Adobe Systems Incorporated, Eastern Europe) and Image J.  
Regarding paraffin sections, antigen retrieval was performed before staining. 
Sections were de-waxed with Histoclear (Fisher Scientific, UK) for 10 minutes, 
rehydrated in decreasing concentrations of ethanols (100%, 75%, 50%, 25% ethanol 
in ddH2O and ddH2O) for 2 minutes each. Slides were subjected to antigen retrieval 
using 10 mM citrate buffer (pH 6.0) or Tris-EDTA buffer (pH 9.0) (see Table 2.1) 
for 10 minutes in a microwave. Slides were allowed to cool for 40 minutes 
afterwards and were rinsed two times with PBS, after which they were immersed in 
blocking buffer for 1h, continuing the immunofluorescence protocol from here 
onwards. A list of all the antibodies used is presented below in Table 2.5. 
Table 2.5: List of antibodies used in ICH/IF throughout this project 
Antibody Manufacturer Host 
species 
Dilution Antigen retrieval 
AP2α DSHB, #3B5-s3 Mouse 1:10 - 
Pax6 Millipore, #AB2237 Rabbit 1:1000 Tris-EDTA, pH 9.0 
Islet-1 DSHB, #40.3A4-s Mouse 1:500 - 
Occludin Invitrogen, #33-1500 Mouse 1:100 - 
ZO-1 
Kindly provided by Prof. 
Karl Matter 
Rabbit 1:100 Tris-EDTA, pH 9.0 
ZO-2 
Kindly provided by Prof. 
Karl Matter 
Rabbit 1:100 Tris-EDTA, pH 9.0 
ZO-3 
Kindly provided by Prof. 
Karl Matter 
Rabbit 1:100 Tris-EDTA, pH 9.0 
Cingulin 
Kindly provided by Prof. 
Karl Matter 
Rabbit 1:100 - 
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β-catenin Cell Signaling, #8480 Rabbit 1:100 Citrate, pH 6.0 
E-cadherin Cell Signaling, #3195 Mouse 1:400 Citrate, pH 6.0 
Vimentin Cell Signaling, #5741 Rabbit 1:100 Citrate, pH 6.0 
Myc Cell Signaling, #2276 Mouse 1:1000 - 
GFP Invitrogen, #A-11122 Rabbit 1:100 - 
Uroplakin-III Fitzgerald, #10R-U103a Mouse 1:100 Tris-EDTA, pH 9.0 
CK18 Abcam, #ab668 Mouse 1:25 - 
Laminin Abcam, #ab11575 Rabbit 1:200 Tris-EDTA, pH 9.0 
CK5 Abcam, #ab75869 Rabbit 1:25 - 
HuC/HuD 
Molecular probes, #A-
16A11 
Mouse 1:200 - 
NeuN Millipore, #MAB377 Mouse 1:100 - 
β-III Tubulin, 
neuronal 
Abcam, #ab18207 Rabbit 1:500 - 
GFAP Millipore, #AB5804 Mouse 1:100 - 
Calbindin Sigma, #C2724 Rabbit 1:1500 - 
NG2 Millipore, #AB5320 Rabbit 1:100 - 
PECAM-1 Santa Cruz,  #sc-1506 Rabbit 1:100 - 
α-SMA Sigma, #C6198 Mouse 1:200 - 
Fibrinogen Abcam, #ab34269 Rabbit 1:100 Tris-EDTA, pH 9.0 
Ki-67 Abcam, #ab16667 Rabbit 1:100 Citrate, pH 6.0 
Mouse Alexa-488 
Molecular Probes, #A-
11001 
Goat 1:500 - 
Mouse Alexa-546 
Molecular Probes, #A-
11030 
Goat 1:500 - 
Rabbit Alexa-488 
Molecular Probes, #A-
11008 
Goat 1:500 - 
Rabbit Alexa-546 
Molecular Probes, #A-
11035 
Goat 1:500 - 
 
2.2.3.5 Preparation of samples for electron microscopy 
Cells or segments of bladders were fixed in 3%glutaraldehyde/1% 
paraformaldehyde in 0.08M sodium cacodylate-HCl buffer(pH7.4) and after washing 
with PBS were immersed in 1% aqueous osmium tetroxide solution for 2h at RT. 
Samples were washed again and dehydrated by single 15 min. incubations in 50%, 
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70%, 90% and 100% ethanol (3x), 2 x 20 minute changes of propylene oxide and left 
overnight in a 1:1 mixture of propylene oxide:araldite for the solution to infiltrate. 
Afterwards, samples were transferred to araldite resin, rotating for 6 hours to remove 
any traces of propylene oxide prior to embedding. Finally, they were embedded in 
fresh resin for 24h at 60°C. Semithin sections were cut using a Leica ultracut S 
microtome with diamond knife, were stained with a mixture of 1% borax and 1% 
toluidine blue in 50% ethanol at 60°C, and after drying were mounted in DPX. 
Ultrathin sections were cut at 60 or 100nm, stained with lead citrate and viewed in a 
JEOL 101 TEM operating at 100kV. Preparation of the samples (cells or tissues) was 
performed by Dr. Peter Munro, while I examined the samples using the TEM.  
2.2.4 Mice 
All animal procedures were performed in accordance to the Animals (Scientific 
procedures) Act 1986 of the UK Government. All mice were housed in compliance 
with the Home Office Code of Practice. Mice were kept in individually ventilated 
cages (IVCs), in a 12 hour light:dark cycle and were fed a complete pelleted mouse 
diet and with constant access to water. Mice on the C57BL/6J background were used 
in this study. 
2.2.4.1 Generation of Knock-out mice 
OMD and PRELP knock-out mice were generated by Takeda Pharmaceutical 
Company and wild type and heterozygote founders were imported to our animal 
facility. Briefly, OMD or PRELP flox ES cells were generated from C57BL/6J ES 
cells by homologous recombination with the targeting vectors which were 
constructed by insertion of the first LoxP sequence in upstream of exon 2, which 
contains the initiation codon on the OMD or PRELP locus, and insertion of the 
neomycin resistant unit, second LoxP sequence and LacZ unit in downstream of exon 
3. Cre expression plasmid was electroporated into the recombinant flox ES cells to 
generate ES cells harboring KO allele. The resulting KO ES cells were injected into 
ICR tetraploid blastocysts to generate chimeric male mice, and the chimeric mice 
were backcrossed to C57BL/6J females. Single knockout mice (OMDLacZ/LacZ and 
PRELPLacZ/LacZ) and their double knock-out (OMDLacZ/LacZPRELPLacZ/LacZ) were 
generated by cross breeding within the colony.  
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2.2.4.2 Collection of embryos, p0 new-borns and adult organs 
Embryonic litters were generated through timed matings, which involved the 
pairing of male and female mice overnight. The next morning, females were checked 
for vaginal plugs and the presence of a plug was designated as 0.5 dpc. If plugs were 
not seen the pair was left together one more night. Pregnant females were euthanised 
in a CO2 chamber at the relevant time point and embryos were dissected from the 
uterus and place in ice-cold PBS. Afterwards embryos were separated from the 
Reichert’s membrane and visceral yolk sac using fine forceps and were fixed either 
in 4% PFA or in 95% ethanol for β-galactosidase staining or skeletal preparation 
respectively. 
P0 new-borns were collected the day of birth after closely monitoring pregnant 
females. They were euthanized with an overdose of by intra-peritoneal (IP) injection 
of pentobarbitone. Afterwards heads and bodies were separated for better penetration 
of the solutions and were fixed for 3h in 4% PFA at 4°C. Organs were isolated from 
adult mice and were directly put in 4% PFA.  
2.2.4.3 Genotyping 
Genotyping of mice for the OMD and PRELP genes was performed by utilising 
gDNA isolated from ear punches as soon as mice were weaned at 3 weeks of age, 
with the help of Steven Bolsover. For embryos, tail snips (<0.5 cm) were used. 
Briefly, ear punches or tail snips were digested overnight at 55oC in 200 µl of the 
commercially available DirectPCR® reagent (Viagen Biotech, LA, USA) containing 
0.01% Proteinase K (Invitrogen, UK).  The following morning samples were 
incubated at 85oC for 15 minutes to deactivate proteinase K. The supernatant was 
collected from the digest mix after centrifugation for 1 min at 13 000 rpm at room 
temperature and was ready to be used as DNA template for the following PCR.  
For PRELP genotyping each PCR was prepared with a master mix of 12.5µl 2X 
Multiplex PCR master mix (Qiagen, UK), 5µl 5X Q solution (Qiagen, UK), 2µM 
primer mix (PRELP-A, PRELP-B, LacZ-A), 3µl of ultra-pure dH2O and 2.5μl of 
DNA template. PCR conditions used were as follows: 9 min denaturation at 95°C 
followed by 40 cycles of 94°C denaturation for 30 sec, 63°C annealing for 120 sec, 
72°C extension for 90 sec, and completed by 10 min final extension at 72°C.  For 
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OMD genotyping two separate master mixes were used with two different primer 
sets. Each PCR reaction contained 2.5µl 10X PCR buffer, 0.5µl of 10mM DNTP 
mixture, 0.75µl of 50mM MgCl2, 0.05µl of Taq polymerase, 1.25µl of 1% W (all the 
above are from Invitrogen, UK), 12.45 µl of ultra-pure dH2O, 2 µM of primer mix 
(one primer mix contained OMD-A & OMD-B, while other mix contained OMD-B 
& LacZ-5756F), and 5μl of DNA template. PCR conditions used were as follows: 
180 sec denaturation at 95°C followed by 35 cycles of 94°C denaturation for 30 sec, 
61°C annealing for 90 sec, 72°C extension for 90 sec, and completed by 10 min final 
extension at 72°C. PCR was carried out in a C1000 Thermocycler (Biorad, UK). 
The following primers were used for OMD and PRELP genotyping: 
OMD-A: 5’ GGGAATGCTTTGACTTTCTGAGTTA 3’ 
OMD-B2: 5’ TGGACCTTAAGTCTTACATCACAGG 3’ 
LacZ-5756F: 5’ CATTGTCAGACATGTATACCCCGTA 3’ 
PRELP-A: 5’ CACTGCAGGAAGAGTCATCTTTTCT 3’ 
PRELP-B: 5’ TACACTTTCTCCCAGCTTCTATTCC 3’ 
LacZ-A: 5’ CATTGTCAGACATGTATAGCCCGTA 3’ 
2.2.4.4 Tissue cryopreservation and sectioning 
For preparation of fresh-frozen sections, embryos or tissues from adult mice 
were fixed in 4% PFA for different amount of time depending on the size. Generally, 
embryos were fixed for 1h, p0 new-borns were fixed for 3h, eyes for 30 minutes, 
bladders for 1h and brains for 3h. After fixation tissues were washed in PBS, 
transferred to 30% sucrose (Sigma, UK) solution and were kept there until they sunk. 
Afterwards, they were embedded in optimal cutting temperature (OCT) compound 
(Tissue Tek, Sakura Finetek) and were snap frozen in a dry ice / isopentane bath. 
Frozen tissues were stored at -80°C until use.  Usually, 10-18 micron serial sections 
were cut with a Leica CM3050 cryostat, mounted onto Superfrost Plus® glass slides 
(Fisher Scientific, UK) and stored at -80°C until use. 
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2.2.4.5 Paraffin embedding of tissues and sectioning  
Embryos and tissues for paraffin sectioning (stored at 4% PFA) were processed 
in the Institute’s Pathology department using an automated machine (Leica ASP 
300S) and were then embedded in plastic moulds with warm wax, left on a cold plate 
to set.  5 μm sections were cut using a sledge microtome in the Pathology 
department. Wax sections were transferred in a 40°C water bath and then were 
mounted onto superfrost slides. Slides were dried off of the excess water and they 
were put on a hot plate (around 60°C) for 30 minutes, allowing the wax to flatten. 
Slides were then stored at room temperature until required for further analysis.   
2.2.4.6 X-gal staining of embryos and tissues 
X-gal staining was performed in whole embryos or tissues (for brain and bone), 
or using single cryo-sections of embryos and the other organs, including brain, 
bladder and eye. The procedure was the same in both cases, where after fixation the 
samples were washed with PBS containing 2mM MgCl2 two times for 20 minutes 
each, and were then incubated overnight in the X-gal staining solution (containing 1x 
X-gal, diluted from the stock solution) at 37°C in the dark. The following day 
samples were washed with dH2O and were either counterstained with eosin and 
mounted, or were directly mounted with DPX.  Images were captured using bright 
field microscopy (Carl Zeiss Axioskop 2 Plus) with the QICAM 12-bit Color Fast 
1394 (Qimaging) and the Openlab 5.5.0 (Improvision) software. Whole-mount 
stained embryos and organs were observed and photographed using a Leica M80 
stereoscope and an attached Leica PFC 420C camera. For expression analysis using 
cryo-sections, immunofluorescence was performed on top of the X-gal staining, 
where after washing the X-gal solution slides were directly immerged in the 
appropriate blocking buffer and the immunofluorescence protocol was then followed. 
Regarding bone analysis, the knee joints were whole-mount X-gal stained, as 
described above, and were then post-fixed for another 24h with 4% PFA. Next, they 
were immersed in 11% formic acid solution in water for 24h in order to decalcify 
them. After decalcification, they were washed extensively with dH2O and were 
prepared for paraffin sectioning, as described in the previous method. 
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Clearing of the X-gal stained embryos was performed in a series or gradual 
glycerol/KOH solutions. Briefly, after washing the X-gal solution embryos were 
post-fixed in 4% PFA for 24hours, after which they were transferred in 70% ethanol 
and stored. Clearing was later performed with a series of 20%, 50%, 80% and 100% 
(v/v) glycerol solutions containing 1% KOH (w/v). Each incubation step lasted 4-5 
days, during which time embryos were kept at 30°C. At the final step embryos were 
observed and photographed using a Leica stereoscope. 
2.2.4.7 Hematoxylin and eosin staining & special stains 
H+E staining was performed in an automated system in the Pathology 
department. Briefly, paraffin sections were de-waxed in xylene and passed through 2 
changes of absolute alcohol, 2 changes of 90% alcohol, 1 change of distilled water 
and were stained in Harris hematoxylin for 5 changes. Then, they were washed in 
running tap water for 1 change, differentiated in 1% acid alcohol for 1 change, 
washed again in tap water for 1 change, passed through 2 changes of 90% alcohol, 
counterstained with eosin for 3 changes, dehydrated in 95% alcohol for 2 changes 
and cleared with xylene. Finally they were mounted using DPX. Every change lasts 
around 10 seconds. Special stains, including von Kossa, alcian blue, congo red and 
MSB, were also performed in the Pathology department following department’s 
specific protocol for each stain. Methylene blue and basic fuchsin staining was 
performed on semi-thin sections of xenografted tumours, where drops of methylene 
blue (Table 2.1) covering the sections were left on the slide for 1 minute at 67°C, 
followed by wash with dH2O. Then slides were covered with basic fuchsin solution 
(Table 2.1) for 2 minutes at room temperature. Finally, they were rinsed with dH2O 
and mounted with DPX. 
2.2.4.8 Mouse urine testing 
Mouse urine was tested for blood and protein using Fisherbrand™ Urine 
Reagent Strips (Fisher Scientific, #23-111-262). Drops of urine were loaded onto the 
appropriate pads on the strips and measurements were calculated within one minute, 
depending on the colouration of each pad. 
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2.2.4.9 Gait ink test 
The gait test was performed using the standard ink method (Girirajan et al, 
2008). The front and hind paws of the mice were dipped in black non-toxic stain and 
the mice were then left to walk through a long corridor on a piece of white paper, 
leaving a trail of the walking pattern. Every mouse was tested thrice. The papers 
were then scanned to a computer and the different parameters were quantified using 
Image J. 
2.2.4.10 Skeletal staining 
Skeletal staining was performed on E15.5 and E17.5 embryos. In both cases 
embryos were collected as described and were fixed in 95% ethanol for four days. 
After fixation all the visceral organs were removed and each embryo was placed in a 
glass vial. Afterwards they were stained with the alcian blue solution (see Table 2.1) 
rotating for 3 days at room temperature, followed by consecutive washes of 70%, 
50%,25% ethanol and lastly water (around 4 hours each), over a period of two days. 
They were then stained with the alizarin red staining solution (see Table 2.1) for 
another 3 days rotating at room temperature, and were washed in dH2O+1% KOH 
two times, for 3 hours each. Next, they were passed through a gradient of glycerol 
and 1% KOH (20%, 50%, 80% glycerol solutions containing 1% KOH) leading to 
clearing of the embryos. Each incubation step lasted 2-3 days, during which time 
embryos were kept at room temperature, rotating. Finally they were transferred to 
100% glycerol, photographed using a Leica stereoscope, and were stored in this 
solution.  
2.2.4.11 Piximus and micro-CT measurements 
Both Piximus and micro-CT experiments were performed in the UCL-Anatomy 
Building, in Professor Tim Arnet’s laboratory. The Lunar PIXImus Densitometer 
(GE Medical Systems) was used according to manufacturer’s instructions. For the 
micro-CT the SkyScan1172 (Bruker, Belgium) X-ray scanner was used, again 
according to manufacturer’s instructions. Embryos were fixed in 70% ethanol prior 
to scanning. The NRecon v1.6 software (Bruker) was used for image reconstruction, 
the CTan v1.9 (Bruker) was used for data analysis and the μCTVol v2.0 (Bruker) for 
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3D model visualisation. The scanner was set at voltage of 90kVp and a current of 
112μA, while the scanning resolution was set at 8.6 μm.  
2.2.5 Statistical analysis 
Statistical analysis and graph compilation was performed using the GraphPad 
Prism5 software (GraphPad Software, Inc, USA). Significance of differences was 
determined by unpaired two-tailed Student’s t-test unless specified otherwise. P 
values less than 0.05 were considered significant.   
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Chapter 3  
 
OMD and PRELP suppress bladder tumour 
growth in vitro and in vivo 
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3.1 Introduction 
Bladder cancer is the ninth most common malignant cancer diagnosed 
worldwide (Lu et al., 2012). About 90% of the diagnosed cases are urothelial cell 
carcinomas that arise from bladder epithelial cells, while the remaining are squamous 
cells carcinomas and adenocarcinomas. At diagnosis, 80% of the patients present 
with low-grade non-muscle invasive papillary carcinoma, which rarely invades and 
metastasizes (classified as superficial Ta/T1 lesions), while 20% have muscle-
invasive tumours (classified as T2 or higher T3/T4 lesions) (El Behi et al., 2013). Of 
note is the marked difference in survival rates between the two cancer types, 
suggesting two distinct underlying genetic profiles. Non-invasive papillomas are 
mainly characterised by alterations in the FGFR3 gene and chromosome 9, 
accompanied by low frequency of TP53 alterations, whilst muscle-invasive tumours 
are marked by high frequency alterations in genes involved in the p53 and Rb 
pathways (Luis et al., 2007).  
As described extensively in the main introduction, SLRPs, as components of the 
ECM and the tumour microenvironment, can modulate cell survival, proliferation 
and migration, and are thereby involved in the biology of various types of cancer. 
Although there are not many findings regarding SLRPs and bladder cancer, there 
have been some studies linking so far only decorin and biglycan with urothelial 
malignancies. More specifically, decorin mRNA levels were found to be markedly 
decreased in primary bladder cancers compared to normal counterparts in two 
independent microarray datasets (Dyrskjot et al., 2004; Morrione et al., 2013; 
Sanchez-Carbayo et al., 2006), while decorin was also shown to negatively regulate 
IGF-IR signalling in urothelial carcinoma-derived cells, inhibiting their migration 
and invasion (Iozzo et al., 2011). In addition, Niedworok et al. recently showed that 
overexpression of biglycan resulted in inhibition of bladder tumour growth both in 
vitro and in vivo, whilst high biglycan expression in human tumour biopsies was 
associated with favourable prognosis (Niedworok et al., 2013).  
Referring again to the genetic backgrounds of bladder cancer, one important 
thing that needs to be mentioned here, in relation to the current project, is the finding 
that loss of heterozygosity (LOH) on chromosome 9 is the most frequent genetic 
alteration identified in bladder tumours, with around 60-70% of the tumours showing 
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LOH of at least one locus on either arm of the chromosome (Keen and Knowles, 
1994; Simoneau et al., 1996; Stadler et al., 1994). In addition, Hirao et al. showed 
that allelic loss at specifically the 9q arm was detected in 74.5% of newly diagnosed 
bladder cancer cases and that this allele loss was associated with invasive forms of 
the disease, thereby suggesting the existence of a tumour suppressor gene at this loci, 
which adding up to p53 alterations, may be important in the development of a more 
aggressive form of the disease (Hirao et al., 2005). While several LOH studies 
managed to localize some candidate tumour suppressor loci on the 9p arm, including 
the MTS1/MTS2 genes, the location of putative TSGs on the q arm is less certain 
with most deletions being between 9q13-21.1 and 9q33-34.1 (Cairns et al., 1994; 
Czerniak et al., 1999; Habuchi et al., 1995; Linnenbach et al., 1993). However, 
because there is considerable variation in the specific regions of loss between 
different patients, it was suggested that even if 9q harbours a bladder cancer 
gatekeeper gene, it is unlikely that the gene will be identified through LOH analysis 
alone (van Tilborg et al., 2002). Of note is that Simoneau et al. identified another 
region, at 9q22.3, that was deleted in 35% of informative cases and was the unique 
LOH in some of the tumours screened (Simoneau et al., 1999). Our gene of interest, 
OMD, is located as well in the 9q22.3 region and the finding that this region might 
contain potent tumour suppressor genes further enhances our hypothesis that 
osteomodulin is involved in cancer acting as a TSG. 
3.1.1 Current findings about OMD and PRELP 
Concerning OMD and PRELP, our collaborators Dr. Hamamoto and Dr. Tamura 
analysed microarray data comparing gene expression in tumours and normal tissue 
for many different types of cancer, and found that OMD and PRELP expression were 
both reduced in bladder cancer to less than a tenth of their normal level. Further 
confirmation of the downregulation was confirmed by RT-PCR using human 
urological tumour biopsies, while further reductions in expression were seen in high 
stage and grade bladder tumours, and in bladder tumours that metastasized. Briefly, 
126 bladder tumours and 31 normal bladder samples were studied, and on average 
OMD and PRELP expression were reduced by 90% (Fig.1.5). More information and 
detailed results of this analysis can be found in Appendix A. Thus, we obtained very 
strong indications that OMD and PRELP are indeed involved in cancer initiation and 
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progression, and that they may represent potential tumour-suppressor genes, 
functioning in a similar way to other SLRPs that were discussed previously. 
 The initial analysis to prove the above hypothesis was conducted by previous 
lab member Dr. Julie Watson, who used the EJ28 human bladder cancer line as a 
model of study. This cell line was chosen as it was one of the cell lines that Dr. 
Hamamoto had found expressed OMD and PRELP at a very low level and it also 
gave the highest transfection efficiency. Therefore, it was decided to perform a gain-
of-function analysis by creating stable transfected EJ28 cells to overexpress OMD or 
PRELP and test whether this would revert the cancer cells to a more normal, 
untransformed phenotype. Indeed, Dr. Watson found that OMD and PRELP 
overexpression inhibited cell cycle progression and proliferation, while it enhanced 
apoptosis and drug-mediated apoptosis. Also, cellular morphology was affected in 
OMD overexpressing cells showing unique round shapes with many pin-like 
extensions, which are significantly different from the flattened fibroblast-like shape 
of control EJ28 cells, while PRELP overexpression resulted in elongated cells with 
stress fibre like filamentous extensions protruding along the substrate. Furthermore, 
Dr. Watson conducted a series of western blotting experiments to determine how 
expression of proximal cell cycle regulators and signalling molecules, that were 
known to be involved in bladder carcinogenesis and/or SLRP activity, are affected in 
OMD and PRELP transfected cells (presented in detail in Section 3.2.6.2). Finally, 
Dr. Hamamoto performed mRNA expression profiling using microarrays after 
overexpression or suppression of OMD/PRELP and with a subsequent pathway 
analysis identified the main pathways affected, which included the p53, tight 
junction, adherens junction and Wnt signalling pathways (Appendix A). 
Having all these initial data, I took over this project from this point and further 
wanted to assess some more in vitro cancer hallmark properties of the transfected 
cells, like anchorage-independent growth and migration. In addition, together with 
Dr. Tamura Toshiya, a collaborator from Takeda Pharmaceutical Company, we 
wanted to assess the effect of OMD and PRELP in vivo using the xenograft mouse 
model and also further analyse the mechanisms of actions involved. Moreover, a 
different system of overexpression was also explored. 
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3.2 Results 
The initial experiments were performed with the cell lines that Dr. Watson had 
constructed via antibiotic selection of stable transfectants and single clonal growth by 
limiting dilution. Also, she used tagged versions of the OMD and PRELP cDNAs, 
where 6 myc tags and a unique sequence between the 5th and 6th tag were placed at 
the C-terminus of the open reading frames for each cDNA. The addition of the tag 
provided an easier way for protein detection through western blotting, as so far no 
working antibodies against the OMD or PRELP proteins have been identified. So, for 
the experiments presented in this chapter, 6 different cell types were used that 
included: 
• EJ28-OMD, EJ28 cells transfected to overexpress the human OMD cDNA and 
an eGFP marker gene 
• EJ28-PRELP, EJ28 cells transfected to overexpress the human PRELP cDNA 
and an eGFP marker gene 
• EJ28-mtOMD, EJ28 cells transfected to overexpress a myc-tagged version of 
the human OMD cDNA and an eGFP marker gene  
• EJ28-mtPRELP, EJ28 cells transfected to overexpress a myc-tagged version of 
the human PRELP cDNA and an eGFP marker gene  
• EJ28-vector, EJ28 cells transfected with the vector expressing only the marker  
eGFP gene, serving as control 
• EJ28-WT, wild type non-transfected EJ28 cells 
We should mention here that Dr. Watson had isolated and tested two different 
clones of all the above transfected cell lines, in order to confirm that the obtained 
results were due to OMD/PRELP overexpression and not because of any functional 
cell changes arising from the insertion site of the plasmids. Indeed, the results she 
acquired in her in vitro assays were very similar between the two different clones of 
each OMD/PRELP/mtOMD/mtPRELP- and vector-transfectants, thereby confirming 
the validity of these results. In most of the in vitro assays presented here we also used 
both clones of the transfected cell lines, which always gave comparable outcomes, 
while occasionally only one clone was used due to time and material limitations. For 
presentation purposes (and since the different clones resulted in the same outcome) 
our results are displayed here as one transfected cell line named as EJ28-OMD, 
EJ28-PRELP etc. 
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The overexpression of OMD and PRELP in the EJ28 stable transfectants was 
confirmed by RT-PCR at RNA level and by western blotting at protein level for the 
myc-tagged constructs, by Dr. Watson. I also reconfirmed the overexpression in the 
above cell lines by RT-PCR, where the expression difference was variable amongst 
the different cell lines from 5 to almost 15 times higher than the EJ28-WT cells (Fig. 
3.1). The same result was obtained when comparing the different transfectants with 
the EJ28-vector control cells. 
  
 
 
 
 
 
 
Figure 3.1: Confirmation of overexpression of untagged and myc-tagged OMD and PRELP 
in EJ28 cells. For each cell line, all of which were seeded in 6-well plates, RNA was collected 
from 3 different wells. Technical triplicates of each biological sample were tested in qRT-PCR. 
Analysis was performed using the Pfaffle method and values were normalised to endogenous 
GAPDH expression levels. Results are presented as fold-difference compared to EJ28-WT cells 
which is set to 1. Error bars indicate standard deviation (SD). 
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3.2.1 OMD and PRELP overexpression inhibit anchorage-independent growth  
The anchorage-independent growth assay, also called the soft agar assay, is the 
gold standard in vitro method to assay tumor–forming ability. It assesses the ability 
of cells to grow suspended in soft agar, without attachment to a substrate or to other 
cells. It has long been known that transformed cells are typically capable of 
anchorage-independent growth, whilst normal cells are not (Stoker et al., 1968).  
 
To test whether OMD or PRELP overexpression affected anchorage-
independent growth, 5.000 cells of each stably transfected EJ28-
OMD/PRELP/mtOMD/mtPRELP/vector control and EJ28 WT cell lines were seeded 
in triplicates into a mixture of growth medium and semi-solid agar in 6-well plates, 
and after 3 to 4 weeks formation of colonies was assessed. As shown in Figure 3.2 
A&B colonies formed from the WT and vector-only cells with a mean number of 
783 ± 46.19 and 814 ± 35.48 colonies per 962mm2 surface area respectively. In 
contrast, anchorage independent growth was completely abolished in the OMD 
transfected cell line (mean number of colonies was 1.12 ± 0.74), while there was a 
significant reduction in the colony number of the other transfected lines, i.e. 461.0 ± 
24.58 for PRELP, 309.5 ± 26.51 for mtOMD and 426.0 ± 33.96 for mtPRELP 
(p<0.05 for all transfected cell lines against WT or vector control). These data are 
collected from three individual experiments, demonstrating complete and consistent 
inhibition of colony formation from the OMD overexpressing cells, and to a lesser 
extent from the other lines tested (which could be attributed to the different levels of 
cDNA expression, i.e. OMD cells had a 15-fold increased expression compared the 
WT versus the mtOMD cells that showed only a 5-fold difference), indicating an 
anti-tumour effect of our genes. 
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3.2.2 OMD and PRELP overexpression alters the 3D morphology of EJ28 cells 
cultured in an ECM-mimicking microenvironment 
 Apart from providing structural support, the extracellular matrix can regulate 
the dynamic behaviour of cells by affecting cell-cell communication, cell-cell or cell-
Figure 3.2: Anchorage independent growth assay of EJ28 cells. (A) Representative images 
of colonies that grew in soft agar. OMD completely abolished, while PRELP, mtOMD and 
mtPRELP strongly inhibited formation of colonies. The experiment was performed thrice and 
each cell line was seeded in triplicate wells. (B) Quantification of formed colonies. Multiple t-
tests were carried out comparing means from every transfected cell line to the WT or vector-
only control, *** equals p<0.0001, against WT or Vector control. Error bars indicate standard 
error of the mean (SEM).  
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matrix adhesion and also cell differentiation, therefore being a major component of 
normal homeostasis. Thus, in vitro 3D cultures of cells in an ECM-mimicking 
microenvironment can allow phenotypic discrimination between malignant and non-
malignant cells, where the former form proliferative and expanding colonies while 
the latter remain as circular, partly-grown colonies. This experiment was performed 
with the help of Dr. Tamura, and we used Matrigel as a biologically active basement 
membrane matrix, where EJ28-WT, vector-only, OMD and PRELP-transfected cells 
were allowed to grow for seven days. On the last day 3D morphogenesis was 
assessed by observation under light microscopy. The experiment was performed 
thrice (in duplicates), and a representative image of each cell type is presented in 
Figure 3.3, demonstrating expanding colonies with spike-like formations in the wild 
type and vector-only transfected cells, whereas OMD and PRELP overexpressing 
cells had smaller and rounded colonies, indicating that the two genes can reduce the 
invasive phenotype of the EJ28 cells and can alter the morphology of the cells in 3D 
Matrigel culture. 
3.2.3 OMD overexpression inhibits invasiveness of the EJ28 cell line 
Migration and invasion of cancer cells into the basement membrane and the 
adjacent ECM is a key step in cancer metastasis, and examining the invading 
potential of cells in vitro is of major interest in cancer studies. The invasiveness of 
the EJ28 cell line was assessed by the Matrigel invasion assay, where cells are plated 
on a Matrigel-coated porous membrane and invasion through the matrix to the 
opposite site of the pores (towards a chemoattractant) is determined by cell staining 
and subsequent quantification (as described in Section 2.2.2.5). This experiment was 
also performed with the help of Dr. Tamura. Since the OMD transfected cells had 
consistently a stronger phenotype in all the assays tested compared to the other cell 
lines, and due to time and material limitations only the EJ28-WT and EJ28-OMD 
overexpressing cells were included in this experiment. Presented in Figure 3.4A, are 
representative images of the bottom side of the porous membrane, where cells, 
stained with Hemacolor hematoxylin, were cultured in 0.1% FBS, and it is visible 
that only few cells invade through the matrix and the pores (left panels). Addition of 
chemoattracant-containing medium (10% FBS) resulted in invasion of the cells 
through the pores. Comparison between the WT and OMD overexpressing cells 
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reveals a much higher invading cell population in the control sample, indicating a 
decrease in the invasiveness potential due to the OMD gene overexpression. 
Quantification of the invaded cells was performed by solubilising the hematoxylin 
dye and measuring the absorbance index, which was subsequently converted to 
relative invasiveness measured as percentage of the control (0.1% FBS) (Fig. 3.4B). 
OMD overexpressing cells had a significantly lower invasion ratio compared to EJ28 
WT cells (p=0.0007), suggesting that OMD has the ability to inhibit matrix cell 
invasion, further confirming its potential as a tumour-supressing gene. 
 Figure 3.3: 3D morphogenesis of EJ28 cells in Matrigel. 10000 cells were mixed with matrigel and 
medium containing 10% FBS and were seeded onto 8-well multi chambers pre-coated with matrigel.  
After 7 days, 3D morphogenesis was assessed by light microscopy. The experiment was performed 
thrice in duplicates, with the help of Dr. Tamura. EJ28-WT and vector-only transfected cells show 
expanding colonies with spike-like formations, demonstrating good ability of the cells to proliferate 
and migrate in an ECM-mimicking microenvironment. In contrast, OMD and PRELP overexpression 
resulted in smaller and rounded colonies, therefore inhibiting the invasive phenotype of cancer cells. 
Scale bar represents 100μm for all images. 
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 Figure 3.4: 2D Matrigel invasion assay of EJ28 cells. Cells were seeded on matrigel-coated porous 
membranes and invasion through the pores was assessed after the addition of 10% FBS as 
chemoattracant. Cells were visualised with Hemacolor hematoxylin. The experiment was performed 
once in triplicates, again with the help of Dr. Tamura (A) Images of the bottom side of the membrane 
in 0.1% FBS (left panel) and 10% FBS (right panel), showing decreased invasion ability of the OMD 
transfected cells through the matrigel covered pores. (B) Quantification of the invaded cells was 
calculated through hematoxylin absorbance and is presented as relative invasiveness, measured as 
percentage of the control (0.1% FBS). Student’s t-test was performed, * equals p<0.05. Error bars 
refer to SD. 
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3.2.4 Secretion of OMD and PRELP inhibits normal cell growth under co-
culture conditions 
As extracellular matrix proteins, OMD and PRELP are expected to be secreted 
from the expressing cells into the culture medium. Therefore, together with Dr. 
Tamura we performed a modified transwell assay to assess the effect of the secreted 
proteins on neighbouring cells. In this assay wild type EJ28 cells are seeded on the 
bottom of 6-well plates and are cultured together with a transwell insert, on the 
surface of which, EJ28-WT or OMD/PRELP/mtOMD/mtPRELP transfected cells are 
seeded. The pores of the membrane are 0.4 μm allowing diffusion of soluble particles 
in the lower compartment while preventing cell migration or cell-cell contact.  A 
schematic illustration of the co-culture assay is shown in Figure 3.5B, where Cell B 
always represents EJ28 wild type cells, and Cell A varies between WT and the four 
different transfected cell lines. In Figure 3.5A representative pictures of Cell B 
(EJ28-WT cells) are shown for each different condition (co-culture with the various 
transfected lines). An empty transwell insert served as a negative control, and as 
shown in panel A, EJ28 cells co-cultured with either no-cells or EJ28-WT had good 
survival index and were confluent after 72h in this experimental setup. On the 
contrary, wells that had transwell inserts with either OMD or mtOMD cells were 
characterized by increased detachment and cell death of the EJ28 WT cells. The 
same effect was observed when mtPRELP cells were seeded in the transwell, while 
the PRELP overexpressing line had a moderate impact on the wild type cells (Fig. 
3.5A). Cell viability of the bottom EJ28-WT cells (Cell B) per condition was 
evaluated with trypan-blue staining and subsequent counting of the living cells after 
72h of co-culture, while Cell A remained confluent until the end of the experiment in 
all conditions. Co-culture with OMD or mtOMD cell lines caused a significant 
reduction on the EJ28-WT cell viability of around 80% compared to the control 
conditions (p=0.0033 and p=0.0057 respectively), data that were consistent between 
two different repeats. The experiment was performed only once for the PRELP and 
mtPRELP cell lines and thus, although presented here, these data are considered 
inconclusive. Overall, even though these are preliminary results, this experimental 
setup demonstrates that secreted OMD (and maybe PRELP) protein, has the ability to 
suppress, and additionally reduce, the viability of EJ28 cancer cells.  
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 Figure 3.5: Transwell co-culture assay of EJ28 cells. The effect of secreted 
OMD/mtOMD/PRELP/mtPRELP proteins on the viability of EJ28-WT cells is assessed, where WT cells are 
seeded in the bottom of 6-well plates and the different transfectants are seeded in a porous insert and placed on 
top of the wells. Diffusion of soluble particles is allowed through the pores but not cell migration. A schematic 
illustration of the assay is presented in (B), while in (A) brightfield images of the bottom EJ28-WT cells after 
72hours of co-culture with the different transfected cells are shown, demonstrating a strong reduction in cell 
viability in the presence of OMD, mtOMD, PRELP and mtPRELP overexpressing cells. Scale bar represents 
50μm for all images. (C) Quantification of the bottom EJ28-WT cell viability under the four different 
transfectants, presented as percentage of the viable cells co-cultured with WT cells on the transwell insert. 
Student’s t-test was performed. ** equals p<0.01. Error bars refer to SD. Co-culture with PRELP and 
mtPRELP transfectants was conducted only once and therefore no statistical analysis was carried out for these 
samples. 
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3.2.5 OMD and PRELP overexpression inhibits tumour development in the 
mouse xenograft model  
Numerous murine models have been developed to study human cancer with the 
most widely used model being the human tumor xenograft. In this model, human 
tumour cells are transplanted, either under the skin or into the organ type in which 
the tumour originated, into immunocompromised or immunodeficient mice (e.g. the 
xenograft will be readily accepted by athymic nude mice or severely compromised 
immunodeficient-SCID mice) (Morton and Houghton, 2007). Depending upon the 
number of cells injected, or the size of the tumour transplanted, the tumour will 
develop over 1–8 weeks (or in some instances 1–4 months, or longer), and the 
response to candidate therapeutic agents can be studied in vivo. 
In order to assess the effect of OMD and PRELP in in vivo tumour progression, 
mouse xenografts were performed using the EJ28 OMD/PRELP transfected cell 
lines.  During this experiment 6 mice were used. Every mouse was injected 
subcutaneously in the flank with wild type cells in the left side, while 3 mice were 
injected with OMD-overexpressing cells and the other 3 mice with the PRELP-
overexpressing cells in the right side, to compare tumour progression for a period of 
42 days. 
In Figure 3.6 A and B the tumour volumes as well as the relative tumour growth 
of the three different cell types are presented over the 42-day period. Wild type EJ28 
cells grew tumours of around 1300 mm3, whereas EJ28-OMD cells completely failed 
to support tumour growth, with volumes of around 100mm3 from the first up to 
200mm3 till the last measurement (Fig. 3.21A, Day 42, p=0.0006, Day35 p<0.0001, 
Day 26 p=0.0003, Day 21 p=0.0209). PRELP overexpressing cells did not show such 
dramatic reduction in tumour growth, but did cause a slower increase of the tumour 
volume in the last two time points. The effect is more pronounced if we compare the 
relative tumour growth, as demonstrated in Figure 4.6B, where EJ28-PRELP cells 
grew statistically slower compared to the wild type cell lines during the last 10 days 
of the experiment (Day 42, p=0.0265, Day35 p<0.0338).  
Overall, the in vitro anti-tumor effects of OMD (and to a lesser extent of 
PRELP) on cancer progression were confirmed as well in in vivo xenograft 
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experiments, demonstrating the potential of the two molecules as anti-cancer 
effectors.  
 
 
 
Figure 3.6: OMD inhibits tumour formation and PRELP supresses tumour growth in the mouse 
EJ28 xenograft model. 5×106 cells of each EJ28-WT/OMD/PRELP cell line were injected in the right 
and left flanks of nude mice. Two weeks after inoculation measurement of the forming tumours started. 
(A) Graph representing the average tumour volume over a period of 42 days, including 6 tumours for 
the WT cells and three tumours for the OMD/PRELP overexpressing cells. (B) Relative tumour growth 
presented as percentage of the first measurement. Student’s t-test was carried out at each time point. * 
equals p<0.05, ** p<0.01, *** p< 0.001, versus WT. Error bars refer to SD. Injections of the EJ28 cells  
in the mice were performed  with the help of Dr. Tamura. 
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3.2.6 Mechanisms of action of OMD and PRELP 
Having already established some of the anti-tumor properties of the OMD and 
PRELP, we wanted to further examine the mechanisms through which these two 
genes/proteins operate. As explained in the introduction of this chapter, initial 
microarray analysis was performed on cell lines over-expressing or under-expressing 
the OMD and PRELP genes, and through KEGG pathway analysis the affected 
signalling cascades were identified. One of these is the tight junction (TJ) pathway (p 
values of 0.0146 and 0.0412 for OMD and PRELP respectively, data provided by Dr. 
Hamamoto), while others include the p53, the adherens junction and the Wnt 
signalling pathways (see Appendix A). Also, Dr. Margaret Dellett, a previous post-
doc in the Ohnuma lab, analysed the microarray data using the Ingenuity Pathway 
Analysis (IPA) software, and generated illustrations of the affected pathways 
showing which molecules are negatively or positively regulated from alterations in 
the OMD or PRELP gene expressions. The tight junction pathway under OMD 
overexpression is displayed in Figure 3.7, showing that some TJ components such as 
ZO-1 and Nectin are transcriptionally activated by OMD overexpression, suggesting 
that OMD or PRELP have the ability to positively regulate these junctions. Hence, 
tight junction formation was further assessed in the stably transfected EJ28 cell lines. 
In addition, since Wnt is also another one of the affected pathways, together with Dr. 
Tamura we analysed some of the pathway’s components in order to establish 
possible mechanisms of action. 
3.2.6.1 OMD and PRELP increase tight junction formation 
Tight junction formation was assessed in the OMD and PRELP over-expressing 
cell lines through immunofluorescence using several different antibodies against TJ 
components. Firstly, occludin staining was performed, and we observed a substantial 
increase of the cell surface, cell-cell contact staining in the OMD and PRELP cells 
compared to the controls (either WT or vector transfected). This was also 
accompanied by a decrease in the nuclear/cytosolic signal, as in the OMD/PRELP 
expressing cells the cytosol and nucleus often appeared dark, in contrast to the 
uniform staining seen in the control cells. More specifically, only around 40% of 
total cell-cell contact surface was positive for occludin in the EJ28 vector-control 
cells, while this figure increased to almost 90% for the OMD cells and 60% for 
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PRELP (p<0.0001 for both) (Fig. 3.8). Continuing, we conducted staining using 
antibodies against ZO-1 and cingulin, both major participants in the TJ protein 
complex, where we noticed the same outcome (Fig. 3.9 & 3.10). For both markers, 
the cell membrane signal (indicative of TJ formation between cells) was significantly 
increased in the OMD overexpressing cells (~90% of total cell-cell surface), and to a 
lesser extent in the PRELP ones (60-65%), against the control samples (30-40%, 
p<0.0001 for all comparisons), indicating that OMD and PRELP have the ability to 
increase tight junction formation. 
Figure 3.7: Tight junction pathway regulated by OMD overexpression. The schematic illustration 
of the pathway was generated using the Ingenuity Pathway Analysis (IPA) software. Red colour 
indicates transcription upregulation, while green colour indicates downregulation of the component. 
Image was kindly provided by Dr. Margaret Dellett.  
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Figure 3.8: Occludin staining of EJ28 cells. OMD and PRELP overexpression results in increased cell-cell 
contact staining.  Cells were cultured in 8-well multi chamber glass slides (in duplicates) and after reaching 
100% confluency they were cultured for another 7 days to allow for junctions to be formed. On the 7th day they 
were fixed with ice-cold methanol and stained. Experiment was performed twice. In panel (A) images of vector-
only, OMD and PRELP transfected EJ28 cells are shown, where (i), (iii) & (v) represent staining with an occludin 
primary antibody, visualised with an alexa-488 (green) secondary antibody. (ii), (iv) & (vi) are the same images 
with the addition of 4',6-diamidino-2-phenylindole (DAPI)-blue to visualize the nuclei. Scale bar represents 
100μm for all images. (B) Percentage of occludin cell surface staining in each cell line tested. Quantification was 
performed in three random areas under 20x magnification, using the Image J software, where the length of 
occludin-positive cell–cell contacts was measured by drawing lines following the staining pattern. Staining inside 
the cells or unclear staining between neighbouring cells was ignored.    Data are presented as mean ± SEM. 
Student’s t-test was carried out. *** equals p<0.001 versus vector-control. 
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 Figure 3.9: ZO-1 staining of EJ28 cells. OMD and PRELP overexpression results in increased cell-cell 
contact staining. Cells were cultured in 8-well multi chambers on a glass slide (duplicates) and after reaching 
100% confluency they were cultured for another 7 days to allow for efficient tight junction formation. On the 7th 
day they were fixed with ice-cold methanol and stained. The experiment was performed twice. In panel (A) 
images of vector-only, OMD and PRELP transfected EJ28 cells are shown, where (i), (iii) & (v) represent staining 
with a rabbit ZO-1 primary antibody, visualised with an anti-rabbit alexa-488 (green) secondary antibody. 
Increased staining in cell-cell surfaces can be observed in the OMD and PRELP overexpressing cells. (ii), (iv) & 
(vi) are the same images with the addition of DAPI (blue) to visualize the nuclei. Scale bar represents 100μm for 
all images. (B) Percentage of ZO-1 staining per cell surface in each cell line tested. Quantification was performed 
in three random areas under 20x magnification, using the Image J software, where similarly to before, the length 
of ZO-1-positive cell–cell contacts was measured by drawing lines following the staining pattern. Staining inside 
the cells or unclear staining between neighbouring cells was ignored.   Data are presented as mean ± SEM. 
Student’s t-test was carried out. *** equals p<0.001 versus vector-control. 
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 Figure 3.10: Cingulin staining of EJ28 cells. OMD and PRELP overexpression results in increased cell-
cell contact staining. Cells were cultured in 8-well multi chambers on a glass slide (in duplicates) and after 
reaching 100% confluency they were cultured for another 7 days to allow tight junction formation. On the 7th 
day they were fixed with ice-cold methanol and stained. Experiment was performed twice. In panel (A) images 
of vector-only, OMD and PRELP transfected EJ28 cells are shown, where (i), (iii) & (v) represent staining with 
a rabbit primary antibody against cingulin, visualised with an anti-rabbit alexa-488 (green) secondary antibody. 
In OMD and PRELP transfected cells a very strong increase of cingulin staining localised in cell-cell 
membranes can be observed. (ii), (iv) & (vi) are the same images with the addition of DAPI (blue) to visualize 
the nuclei. Scale bar represents 100μm for all images. (B) Percentage of cingulin staining per cell surface in 
each cell line tested. Quantification was performed in three random areas under 20x magnification, using the 
Image J software, where, as previously, the length of cingulin-positive cell–cell contacts was measured by 
drawing lines following the staining pattern. Staining inside the cells or unclear staining between neighbouring 
cells was ignored.  Data are presented as mean ± SEM. Student’s t-test was carried out. *** equals p<0.001 
versus vector-control. 
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In order to further confirm the formation of tight junctions, the OMD 
overexpressing cells (having the strongest effect) and control EJ28 wild type cells 
were examined by electron microscopy. Shown in Figure 3.11 are representative EM 
images of both samples, demonstrating  tight junctions between neighbouring cells in 
the OMD overexpressing cell line (arrows). On the other hand, similar TJ complexes 
were not seen that often in the WT cells even though adjacent cells were in close 
proximity. However, in order to have a more conclusive result regarding functional 
tight junction formation in these cells, a more careful analysis needs to be conducted 
including more samples, quantification of the observed tight junctions and maybe 
gold-labelled staining of TJ components.    
 
Next, together with Dr. Tamura, we examined the expression of β-catenin, E-
cadherin and vimentin, which provide information related to adherens junction, the 
canonical Wnt pathway, and epithelial to mesenchymal transition (EMT). Figure 
3.12A demonstrates an increase of β-catenin staining intensity in the OMD/PRELP 
Figure 3.11: Electron microscopy analysis of EJ28-WT and EJ28-OMD cells. Cells from 
both lines were seeded in 6-well plates and after reaching confluency were cultured for one 
more week to allow formation of junctions. Left panel represents EJ28 wild type cells and right 
panel EJ28-OMD transfected cells, where arrows denote tight junctions seen between 
neighbouring cells, which were scarcely observed in the WT samples.  Scale bars in the top 
images equal to 1μm, in the bottom images to 0.5μm. 
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transfectants compared to the vector-transfected control, accompanied by enhanced 
localization of the signal in the plasma membrane of the cells. This might suggest an 
activation of adherens junction and potential inhibition of the canonical Wnt 
pathway. However, E-cadherin expression was not increased in any of the transfected 
samples and we could not observe specific localization around the cell membranes 
(Fig. 3.12B), which might be due to incomplete adherens junction formation or 
insufficient staining conditions. Furthermore, alternation of adherens junction often 
is linked with EMT. Thus, staining with vimentin, which can be used as a marker of 
EMT, was performed, where the staining pattern between the control and 
OMD/PRELP transfected cells appeared quite similar (Fig. 3.12C), indicating no 
apparent cell status transition under these conditions. 
Figure 3.12: β-Catenin, E-Cadherin and vimentin staining of EJ28 cells. EJ28-vector only, OMD and 
PRELP transfected cells were seeded in 8-well multi chamber glass slides (in duplicates) and after 
reaching confluency were cultured another 7 days, followed by fixation and staining. For all three markers, 
secondary alexa-488 (green) antibodies were used. (A) β-catenin staining intensity is increased in 
OMD/PRELP transfectants compared to vector-control cells and enhanced localisation in the plasma 
membrane can be observed. (B) E-cadherin and (C) vimentin staining did not show differences in the 
staining pattern between the different cell lines. Scale bar represents 100μm for all images. 
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3.2.6.2 Signalling pathways affected by OMD and PRELP 
The initial analysis involving components of the affected signalling pathways in 
the OMD and PRELP transfected cell lines was performed by Dr. Watson, where 
through western blotting she examined expression of several signalling molecules 
including AKT/p-AKT, ERK1/2 and p-ERK1/2, c-Jun/p-c-Jun, p38 and p-p38, 
Smad2 and p-Smad2, β-catenin and lastly EGFR. Some of these molecules remained 
unaffected by OMD and PRELP over-expression, while others were affected 
positively or negatively in the various transfectants. The most prominent changes 
included inhibition of phospho-Akt, EGFR and phospho-Smad2, while β-catenin 
expression was increased, as we also demonstrated with immunofluorence staining in 
Fig. 3.12. For reference, Dr. Watson’s findings are summarized below, in Table 3.1. 
Table 3.1: Expression of signalling mediators in stably transfected cell lines 
compared to controls. - means no change in expression, one arrow indicates small 
difference, two arrows indicate significant difference.  
 OMD mtOMD PRELP mtPRELP 
ERK1/2 - - - - 
p-ERK1/2 - - - - 
Akt - - - - 
p-Akt     
c-Jun   - - 
p-c-Jun -  -  
p38 - -  - 
p-p38     
EGFR     
b-Catenin    - 
Smad2 - - - - 
p-Smad2     
 
Since our purpose was not to replicate all the previous findings, but at the same 
time wanted to establish a more conclusive mechanism of action, we chose to further 
complement only few of the involved pathways using the EJ28 OMD over-
expressing cell line. Therefore the EGF pathway was examined, and in addition the 
IGF pathway was  chosen as well, since both molecules are involved in the 
downstream signalling of other SLRP family members (Iozzo et al., 2011; Santra et 
al., 2002).  
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More specifically, together with Dr. Tamura, we performed ligand-induced 
activation of EGFR and IGF1R and examined their downstream targets p-Akt and p-
ERK1/2. As shown in Figure 3.13A, addition of EGF (ligand) resulted in 
phosphorylation of the receptor (EGFR) in both the WT and OMD over-expressing 
cells. However, this phosphorylation was reduced in the OMD samples, indicating 
that somehow OMD inhibits normal activation of the receptor. Moreover, while p-
Akt levels are generally decreased in the OMD cells under normal conditions (as Dr. 
Watson also established), under EGF ligand induction, although increased, p-Akt still 
remains inhibited compared to the control. In addition, phosphorylation of ERK1/2, 
which is downstream of the Ras component of the pathway, was strongly activated 
by EGF. This phosphorylation was slightly suppressed by OMD, in both absence and 
presence of exogenous EGF ligand. Following that, an immunoprecipitation assay 
was performed by Dr. Tamura in order to investigate any possible physical 
interaction between the OMD protein and the EGF receptor. Since we did not have a 
good antibody against OMD, for this experiment the mtOMD cell line was used, as 
through the myc-tag the OMD protein could be strongly bound by anti-myc binding 
beads and subsequently detected in western blotting.  Shown in Figure 3.13B is the 
blot from the co-IP, demonstrating that indeed OMD interacts with the EGFR. Given 
that the EGFR total protein level is also reduced in the OMD transfectants (around 
2/3 reduction compared to the WT, unpublished data by Dr. Watson), we can 
conclude that OMD acts through direct inhibition of the EFG pathway, affecting both 
the receptor as well some of the downstream components.  
The same experimental approach was also employed for the IGF-1 pathway, 
where addition of the IGF-1 (the ligand) phosphorylated the receptor (IGF-1R), as 
expected (Fig. 3.13C). However, this time IGF-1 mediated phosphorylation of the 
IGF-1R was not inhibited by OMD overexpression. In addition, IGF-1 application 
strongly activated downstream phosphorylation of Akt, which again was not further 
inhibited by OMD. Also, p-ERK1/2 levels increased only slightly upon ligand 
activation of the receptor and they did not differ between OMD transfectants and WT 
control samples. Lastly, co-IP did not reveal any interactions between mtOMD 
protein and the IGF-1 receptor, suggesting that there is no profound or direct effect 
of the OMD protein with this signalling cascade (Fig. 3.13D).  
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 Figure 3.13: EGF and IGF signalling analysis of EJ28 OMD overexpressing cells. (A) Activation of 
the EGF pathway via addition of EGF ligand (10ng/ml). EGF-mediated phosphorylation of tyrosin-1068 
of EGF receptor (EGFR) was strongly suppressed by OMD expression. Downstream phosphorylation of 
Akt and ERK1/2 is lower in OMD overexpressing samples compared to WT controls. (B) Protein 
binding assay showing interaction of mtOMD with EGFR. (C) Activation of IGF pathway via addition of 
IGF ligand (10ng/ml). Phosphorylation of the IGF receptor (IGF-1R) is not affected by OMD 
overexpression. (D) Co-IP showing no interaction between mtOMD and the IGF receptor. Experiments 
were performed with three different biological samples (lysates). Blots from (B) and (D) are kindly 
provided by Dr. Tamura, who performed the co-ip experiments. (E) Effect of OMD on Cdc42 activity. 
EJ28 WT/Vector control and OMD-transfected cells were seeded in triplicates in a density of 1 x 105 
cells/well after 24h cells were analysed for levels of active Cdc42 using a G-LISA assay kit. Data are 
presented as means ± SD, ***p<0.001. These data are also kindly  provided by Dr. Tamura, who 
performed the Cdc42 activation assay. 
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All SLRP family members previously tested are known to directly interact with 
TGF-β family members and to regulate transcription of downstream targets mainly 
via phosphorylation of Smad2. Indeed, Smad2 phosphorylation is suppressed by 
OMD over-expression (Table 3.1, data acquired by Dr. Watson). In addition, β-
catenin, which is a major component of the Wnt pathway, is also affected (its 
expression is increased, Table 3.1), and, as also shown in the previous section, 
localization of β-catenin to the plasma membrane is strongly activated in OMD and 
PRELP transfected cell lines. Furthermore, Cdc42 is known to be regulated by EGF 
and Wnt pathways and is also involved in the regulation of tight junction formation. 
Hence, it was decided to examine Cdc42 expression in the OMD transfected cells, 
and discovered that Cdc42 activity was strongly activated by OMD overexpression 
(Figure 3.13E), indicating a further connection of OMD activity with the Wnt/EGF 
pathways and tight junction regulation. 
Finally, having established an apparent connection between OMD and the EGF, 
and TGF-β pathways, probably in a context dependent manner, together with Dr. 
Tamure we decided to examine the roles of those components in relation to tight 
junctions. To this end, EGF (10 ng/ml), TGF-β1 (10 ng/ml) and also IGF-1 (100 
ng/ml) ligands were applied to OMD over-expressing EJ28 cells, and the effects on 
tight junction formation were analysed through occludin staining. Figure 3.14 
demonstrates that EGF and TGF-β strongly inhibited OMD-induced tight junction 
formation, while IGF-1 did not affect the tight junction status, indicating that OMD-
mediated modulation of EGF and TGF-β pathways is important for the sequential 
regulation of tight junction formation. 
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 Figure 3.14: Occludin staining of EJ28 cells after addition of EGF, IGF-1 and TGF-β1 
ligands.  Cells were seeded on 8-well multi chamber glass slides (in duplicates) and after reaching 
confluency were cultured for another seven days to allow tight junction formation. Ligands were 
applied every other day after reaching confluency. The last day cells were fixed in ice-cold 
methanol and stained with a primary antibody against occludin, visualized by a secondary alexa-
488 (green). OMD-induced tight junction formation was inhibited by the addition of EGF and 
TGF-β1. Scale bar represents 100μm for all images. 
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3.2.6.3 Analysis of xenograft tumours 
Further analysis was performed on the xenografted tumours, where H+E staining 
revealed slightly different cellular contents between the wild type and OMD samples 
(Fig. 3.15A). Quantification of the nuclei number was conducted in 8 random areas 
in the centre of the tumour mass, demonstrating less nucleuses in the EJ28-OMD 
overexpressing tumours compared to the wild types (Fig. 3.15B, p=0.0002). In 
addition, the nuclear to cytoplasmic ratio was increased in the OMD samples, with a 
value of 36.60 ± 0.7945 versus 26.43 ± 1.535 for the WT (p<0.0001), suggesting a 
more organised distribution and an increased cytosolic content in the OMD cell 
masses (Fig. 3.15C).   
Another set of the xenografted tumours was prepared for electron microcopy 
imaging and semi-thin sections were stained with methylene blue and basic fuchsin, 
thereby coloring the cells blue and the extracellular matrix pink. As presented in 
Figure 3.15 D&E the OMD sample has a lot more matrix between the cells in the 
main tumor mass compared with the wild type, suggesting a possible role of OMD in 
matrix deposition or maintenance in the tumor microenvironment. 
Finally, the samples were examined under electron microscopy where indeed 
more extracellular matrix between the cells was observed in the EJ28-OMD tumour, 
but also more tight junctions between neighboring cells could be seen compared to 
the control. Two representative images are shown in Figure 3.16 A&B, where no 
tight junctions are present in three adjacent EJ28 wild type cells, whereas TJ have 
formed in the OMD over-expressing cells (arrows), further supporting our previous 
in vitro analysis. Immunofluorescence using an antibody against occludin was also 
attempted on snap-frozen tumors, where, although clear tight junctions between cells 
could not be seen, an overall higher intensity of the staining was observed in the 
OMD samples compared to the WT controls (Fig. 3.16 C&D). 
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 Figure 3.15: Analysis of the EJ28-WT and EJ28-OMD xenografted tumours. OMD 
overexpression alters the tumour cellularity. (A) H+E staining of tumour sections. (B) 
Quantification of the nuclei in 8 random100μm2 areas in WT and OMD EJ28 tumour sections and  (C) 
ratio of the nuclei/cytoplasm in the same areas. Measurements were calculated using the Image J 
software. Student’s t-test was carried out, * equals p<0.05, data are presented as mean ± SEM. (D) and  
(E) are images of tumour semi-thin sections stained for methylene blue and basic fuchsin, staining the 
cells blue and the intermediate stroma pink, demonstrating more extracellular matrix in the OMD 
tumour compared to the wild type. Scale bars represent 100 μm in all images. 
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Figure 3.16: Increased occludin staining  in the xenografted EJ28-OMD tumours compared to the 
WT. (A) & (B) Electron microscopy analysis of the xenografted tumours showing tight junction 
formation (arrows) in the OMD samples but not in the WT. Also more extracellular matrix can be seen 
between the OMD-overexpressing cells (arrowhead). (C) & (D) EJ28-WT and OMD tumours were snap-
frozen and after sectioning were stained using an occludin antibody and an alexa-488 (green) secondary. 
Panel D(i): OMD sample demonstrates a higher staining intensity when compared to the WT tumour-
panel C(i), indicating increased TJ components expression in the OMD-overexpressing cells. Scale bars 
represent 0.5μm in panels (A) & (B), and 100μm in panels (C) & (D).  
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3.2.7 Overexpression of OMD with an inducible lentivector      
3.2.7.1 Choosing the right vector 
As mentioned earlier, Dr. Julie Watson who worked previously on this project, 
showed that overexpression of OMD and PRELP in the EJ28 bladder cancer cell line 
inhibited cell cycle progression and proliferation, while it enhanced apoptosis. As a 
result, study of the overexpression effects was difficult because transfected cells had 
a tendency to die and/or gradually lose the plasmid expression after several passages. 
Indeed, all the in vitro assays described earlier in this chapter were performed using 
early passages of Dr. Watson’s transfected cells lines, as in later passages expression 
of the two genes became undetectable. Hence, it was decided to overexpress the 2 
genes with a different expression system.  
We ideally wanted to have controllable expression under an inducible promoter, 
and thus chose the doxycycline Tet-on system, where transcription can be activated 
in the presence of tetracycline or doxycycline (dox) and is often preferred to the Tet-
off system, as maintenance in the off state does not require chronic drug 
administration (Figure 3.17A). The vector we decided to use is a lentiviral gene 
transfer vector, as lentiviruses have now emerged as the most efficient and versatile 
system for permanent in vitro, as well as in vivo, gene transfer. More specifically, 
this vector can be characterised as an “all-in-one” vector, because it contains all the 
elements needed for the tet-on system, where a TRE/CMVmin promoter, composed 
of the tetracycline responsive element (TRE) and the minimal CMV promoter, is 
used for the transcription of our genes of interest. In parallel, the tetracycline 
transactivator protein, rtTA2S-M2, is transcribed under a human PGK promoter, 
while we also have the expression of the GFP marker protein under the IRES 
(Internal ribosome entry site) element (Fig. 3.17B). In that way, one single 
transfection of either our cell lines or animal model is enough for a controllable 
expression system, and the need for an extra transfection to provide the rtTA protein 
becomes abolished, which is quite important and useful for in vivo studies. This 
vector was originally engineered by Olivier Danos’s group (Barde et al., 2005), and 
was kindly provided to us by Professor Sam Janes (UCL).  
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 Figure 3.17:  Schematic presentation of the Tet-On expression system and plasmid map of the 
lentivector used for overexpression of OMD and PRELP. (A) The reverse tetracycline-controlled 
transactivator (rtTa) is a fusion of a mutant TetR with the VP16 activator. In the absence of 
tetracycline, rtTa is free and transcription does not occur. When doxycycline is added to the system, it 
binds to rtTa which in turn binds tetracycline response elements (TRE), activating transcription of the 
cDNA. PminCMV = Minimum cytomegalovirus promoter. (B) Plasmid map of the inducible-promoter 
lentivector provided by from Prof. Sam Janes (UCL). In this case, the KGF gene (mKGF) is under the 
TRE (TRE/CMVmin) promoter, followed by the IRES element transcribing for the GFP (EGFP) gene. 
The transactivator rtTA2 is under the human PGK promoter (Hum PGK1), while some of the viral 
sequences are visible, like the Woodchuck Hepatitis Virus (WHP), the posttranscriptional Regulatory 
Element (WPRE), and also the ampicillin resistance gene (rAMP) among others. Two of the restriction 
sites used for cloning by Prof. James’s group, utilizing the MluI and EcoRV restriction enzymes (which 
we will use as well), are also visible. 
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3.2.7.2 Cloning of OMD, mtOMD, PRELP and mtPRELP into the vector 
 I wanted to clone the human OMD, mtOMD, PRELP and mtPRELP cDNAs 
under the TRE promoter and for this purpose a triple ligation consisting of: (a) the 
cDNAs, (b) the IRES-EGFP fragment and (c) the vector, was conducted. Specific 
primers were designed to amplify the four cDNAs and the IRES-EGFP fragment so 
that the desired restriction sites were inserted in their 5′ and 3′ prime ends, as 
presented in the following table (Table 3.2). A schematic representation of the 
cloning strategy is also displayed in Figure 3.18A.  
Table 3.2: Triple ligation fragments and restriction sites 
Prime end 
OMD + 
mtOMD cDNA 
PRELP + 
mtPRELP cDNA 
IRES-EGFP Vector 
5′ MluI MluI NheI MluI 
3′ NheI NheI EcoRV EcoRV 
 
PCR was successful for the 5 inserts, and after gel extraction and double 
restriction digestion with the appropriate enzymes (as mentioned in table 3.2), the 
fragments were ready for the ligation. In parallel, after restriction digestion of the 
lentivector with the MluI and EcoRV enzymes, the vector was separated from the 
KGF-IRES-EGFP sequence with gel extraction, and following treatment with 
alkaline phosphatase was ready for the ligation. The four triple ligations (consisting 
of OMD or mtOMD cDNA-IRES.EGFP-vector and PRELP or mtPRELP cDNA-
IRES.EGFP-vector) were set up and left to ligate overnight, and after transformation, 
colony retrieval, and DNA extraction, restriction enzyme digestions were set up to 
confirm successful ligated clones. A representative image of a positive clone for each 
of OMD and PRELP inserts is shown in Figure 3.18B, demonstrating the expected 
band sizes (as explained in Table 3.3), while similar results were obtained also for 
the myc-tagged cDNAs of the two genes. After validating the insertion of our 
cDNAs into the lentivector, in the correct position, the samples were sent for 
sequencing and all sequences were confirmed to be as expected.   
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Table 3.3: Expected and obtained band sizes from restriction enzyme digestion of OMD and PRELP 
clones, as shown in Figure 3.18B 
Restriction Enzymes 
Expected bands (bp) Obtained bands (Kbp) 
OMD PRELP OMD PRELP 
MluI+NheI 1266 1149 ~1.3 ~1.2 
NheI+EcoRV 1330 1330 ~1.4 ~1.4 
MluI+EcoRV 2596 2479 ~2.8 ~2.7 
NheI 10590 10473 ~10.1 ~10.1 
Undigested 10590 10473 ~10.1 ~10.1 
 
 
Figure 3.18: Cloning strategy for insertion of the OMD, mtOMD, PRELP and mtPRELP cDNAs into the 
inducible lentivector. (A) Schematic presentation of the triple ligation fragments consisting of the four different 
cDNAs, the IRES-eGFP fragment and the vector backbone. The position of the different cDNAs is marked with 
red colour, while the IRES-EGFP fragment is marked green. The restriction enzymes used for the insertion of the 
fragments are also visible, together with the mCMV-TRE promoter and the human PGK promoter transcribing for 
the tetracycline transactivator protein (HumPGK1/rtTA2). (B) Agarose gel after restriction enzyme digestion of 
the ligated vectors, showing successful cloning of the cDNAs into the vector, with expected insert sizes. Lanes 1-5 
are for OMD-IRES.EGFP-vector ligation, and lanes 6-10 are for PRELP-IRES.EGFP-vector. Inserts are color-
coded as in (A). The sizes of the expected bands and the sizes of the obtained bands are demonstrated in detail in 
Table 3.3 
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3.2.7.3 Lentiviral production and titration 
Production of the lentiviruses was performed in co-operation with Prof. Sam 
Jane’s lab, at the Rayne Building at UCL, as our lab did not have the necessary 
safety-level equipment for this kind of experiments. 293T cells were used as the 
producer cells and the standard protocol of 3-plasmid co-transfection was performed 
(for details see Section 2.2.2.9). Two batches of viruses were collected at day 4 and 5 
of production and after ultra-centrifugation, were transferred back to our building 
and stored at -80°C until use. Unfortunately, due to health and safety management 
issues at the Rayne building, the one-week production protocol was conducted only 
once, and we managed to produce only two instead the five viruses we wanted. The 
produced lentiviruses included the control eGFP-only (TRE.minCMV-IRES.eGFP 
days 4&5), and the mtOMD-coding (TRE.minCMV-mtOMD-IRES.eGFP days 4&5) 
viruses. 
In the meantime, even though only the above two viruses were produced, it was 
decided to use them for some in vitro and in vivo preliminary experiments, in order 
to confirm some of our previous results and also acquire some more information on 
the OMD protein. Before conducting any work on the EJ28 cell line, titration of the 
viruses was necessary, as it ensures viral viability and provides a measure of what 
fraction of target cells can be transduced, i.e. how infectious the virus is. Titration 
was performed by lentiviral transfection of 293T cells in several different viral 
dilutions and subsequent FACS analysis of the transfected cells through the reporter 
GFP marker, resulting in the biological titre being measured in transducing units per 
ml (TU/ml). An example of the cells after 3 days of transduction (2 days of 
doxycycline treatment) is shown in Figure 3.19, where strong expression of the GFP 
marker protein can be seen, demonstrating high transduction efficiency of the 
viruses. Also, declining GFP expression according to the different viral volumes can 
be observed (as expected), while slightly stronger signal can be seen in the control 
GFP-only transduced cells compared to the mtOMD (Fig. 3.19 A vs. B). Finally, 
after FACS analysis of the transduced cells viral titres were calculated, ranging from 
4.45 x 106 TU/ml to 8.5 x 106 TU/ml, as shown in detail in Table 3.4. This range of 
biological titre is considered low for direct in vivo applications, but is sufficient for in 
vitro cell line transductions, which comprises my primary aim. 
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Figure 3.19: Viral titration of the control-GFP and mtOMD lentiviruses, through transduction of 
HEK293T cells. HEK293T cells were infected with several different dilutions of lentiviruses and after 
two days of doxycycline induction strong GFP fluorescence can be seen, indicating successful viral 
transduction. (A) (i)-(iv) Fluorescent images of 293T cells transduced with the TRE.minCMV-
IRES.eGFP virus showing declining GFP intensity according to the different viral volumes that were 
used, i.e. 20μl, 15μl, 3.75μl, and 0.23 μl, while (v) shows a bright field image of panel (iv). (B), the 
same as (A) but for the TRE.minCMV-mtOMD-IRES.eGFP virus. Scale bars represent 50μl for all 
images. 
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  Table 3.4: Viral titres of the two lentiviruses after HEK293T cell transduction 
Viral preparations Titer (TU/ml) 
TRE.minCMV-IRES.eGFP day 4 5.1 x 106 
TRE.minCMV-IRES.eGFP day 5 8.5 x 106 
TRE.minCMV-mtOMD-IRES.eGFP day 4 4.45 x 106 
TRE.minCMV-mtOMD-IRES.eGFP day 5 5.2 x 106 
    
3.2.7.4  Lentiviral transfection of the EJ28 cell line 
After lentiviral production and titration, EJ28 cells were transfected with the 2 
viruses (collected at day 4) at an MOI of 5, and after doxycycline treatment GFP-
positive cells were isolated by FACS sorting. Initially, real-time PCR was performed 
to confirm overexpression of the OMD cDNA in the TRE.minCMV-mtOMD-
IRES.eGFP transfected cells (written onwards as TRE-mtOMD), against EJ28 wild 
type cells and TRE.minCMV-IRES.eGFP control cells (written as TRE-GFP). In both 
cases OMD mRNA transcripts of TRE-mtOMD cells after doxycycline treatment 
(+dox) were considerably higher than the control, with the fold difference reaching 
around 30-40 thousand, confirming strong overexpression (Fig. 3.20A). However, 
increased OMD mRNA expression was also seen in the transfected but not induced (-
dox) samples, of about 5000-fold difference, indicating quite high background 
transcription under the TRE-minCMV promoter.         
Confirmation of the OMD overexpression was also performed through protein 
detection using a primary antibody against the myc-tag, which usually provides 
strong and specific signal. Cell lysates were taken at 3h, 6h and 24h post doxycycline 
addition and representative western blots from all three different time points can be 
seen in Figure 3.20B, demonstrating strong induction of the mtOMD transcript even 
at 3h, with the signal getting stronger in the following hours. The same results were 
obtained even after 48 or 72 hour post transduction, replicated through different 
biological samples.  In addition, four bands are always observed, with the strongest 
at 75kDa, the middle around 55kDa and two smaller bands around 45kDa, with the 
latter probably representing the core OMD protein and the rest different post-
translational modifications. These bands are not present in the TRE-GFP or WT 
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control samples, suggesting that they are specific for the mtOMD protein. 
Furthermore, faint bands at 75kDa are also visible at the TRE-OMD (-dox) samples, 
representing background transcription without doxycycline induction, confirming the 
real-time PCR data (arrowheads). Detection of the GFP protein in TRE-GFP both 
+dox and –dox samples also implies background transcription without induction. 
Overall, expression of the mtOMD protein through the lentiviral transfections is 
quite high under induction of the inducible promoter, accompanied by medium 
background expression indicating a degree of leakage in this inducible system.  
Given the fact that OMD is an extracellular-matrix protein, we also wanted to 
test the cell medium for secreted levels of OMD since detection of the myc-tagged 
protein in cell lysates under the inducible system is very strong. Plain media without 
any FBS was collected after 72h of doxycycline induction from TRE-mtOMD, TRE-
GFP and WT cell culture wells. The different media were additionally concentrated 
with TCA treatment or through protein-specific filter centrifugations and were 
afterwards applied to SDS-PAGE electrophoresis. Presented in Figure 3.21 is a 
representative blot, showing strong expression of the myc-tagged protein in the 
media of the TRE-mtOMD samples indicating high levels of OMD secretion, with or 
without the addition of doxycycline. Although, there is a small size difference in the 
bands between these two conditions, this is due to the concentration of the samples 
and the accumulation of high levels of protein in very small volumes, which do not 
run equally through the acrylamide gel. For instance, looking at the TCA-
concentrated bands, very strong expression can be seen in the dox treated sample-
media, with the lower edges of the band being at 75kDa, which is the same size as 
the –dox sample and also the bigger band seen at the TRE-mtOMD lysates (which 
are included in the blot, acting as positive control). More importantly, only one band 
is observed in the cell medium as opposed to the 4 bands of the cell lysates, 
suggesting that the 75kDa variant of the protein is the one with the final post-
translational modifications and is subsequently secreted outside the cell. Finally, 
these results were replicated with three different biological samples and 
concentration of the medium with TCA was more effective, always producing 
stronger bands than the filter-processed samples. The positive signal seen in the non-
induced samples can be attributed to the background expression of the vector, as 
explained earlier.   
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 Figure 3.20: Confirmation of mtOMD overexpression in TRE-mtOMD EJ28 cells after induction 
with doxycycline. (A) qRT-PCR of EJ28-WT and TRE-mtOMD transfected cells showing successful 
overexpression of mtOMD. Increased quantity of mtOMD transcripts is also seen in the non-induced (-
dox) transfected samples, displaying high background expression. Analysis was performed using the 
Pfaffle method and values were normalised to endogenous GAPDH expression levels. Results are 
presented as fold-difference compared to EJ28-WT cells which is set to 1, while the same results are 
obtained when compared with the control TRE-GFP transfected cells. Error bars refer to standard 
deviation (SD). (B) Western blot of EJ28-WT/TRE-mtOMD/TRE-GFP cell lysates demonstrating 
expression of the mtOMD protein at 3h, 6h and 24h after doxycycline induction. In the right panel GFP 
expression can be also seen after induction. Arrowheads indicate background expression in the absence of 
dox. The bands around 40kDa probably represent the core protein, while the other bands correspond to 
post-translational modifications. Experiments were performed thrice with different biological samples 
(RNA or lysates).  
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 3.2.7.5 Detection of mtOMD through IF 
Immunofluorescence staining was performed using antibodies against the myc-
tag and the GFP, in order to visualise the mtOMD protein in the EJ28 transfected 
cells. TRE-mtOMD, TRE-GFP and WT cells were fixed and stained after 42h of 
doxycycline induction and representative images are shown in Figure 3.22 & 3.23. In 
detail, strong myc staining was always visible outside and around the cell nuclei, 
often in “spotty” formations.  Looking closer to high magnification images (Fig. 3.22 
B&C), it can be speculated that mtOMD signal may be localised in the endoplasmic 
reticulum, and especially the rough ER, whose membranes are continuous with the 
outer membrane of the nuclear envelope, indicating OMD protein synthesis. In 
addition, signal might be also localised in the Golgi apparatus and in vesicles either 
travelling between the ER and Golgi, or in preparation for secretion outside the cell. 
Since the Golgi system plays a key role in the production of GAG chains forming the 
final form of proteoglycans, it can be hypothesized that the myc signal observed in 
these cells represents different forms of the OMD protein relative to the degree of 
post-translational modifications that have occurred. These may also correspond to the 
four different bands seen at western blots of lysates from the same cells.  
Figure 3.21: Secretion of the mtOMD protein in the extracellular space. Western blot of 
concentrated media collected from EJ28-WT/TRE-mtOMD/TRE-GFP cell cultures after 48h of 
doxycycline induction, using anti anti-myc primary antibody. Concentration was performed with TCA 
and protein-specific filter centrifugations. The last two lanes on the left represent TRE-mtOMD cell 
lysates (after 6h of dox induction), acting as a positive control for the myc signal.  
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In contrast to the western blot data, no myc positive signal was seen in the TRE-
mtOMD non-induced cells, while moderate background GFP signal was observed in 
the TRE-GFP (-dox) samples (Fig. 3.22 D and 3.23 B). In addition, no staining 
against myc was seen in the WT or TRE-GFP induced samples, confirming the 
specificity of the antibody staining. Finally, even though transfected cells were 
FACS-sorted through GFP expression, we can observe that even after dox induction 
not all present cells are GFP positive, suggesting a possible mixture of successfully 
transfected and not-transfected cells in the culture.  
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 Figure 3.22: Expression and localisation of mtOMD in EJ28 cells (part one). EJ28 TRE-mtOMD cells were 
seeded on cover-slips in 6-well plates and after 48hours of doxycycline induction were fixed and stained with 
anti-myc and anti-GFP primary antibodies. Secondary alexa-546 (red) was used to visualise the myc signal-
panels (i) and alexa-488 (green) was used for GFP-panels (ii), while panels (iii) show the merged images with 
the addition of DAPI as nuclear staining. Images (A), (B) & (C) represent dox-induced samples showing strong 
staining for both myc and GFP, where mtOMD signal is always seen outside and around the cell nuclei. Panel 
(D) shows non-induced transfected cells, demonstrating minor background staining. Scale bars represent 50μm. 
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 Figure 3.23: Expression and localisation of mtOMD in EJ28 cells (part two). Continuing from Figure 3.22, 
the control EJ28 TRE-GFP and WT samples are presented here. Only minor background myc signal is seen in 
both control cell lines, showing the specificity of the staining in the induced TRE-mtOMD samples. All TRE-
GFP cells are positive for GFP after dox induction, while moderate GFP signal can be also seen in the (-dox) 
non-induced samples-panel B(ii), demonstrating background expression under the TRE promoter. Scale bars 
represent 50μm. 
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3.2.7.6 EJ28 anchorage-independent growth under doxycycline induction 
The soft agar assay was performed again, as previously described, including now 
EJ28-WT, TRE-mtOMD and TRE-GFP transfected cells, which were also FACS-
sorted in order to have a more uniform population of positively transfected cells. 
Doxycycline was added to the medium of both the bottom and top gel layers, as well 
as in the media covering the gels, which was replaced twice a week. The experiment 
was performed twice, in triplicates for each different cell group and as presented in 
Figure 3.24 the results were variable. Initially, our control TRE-GFP transfected cells 
did not behave similarly to the wild type cells, forming less than half the colonies 
observed in the WT samples. More specifically, TRE-GFP (-dox) had 377.7 ± 82.53 
vs. 769.8 ± 73.78 for the WT, indicating a possible functional problem with the 
transfected cells. Addition of doxycycline further inhibited colony formation, even 
though induction of GFP alone should not have this kind of effect. Therefore, we 
concluded that lentiviral transfection, conducted at least under the current 
circumstances, must have had additional unexpected effects on the cells.  
Low number of colonies was observed as well in the TRE-mtOMD ±dox 
samples, but due to the control irregularities we cannot know if this results from the 
OMD protein overexpression. If indeed, inhibition of colony formation was due to 
the mtOMD protein (over-expression of the protein was doubly-confirmed), then the 
same effect seen in the –dox samples can be attributed to the background expression 
without induction (as seen in the western blot analysis).  
Furthermore, in this assay non-sorted transfected cells were included as well 
(named ns.TRE-mtOMD), in order to discriminate the potential anti-tumour effects 
between a mixture of non/over-expressing cells and a pure population expressing the 
mtOMD protein. We did notice a small reduction in the colony number in the 
ns.TRE-mtOMD induced cells versus the non-induced, which could be due to the 
further increased over-expression of the protein under doxycycline treatment. 
However, more prominent was the difference between the sorted and non-sorted 
samples, suggesting that having pure populations of expressing cells is important for 
the anti-cancerous effect mediated by the mtOMD protein.    
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Because of the control problems mentioned above, the data arising from this 
assay were not considered conclusive, and hence no statistical comparisons were 
made. Moreover, since we had already confirmed the effects of OMD/PRELP 
overexpression using Dr. Watson’s stably transfected cell lines and due to time 
limitations, no more in vitro assays were performed using the inducible EJ28 cells. 
116 
 
 Figure 3.24: Anchorage independent growth assay of the lentiviral transfected EJ28 cells. (A) 
Representative images of colonies that grew in soft agar. Although TRE-mtOMD cells inhibited the 
formation of colonies, the control TRE-GFP transfected cells did not respond similarly to the WT cells, 
having much fewer colonies. However, the non-sorted TRE-mtOMD cells (ns.TRE-mtOMD) did 
present with more colonies than the sorted cell lines, indicating the importance of having a pure 
population overexpressing OMD. (B) Quantification of formed colonies per well (962mm2). Data are 
presented as mean ± SD. No statistical analysis was conducted due to the control TRE-GFP abnormal 
cell behaviour. 
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3.3 Discussion 
The small leucine-rich proteoglycans (SLRPs) are emerging as important 
regulators of extracellular matrix structure and of several signalling pathways, and 
their mutation or aberrant expression can cause developmental disorders and 
diseases, including cancer. Already, there is an emerging body of evidence 
suggesting that SLRPs are involved in carcinogenesis, including altered expression 
patterns in resected tumours compared to normal tissue, utility of decorin and 
lumican as predictive biomarkers in breast cancer, enhanced susceptibility of the 
decorin knockout mouse to cancer and several lines of functional evidence from in 
vitro and in vivo models. 
Previous lab members, including Dr. R. Hamamoto, Dr, T. Toshiya and Dr. J. 
Watson had found, by RT-PCR, that expression of two SLRPs, OMD and PRELP, is 
greatly reduced in urothelial cell carcinoma and renal cell carcinoma compared to 
normal tissue.  Based on these initial findings, Dr. Watson studied these two proteins 
in the EJ28 bladder cancer cell line, where she found that overexpression of OMD 
and PRELP leads to inhibition of cell cycle progression/proliferation, while at the 
same time it enhances apoptosis and drug susceptibility. These conclusions lead us to 
hypothesize that OMD and PRELP act as tumour suppressor genes and are able to 
affect tumour development and progression.  
 Indeed, together with Dr. Toshiya Tamura, we managed to show that OMD and 
PRELP exert certain anti-tumour effects on cells derived from human bladder cancer, 
and can also inhibit tumour growth in vivo. Furthermore, we carried out functional 
analysis and discovered that one of the ways OMD and PRELP act is through 
regulation of tight junction formation. In addition, we demonstrated that OMD 
interacts with the endothelial growth factor receptor (EGFR), therefore affecting 
downstream components of the pathway and further modulating cell behaviour. 
Anti-cancer effects of OMD and PRELP on the EJ28 bladder cancer cell line 
and in in vivo mouse xenografts 
The in vitro experimental analysis that was conducted during this project 
demonstrated that OMD and PRELP regulate cell functions that are essentially 
related to the "hallmark" characteristics of cancer cells, as specified by Hanahan and 
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Weinberg (Hanahan and Weinberg, 2011). More specifically, overexpression of 
OMD and PRELP in EJ28 cells inhibited anchorage independent growth (Fig. 3.2), 
led to altered 3D cell morphology when cultured in a matrix medium (Fig. 3.3) and 
OMD additionally inhibited cell invasiveness through a matrix-coated porous 
membrane (Fig. 3.4). Inhibition of anchorage-independent growth has previously 
been reported with other SLRPs, like lumican and decorin. For instance, stable 
expression of lumican induced a 6-fold reduction in anchorage-independent growth 
of melanoma and breast cancer cells, and also reduced the invasive potential of these 
cells (Li et al., 2004; Vuillermoz et al., 2004). The same effect was seen when 
decorin was overexpressed in colon cancer cells, whereas addition of decorin protein 
in mammary carcinoma cells also inhibited colony formation in soft agar (Goldoni et 
al., 2008; Santra et al., 1995).  Moreover, we demonstrated that secreted OMD and 
PRELP proteins decrease EJ28 cell viability (Fig. 3.5). In the same context, addition 
of biglycan inhibited proliferation of J82 bladder cancer cells (Niedworok et al., 
2013), while overexpression of decorin reduced the proliferation index of RT4 and 
T24 human bladder cancer cell lines (Sainio et al., 2013). Therefore, there is very 
strong evidence that SLRP molecules, now including OMD and PRELP, can act as 
tumour suppressors.   
One thing we should mention here is the clonal nature of the different cell lines 
we used for this part of the project. As mentioned in the results section, Dr. Watson 
had isolated two different clones of each OMD, mtOMD, PRELP, mtPRELP and 
control vector-EGFP overexpressing cells through limiting dilution and after 
antibiotic selection. When creating stable transfected cell lines it is preferable to 
select more than one clones and test if the effects of overexpression (in our case) are 
reproducible between the different clones, and also if the levels of expression are 
comparable. In this way, we can be sure that the results we obtain are valid and are 
indeed due to OMD/PRELP overexpression and not due to an adverse insertion site 
that could alter the general properties of the cells.  
Dr. Watson indeed obtained comparable results between the different clones she 
generated, demonstrating the true effects of OMD/PRELP overexpression. In 
agreement with this, we also got similar results in the experiments where both clones 
of each overexpressing cDNA were used. Additionally, the observed effects were 
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also usually similar between the tagged and non-tagged versions of the 
overexpressed proteins, further enhancing the validity of our results.  Occasionally, 
small differences were seen in some of the in vitro experiments, such as the formed 
colonies between the OMD and mtOMD cells in the soft agar assay (Fig. 3.2), 
implying that the tag might have a small impact in the overexpression effects, under 
certain circumstances. However, we did not see any other differences in the assays 
we performed that included both tagged and non-tagged versions of the proteins.  
Therefore, we can confirm that OMD and PRELP can truly enhance and promote 
anti-tumor properties of the EJ28 cells.  
Previous studies have shown that overexpression of decorin or injection of 
recombinant decorin protein into mouse xenograft models slows the growth of lung, 
squamous, mammary and colon carcinoma cells and also in some cases can prevent 
metastasis of the primary tumour (Buraschi et al., 2010; Goldoni et al., 2008; Reed et 
al., 2002; Reed et al., 2005; Tralhao et al., 2003).  In addition, overexpression of 
lumican blocked melanoma invasion and metastasis, and also induced tumour cell 
apoptosis (Brezillon et al., 2009). In this project we show for the first time that OMD 
and PRELP can have similar anti-cancer effects in mouse xenograft models. The in 
vitro anti-tumour effects of OMD and PRELP were replicated in in vivo mouse 
xenografts of the EJ28 cell line (Fig. 3.6), thereby strongly confirming that OMD, 
and PRELP to a lesser extent, have the ability to inhibit in vivo tumour growth.   
OMD and PRELP are regulators of tight junction formation and cancer-related 
signalling pathways   
Microarray expression profiling analysis after overexpression or depletion of the 
OMD and PRELP genes was conducted by our collaborator Dr. Hamamoto, who 
identified many of the affected targets and the involved signalling pathways. Among 
those, tight junction and adherens junction pathways appear to play particularly 
important roles (Fig. 3.7, KEGG pathway analysis, Appendix A). Indeed, OMD and 
PRELP overexpression increased tight junction formation, as demonstrated by 
increased cell-cell membrane staining of the TJ components occludin, ZO-1 and 
cingulin, and also by electron microscopy of EJ28-OMD transfected cells (Fig. 3.8, 
3.9, 3.10 & 3.11, the same was also observed in xenografted tumours-Fig. 3.16).  A 
similar effect was seen regarding the adherens junctions, where increased β-catenin 
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expression and translocation to the membrane, due to OMD and PRELP 
overexpression (Fig. 3.12A), may be indicative of activation of the adherens junction 
pathway. However, E-cadherin signal could not be observed in cell-cell membranes 
in either the WT or the transfected cells (Fig. 3.13B). This could be due to faulty 
adherens junction formation, as a general characteristic of the EJ28 cell line, or could 
be attributed to defective staining procedure. Overall, it can be observed that OMD 
and PRELP reorganize cellular architecture (changes in cell morphology were seen 
by Dr. Watson) and cell-cell adhesion towards the epithelial cell type, which is 
characterised by well-developed junctions and an apical-baseolateral polarization. 
 The epithelial to mesenchymal transition (EMT) is an important feature of 
embryonic development and its importance in the pathogenesis of cancer and other 
human diseases is increasingly being recognised (Polyak and Weinberg, 2009). 
During EMT epithelial cells lose their junctions and polarity, and reorganize their 
cytoskeleton acquiring instead mesenchymal features like increased motility, 
invasiveness and resistance to apoptosis. This reorganization is accompanied by 
changes in gene expression of junctional proteins, i.e. downregulation of claudins, 
occludin, ZO-1 and E-cadherin, and activation of N-cadherin and vimentin 
(Lamouille et al., 2014). Overexpression of OMD and PRELP did not cause any 
changes in vimentin expression (Fig. 3.12C), therefore indicating no apparent EMT 
transition. On the contrary, localization of β-catenin to the cell membranes and 
increased expression of occludin, ZO-1 and cingulin in apical tight junctions could 
suggest a mesenchymal to epithelial transition (MET), the reverse process of EMT, 
where cells acquire a more epithelial character and are more "immune" towards a 
cancer phenotype.      
Moreover, apart from EMT, altered expression of many TJ components has been 
related with cancer cells transformation and metastasis (Runkle and Mu, 2013). For 
example, loss of the tumour suppressor von Hipperl-Lindau (VHL) causes down-
regulation of occludin and claudin-1, independent of E-cadherin, in early lesions of 
renal cell carcinomas (Harten et al., 2009), while decreased occludin expression is 
often seen in other tumour types (Tsukita et al., 2008). Therefore, regulation of tight 
junction is a critical step in both early tumourigenesis and in later stages during EMT 
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and metastasis. Regulation of TJ components by OMD and PRELP indicates their 
anti-tumour potential and emphasizes their roles as tumour suppressor genes. 
In addition, we have managed to identify some of the critical signalling 
mediators that are affected by OMD and PRELP overexpression. Dr. Hamamoto’s 
expression profiling analysis showed that mRNA levels of Akt, a key intracellular 
regulator in multiple signalling pathways, were significantly affected by both OMD 
and PRELP, and also Dr. Watson had previously shown that phosphorylation of Akt 
is reduced under OMD/PRELP overexpression (Table 3.1). Together with Dr. 
Tamura we confirmed that in non-stimulated EJ28 cells OMD overexpression 
reduced phosphorylation of both Akt and the critical cell proliferation mediators 
ERK1/2 (Fig. 3.13A). Since Akt phosphorylation is regulated by EGF and IGF 
pathways (Pollak, 2012; Takeuchi and Ito, 2010), we tested the effects of EGF and 
IGF-1 ligands on EJ28-WT and -OMD cells, and discovered that phosphorylation of 
the EGF receptor was reduced in the OMD cells, while no effects were seen in the 
IGF pathway (Fig. 3.13 A&C). Performing a co-IP assay revealed that OMD binds to 
the EGF, but not the IGF, receptor (Fig. 3.13 B&D).  
Previously, decorin was found to directly bind the EGFR (Iozzo et al., 1999; 
Moscatello et al., 1998), leading to autophosphorylation, and a sustained 
downregulation of the receptor, as well as other EGFR-like receptors, such as ErbB4 
and ErbB2 (Csordas et al., 2000; Santra et al., 2000; Santra et al., 2002). Decorin was 
also able to bind the IGF-IR and its ligand, thus attenuating the IGF-I-induced Akt 
and ERK1/2 pathways, resulting in decreased migration and invasion of bladder 
cancer cells (Iozzo et al., 2011). Furthermore, the TGF-β/Smad2 pathway is a 
common signaling target of SLRPs (Morris et al., 2007; Nikitovic et al., 2011) and 
significantly contributes to the inhibition of epithelial properties and activation of the 
epithelial-mesenchymal transition (Lui et al., 2003). Therefore, the EFG, IGF, TGF-
β/Smad2 pathways and also other molecules like β-catenin, which is involved in the 
Wnt signaling cascade, are all targets of SLRPs in cancer signaling (presented in 
detail in Chapter 1).  
 In addition, the role of Cdc42 in epithelial cells has been of particular interest as 
one of its targets is the Par6–aPKC complex, a major regulator of cell polarity and TJ 
assembly (Iden and Collard, 2008; Lin et al., 2000; Matter and Balda, 2003). 
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Increased Cdc42 activity by OMD overexpression could therefore be related to its 
ability to regulate tight junction formation. Finally, application of EGF and TGF-β 
strongly inhibited OMD-induced tight junction formation (Fig. 3.14), indicating that 
OMD-mediated modulation of EGF and TGF-β pathways is also important for the 
regulation of tight junction formation. 
 In this context, it has already been shown that TGF-β can modulate epithelial 
polarity by regulation of the polarity protein Par6. More specifically, the TGF-β type 
I receptor (TβRI) was found to be co-localised with occludin and Par6 at tight 
junctions, while cell stimulation with TGF-β induced redistribution of the TGF-β 
type II receptor (TβRII) to the tight junctions (instead of its normal localization in 
puncta distributed over the cell surface) and subsequent interaction with the 
TβRI/Par6 complex (Barrios-Rodiles et al., 2005; Ozdamar et al., 2005). Through 
this interaction TβRII phosphorylates Par6 on serine 345, an event which in turn 
recruits the E3 ubiquitin ligase Smurf1 resulting in RhoA ubiquitination and 
localised degradation (Ozdamar et al., 2005). RhoA is a small GTPase protein which 
is responsible for stress fiber formation and for the maintenance of apico-basal 
polarity and junctional stability (Perez-Moreno et al., 2003), and hence, its 
degradation at TJs leads to the dissolution of these junctions and promotes an EMT 
state. Overall, these studies have shown that this Smad-independent TGF-β-induced 
mechanism facilitates the disassembly of tight junctions during TGF-β-mediated 
EMT. Another study by Kojima et al., showed that TGF-β-mediated TJ disassembly 
and EMT was alternatively induced by down-regulation of claudin-1 expression and 
the fence function (Kojima et al., 2007).  
Finaly, regarding EGF, a previous study has shown that EGF-induced EGFR 
activation in MDCK II cells  significantly inhibited claudin-2 expression while 
simultaneously inducing cellular redistribution and increased expression of claudin-
1, -3, and -4 (Singh and Harris, 2004). Therefore, we see that EFG and especially 
TGF-β have multiple roles in TJ disassembly and function and any possible 
association of OMD with these pathways could indirectly regulate tight junction 
formation/function. Definitely, a more thorough investigation of the tight junction 
components and TJ-related signaling pathways is necessary in order to discover how 
OMD and PRELP can regulate TJs.   
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EJ28-OMD xenografted tumours have different cellularity and increased extra-
cellular matrix  
The strong anti-tumour effect of OMD and PRELP was observed also in in vivo 
xenograft models of the EJ28 bladder cancer cells. A preliminary analysis of the 
xenografted tumours revealed different cellularity in the OMD and WT tumours, 
where the wild type samples had more nucleuses and less cytoplasm compared to the 
OMD-transfected derived tumours (Fig. 3.15 A-C). Differences in tumour cellularity 
are observed in different stages of breast tumours, where often smaller pathological 
lesions present with reduced cancer-cellularity (Rajan et al., 2004). Hence, cell 
consistency of OMD-overexpressing samples might indicate a less proliferative and 
aggressive tumorigenic potential.  
Finally, OMD-derived tumours had more extra-cellular stroma within the 
tumour mass (Fig. 3.15 D&E). This could be attributed to the mechanical properties 
of the OMD protein, which as an SLRP and ECM component, participates in ECM 
architectural organization and assembly of collagen fibrils (Lucchini et al., 2004; 
Tillgren et al., 2009). The architecture of tumour-associated ECM is fundamentally 
different from the normal tissue stroma (Clarijs et al., 2003), and OMD 
overexpression could be driving the on-going ECM assembly during tumorigenesis 
towards the latter direction. In addition, it is possible that overexpression of OMD 
protein can reorganize the tumour stroma in a way that makes it less sensitive to 
matrix metalloproteinases (MMPs) degradation. MMPs are involved in cancer 
progression by cleavage of the ECM, therefore releasing matrix molecules that can in 
turn inhibit apoptosis and enable cell invasion (Sternlicht and Werb, 2001). In 
tumours the tight regulation of MMPs expression and activity is lost and usually 
overexpression of some members, such as MMP-2 and MMP-9, correlates with poor 
survival and increased disseminating capability of cancer cells (Littlepage et al., 
2010; Strongin, 2006). In a recent study it was shown that integrin αvβ3 expression 
induced up-regulation of MMP-2, resulting in prostate cancer metastasis (Dutta et al., 
2014). Knowing that OMD binds αvβ3 integrin (Lucchini et al., 2004), it may be 
possible that osteomodulin can indirectly affect MMP expression or vice versa. 
Another SLRP, lumican, was shown to affect cell migration and angiogenesis via 
mechanisms that involve a decrease of MMP-14 expression and activity (Malinowski 
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et al., 2012; Niewiarowska et al., 2011). Therefore, it is highly likely that SLRPs can 
also affect tumour development or metastasis through modulation of MMPs. Due to 
time limitations, MMP status of EJ28-WT and -OMD tumours was not investigated 
in the current project, but it is of primary interest to explore the possible interplay 
between OMD/PRELP and MMPs.   
Overexpression of OMD using an inducible system – findings and technical 
difficulties 
As it was mentioned earlier in this chapter, study of the overexpression effects 
was not always easy because transfected cells had a tendency to die and/or gradually 
lose the plasmid expression after several passages. It was therefore desirable to 
overexpress OMD and PRELP under an inducible promoter. The doxycycline tet-on 
system was employed and OMD, PRELP and myc-tagged versions of the two 
cDNAs were successfully cloned into a lentivector, coding at the same time for an 
eGFP marker protein and also for the tetracycline transactivator protein, rtTA2S-M2, 
which is necessary for activation of the TRE promoter (Fig. 3.17, 3.18). 
Unfortunately, due to technical problems during the lentiviral production only the 
control GFP- and the mtOMD- coding viruses were produced. Nevertheless, 
transfection of EJ28 cells with the above viruses was conducted and expression 
levels of OMD transcripts were very high (Fig. 3.20). At that point, it became 
noticeable that the non-induced samples also showed high levels of OMD 
expression, indicating a moderate degree of leakage in this inducible system. This 
system was firstly used in CHO cells, where it was satisfying in terms of basal 
activity, inducibility and dox responsiveness (Barde et al., 2006). Transduction of the 
EJ28 cells was indeed efficient and expression of mtOMD protein was very strong 
after doxycycline treatment, but was always accompanied by expression in the non-
induced samples (Fig. 3.20).  
Even though this system did not appear to be totally controllable (not in the 
degree we had expected), useful information was gathered regarding the OMD 
protein expression. Firstly, it was confirmed that OMD can be found within the cells 
but also in the extracellular space, demonstrating secretion of the protein (Fig. 3.21). 
Also, different band sizes from cell lysates indicate presence of the core protein 
(~40kDa) and the modified proteoglycan after addition of the GAG side chains, 
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~50kDa and 75kDa, the latter of which was also the secreted form of the protein 
(Fig. 3.20 & 3.21). Furthermore, intracellular localization of the protein was always 
seen outside and around the cell nuclei, often in "spotty" formations (Fig. 3.22). 
During cell staining no background myc-tag or GFP signal was seen in the non-
induced mtOMD cells, whereas GFP signal could be observed in the non-dox GFP-
transduced control cells (Fig. 3.23), suggesting strong activation even at the tet-off 
state.  
Lastly, anchorage independent growth of the lentiviral transduced cells was 
assessed, where the control-GFP cells did not correspond similarly to the wild type 
EJ28 cells, indicating possible functional transformation of the cells due to the 
lentiviral transfection. Addition of doxycycline resulted unexpectedly in even lower 
number of colonies, suggesting that very high GFP expression somehow could 
become toxic for the cells (Fig. 3.24). However, during culturing of the cells, with or 
without addition of dox, no cell death or phenotypic changes were seen under 
microscopic observation. Given the fact the control transfected cells behaved 
strangely in the soft agar assay, no more experiments were conducted with these cell 
lines. Transduction of EJ28-cells with lower multiplicities of infection would be the 
next step, in order to optimize the inducible system so that background expression 
can be minimum and at the same time viral infection cannot transform the cells and 
change their properties.  
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Chapter 4  
 
Expression patterns of the OMD gene in mouse 
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4.1 Introduction 
Osteoadherin or osteomodulin (OMD) is a leucine- and aspartic acid-rich 
keratan sulfate proteoglycan belonging to class II of the SLRP family. OMD was 
firstly isolated from the mineralized matrix of bovine bone, where it was shown that 
the protein is rather acidic and binds to hydroxyapatite, which was used to purify the 
protein (Sommarin et al., 1998; Wendel et al., 1998). Expression of OMD mRNA 
was detected in mature osteoblasts located in trabecular bovine bone, while northern 
blot analysis from various bovine tissues also confirmed expression only in bone, 
suggesting that OMD may be involved in mineral deposition (Sommarin et al., 
1998). The same pattern was also seen in rat tissues, where OMD mRNA was 
detected in osteoblasts of the trabeculae, and was especially strong in the area 
between cartilage and bone (Shen et al., 1999). In addition, OMD was located to the 
mineralized bone matrix, with highest concentration again at the border between 
bone and cartilage, a pattern similar to that of bone sialoprotein (Ramstad et al., 
2003). 
A later study by Buchaille et al., showed for the first time expression of OMD 
mRNA in human odontoblasts and also in mature rat molars, specifically in 
odontoblasts, ameloblasts and in cells of the alveolar bone surrounding the teeth 
(Buchaille et al., 2000).  Expression of OMD in rat and mouse developing teeth was 
also described in another two studies, while ultrastructural analysis demonstrated 
localization of OMD close to collagen fibers, indicating its role in ECM organisation 
(Couble et al., 2004; Petersson et al., 2003). A recent paper demonstrated that 
osteoadherin starts to be expressed within the alveolar bone of mouse embryos at 
E17 stage of development and it is later specifically localised in the growing teeth, in 
the predentin/dentin interface and the mineralization front, in new-born mice (Nikdin 
et al., 2012). In the same study, expression of OMD was examined in rat dental pulp 
in vitro cultures, where the levels of OMD expression peaked when ECM maturation 
and mineralization had initiated, suggesting that osteoadherin can be considered a 
marker for mineralizing cells such as mature odontoblasts and osteoblasts (Nikdin et 
al., 2012).   
Thus, OMD is so far mainly linked with bone ECM, and it has been shown that 
OMD expression is regulated by the transcription factor Runx2, Smads and the 
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cytokines TGF-β1 and BMP2, all important factors for hard tissue development 
(Rehn et al., 2006; Tasheva et al., 2004). Moreover, overexpression of OMD in the 
MC3T3E1 mouse calvariae osteoblast cell line led in increased osteoblast 
differentiation features, while it also reduced proliferation and migration probably 
through affecting the EGF receptor activity (Rehn et al., 2008).  
Among other members of the SLRP family, decorin, biglycan, fibromodulin and 
lumican have been reported to be expressed in bone and dentin, thereby regulating 
osteoid ECM deposition and organization (Cam et al., 1997; Gori et al., 2001; Raouf 
et al., 2002; Scholzen et al., 1994; Wegrowski et al., 1995). In addition, asporin, 
another SLRP, is involved in the regulation of chondrocyte activity mediated by 
TGF-β (Kizawa et al., 2005). Apart from skeletal tissues, SLRPs are differentially 
expressed in other organs as well. For example, lumican is expressed in mouse 
cornea stroma, heart, lung and kidney (Ying et al., 1997); keratocan is expressed in 
mouse/chick cornea and in the chick brain (Conrad and Conrad, 2003); fibromodulin 
has been found in the mouse adult retina (Ali et al., 2011); opticin has been found in 
the human and mouse eye, and specifically in the vitreous and the non-pigmented 
ciliary body (Ramesh et al., 2004; Takanosu et al., 2001); and lastly decorin has been 
also found to be expressed in the developing postnatal rat brain (Kappler et al., 
1998).  
There have been several engineered models of SLPR-deficient mice, involving 
mostly biglycan, decorin, lumican, fibromodulin and some double knock-outs (KO) 
of the aforementioned proteins. Most of these models exhibit phenotypes of reduced 
bone mass, skin fragility and abnormal collagen fibrillogenesis, while decorin-
deficient mice present also with intestinal tumour formation (all SLRP-KO models 
are presented in detail in section 6.1). To date, no knock-out models for OMD have 
been established. Also, most of the studies presented earlier used in situ 
hybridization for the identification of OMD mRNA expression or custom-made 
antibodies against osteoadherin in order to explore protein expression patterns, 
focusing mainly on dental or skeletal tissues, while there has been no detailed 
examination of OMD expression during mouse development or in any adult soft 
tissues. A more straightforward and sensitive method for establishing OMD 
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expression, and a more extensive analysis that expands from early embryonic life to 
adult tissues, are therefore required.  
In collaboration with Takeda Pharmaceutical Company, we have established the 
first OMD KO mouse model, where the coding sequence of the OMD gene has been 
replaced with a Lac-Z reporter gene so that transcription under the OMD 
promoter/enhancer leads to β-galactosidase expression instead of OMD. Apart from 
studying the effects of OMD depletion, this system provides an excellent model for 
analysis of expression patterns with just X-gal staining of heterozygote animals. The 
aim of this part of the project was therefore to examine the temporal and spatial 
expression of OMD during mouse embryonic development and in adult organs, 
before assessing any phenotypic effects due to OMD absence. 
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4.2 Results 
OMD knock-out mice were constructed in Takeda Pharmaceutical Company. 
Briefly exons 2 and 3 (where the transcription domain is located) were replaced with 
a Lac-Z reporter gene. A detailed description of the knock-out strategy is described 
in section 2.2.4.1, while a simple graphic showing the OMD gene locus and the Lac-
Z insertion site is shown in Figure 4.1A. Transgenic mice founders were received 
and our mouse colony was established through heterozygote-pair breeding as 
OMD+/LacZ animals were fertile and produced litters containing all three genotypes. 
Heterozygote and knock-out animals grew normally into adulthood and had a life-
span comparable to the wild type mice, while no apparent phenotypic differences 
could be seen during expansion of the colony. A typical example of a genotyping set 
is shown in Figure 4.1B, demonstrating the different DNA bands corresponding to 
the three genotypes.  
Figure 4.1: Knock-out strategy and genotyping of OMD mice. (A) Schematic drawing of the OMD 
gene locus and the Lac-Z insertion site together with the primer pairs used for genotyping. (B) An 
exemplar agarose gel from a genotyping set demonstrating the bands corresponding to the different 
genotypes. 
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As mentioned in the introduction of this chapter, before analyzing the effects of 
OMD depletion, the expression pattern of the gene/protein through Lac-Z detection 
was first studied in heterozygote animals. More specifically, OMD gene expression 
was examined in embryonic life through X-gal staining of mouse embryos at 3 
developmental stages (12.5dpc, 15.5dpc and 17.5dpc) and at day of birth (P0), where 
it was most predominantly expressed in craniofacial and skeletal tissues. In addition, 
this expression pattern appeared to be expanding during adulthood, including internal 
organs as well, where specific areas of the brain, bladder and eye were positive for β-
gal signal. Detailed analyses of the gene expression in every developmental stage and 
in several organs will be presented and discussed below. 
4.2.1 OMD expression in E12.5 embryos 
Embryos were collected at 12.5dpc after arranged time-matings and entire litters 
were whole-mount stained for β-galactosidase. OMD+/+ embryos had no staining at 
all, while OMD+/LacZ and OMDLacZlLacZ embryos showed staining around the mouth 
area, and more specifically in the developing mandible and maxilla (Fig 4.2). In 
knock-out litter-mates staining was more intense than heterozygotes, where long-
bone cartilage primordia of the forelimb and the developing somites were 
additionally stained for β-gal (Fig. 4.2 arrows). Also, faint staining could be seen 
around the brain, in the developing frontal bone. 
Upon sectioning of OMD+/LacZ embryos β-galactosidase positive cells appeared 
to be confined to the mesenchyme of the developing mandible, while there was no 
visible staining in other areas, such as the somites, the forelimb and the developing 
cranium (Fig 4.3). 
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Figure 4.2: OMD expression in E12.5 transgenic embryos. X-gal signal is seen mostly in the developing 
mouth and maxilla, while arrows indicate expression in the developing somites and cartilage primordia of 
the front limbs. Scale bar, 1mm for all images. 
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Figure 4.3: OMD expression in sections of an X-gal stained OMD+/LacZ E12.5 embryo. (A), (B) and 
(C) denote three different section planes, while in picture (D) X-gal expression can be seen in the 
developing mandible  mesenchyme. Scale bar for (A), (B), (C) is 1mm, for (D) 50μm. 
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4.2.2 OMD expression in E15.5 embryos 
Embryos were again collected at 15.5dpc after time-matings and the whole litter 
was stained for β-galactosidase overnight. Wild type embryos had no staining, while 
heterozygotes and homozygous knock-outs showed intense staining, mostly in the 
developing skeleton (Fig. 4.4). As shown in Figures 4.4 & 4.5A, Lac-Z activity can 
be seen at the digit tips, the metatarsals (hindlimb), metacarpus (frontlimb) and in 
phalanges, the ribs, the developing long bones of hands and legs, the vertebrae, the 
maxillary region, the developing jaw, the nasal septum, the intramembranous bones 
of the head (frontal and parietal cranial bones), the zygomatic as well as the 
endochondral occipital bone. After clearing the stained embryos, all the areas 
described above can be seen in greater detail (Fig. 4.5B), while in Fig. 4.5C & 4.5D 
it is visible that Lac-Z activity in the long bones is localized in the osteogenic 
perichondrium surrounding the developing ossifying centers. Also, the intensity of 
the staining in the OMDLacZ/LacZ embryos was usually stronger compared to the 
OMD+/LacZ heterozygotes.  
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Figure  4.4: OMD expression in E15.5 embryos. Whole mount X-gal staining of wild type, heterozygous and homozygous knock-out embryos demonstrating Lac-Z 
activity in the developing skeleton. Signal is seen in the long bones of hands and legs, the ribs, the metatarsals and metacarpals, the digit tips, the vertebral bodies, the 
snout and the bones of the head, i.e. frontal, parietal, zygomatic and occipital bones. No background signal is seen in the wild type embryos. Scale bar, 2mm for all 
images. 
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Figure  4.5: Cleared OMD+/LacZ embryos after X-gal staining. (A) A closer image of the limbs showing 
Lac-Z activity in the digit tips, the metatarsals and metacarpals, and the long bones of the hand and leg. (B) 
A whole-mount X-gal stained and cleared embryo, where all the β-gal positive areas can be seen in greater 
detail. (C) Magnified view of (B) demonstrating β-gal signal in the periosteum of tibia, fibula and femur. 
(D) Another close-up view of (B) showing OMD expression in the osteogenic perichondrium of radius, 
ulna, humerus, metacarpals (arrows), digit tips (arrowheads) and also the lower jaw (mandible) and 
zygomatic bone around the eye. Scale bars, 2mm. F, femur; Fi, fibula; T, tibia; H, humerus; M, mandible; 
R, radius; U, ulna; Z, zygomatic bone. 
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As most of the signal observed was related to skeletal tissues, the bone 
formation process will be briefly described here in order to understand in detail the 
areas where OMD is expressed. Osteogenesis can be divided into two major modes, 
both of which involve the transformation of pre-existing mesenchymal tissue into 
bone tissue. The bones of the skull are formed by the process known as 
intramembranous ossification, where mesenchymal tissue is directly converted into 
bone, whereas the axial skeleton and the long bones of the limbs are formed by the 
other pathway, called endochondral ossification. In the later process mesenchymal 
cells aggregate to form cartilage tissue which is subsequently replaced by bone 
(Horton, 1990). Endochondral ossification can be divided into five stages, starting 
with the commitment of mesenchymal cells to become cartilage cells (induced by the 
transcription factors Pax1 and Scleraxis). Secondly, these mesenchymal cells 
condense and differentiate into chondrocytes (cartilage cells), which then rapidly 
proliferate to form a spatial model for the future bone, secreting at the same time a 
cartilage-specific ECM. At this stage the cartilage model is surrounded by the 
perichondrium.  In the next stage the perichondrium around the diaphysis (the central 
area where calcification occurs) becomes periosteum (containing a layer of 
undifferentiated-osteoprogenitor cells) and a bone collar is produced. Internally, the 
chondrocytes stop dividing and increase their volume becoming hypertrophic 
chondrocytes, also enhancing their secreted matrix with collagen X and fibronectin 
so it can now be mineralised by calcium carbonate. Finally, while blood vessels 
invade this cartilage model, hypertrophic chondrocytes die by apoptosis and the 
space that is created becomes the bone marrow. At the same time, cells of the 
periosteum differentiate into osteoblasts, which also begin forming matrix in the 
partially degraded cartilage, and eventually most of the cartilage is replaced by the 
newly-forming bone. A schematic representation of osteogenesis, together with an 
example of X-gal stained E15.5 frontlimbs from OMD wild type and heterozygote 
embryos, is shown in Figure 4.6. 
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Figure 4.6: A brief description of osteogenesis. (A) The five basic steps of endochondral ossification. 
Detailed explanation is described in the text. Adopted by McGraw-Hill. (B) Schematic diagram of 
intramembranous ossification. Mesenchymal cells condense and differentiate into osteoblasts, which 
deposit osteoid matrix. These osteoblasts are arrayed along the calcified region of the matrix and become 
osteocytes once they are trapped within the bone matrix. Adopted by Gilbert SF, 2006.  (C) & (D) X-gal 
stained sagittal sections of E15.5 OMD+/+ and OMD+/LacZ frontlimbs demonstrating Lac-Z activity in the 
perichondrium/periosteum and the primary ossification groove of the heterozygote ulna (lower bone). 
Scale bar, 100μm for both images. mc, mature chondrocytes; hc, hypertrophic chondrocytes; poc, primary 
ossification center; ph, perichondrium; ps, periosteum.  
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The long bones of many mammals (including mice and humans) continue to 
grow after birth and this is possible due to the remaining cartilaginous tissue 
surrounding the ossified matrix. During bone formation, endochondral ossification 
grows outward in both directions from the center of the bone, but when the 
ossification front approaches the ends of the cartilage model the chondrocytes 
located close to the ossification front proliferate before they undergo hypertrophy so 
that they push the cartilaginous ends of the bone to extend. These areas at the two 
ends of the long bones are called epiphyseal growth plates and are essentially 
composed of three distinct chondrocyte regions, comprising of small proliferating 
chondrocytes, mature chondrocytes and hypertrophic chondrocytes. Thus, the bone 
can continue to grow for as long as the epiphyseal growth plate can produce 
chondrocytes. 
Following the whole-mount Lac-Z staining, embryos were embedded in paraffin, 
sectioned and counterstained with eosin in order to further analyze the β-gal 
expression in detail. In coronal sections of heterozygote 15.5 dpc embryonic heads 
we can see more clearly some of the areas described earlier. For example, β-gal 
signal can be seen in chondrocytes of the developing nasal septum (those located 
mostly around the edges), the mesenchyme in the distal tongue and the regions of the 
head undergoing ossification including the developing maxilla and the 
intramembranous frontal/parietal bones (Fig. 4.7). In contrast, the fatal brain and eye 
showed no signs of β-gal and therefore OMD expression. On sagittal sections of 
OMD+/LacZ embryos Lac-Z activity was detected in the perichondrium and mostly in 
the periosteum of long bones, i.e. humerus, scapula, radius, ulna, femur and tibia, as 
well as around the ribs and in chondrocytes of the vertebral bodies (Fig. 4.8). More 
specifically, cells in the primary spongiosa and the ossification grooves of the 
various bones in the developing appendicular and axial skeleton were always positive 
for β-gal, suggesting OMD expression in osteoblasts. In addition, X-gal staining was 
also observed in the ossified regions of the parietal and frontal cranial bones, as well 
as  in the ossified mandible, pre-maxilla, the nasal septum and the mesenchyme 
forming the tip of the tongue (Fig. 4.8 B, C&E), as shown already in the coronal 
sections of the head. Finally, in Figure 4.8 G&H and 4.8 I sections of the two femurs 
from a heterozygous embryo are shown, where it is clearly visible that OMD is 
expressed in the perichondrium/periosteum and in the forming ossification groove of 
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the diaphysis, where the primary ossification center is located.  There is no staining 
in mature or proliferating chondrocytes, whereas occasionally in some of the long 
bones a lower level of staining can be seen in the apoptotic hypertrophic 
chondrocytes (Fig. 4.8H).   
Figure 4.7: OMD expression in the E15.5 embryonic head. (A)-(D) Four different coronal sections 
of an OMD+/LacZ head demonstrating Lac-Z activity in the nasal septum, the ossifying maxilla and 
mandible, part of the tongue and the ossified frontal bone. (E) A magnified view of (A) showing β-gal 
signal in chondrocytes and in mesenchymal condensations around the edges of the cartilaginous nasal 
septum. Scale bars, 2mm for (A), (B), (C) & (D), 100μm for (E). M, mandible; Fr, frontal bone; To, 
tongue.  
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Figure 4.8: OMD expression in sagittal sections of X-gal stained OMD+/LacZ E15.5 embryos.  (A)-(C) Three different sagittal planes of a stained heterozygote 
15.5dpc embryo, demonstrating OMD expression in the long bones, the cranial bones, the nasal septum and the vertebrae. (D) View of a forelimb showing Lac-Z 
activity in the periosteum (ps) and perichondrium (ph) of ulna (U). (E) Magnified view of the lower jaw, where expression can be seen in the ossified mandible 
(M). (F) X-gal staining in chondrocytes of the vertebral bodies (vb). (G)-(I) Femurs exhibiting OMD expression in the periosteum and the primary ossification 
centre (poc). Scale bars, 2mm for (A)-(C), 140μm for (D), 100μm for (E)-(I).  
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4.2.3 OMD expression in E17.5 embryos 
Embryos at stage E17.5 were collected and whole mount-stained for X-gal 
overnight. Although the staining procedure worked, due to the big size and complete 
skin development of these embryos, penetration of the staining solutions in all 
internal tissues was unequal, resulting in variable coloration of the β-gal substrate, 
even between the same genotypes within a litter. Thus, it was decided to freeze down 
E17.5 embryos and subsequently stain single cryo-sections for β-gal expression. In 
addition, head and body were separated in all embryos (for better penetration of 
fixative and cryopreservation solutions) and were sectioned individually.  
Similar to E15.5 embryos, most of the β-gal signal can be seen in developing 
skeletal elements. After X-gal staining and clearing of E17.5 embryos, β-gal signal 
can be seen in the developing long bones and ribs of the axial skeleton, as well as in 
the cranial bones, the jaw and the tip of the tongue, as shown in Figure 4.9A. 
Sectioning and subsequent staining of OMD+/LacZ embryos revealed OMD expression 
in the periosteum and probably perichondrium all around the calcified long bones 
(Fig. 4.9). In addition, OMD expression is occasionally seen in proliferating or pre-
hypertrophic chondrocytes away from the ossification centres, for example in the ribs 
and the upper limb joints (Fig. 4.9B). Furthermore, expression of OMD in the 
vertebral column is located in the chondrocytes but also around the ossified regions 
of the vertebrae, as shown in Figures 4.9 D&E. More specifically, OMD appears to 
be expressed in the proliferating/resting chondrocytes of the vertebral discs but not in 
the hypertrophic/apoptotic chondrocytes (ossifying vertebral bodies) with only few 
cells of the inner annulus fibrosus (af) positive, while the collar bone around the 
ossified areas is again OMD-positive (Fig. 4.10 D&E). Faint β-gal signal can also be 
seen in the spinal cord (Fig. 4.9E). Moreover, in a longitudinal section of the femur 
β-gal positive signal can be seen in the primary spongiosa (psp), while less signal is 
seen now in the bone collar probably due to the fact that ossification has advanced 
and many more osteoblasts are now found in the forming bone matrix (Fig. 4.9 
F&G). Finally, very strong signal is observed in the digit tips of forelimb and 
hindlimb, and as shown in X-gal stained cryo-sections of the forelimb in Fig. 4.9H, 
mesenchymal cells between the outer skin and the chondrocytes of the digits are 
OMD positive along with the periosteum/perichondrium of the phalanges.
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Figure 4.9: OMD expression in sagittal sections of X-gal stained OMD+/LacZ E17.5 embryos. (A) Whole-mount stained and cleared E17.5 heterozygote embryo 
demonstrating X-gal staining in all the skeletal elements. (B) Part of the ulna showing β-gal signal in mature/proliferating and occasionally pre-hypertrophic, but not 
in hypertrophic chondrocytes. (C) Sagittal section of the whole embryo body. (D)-(E) Lac-Z activity in the vertebral discs and bodies can be seen in 
resting/proliferating chondrocytes and around the ossified matrix, while some signal is seen in the chondrocytes of the annulus fibrosus and the spinal cord. X-gal 
staining is observed all around the primary spongiosa in the femur (F)-(G), in the mesenchyme between the skin and the chondrocytes and also in the perichondrium of 
the digit tips (H), and in the perichondrium/periosteum and chondrocytes of the phalanges (I)-(J). Scale bars, 3mm for (A), (C), 140μm for (F), (I), 100μm for all the 
rest. af, annulus fibrosus; np, nucleus pulposus; ph, proliferating chondrocytes; phc, pre-hypert rophic chondrocytes; hc, hypertrophic chondrocytes; ph, perichondrium; ps, periosteum; 
psp, primary spongiosa. 
A wider view of the forelimb including phalanges and metacarpals is shown in Fig. 
4.9I, while in Fig. 4.9J a magnified view of the distal phalanx is demonstrated 
showing Lac-Z (and thus OMD) expression in the periosteum/perichondrium and the 
proliferating and pre-hypertrophic chondrocytes around the primary ossification 
center.  
In order to further analyse the expression of OMD in the embryonic E17.5 
mouse eye, brain and the rest of the head structures, frozen OMD+/LacZ heads were 
sectioned coronally from front to back and subsequently stained with X-gal. In Fig. 
4.10 four representative sections are presented. As shown in sections A and E, 
chondrocytes of the cartilaginous nasal capsule are positive for β-gal.  Further 
inwards the signal is decreased but maintained in the nasal septum chondrocytes 
closer to the epithelium (at the perichondrium), while there is no staining in the 
olfactory epithelium or the developing teeth (currently at the bell stage). In addition, 
cells around the ossifying regions of the maxilla and the mandible are also positive 
(resembling the expression found in the periosteum/perichondrium during 
endochondral ossification of the long bones) (Fig. 4.10 C, F, G).  Although staining 
was seen in the parietal and frontal bones of the head in the whole-stained and other 
paraffin-embedded sagittaly-sectioned embryos, when cryosectioning the head 
coronally we could not see the same strong signal possibly due to the small thickness 
of the sections. At the very back of the head signal was seen again around the 
periosteum/perichondrium of all the forming bones and in resting chondrocytes 
flanking the already ossified regions. Finally, no staining was observed either in the 
eye or the developing brain. 
Overall, during this developmental stage OMD is expressed mainly in skeletal 
elements, including mostly the perichondrium and periosteum of the long bones 
together with a population of resting chondrocytes, as well as in the cartilaginous 
nasal capsule, the mandible and maxillae, and the ossifying regions of the cranial 
bones.      
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Figure 4.10: OMD expression in coronal sections of X-gal stained OMD+/LacZ E17.5 heads. (A)-(D) 
Four different coronal planes showing Lac-Z activity in the nasal capsule and the ossified regions of the 
cranial bones. (E) Chondrocytes of the nasal septum positive for β-gal and therefore OMD. (F) β-gal 
signal in the periosteum of the alveolar bone, where osteoblasts are usually localized. (G) Deeper nasal 
septum demonstrating X-gal staining in chondrocytes located at the edges of the septum and around the 
ossified matrix of the maxilla. Scale bars, 3mm for (A)-(D), 100μm for (F) and (G).  
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4.2.4 OMD expression in new-born (P0) mice 
New-born (P0) neonates were collected within 16 hours of their birth time from 
OMD+/LacZ ♂ x OMD+/LacZ ♀ crossings, so all the 3 genotypes would occur within the 
same litter.  Size of the litters varied between 8-11 pups and the ratio of genotypes 
followed Mendelian inheritance, while no differences were observed in the size or 
gross anatomy between individual new-borns. Similarly to E17.5 embryos, after 
euthanization heads and bodies were separated and processed for freezing, followed 
by subsequent sectioning and staining with X-gal. Again, no staining was observed 
in any OMD+/+ sections, while β-gal signal was very strong in all the skeletal 
elements in OMD+/LacZ sections. 
 More specifically, in coronal sections of the head X-gal staining was seen 
initially in the chondrocytes of the cartilaginous snout and in some mesenchymal 
cells around the infranasal depression (Fig. 4.11A). In sections further into the head, 
staining was restricted to the perichondrium all around the cartilaginous nasal septum 
and in some of the chondrocytes forming the main part of the septum/nasal capsule. 
B-gal signal was observed in a few cells of the prospective olfactory epithelium, 
whereas in the vomeronasal organ (VNO) signal was only present in the vomeronasal 
cartilage and not in the epithelium (Fig. 4.11 B-D). B-gal was also observed in all the 
ossified regions of both the maxilla and mandible, with the signal being very strong 
in the periosteum and less intense within the osteoid matrix, while the areas around 
the palatal shelf fusions were also stained blue (Fig. 4.11 & 4.12). Furthermore, 
substantial staining was observed in all the developing teeth, including the maxillary 
and mandibular incisors and molars, where most of the dental papilla was β-gal 
positive together with a proportion of the pre-odontoblasts/odontoblasts (Fig 4.11B 
& 4.12 A-B). Signal was also seen in mesenchymal cells of the tongue, initially 
located mostly between central muscle groups and under the dorsal epithelium, while 
further in the tongue positive cells were mostly confined under the epithelium, 
possibly in the lamina propria.      
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Figure 4.11: OMD expression in coronal sections of X-gal stained OMD+/LacZ P0 heads. Lac-Z activity can 
be seen in chondrocytes of the nasal septum and around the infranasal depression, in (A). The signal is 
expanded to the incisors and the ossified regions of the maxilla and mandible, in (B) and (C). (D) B-gal signal 
can be seen in the edges of the cartilaginous vomeronasal organ (VNO), in chondrocytes of the nasal septum 
and in the surrounding ossified matrix. (E) Magnified view of ossified maxilla demonstrating β-gal signal, and 
thus OMD expression, in the periosteum and within the matrix of the bone, probably in osteoblasts. Scale bars, 
3mm for (A)-(C), 150μm for (D), 50μm for (E). id, infranasal depression; ns, nasal septum; i, incisors, Max, 
maxilla; Man, mandible; to, tongue.  
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Figure 4.12: OMD expression in coronal sections of X-gal stained OMD+/LacZ P0 heads (continued). (A) 
Lac-Z activity is observed in the cartilaginous nasal septum, the ossified alveolar bones of the mandible and 
maxilla, the ossified frontal bones and in the developing mandibular and maxillary molars. (B) Magnified 
view of the mandibular molar demonstrating strong β-gal signal in the dental papilla and in a proportion of 
the odontoblasts, but not in the ameloblasts. (C) Lac-Z expression is seen in the marginal chondrocytes of the 
nasal septum and in the periosteum of the neighbouring bones. (D) β-gal signal in the periosteum (arrow) and 
within the matrix of the frontal bone. Scale bars, 3mm for (A), 100μm for (B)-(D). m, molar; Max, Maxilla; 
Man, mandible; ns, nasal septum; to, tongue; dp, dental papilla; od, odontoblasts; am, ameloblasts. 
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As mentioned earlier, all the ossified regions of the head are positive for OMD, 
including the calvaria bones, i.e. the frontal and parietal, as well as the zygomatic 
and occipital bones. In the posterior half of the head positive for b-gal are also the 
hyoid and basisphenoid bone/canals, the exoccipital bones and the ossified atlas 
(again the signal is stronger in the periosteum/perichondrium), as seen in Figure 4.13 
A&B. Unlike the calvaria and the rest of the mouse skull bones that develop by 
intramembranous ossification, these last bones belong to the cranial base and develop 
by endochondral ossification. Thus, cranial base bones harbor all the different zones 
of the maturing chondrocytes flanking the ossification centers, similar to developing 
long bones. In Figure 4.13C and 4.13D the ossified center of the basisphenoid bone 
and the chondrocytes flanking the center of the hyoid bone are shown respectively, 
where OMD expression is strongly localised to the periosteum (and maybe a small 
area of the perichondrium) and to the zone of proliferative chondroblasts. Weaker 
signal can be seen within the osteoid matrix, indicating that OMD is either secreted 
from or expressed in the osteoblasts trapped in the forming osteoid, as well as in 
some of the resting chondrocytes, probably the ones that are committed to divide 
later or will be part of the perichondrium. The same expression pattern can be seen in 
the ossified exoccipital bones and atlas (Fig. 4.13B and in detail Fig.4.13E). Finally, 
weak, "spotty" OMD expression can be seen in the developing choroid plexus and 
other thalamic areas of the brain, as well as in areas of the spinal cord (Fig. 4.13F). 
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Figure 4.13: OMD expression in coronal sections of X-gal stained OMD+/LacZ P0 heads (last). In the 
posterior part of the head Lac-Z activity is observed in the hyoid and basisphenoid bones & canals, as well as 
in the exoccipital bones and the atlas, in (A) & (B). (C) Magnified view of the basisphenoid bone 
demonstrating β-gal signal in the periosteum and inside the osteoid matrix (arrows). (D) Magnified view of 
the hyoid bone, which develops by endochondral ossification and therefore harbours all the different 
chondrocytic populations around the ossification centre. X-gal staining is visible in the periosteum as well as 
in the proliferating chondrocytes and in part of the pre-hypertrophic chondrocytes, but not in the hypertrophic 
ones, reminding the expression pattern seen in the long bones. (E) Similar expression can be observed in the 
growing atlas, where columnar chondrocytes but also the forming osteoid matrix (arrow) is positive for β-gal. 
(F) Lac-Z activity is observed for the first time in the spinal cord. Scale bars, 3mm for (A)-(B), 100μm for 
(C)-(D), 50μm for (E)-(F). bb, basisphenoid bone; bc, basisphenoid canals; hb, hyoid bone; eb, exoccipital 
bone; at, atlas; pc, proliferating chondrocytes; phc, pre-hypertrophic chondrocytes; hc, hypertrophic 
chondrocytes. 
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Regarding OMD expression in the body of newborn OMD+/LacZ mice, sagittal 
sections from a heterozygote mouse are displayed in Figure 4.14, where it is visible 
that OMD is mostly expressed in the periosteum and within the osteoid matrix of all 
the skeletal elements. This is very noticeable when looking at the long bones of the 
forelimb, i.e. radius and ulna at Figure 4.14C and humerus at Fig. 4.14D. Strong b-
gal signal is very specific around the forming cortical bone, as well as in the 
trabecular osteoid matrix found in the bone marrow cavity, indicating probable 
expression of OMD by osteoblasts (Fig. 4.14E). Also, some proliferating or probably 
resting chondrocytes at the edges of the growing bone are positive for X-gal, as well 
as chondrocytes found at the ribs (Fig. 4.14 A and D, arrows). In addition, signal can 
be observed in and around the ossified vertebrae, while resting and/or proliferating, 
but not hypertrophic, chondrocytes are also positive (Fig. 1.14 F&H). Similarly to 
E17.5 embryos, faint signal is also seen in the spinal cord (Fig. 4.14F). Finally, in a 
magnified cross-section of the clavicle bone, we can observe clear OMD expression 
around the bone cavity, where cortical bone is being synthetized (Fig. 4.14G).  
Overall, OMD expression is quite strong in p0 mice and is confined around all 
the ossified bone structures in both axial and appendicular skeletal elements, while at 
this stage expression can be also observed in the growing teeth, as well as in areas of 
the brain.  
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Figure 4.14: OMD expression in sagittal sections of X-gal stained OMD+/LacZ P0 bodies. Lac-Z activity can be seen in the ribs and the vertebral bodies 
in sagittal whole-body sections in (A) and (B), while signal is also seen in the periosteum and within the bone matrix in the upper limb (i.e. radius and ulna) 
in (C). (D) Β-gal signal in the humerus bone is localised in the periosteum and within the osteoid matrix, but also in proliferating or resting chondrocytes 
(arrows). (E) Magnified view of the humerus demonstrating expression in the developing cortical (periosteum) but also trabecular bone (within the forming 
osteoid matrix), indicating OMD expression by osteoblasts. (F) & (H) X-gal staining in the vertebral bodies is observed in the ossified matrix and in 
chondrocytes surrounding the ossification centres and in the annulus fibrosus. No signal is seen in the nucleus pulposus of the vertebral discs. (G) Cross-
R, radius; U, ulna; vb, vertebral bodies; np, nucleus pulposus; af, annulus fibrosus, sc, spinal cord.
section of the clavicle showing Lac-Z activity in the cortical bone. Scale bars 3mm in (A)-(B),140μm in (C)-(D), 100μm in (F), (G), (H) and 50μm in (E). 
4.2.5 OMD expression in adult mice 
Heterozygous and homozygous transgenic mice grew into adulthood, were 
fertile and had a normal life span without any apparent abnormalities and with 
normal reproductive rate. In order to examine OMD expression during adult life 
various internal organs were isolated from OMD+/LacZ adult mice and subsequently 
stained for β-galactosidase. The organs that were analysed are brain, eye, bladder, 
and bone, and all will be presented and discussed below, each in a separate sub-
section. Due to the nature of the speciments, X-gal activity in the bone, and 
specifically in the knee joint, covering part of femur and part of tibia, was assessed 
by whole-mount staining, followed by decalcification and subsequent cryo-
sectioning, while all the other organs where fixed, sectioned and afterwards stained 
for X-gal. Unfortunately, X-gal staining was inadequate to confirm specific OMD 
expression in other organs, such as kidney and spleen, due to endogenous b-
galactosidase activity in the control OMD+/+ sections. In such cases in situ 
hybridization was performed to explore the expression of mRNA OMD gene 
transcripts using wild type OMD+/+ samples. However, this approach failed twice and 
therefore focus was given on the other organs. In addition, after confirming the 
expression patterns of OMD in each organ, immunofluorescence staining was 
performed to identify the specific cell types that were positive for β-gal, and thus 
OMD.  
4.2.5.1 OMD expression in the adult mouse bladder 
In order to investigate if OMD is expressed in the mouse bladder, whole 
bladders were isolated from adult OMD+/LacZ and OMD+/+ littermates and after 
processing and sectioning were subsequently stained for hematoxylin and eosin 
(H+E) and X-gal.  As shown in figure 4.15A, the mouse bladder, similarly to 
humans, is composed of two distinct parts, the epithelium that coats the urogenital 
tract from the renal pelvis to the urethra called the urothelium, and the surrounding 
muscle layer, which includes the internal and external layers. The mouse urothelium 
consists of 3 different cell layers: the basal cells (which form a single layer resting on 
the basal membrane of the epithelium), the intermediate cells and the most 
superficial “umbrella” cells (which are parallel to the basal membrane and “cover” 
the intermediate cells, Fig. 4.15B arrows).  X-gal staining of OMD+/LacZ bladders 
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revealed β-gal expression only at the urothelium  and specifically in or around the 
umbrella cell layer (Fig. 4.15 C-D), while OMD+/+ samples didn’t have any β-gal 
positive staining. 
Further staining with several markers against the three different layers of the 
bladder urothelium confirmed β-gal, and thus OMD, expression in the superficial 
umbrella cell layer. More specifically, antibodies against uroplakin-3 (umbrella 
cells), laminin (basement membrane of the epithelium), CK5 (cytokeratin 5-
intermediate/basal cells), and CK18 (cytokeratin 18-umbrella cells) were used. In 
OMD+/LacZ bladders β-gal positive cells were always co-localised with uroplakin-3 
and CK18, but not with laminin or CK5, and thus we can conclude that OMD is 
expressed in a subpopulation of the umbrella epithelial cells (Fig. 4.16).  
 Figure 4.15: Mouse bladder morphology and OMD expression in X-gal stained OMD+/LacZ 
bladders. (A) H+E stained OMD+/+ bladder where the different parts, i.e. lumen (Lu), urothelium (U) 
and muscle (MlIn, musclaris internal; MlE, muscularis external) are visible. (B) Magnified view of 
the urothelium (U) and underlying lamina propria (LaPr). Outer umbrella cells are marked with 
arrows. (C)-(D) X-gal staining in OMD heterozygote bladders is observed in the outer urothelial 
layer, probably in umbrella cells. In (D) the X-gal signal is coloured red and DAPI is used to stain 
cell nuclei. Scale bars, 500μm for (A), 100μm for (B)-(D).  
Figure 4.16: OMD expression in the adult mouse bladder is localised in the umbrella cell layer. Panels (i) represent X-gal staining, (ii) are specific antibody staining using 
alexa-488 (green) as secondary, while in panels (iii) are the merged images with the X-gal signal coloured red and DAPI used as a cell nuclei stain. B-gal signal is co-localised with 
uroplakin (A-iii) and CK18 (B-iii), but not with laminin (C-iii) or CK5 (D-iii), indicating OMD expression in the umbrella cell layer. Scale bar, 100μm for all images.  
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4.2.5.2 OMD expression in the adult mouse eye 
Whole eyes from OMD+/LacZ and OMD+/+ littermates were isolated, 
cryopreserved and sectioned sagittaly after freezing. Initially, H+E staining was 
performed in sections from a wild type control sample in order to identify and 
familiarise with all the separate areas of the mouse eye. As shown in figure 4.17A, 
the major components are the lens, which occupies most of the space and is 
surrounded by the vitreous, the cornea and sclera, the ciliary body (CB), the retinal 
pigment epithelium (RPE) and the multi-layered retina with the optic nerve 
connecting to the brain. Figure 4.17B shows all the retinal cell layers in detail, while 
in Figure 4.17C a higher magnification of the CB is shown, where the inner 
pigmented cell layer can be distinguished from the outer non-pigmented epithelial 
cell layer. The trabecular meshwork can also be recognised just below the CB and 
above the sclera. 
Performing X-gal staining in OMD+/LacZ eye sections revealed OMD expression 
in the retinal ganglion cell layer and part of the inner nuclear layer (Fig. 4.17D). In 
addition, positive β-gal signal was seen in the ciliary body, and more specifically at 
the non-pigmented epithelium of the CB (Fig. 4.17E). In order to identify the specific 
cell types where OMD is expressed, immunofluorescence staining against various 
mouse retinal markers was performed after the X-gal reaction. Initially, OMD was 
co-localised with Pax6 (a marker for retinal ganglion cells-RGCs, amacrine, 
displaced amacrines and retinal stem cells of the CB) in a sub-population of cells 
both in the retinal ganglion cell layer and the inner nuclear layer. In addition, a 
number of cells of the non-pigmented epithelium of the CB were also positive for 
Pax6 and β-gal (Fig. 4.18). Moreover, all the cells exhibiting b-gal signal were also 
positively stained with HuC/HuD, a marker for new-born neurons (which essentially 
stain all RGCs), horizontals and amacrine cells, thereby confirming that OMD is 
expressed in the retinal ganglion cell layer and in the amacrines of the inner nuclear 
layer, but not in horizontal cells (Fig. 4.19A). In addition, using AP2-alpha which 
marks only the displaced amacrines at the RGC and the amacrines at the INL, shows 
that a small sub-population of the cells expressing OMD at the RGC are displaced 
amacrines (Fig. 4.19B). Looking closer at the INL, we can see that OMD is 
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expressed in the space between the amacrine cells but does not overlap with the cell 
bodies (Fig. 4.19B).  
Figure 4.17: Mouse eye morphology and OMD expression in X-gal stained OMD+/LacZ eyes. (A) 
Section of a wild type sample stained with H+E demonstrating the major parts that form the mouse 
eye. (B) H+E stained mouse retina with all the different retinal cell layers labelled. RGC, retinal 
ganglion cells; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexifrom layer; ONL, 
outer nuclear layer; IS, inner segments; OS, outer segments; RPE, retinal pigment epithelium; CH, 
choroid; SC, sclera. (C) Ciliary body (CB) of the eye stained with H+E. TM, trabecular meshwork; 
SC, sclera. (D) Lac-Z activity in the OMD heterozygous retina can be seen in the ganglion cell layer 
and in part of the INL. (E) In the ciliary body Lac-Z activity is observed in the non-pigmented 
epithelial cells. Scale bars, 1mm for (A), 100μm for (B)-(D), 50μm for (E).  
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Moreover, Islet-1, a marker for horizontals, bipolar and RGCs, was co-localised 
with the x-gal signal only in few cells in the retinal ganglion cell layer, whereas there 
was no X-gal activity in bipolar or horizontal cells (Fig. 4.19C). In conclusion, OMD 
was found to be expressed in the retinal ganglion cells, but also in a sub-population 
of amacrines and displaced amacrines.  As expected, no β-gal signal was seen in the 
wild type samples. 
Figure 4.18: OMD expression in the adult mouse retina and CB is co-localised with Pax6-positive 
cells. Panels (i) represent X-gal staining, (ii) are Pax6 antibody staining using alexa-488 (green) as 
secondary, while in panels (iii) are the merged images with the X-gal signal coloured red. B-gal signal 
in the retina can be observed in a sub-population of Pax6 positive cells in the RGC and INL layers, 
while in the ciliary body the signal is always around Pax6-positive epithelial cells. Scale bar, 50μm for 
all images. RGC, retinal ganglion cells; IPL, inner plexiform layer; INL, inner nuclear layer. 
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Figure 4.19: OMD is expressed in retinal ganglion cells, amacrines and displaced amacrines. Panels (i) represent X-gal staining, (ii) are 
specific antibody stainings using alexa-488 (green) as secondary, while in panels (iii) are the merged images with the X-gal signal coloured 
red. B-gal signal is co-localised with HuC/HuD-positive cells, indicating OMD expression in RGCs and amacrines (A). X-gal staining is also 
co-localised with AP2-α-positive cells indicating OMD expression in displaced amacrine cells in the RGC layer and in a sub-population of 
amacrine cells in the INL (B), while no signal is present in horizontal cells, marked with Islet-1 (C). Scale bars, 50μm for (A)-(B), 100μm for 
(C). RGC, retinal ganglion cells; IPL, inner plexiform layer; INL, inner nuclear layer. 
4.2.5.3 OMD expression in the adult mouse brain 
As described before, whole brains were isolated from adult OMD+/LacZ and 
OMD+/+ littermates and were either whole-mount stained for X-gal, or processed for 
cryo-sectioning and subsequently stained. In the latter case, X-gal staining was 
performed in serial sections covering the whole brain from the olfactory lobes to the 
end of the cerebellum. 
Starting with the whole-mount stained heterozygote sample, intense X-gal signal 
was observed in the whole cerebrum area, but not in the olfactory lobes, the 
cerebellum, the optic nerves (arrows) or the optic chiasm (arrowhead) (Fig. 4.20 
A&B). Sagittaly cutting the brain in the middle of the left hemisphere revealed that 
all the areas of the cortex, the accessory olfactory bulb, the caudate putamen 
(striatum), the hippocampus and the hypothalamic areas were strongly stained, while 
less signal is present in the midbrain, the thalamic areas and the pons/medulla (Fig. 
4.20C). No staining at all was seen the corpus callosum or the anterior commissure. 
Magnified views of the striatum and the hippocampus are shown in Figure 4.20 E 
and F respectively, demonstrating blue "spotty" staining all around the fibres of the 
internal capsule, whereas all the pyramidal neuronal areas together with the dentate 
gyrus were also positive for β-gal, and thus OMD. In addition, faint staining was 
observed around the main blood vessels (Fig. 4.20G) as well as in specific cells 
lining the cortex of the cerebellum (Fig. 4.20H). No background staining was seen in 
the wild type brain (Fig. 4.20D), indicating the specificity of the β-gal signal in the 
heterozygote animals. 
All these areas were studied in more detail using cryo-sectioned OMD+/LacZ 
brains, and as expected blue "spotty" staining was seen in all the aforementioned 
areas. Firstly, β-galactosidase activity was observed in all the parts of the anterior 
olfactory area (dorsal, medial, lateral and ventral), the frontal association cortex, all 
the parts of the orbital cortex (dorsolateral, lateral, ventral and medial) and at the 
prelimbic cortex. Moving closer to the bregma, the positive staining continued 
throughout most of the regions of the brain, including the caudate putamen and all 
the areas of the cortex, but not the corpus callosum, the anterior commissure or the 
optic nerves (Fig. 4.21 A&E). In addition, β-gal signal was occasionally seen around 
the capillaries (Fig. 4.21, arrowheads). Moving further along the posterior axis and 
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after passing the bregma, β-gal activity, and thus OMD expression, is continued 
throughout the cerebral cortex, the striatum and the globus pallidus, around all the 
thalamic regions and also at the hippocampal region, as already shown. More 
specifically, all three fields of CA1, CA2 and CA3 pyramidal cell populations of the 
hippocampus as well as the dentate gyrus are expressing OMD (Fig. 4.21 B&D), 
while very modest signal can be observed in the choroid plexus (Fig. 4.21G). Lastly, 
in the cerebellum area there is distinct β-gal staining between the cerebellar 
commissure and the ansiform lobules, somewhere between the granular and the 
molecular layer, probably where the Purkinje cells reside (Fig 4.21 C&F).  
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 Figure 4.20: OMD expression in the adult mouse brain. Brains were isolated from OMD+/+ and 
OMD+/LacZ animals and were whole-mount stained for X-gal. (A)-(B) Dorsal and ventral sides of the 
brain demonstrating Lac-Z activity in the whole cerebrum but not the optic verves (arrows) or the 
optic chiasm (arrowhead). Cutting the brain sagittaly revealed β-gal signal in all the internal areas, 
including the cortex, the hippocampus, the striatum and the thalamic areas (C), while no background 
staining is observed in the wild type sample (D). (E) & (F) Magnified views of the hippocampus and 
the striatum respectively. Faint β-gal signal can be seen occasionally in the ventricles (G), while in 
(H) X-gal staining in specific cells of the cerebellum is visible. Scale bars, 2mm for (A)-(D), 250μm for 
(E), 200μm for (F), 150μm for (G), 1mm for (H). cr, cerebrum; ce, cerebellum; ol, olfactory lobes; sc, spinal 
cord; co, cortex; cp, caudate putamen (striatum); aob, accessory olfactory bulb; h, hippocampus; t, thalamus; ht, 
hypothalamus; p, pons; m, medulla. 
Figure 4.21: OMD expression in sections of the adult mouse brain. Brains from OMD heterozygous 
mice were cryo-sectioned and subsequently stained with X-gal. (A)-(C) Three different coronal planes 
demonstrating Lac-Z activity, and thus OMD expression, all around the cortex, striatum, hippocampus, 
thalamic areas and in the cerebellum. (D) Magnified view of the hippocampus showing Lac-Z activity in all 
the pyramidal cell populations and the dentate gyrus. B-gal signal as seen in the striatum area (E), in the 
cerebellum between the molecular and granular cell layer, where Purkinje cells are located (F), whereas 
faint staining is occasionally seen in the choroid plexus (G). Scale bars, 1mm for (A)-(C), 140μm for (D) 
and (F), 100μm for (E) and (G). co, cortex; cp, caudated putamen (striatum); cc, corpus callosum; ac, anterior 
commissure; on, optic nerve; h, hippocampus; t, thalamus; ht, hypothalamus; gp, globus pallidus; ml, molecular layer; 
gcl, granular cell layer; wm, white matter; cp, choroid plexus; dg, dentate gyrus; CA1/2/3, pyramidal cell populations of 
the CA1/2/3 fields.
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As explained before, in order to identify the specific cell types where OMD is 
expressed, immunofluorescence against various mouse neural markers, following X-
gal staining, was performed on OMD+/LacZ samples. The antibodies that were used 
included NeuN (a neuron-specific protein which is present in most CNS and PNS 
neuronal cell types), β-III Tubulin-neuronal (an antibody against beta III tubulin 
specific for neuronal cell types of the CNS/PNS), GFAP (Glial Fibrillary Acidic 
Protein-a marker for astrocytes) and calbindin (a marker for Purkinje cells). In Figure 
4.22 co-localisation of OMD with NeuN-positive neurons is demonstrated in two 
different areas of the brain, i.e. the cortex and part of the hippocampus in panels A 
and B respectively. As also indicated by arrowheads, the spotty X-gal signal is 
always found within or in the periphery of NeuN positive cells, suggesting that OMD 
is largely expressed by neurons. Moreover, using the neuronal specific anti-β-III 
tubulin marker, we observe that, although the majority of OMD expressing cells are 
not positive for the marker, in certain areas (including parts of the hippocampus and 
the cortex) β-III tubulin neurons do express OMD (Fig. 4.23 panel A, hippocampus). 
In addition, as demonstrated in a higher magnification image (Fig. 4.23 panel B), β-
signal appears to be systematically localised in the cytoplasm or around the nucleus 
of the expressing cell (arrowheads). Furthermore, regarding astrocytic populations, 
only few GFAP-positive cells co-expressed β-gal. However, as the X-gal staining is 
mostly found around the nuclei and not within neuronal dendrites or axons, it was 
quite difficult to identify the localisation of the signal in cells with neuronal 
processes, like astrocytes. An example is given in Figure 4.24A, where OMD 
expression is seen around a cell nucleus, which in this case probably belongs to the 
neighbouring GFAP positive astrocyte (arrowhead). Finally, in the cerebellum, OMD 
expression was confirmed in the Purkinje cell layer using the calbindin marker, 
whereas signal was also seen in the molecular layer, where it is either localised in 
Purkinje axons or is additionally expressed in nearby basket cells (Fig. 4.24B). 
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Figure 4.22: OMD is expressed in adult neurons. Panels (i) represent X-gal staining, (ii) are NeuN antibody 
staining using alexa-488 (green) as secondary, while in panels (iii) are the merged images with the X-gal signal 
coloured red and DAPI (blue) used as a nuclei stain. B-gal signal is co-localised with NeuN-positive neurons in 
the cortex (A) and in pyramidal cells of the hippocampus (B), as also noted with arrowheads. Scale bar, 100μm 
for all images. C, cortex; GrDG, granule dentate gyrus; CA3-Py, pyramidal cells of CA3 field. 
166 
Figure 4.23: OMD is expressed in adult neurons (continued). Similarly to before, panels (i) represent X-gal 
staining, (ii) are β-ΙΙΙ neuronal tubulin staining using alexa-488 (green) as secondary antibody, while in panels 
(iii) are the merged images with the X-gal signal coloured red and DAPI (blue) used as a nuclei stain. In (A) 
strong Lac-Z activity can be seen in the granule dentate gyrus (GrDG), where not many cells are positive for 
β-ΙΙΙ tubulin. B-gal signal is also seen in polymorph cells (PoDG), where it is co-localised with β-III positive 
neurons, while more diffuse X-gal staining can be seen in the molecular layer (MoDG). (B) A magnified view 
of cells in the PoDG demonstrates X-gal staining (and therefore OMD expression) in β-ΙΙΙ tubulin positive 
neurons, and specifically in the cytoplasm adjacent to the cell nuclei (arrows). Scale bars, 100μm for (A), 
50μm for (B). GrDG, granule dentate gyrus; PoDG, polymorph dentate gyrus; MoDG, molecular dentate 
gyrus. 
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Figure 4.24: OMD is expressed in Purkinje cells and occasionally in astrocytes. (A) X-gal staining 
overlapped with anti-GFAP immunostaining (marking astrocytes), using an alexa-488 (green) as secondary 
and DAPI to stain the cell nuclei. As indicated by the arrowhead Lac-Z activity is occasionally seen in close 
vicinity of GFAP-positive cells, suggesting that it might be also expressed by these cells. (B) X-gal staining in 
the cerebellum overlapped with anti-Calbindin immunostaining (marking Purkinje cells), visualised with an 
alexa-546 (red) secondary antibody. In panel (iii) X-gal is coloured green and DAPI is used as nuclei stain. B-
gal signal is localised within the soma of the Purkinje cells, while faint signal can be observed in either the 
Purkinje dendrites or in the adjacent basket cells. Scale bars, 50μm for all images. 
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4.2.5.4 OMD expression in the adult mouse bone 
Evaluation of OMD expression in the adult bone was performed on the knee 
joint including part of the femur and the tibia. As mentioned before, X-gal activity 
was assessed through whole-mount staining of the tissue, followed by decalcification 
and cryo- or paraffin-sectioning.  Sectioning and subsequent X-gal staining, that 
would give more accurate results, was not applicable in this case, as decalcification 
(which is necessary at this stage) would nullify the β-gal enzyme. Figure 4.25A is a 
representative image of an OMD+/LacZ knee joint, where X-gal staining can be 
generally seen in the periosteum, in articular cartilage of the femur and the patella, 
and in part of the meniscus. More specifically, in Figures 4.25 B&C we can observe 
strong OMD expression in the outermost layer of articular chondrocytes, while 
strong signal is also seen in the deposited osteoid matrix in the dorsal part of the 
femur as well as in the matrix/periosteum of the patella (arrows) and additionally in 
the tendon (arrowhead). Expression at the articular cartilage located at the centre of 
the joint is either not present or cannot be observed due to inadequate X-gal staining 
in deeper parts of the tissue, while another view of the positively stained cartilage 
including part of the femur and the meniscus is shown in panel E. Furthermore, 
intense staining is observed again in the cortical osteoid at the ventral side of the 
femur, suggesting OMD expression or deposition of the protein in the surrounding 
matrix by osteoblasts/osteocytes (Fig. 4.25D). In addition, in a magnified view of the 
cortical bone surrounding the bone marrow, clear OMD expression can be seen in the 
outer cortical layer (maybe the periosteum, arrow), but also within the matrix, where 
trapped osteoblasts (osteocytes) usually reside (arrowheads), further supporting 
expression of the protein by the latter cells. Interestingly, very faint "spotty" X-gal 
staining was also seen within the bone marrow (black arrowheads). Finally, in Figure 
4.25G a section from an OMD+/+ sample is presented, demonstrating minor 
background staining just below the chondrocytic growth plate (in detail in panel H), 
confirming the specificity of the β-gal signal under the OMD promoter in the current 
circumstances.  
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Figure 4.25: OMD expression in the adult bone. (A) X-gal stained knee joint from OMD+/LacZ animals demonstrating Lac-Z activity in 
the periosteum of the femur and tibia, and in articular cartilage. (B) B-gal signal can be seen in greater detail in the periosteum of the 
patella and within the osteoid matrix of the femur (arrows), but also in the patella tendon (arrowhead). Further signal in the articular 
cartilage is shown in (C) and (E), while OMD expression in the cortical bone (or periosteum) of the femur is also displayed in (D) and (F-
arrow). Lac-Z activity is also seen in the trapped osteoblasts of the cortical bone (arrowheads), while faint signal can be observed in the 
bone marrow (black arrowheads), in (F). (G) & (H) Section of a wild type sample showing minor background staining just below the 
chondrocytic growth plate. Scale bars, 500μmfor (A), (G), 200μm for (B), 50μm for (F), 100μm for all the rest. f, femur; t, tibia; p, patella; m, 
meniscus; ac, articular cartilage; cb, cortical bone.
4.3 Discussion 
In this part of the project the newly engineered OMD knock-out mice were used 
to characterise OMD expression during embryogenesis and in adult life. In this 
model, exons 2 and 3 (where the transcription domain is located) are replaced with a 
Lac-Z cassette, generating viable and fertile heterozygous (OMD+/LacZ) and 
homozygous (OMDLacZ/LacZ) mice, without any obvious congenital abnormalities 
during development or after birth. During development most of the Lac-Z activity 
was seen in craniofacial and skeletal tissues, in agreement with some of the previous 
studies showing OMD expression in bovine, rat and mouse bone (Petersson et al., 
2003; Sommarin et al., 1998; Sugars et al., 2013). During adulthood Lac-Z activity 
remained present in the mature bone, but was also expanded to other tissues, such as 
bladder, eye and brain.  
OMD expression during embryonic development is localised in the developing 
axial and appendicular skeleton 
OMD expression was examined through whole-mount and whole-body section 
X-gal staining of embryos at stages E12.5, E15.5, E17.5 and new-borns (P0). 
Intensity of the staining was always higher in the OMDLacZ/LacZ than OMD+/LacZ 
animals, while no background staining was present in OMD+/+ embryos, 
demonstrating the efficiency of the new mouse model. At the earliest stage (12.5 
dpc) Lac-Z activity was limited in mesenchymal condensations of the developing 
mandible, while signal was also visible in the cartilage primordia of the front limbs 
in homozygote knock-out embryos (Fig. 4.2 & 4.3). The previous studies that have 
been published so far demonstrate OMD expression mainly in mature osteoblasts and 
do not include analysis at this early stage of mouse development. It is therefore 
noticeable that, OMD was found to be expressed in non-differentiated mesenchymal 
cells or pre-cartilage mesenchymal condensations, indicating a possible role the gene 
might play from the very early events of skeletogenesis. 
  In E15.5 embryos the development has progressed and osteogenesis has already 
initiated, with most of the long bones consisting of an avascular cartilage anlagen 
and pre-hypertrophic/hypertrophic chondrocytes in the diaphysis, while the 
perichondrium around that area becomes periosteum and cells start to differentiate 
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into osteoblasts (Gilbert SF, 2000). During this stage X-gal activity is seen in all the 
long bones, the digit tips, the ribs, the metacarpals/metatarsals and also the 
mandible/maxilla and the developing bones of the head (Fig. 4.4, 4.5, 4.7, 4.8). In 
sagittal sections of heterozygote embryos β-gal signal is specifically observed in the 
perichondrium/periosteum of long bones (such as radius, ulna, and femur, Fig. 4.8), 
suggesting expression of OMD in differentiating osteoblasts surrounding the primary 
ossification centre. These findings are in partial agreement with the recently 
published study on OMD expression during endochondral bone formation (Sugars et 
al., 2013). In this study, Sugars et al. focused on OMD expression in mouse 
metatarsal bones during stages E15, E18, P0, 5-days old and adult mice, where they 
showed expression within the primary ossification centre from stage E18 onwards, 
but not in E15 metatarsals. This can be attributed partly to the slightly earlier stage 
(E15 vs. E15.5), where the developing metatarsal is consisted still of only 
chondrocytes and mainly perichondrium and therefore, if no differentiating 
osteoblasts are present, OMD might not be expressed yet. In addition, in that study 
immunohistochemistry was performed using an anti-OMD antibody, which might 
not have been very efficient. During this project many anti-OMD antibodies were 
tested (Table 2.4) with either cell lysates of our over-expressing EJ28 cells or mouse 
tissues where we had confirmed expression through X-gal, and none of these 
antibodies showed a constant and specific signal. Finally, β-gal signal is also seen in 
some parts of the vertebral bodies, which at this stage are mostly consisting of 
chondrocytes (Fig. 4.8F), suggesting OMD expression in non-differentiated cartilage 
cells that are though probably committed to become osteoblasts.  
Regarding expression in the cranio-facial tissues during this stage, X-gal activity 
was present in the forming intramembranous bones (frontal, parietal), the ossified 
regions of the mandible and maxilla, and also in chondrocytes of the nasal septum 
together with mesenchymal condensations of cells surrounding the latter area (Fig. 
4.7). Again, there have been no studies describing OMD expression in the current 
context, with the exception of one paper by Nikdin et al. focusing in OMD 
expression during mouse tooth development and dentinogenesis during stages E15, 
17, new-born and adult animals (Nikdin et al., 2012). In this study, OMD was 
detected by immunohistochemistry in the alveolar bone from E17 onwards, while no 
signal was seen in the tooth until dentinogenesis was well-established in P0 mice. In 
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agreement with these findings, we did not observe any β-gal signal at the early bell 
stage of the tooth in E15.5 mice, but we did see some expression in the surrounding 
bone, which again could be attributed to the slightly different stage and the method 
of detection.  
X-gal staining persisted in the same pattern in E17.5 OMD+/LacZ embryos, where 
signal is seen again in all the long bones, the ribs, the vertebrae, the nasal septum and 
the alveolar bone in the head (Fig. 4.9 & 4.10).  During this stage osteogenesis has 
advanced and the primary spongiosa is now properly formed, while osteoid matrix 
has been deposited in place of the hypertrophic chondrocytes. In the long bones, 
OMD expression is again evident in the periosteum, but with more specific 
localization now around the ossifying matrix (e.g. femur in Fig. 4.9 F-G), while 
smaller bones that have not advanced in the same stage yet (e.g. phalanges in Fig. 4.9 
H-I-J) show strong staining in the perichondrium/periosteum surrounding the pre-
apoptotic/apoptotic chondrocytes. It is noticeable that during this stage of 
development X-gal activity is observed in proliferating/mature chondrocytes of the 
vertebrae and occasionally in long bones (e.g. upper limb bone Fig. 4.9B and 4.9 D-
E, J). While Sugars et al. also showed OMD expression in the endosteal surface and 
the deposited osteoid of the primary spongiosa in E18 metatarsals (Sugars et al., 
2013), no localization of OMD was shown in any type of chondrocytes in previous 
studies. 
Also, we can only assume the stage of chondrocytic maturation where β-gal 
signal is observed judging from the shape and size of the cells. It is known that 
during endochondral bone formation the epiphyseal growth plates are surrounded by 
chondrocytes divided into three distinct types/regions, including the 
proliferating/columnar cells (which are flattened and small), the mature/pre-
hypertrophic (which are round and enlarged) and the hypertrophic/apoptotic (which 
become 5–12 times bigger and eventually die, triggering vascularisation and bone 
formation) (Kronenberg, 2003). Each chondrocyte, but also osteoblast, 
developmental stage is characterized by expression of specific genes, which include 
Col2a1 (collagen 2) and Acan (aggrecan) for early chondrocytes; Fgfr3 (fibroblast 
growth factor receptor 3) for columnar cells; Ppr (parathyroid hormone-related 
protein receptor), Ihh (Indian hedgehog), and Col10a1 (collagen 10) for 
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prehypertrophic cells; Mmp13 (matrix metalloproteinase 13) and Bsp (bone 
sialoprotein) for apoptotic chondrocytes  and also mature osteoblasts, whereas early 
osteoblasts express Osx (Osterix) and Col1a1 (collagen 1) (Dy et al., 2012; Lefebvre 
and Smits, 2005; Zuscik et al., 2008).  Therefore, utilization of the above markers 
together with X-gal staining can define the exact cell types where OMD is expressed 
during endochondral bone formation as it progresses throughout the different 
developmental stages.  
 Lastly, β-gal expression remained through some chondrocytes of the nasal 
septum, while signal was also seen in the ossified regions of the mandible and 
maxilla, including the alveolar bone but not the developing teeth (Fig. 4.10) in line 
with previous findings (Nikdin et al., 2012). X-gal activity was not observed in any 
of the visceral organs (bladder, kidney, liver, etc.) or the eyes and brain during the 
three developmental stages that were examined, suggesting that OMD is not 
expressed in any pre-mature soft tissues, at least up to this developmental time point.  
The expression pattern of five SLRPs (not including OMD or PRELP) was 
analysed by RNA in situ hybridisation at E14.5 mouse embryos by Wilda and 
colleagues (Wilda et al., 2000). At this stage (which is relatively close to E15.5), 
chondroadherin and fibromodulin are both expressed in the cartilaginous skeleton, 
lumican is lowly expressed in the nasal capsule and cartilaginous vertebrae, while 
decorin and biglycan show a more diffused expression pattern in connecting tissue 
derivatives, such as organ capsules, blood vessels walls, meninges and mesenchymal 
surroundings of skeletal structures (Wilda et al., 2000). Therefore, it is obvious that 
expression of SLPRs during development is quite variable, and although some 
proteins may share similar patters others are expressed in completely different 
tissues, indicating the multiple roles these molecules have even during early mouse 
development.  
OMD expression in new-born mice persist mainly in the developing skeleton 
In new-born OMD+/LacZ mice the X-gal activity was overall increased compared 
to the previous stages, indicating elevated OMD expression. In both the head and 
body β-gal signal is very strong in all the ossified regions, and specifically at the 
periosteum, but also within the deposited osteoid matrix (Fig. 4.11, 4.12, 4.13 and 
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4.14). This pattern suggests OMD expression in osteoblasts, in consonance with 
previous studies demonstrating osteoadherin expression in mouse tibia, bovine 
trabecular bone and in mouse osteoblast cell cultures (Rehn et al., 2008; Sommarin et 
al., 1998; Sugars et al., 2013; Wendel et al., 1998). Expression in chondrocytes can 
still be observed, but is now limited in the vertebrae, in some of the long bones 
depending on the cutting angle of the sample (e.g. Fig. 4.14D), in the nasal septum 
and also in the bones of the cranial base (hyoid, basisphenoid, exoccipital bones), 
which develop by endochondral ossification (Fig. 4.13). Similarly to before, X-gal 
activity seems to be present in the proliferating/mature chondrocytes, but staining 
with markers is needed to confirm this assumption. Overall, OMD expression seems 
to follow a specific pattern during endochondral osteogenesis, where expression 
starts in the perichondrium/periosteum surrounding the primary ossification centers, 
while at the same time expression is seen also in columnar chondrocytes surrounding 
the ossification groove. When ossification progresses, OMD is expressed 
additionally within the osteoid matrix.  
Characteristic at this stage is also the strong Χ-gal activity observed in the 
developing teeth, including the top and bottom incisors, (Fig. 4.11 B & C 
respectively), as well as the top and bottom molars, which are currently at the bell 
stage (Fig. 4.12). Intense signal is seen in the dental pulp and also in the odontoblast 
layer, excluding though some polarized odontoblasts located under the secondary 
enamel knots and also the ameloblast cell layer (Fig. 4.12B).  These findings are in 
opposition to previous studies showing OMD expression only in the pre-
dentin/dentin phase and not in the pulp or the osteoblasts of P0 mice (Couble et al., 
2004; Nikdin et al., 2012). These differences could be attributed to the different 
detection methods used. However, X-gal staining of OMD+/LacZ embryos was always 
consistent and very specific to the described areas and no activity was seen in any 
OMD+/+ samples, indicating true and precise signal. In addition, the pre-
dentin/dentin phase is still very thin in P0 mice and staining with H+E or specific 
markers is probably needed to differentiate between this area and the adjacent 
osteoblasts in our sections. Thus, we cannot exclude Χ-gal staining in the dentin 
layer under the current observations, but more focused study of the developing teeth 
is needed, including also later stages of development where the dentin gets thicker 
and enamel is also deposited. Another study by Lucchini et al. showed expression of 
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osteoadherin in human dental pulp and odontoblasts, while the same group had 
shown previously OMD expression in ameloblasts and odontoblasts of 19-day old rat 
embryos (Buchaille et al., 2000; Lucchini et al., 2004). Hence, OMD expression 
pattern in the developing tooth is quite variable, possibly owning to the efficacy of 
different antibodies or the detection of different forms of the protein, like the core 
protein versus different levels of glycosylated proteoglycan with added GAG chains.  
Finally, no Χ-gal activity was observed in new-born heterozygote internal 
organs, although, as shown in Figure 4.14 A&B, it was technically difficult to study 
the viscera, as this part of the embryo body had the tendency to fall off the slide and 
was not stained properly. Thicker sections and increased fixation (which was avoided 
in order to keep the enzymatic activity of the β-galactosidase intact) might help solve 
this problem.  
OMD is expressed in the adult mouse bladder, eye, brain and bone 
Identifying OMD expression in the mouse bladder was of primary interest since 
this project was initially based on the lack of OMD and PRELP in human bladder 
cancer cells. Using our novel knock-out mice and through X-gal staining of 
OMD+/LacZ samples, OMD expression was defined in the adult mouse bladder. As 
discussed in the previous section, β-gal was not seen in any of the internal organs 
during mouse embryonic development, suggesting that OMD is mainly functioning 
in skeletogenesis in the course of embryonic growth. Interestingly, OMD expression 
expanded to several other organs during adulthood, including the bladder, the eye 
and the brain. 
The mouse bladder is mainly composed of two distinct parts, the urothelium and 
the surrounding muscle layer; the urothelium in turn consists of three different cell 
layers, the basal, intermediate and the superficial umbrella cells (Birder and 
Andersson, 2013). X-gal activity of heterozygote OMD+/LacZ samples was observed 
in the surface of the umbrella cell layer (Fig. 4.15 C&D), while co-localisation of the 
β-gal signal with uroplakin and CK18, both specific markers for umbrella cells, 
confirmed this result (Fig. 4.16). Studies on SLRP expression in bladder are very 
limited, and mostly include decorin and biglycan. These two SLRPs were found to be 
expressed in the surface of umbrella cells in human bladders in a study conducted by 
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Hauser et al., while in another paper expression was seen in the interstitial area 
surrounding the muscle layer and not in the urothelium (Hauser et al., 2008; 
Maciejewski et al., 2012). Since the bladder urothelium is also densely coated with a 
layer of proteoglycans and glycoproteins referred to as the glycosaminoglycan 
(GAG) layer (Grist and Chakraborty, 1994), it is not surprising to find proteins that 
are characterised by chondroitin, keratan and dermatan sulphate side chains, like the 
SLRPs, in the umbrella cells. Furthermore, this GAG layer was proposed to play a 
major role in maintaining impermeability of the bladder urothelium and disruption of 
this layer is often seen in interstitial cystitis (IC) (Parsons et al., 2002), indicating a 
possible role that SLRPs and other proteoglycans might have in this environment. 
Lastly, a more recent study by Hurst et al. demonstrated a decrease of chondroitin 
sulphate in human IC bladders correlating with decreased ZO-1 staining (Hurst et al., 
2007), showing a possible connection of proteoglycans and tight junction formation, 
which we already demonstrated in Chapter 3. 
Expression of OMD in the mouse adult eye, through Χ-gal staining, was 
observed in the retinal ganglion cell layer (RGC), in part of the inner nuclear layer 
(INL) and in the non-pigmented epithelial cells of the ciliary body (CB) (Fig. 4.17). 
Immunostaining with specific retinal markers like Pax6, HuC/HuD, AP2-alpha and 
Islet-1 confirmed β-gal signal in the RGCs, in a sub-population of amacrines in the 
INL/displaced amacrines in the RGC layer, and in the epithelium of the CB (Fig. 
4.18 & 4.19). Six other SLRPs have been found to be expressed in the mouse eye, 
including keratocan in mouse/chick cornea (Conrad and Conrad, 2003); fibromodulin 
and decorin in the mouse adult retina (Ali et al., 2011); opticin in the human and 
mouse eye, specifically in the vitreous and the non-pigmented CB (Ramesh et al., 
2004; Takanosu et al., 2001), lumican in mouse corneal stroma (Ying et al., 1997) 
and tsukushi (TSK) in the lens epithelium and CB (Ohta et al., 2011). SLRPs that are 
localised in the cornea are considered to play key roles in modulating hydration of 
the corneal stroma and regulate corneal transparency, while for those localised in the 
retina it has been suggested that they can contribute to retinal cell differentiation and 
survival (Ali et al., 2011; Liu et al., 2003).  In addition, TSK affects peripheral eye 
development through regulation of Wnt2b signaling in the CB area (Ohta et al., 
2011). It is therefore obvious that SLRPs affect eye formation and function in 
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various ways. Expression of OMD in both the mouse retina and CB suggests it may 
have multiple roles in mouse eye biology. 
X-gal staining of the heterozygote adult mouse brain revealed wide OMD 
expression in almost the whole brain with the exception of few areas like the 
olfactory bulbs, the corpus callosum and the optic nerves. All the other areas, 
including cortex, caudate putamen, hippocampus, choroid plexus, hypothalamic 
areas, cerebellum and pons were stained positively for Lac-Z activity, while there 
was no staining in the wild type samples indicating the specificity of the β-gal signal 
(Fig. 4.20 & 4.21). Moreover, double staining with X-gal and several different 
neuronal and glial markers showed widespread localisation of the β-gal signal in 
neurons, Purkinje cells and probably a sub-population of astrocytes (Fig. 4.22, 4.23 
and 4.24). The above novel findings suggest that OMD must play a crucial role in 
neuronal cell functions or signaling. To date, involvement of SLRPs in brain biology 
is very narrow and few studies have been published on this subject. Two of these 
studies involve tsukushi, demonstrating TSK expression in the sub-ventricular zone 
of the adult mouse brain, while TSK null mice fail to form the anterior commissure 
(Hossain et al., 2013; Ito et al., 2010). Another two studies assessed the expression of 
SLRPs in the rat anterior pituitary gland and showed that decorin, biglycan, 
fibromodulin, lumican, PRELP and also OMD are all expressed in this area, where 
some of them are specifically localised in folliculostelate cells and pericytes 
(Horiguchi et al., 2013; Syaidah et al., 2013). Lastly, decorin was also found to be 
expressed in many areas of the brain in P21 young rats, including the neocortex, 
hippocampus, thalamus, choroid plexus and blood vessels (Kappler et al., 1998). 
Thus, many SLPRs are quite likely to have variable expression patterns in the murine 
brain and could play multiple roles in the neural environment, a field that is 
unfortunately highly under-studied so far.   
Finally, OMD expression was assessed in the adult bone, in the area of the knee 
joint including part of the femur and tibia. Lac-Z activity was observed in the 
periosteum and the cortical bone, while osteoblasts trapped in the bone matrix were 
also positive (Fig. 4.25F). These findings are in agreement with previous studies 
showing consistent OMD expression in mouse and bovine bones and osteoblasts 
(Ninomiya et al., 2007; Sommarin et al., 1998; Sugars et al., 2013; Wendel et al., 
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1998), indicating the role OMD has in bone matrix mineralisation. Lac-Z activity 
was also seen in the articular chondrocytes of the femur and also the meniscus, 
whereas no staining was seen in any of the chondrocytes in the epiphyseal plate (Fig. 
4.25A, B, C & E). We therefore observe a shift of OMD expression from the 
proliferating chondrocytes in the developing embryo and new-born to only articular 
cartilage in the adult mouse.  Also, this is the first time OMD expression has been 
reported in any kind of cartilage in the mouse. Finally, Lac-Z activity was not seen in 
the trabecular bone. However, the staining method has to be taken into consideration 
here, since whole-mount X-gal staining before sectioning may lead to partial and 
insufficient colouration of all parts of the tissue.     
Summary  
In summary, OMD is expressed in all the skeletal elements during mouse 
embryonic development and this expression is maintained in the adult bone. 
Expression appears to be localised in different cells, including chondrocytes and 
mesenchyme, but is mostly seen in osteoblasts, indicating its role in matrix 
mineralisation. OMD is also expressed in the mouse adult bladder, eye and brain, 
suggesting multiple and probably different roles in every organ. 
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Chapter 5  
 
Expression patterns of the PRELP gene in 
mouse  
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5.1 Introduction 
PRELP (proline, arginine-rich end leucine-rich repeat proteoglycan) is an 
extracellular matrix leucine-rich repeat protein, which belongs to class II of the 
SLRP family. PRELP is the only member of this family with a basic amino-terminal 
region that contains a high number of proline and arginine residues, while this 
domain has been shown to bind heparin and heparan sulfate (Bengtsson et al., 2000; 
Bengtsson et al., 1995).  In addition, PRELP binds perlecan (a basement membrane 
heparin sulfate proteoglycan) and also collagen types I and II through its LRR 
domain (Bengtsson et al., 2002). Based on its extracellular localization and its 
interaction with the above factors, PRELP was proposed to function as a link 
between cells and ECM, but also as a molecule anchoring basement membranes to 
the underlying connective tissue (Bengtsson et al., 2000; Bengtsson et al., 2002). 
PRELP was firstly isolated as a component of bovine articular cartilage with a 
molecular mass of 58 kDa, while radioimmunoassays demonstrated its presence in 
other bovine tissues as well, including kidney, sclera, liver, skeletal muscle, cornea, 
skin, and tendon  (Heinegard et al., 1986). Grover et al. demonstrated PRELP 
expression in human adult, but not fetal, cartilage and meniscus (Grover et al., 1995). 
The same group found later, by immunohistochemistry and in situ hybridization, that 
PRELP is widely expressed in the mouse skeletal cartilage during development, 
whereas in adults the expression becomes more pronounced in the growth plates 
rather than the articular surface of the joints, in contrast to the human expression 
pattern (Grover and Roughley, 2001). Furthermore, Lui et al. demonstrated that 
PRELP is specifically expressed in proliferating chondrocytes of the adult rat tibia, 
while high PRELP expression was also found in human chondrocytes and 
intraarticular mesenchymal stem cells (Lui et al., 2010; Segawa et al., 2009). Lastly, 
apart from skeletal elements, PRELP was also found to be expressed in the human 
sclera, together with other SLRPs, where it was suggested as a possible candidate in 
regulating the biomechanical properties of scleral extracellular matrix (Johnson et al., 
2006). 
  Although the exact biological functions of PRELP have not been elucidated 
yet, there are some studies showing involvement of this SLRP in pathological 
conditions. For instance, PRELP deficiency may account for Hutchinson-Gilford 
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progeria, which is characterized by the lack of collagen binding in basement 
membranes and cartilage (Lewis, 2003). Moreover, overexpression of PRELP in 
transgenic mice resulted in structural changes in the skin, accompanied by a decrease 
in collagen fiber bundles, and the hypodermal fat layer, suggesting interaction of 
PRELP with fibroblasts, adipocytes and the ECM components (Grover et al., 2007). 
On a different course, PRELP has been shown to inhibit the formation of the 
complement membrane attack complex (MAC), thereby limiting pathological 
complement activation in inflammatory diseases such as rheumatoid arthritis (RA) 
(Happonen et al., 2012; Happonen et al., 2009). Recently, PRELP-mediated 
inhibition of the MAC complex was successfully employed in adeno-associated virus 
gene therapy of an in vivo mouse model of wet age-related macular degeneration 
(AMD) (Birke et al., 2014). Complement inhibition has also been proposed as a new 
concept for cancer treatment, so this might constitute another possible mechanism 
through which PRELP could affect tumour growth (Pio et al., 2013). Finally, two 
studies by Rucci et al. demonstrated the ability of the heparan-binding domain of 
PRELP (hbdPRELP) to impair osteoclastogenesis via cell type-specific NF-κB 
inhibition, resulting in the prevention and cure of both osteoporosis and breast cancer 
osteolytic metastases in a variety of preclinical in vivo models (Rucci et al., 2013; 
Rucci et al., 2009), highlighting the therapeutic potential of PRELP in various 
pathological conditions.  
 In vivo knock-out models are very important as they provide essential 
information on the functional roles of genes. However, no knock-out murine models 
for PRELP have been established to date. In collaboration with Takeda 
Pharmaceutical Company, we have generated the first PRELP KO mouse model, 
where, similarly to the OMD model, the coding sequence of the PRELP gene has 
been replaced with a Lac-Z reporter cassette so that transcription under the PRELP 
promoter leads to β-gal expression instead of PRELP. Since the expression patterns 
of PRELP have only been roughly studied in mice, the primary aim of this chapter is 
to examine in detail the temporal and spatial expression of PRELP during embryonic 
development and in adult life. Similarly to OMD, this is achieved through X-gal 
staining of heterozygote PRELP+/LacZ animals, while the effect of PRELP depletion is 
analysed in the next chapter. 
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5.2 Results 
PRELP knock-out mice were constructed in Takeda with a similar strategy as 
the OMD knock-out model, where exons 2&3 (where the transcription domain is 
located) were replaced with a Lac-Z reporter gene. After receiving founders of the 
transgenic mice, our mouse colony was established through heterozygote-pair 
breeding as PRELP+/lacZ animals were fertile and produced litters containing all three 
genotypes. Heterozygote and knock-out animals grew normally into adulthood, while 
no apparent phenotypic differences could be seen during expansion of the colony. In 
Figure 5.1A a simple schematic of the PRELP gene locus and the position of the 
reporter gene are shown, while Figure 5.1B demonstrates the result of an example 
genotyping set. 
Figure 5.1: Knock-out strategy and genotyping of PRELP mice. (A) Schematic drawing of the 
PRELP gene locus and the Lac-Z insertion site together with the primer pairs used for genotyping. (B) 
An exemplar agarose gel from a genotyping set demonstrating the bands corresponding to the 
different genotypes. 
 
 
-ve 
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PRELP protein expression – similarly to OMD – was examined through X-gal 
staining of mouse embryos during 3 developmental stages (12.5dpc, 15.5dpc and 
17.5dpc), where expression was mostly seen in the developing cartilaginous skeleton 
and partly in the early developing brain, and also at day of birth (P0) where it was 
mainly localised in cartilaginous tissues. Interestingly, during adulthood (again 
similarly to OMD) this expression pattern appeared to be expanding to many internal 
organs, including specific areas of the brain, bladder and eye. Detailed analyses of 
the gene expression in every developmental stage and in several organs will be 
presented and discussed below.  
5.2.1 PRELP expression in E12.5 embryos 
Embryos were collected at 12.5dpc after arranged time-matings and litters were 
whole-mount stained for β-galactosidase. PRELP+/+ embryos had no staining at all, 
while PRELP+/LacZ and PRELPLacZ/LacZ embryos showed staining in the forebrain, 
interestingly in a symmetrical pattern of two lines starting from the anterior part of 
the forebrain and extending towards the midbrain; the  hindbrain, the developing 
somites and the chondrocytic condensations of the developing limbs (Fig. 5.2).  In 
knock-out litter-mates expression pattern was exactly the same as seen in 
heterozygotes but with more intense staining, and long-bone cartilage primordia of 
the hindlimb were stained in addition to the frontlimb. After tissue-clearing the 
already X-gal stained embryos, all the stained areas can be seen more accurately 
(Fig. 5.3). In particular, we can see that the two lines of PRELP-positive cells in the 
head are indeed part of the forebrain; the neural tube and the notochord are both also 
stained, while in the hindbrain it appears that the 4th ventricle roofplate has the most 
intense signal. Looking closer at the hindbrain area we can see β-gal signal at the 
midbrain/hindbrain boundary, probably co-localised with the expression domains of 
Wnt1 and Fgf8 where, together with the floorplate, the isthmic organizer is located 
(Fig. 5.3C, arrows). 
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Figure 5.2: PRELP expression in E12.5 transgenic embryos. Whole-mount X-gal staining of PRELP 12.5 
dpc litters. Lac-Z activity is seen in the PRELP+/LacZ and PRELPLacZ/LacZ embryos in two symmetrical lines 
starting from the anterior part of the brain and extending towards the midbrain, and also in the hindbrain 
around the 4th ventricle roofplate area (arrows). B-gal signal can be also observed in the developing limbs and 
in the somites (arrowheads). Scale bar, 1mm for all images. 
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Sectioning of stained PRELP+/LacZ embryos was performed separately for head 
and body in the coronal direction and in whole embryos in sagittal direction (Fig. 
5.4). In sections of the head the β-gal signal found in the forebrain appeared to be 
confined in the hippocampal allocortex and specifically in the cortical hem just 
above the developing choroid plexus (Fig. 5.4 A-C, arrowheads). However, the 
strong signal seen in the hindbrain of the whole-mount stained embryos is not that 
visible upon sectioning. As shown in Figure 5.4D, only faint signal is seen in the 
dorsal area of the 4th ventricle, maybe in the cerebellum ventricular zone (Fig 5.4D, 
arrow).  In addition, in sagittal sections of the whole embryo faint staining is visible 
in the chondrocytic condensations of the forelimb (Fig. 5.4F), while we can also see 
signal in the notochord (Fig. 5.4G). 
 
Figure 5.3: PRELP expression in cleared X-gal stained PRELP+/LacZ E12.5 embryos. Embryos 
were cleared after being whole-mount stained for X-gal. Lac-Z activity can be seen in the forebrain 
and hindbrain, the somites, the neural tube (Leatherbarrow et al.) and the notochord (arrowhead), 
and also in the developing limbs. Scale bar, 1mm for all images. 
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 Figure 5.4: PRELP expression in sections of an X-gal stained PRELP+/LacZ E12.5 embryo. (A)-(D) Four 
different coronal planes of the embryonic head demonstrating Lac-Z activity in the area of the hippocampal 
allocortex and specifically in the cortical hem(arrowheads), just above the developing choroid plexus (marked 
with an arrow); cp, choroid plexus. The same area can be seen in a sagittal section of the whole embryo (E, 
arrowhead), while only faint signal is seen the hindbrain upon sectioning, which is localised in the dorsal area 
of the 4th ventricle (D, arrow). (F) Enlarged view of the developing forelimb showing β-gal signal in 
chondrocytic condensations. (G) Lac-Z activity can be seen in the notochord of sagittaly sectioned embryos. 
Scale bars, 1mm for (A)-(E), 100μm for (F), 140μm for (G).  
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5.2.2 PRELP expression in E15.5 embryos 
Embryos were again collected at 15.5dpc after time-matings and the whole litter 
was stained for β-galactosidase overnight. Wild type embryos had no staining, while 
heterozygotes and knock-outs were both stained in some areas of the head but mostly 
in the developing skeleton (Fig. 5.5). Also, the intensity of the staining was much 
stronger in PRELPLacZ/LacZ compared to PRELP+/LacZ animals, as expected. As 
demonstrated in Figure 5.5, Lac-Z activity can be seen in the snout, in what probably 
is the nose cartilage, and in the back of the head in the whole area surrounding the 
future parietal and occipital bones, while in knock-out embryos (where the signal is 
stronger) faint staining can also been seen in the midbrain area. Furthermore, 
regarding the axial skeleton, β-gal activity can be seen in the developing vertebrae, 
the long bones of hands and legs, as well as in the cartilaginous formations of the 
digits including the metacarpals and phalanges of the forelimb and hindlimb. An 
enlarged view of the limbs showing the area in greater detail can be seen in Figure 
5.6A. In addition, the ribs and the sternum are also positive for β-gal and thus 
PRELP (Fig. 5.5). 
Similar to before, tissue clearing was performed in order to visualize the stained 
areas in greater detail. In Figure 5.6 B-D a cleared PRELPLacZ/LacZ embryo is 
presented, where it is visible that PRELP is expressed in the cartilaginous parts of the 
developing long bones, whereas it is absent from the center of the bones where the 
primary ossification center is localised. This is more obvious when looking at the 
forelimb, i.e. radius and ulna, together with the humerus and scapula (Fig 4.6D, 
arrows). Moreover, looking closer at the ribs we can see that the area adjacent to the 
vertebral column, where ossification firstly takes place, is not positive for PRELP, 
while the distant cartilaginous parts are expressing PRELP. In addition, apart from 
the nasal capsule some signal is also seen in the mandible area, probably in the 
forming lower jaw or in Meckel’s cartilage (Fig 4.6B). Thus, it appears that PRELP 
expression is mostly confined to the cartilaginous elements of the growing axial and 
appendicular skeleton.       
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Figure 5.5: PRELP expression in E15.5 embryos. Whole mount X-gal staining of wild type, heterozygous and homozygous knock-out embryos demonstrating Lac-Z 
activity in the developing skeleton, and specifically in the ribs, the long bones of the limbs, the phalanges and metatarsals/metacarpals, and the vertebrae. In the head, staining 
can be seen in the nasal area and also in the back of the head. No background signal is seen in the wild type embryos. Scale bar, 2mm for all images. 
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Following the whole-mount LacZ staining, embryos were embedded in paraffin, 
sectioned and counterstained with eosin in order to further analyze the β-gal 
expression in detail. Some embryos were sectioned whole either sagittaly or 
coronaly, while in others head and body were separated for better angle positioning. 
Here, coronal sections of the head and sagittal sections of the body of a PRELP+/LacZ 
are presented, where the different elements expressing PRELP are clearer. Starting 
with the head, as demonstrated in Figure 5.7 A&C, β-gal signal is seen all around the 
nasal capsule and the cartilage primordium of the nasal septum. A little bit further 
into the snout (Fig. 5.7B) expression in the chondrocytes of the nasal capsule is 
decreased, while very faint signal can be seen the center of the tip of the tongue  and 
in the cartilage of the vomeronasal organ (Fig. 5.7D). On the contrary, intense β-gal 
Figure 5.6: Cleared PRELPLacZ/LacZ embryo after X-gal staining. (A) An enlarged view of the limbs 
from a heterozygote embryo showing Lac-Z activity in the metatarsals/metacarpals and their 
connections. (B)-(C) Lateral and dorsal view of a homozygote knock-out embryo after X-gal staining 
and clearing, showing Lac-Z activity in the developing skeleton, in the nasal area, the ribs and 
vertebrae, and also in the back of the head probably in developing cranial bones. (D) Closer view of 
the upper limbs, where X-gal staining is observed in the cartilaginous parts of the growing long bones 
but not in the middle where the primary ossification centre is located (arrows). The same pattern can be 
seen in the ribs with the staining declining in the ossified areas closer to the vertebral column 
(arrowhead). Scale bars, 2mm for all images. M, mandible; R, radius; U, ulna; H, humerus; S, scapula. 
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staining is present at the chondrocytes of both left and right Meckel’s cartilage as 
well as in the mesenchyme close to their fusion site (Fig. 5.7 E&F). While no 
staining is present at the primordia of incisors, moving towards the middle of the 
head very faint staining can be seen in the dental mesenchyme (dental papilla) of the 
upper and lower molars, which are at the dental cap stage (Fig. 5.8 A&D). In 
addition, moderate X-gal activity is seen in the cartilage primordia of all the cranial 
bones that develop by endochondral ossification, i.e. in the chondrocytes and the 
perichondrium of the basioccipital, sphenoid, exoccipital and temporal bones (Fig. 
5.8 A-C & E). Finally, as shown in Figure 5.8F, there is some diffused β-gal signal at 
the roof plate of the future aqueduct.     
Continuing with sagittal body sections of a PRELP+/LacZ embryo, LacZ activity is 
detected in all the cartilaginous tissues of the developing skeleton. In detail, β-gal 
signal is observed in the cartilage primordia of the tarsal and metatarsal bones, where 
it is visible that PRELP is expressed in almost all the different chondrocytic types 
apart from the hypertrophic ones, which are found around the middle of the bone 
where the primary ossification center will take place (Fig 5.9 A&H). Moreover, 
PRELP expression is seen in all the cartilaginous parts, which are not yet ossified, of 
the ribs, the sternum and the vertebral bodies (Fig 5.9 I&J). In all these elements 
expression is strong in the resting, proliferating, and pre-hypertrophic chondrocytes, 
while it decreases in the apoptotic hypertrophic chondrocytes until it is no longer 
present in the ossification groove (Fig. 5.9F). The same pattern of expression is 
observed as well in all the long bones of the frontlimb (i.e. radius, ulna, humerus) 
and the hindlimb (iliac bone, femur, tibia, fibula), where in addition signal is also 
visible in the perichondrium of the forming bones, and specifically around the 
proliferating and resting chondrocytes (Fig 5.9 D, E, G).  No signal is observed in the 
ossification grove, where osteoid matrix is deposited, or the periosteum around the 
primary ossification center. Lastly, X-gal staining is noticed in the deposits of brown 
(multiocular) fat (Fig. 5.9B).  
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 Figure 5.7: PRELP expression in the E15.5 embryonic head. (A)-(B) Two different coronal sections of an 
X-gal stained  PRELP+/LacZ head demonstrating Lac-Z activity in the nasal septum and in Meckel’s cartilage. 
(C) High magnification of the cartilaginous septum showing strong Χ-gal staining in the chondrocytes and 
the surrounding border. (D) Magnified view of the vomeronasal organ where faint β-gal signal can be seen 
only in the cartilaginous part. (E) & (F) Meckel’s cartilages characterized by strong X-gal staining in the 
chondrocytes and in the mesenchyme close to their fusion site. Scale bars, 2mm for (A)-(B), 100μm for (D) 
and (E), 50μm for (C) and (F). 
192 
Figure 5.8: PRELP expression in the E15.5 embryonic head (continued). (A)-(C) Three different coronal sections of an X-gal stained PRELP+/LacZ head 
demonstrating Lac-Z activity mainly in the cartilage primordia of all the cranial bones that develop by endochondral ossification, i.e. the sphenoid bones (sp), the 
temporal bones (tb) and the petrous parts of the temporal bones (ptb). Faint signal can also be seen in the dental papilla of the molars (D). (E) Magnified view of 
the sphenoid bone showing X-gal staining in the chondrocytes and in the perichondrium. (F) Diffuse X-gal staining is observed at the roof plate of the future 
aqueduct. Scale bars, 2mm for (A)-(C), 50μm for (D)-(F). 
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Figure 5.9: PRELP expression in sagittal sections of X-gal stained PRELP+/LacZ E15.5 embryos.  (A)-(C) Three different sagittal planes demonstrating PRELP 
expression in the cartilaginous skeletal elements of all the developing bones. (D)-(E) Two femurs exhibiting X-gal staining in almost all the chondrocytic 
populations surrounding the primary ossification centre, while β-gal signal is also seen in the perichondrium (arrow). (F) Magnified view of the primary ossification 
groove of the femur in (E), showing strong Lac-Z activity in proliferating chondrocytes (pc), moderate activity in pre-hypertrophic (phc) and very faint signal in the 
hypertrophic chondrocytes (hc). Also there is no staining in the periosteum. The same pattern can be seen in the upper limb joint (G), and also in the digits and the 
vertebral bodies, where β-gal signal is decreased in the hypertrophic chondrocytes where ossification will take place (H) & (I). Finally, X-gal staining is observed in 
the chondrocytes of the sternum/ribs (J), while some staining is also seen in the deposits of multiocular fat (mf) just above the shoulders. Scale bars, 2mm for (A)-
(C), 150μm for (D)-(E), 140μm for (G), 100μm for (H)-(I)-(J), 50μm for (F). R, radius; U, ulna; Hu, humerus. 
5.2.3 PRELP expression in E17.5 embryos 
Embryos at stage E17.5 were collected and whole mount-stained for X-gal 
overnight. Although the staining procedure worked, due to the big size and complete 
skin development of these embryos, penetration of the staining solutions in all 
internal tissues was unequal, resulting in variable coloration of the β-gal substrate, 
even between same genotypes within a litter. An example of a stained and cleared 
PRELP+/LacZ embryo is presented in Figure 5.10A, where it is visible that the 
enzymatic reaction took place only in the ventral part of the embryo. Thus, it was 
decided to freeze down E17.5 embryos and subsequently stain single cryo-sections 
for β-gal expression. In addition, head and body were separated in all embryos (for 
better penetration of fixative and cryopreservation solutions) and were sectioned 
individually.  
Staining pattern in E17.5 embryos is very similar to E15.5 with most of the β-gal 
signal seen in the cartilaginous elements of the developing axial and appendicular 
skeleton. As observed initially, in the partially stained whole-mount embryo, β-gal 
signal is present in the forelimb and hindlimb, where all the small bones i.e. 
phalanges and metatarsals are strongly stained. In the long bones signal appears to be 
confined to the cartilaginous parts extending towards the edges, while it is absent 
from the primary ossification center in the middle of the bones (Fig. 5.10A, arrows). 
In addition, signal is seen in the ribs and sternum, whereas in the head, the nasal 
septum together with some of the cranial bones is positive for X-gal.  
In X-gal stained sagittal cryo-sections of a PRELP+/LacZ embryo body all the 
areas described above can be seen in detail (Fig. 5.10 B&C). Firstly, PRELP signal 
in the metatarsals is present in all the chondrocytes apart from the apoptotic ones 
which will give space to the ossification groove (Fig 5.10D). Secondly, in the long 
bones of either hands or legs, PRELP is expressed only in the chondrocytes towards 
the edges of the bones (epiphyseal cartilage), while there is no expression at all in the 
diaphysis, including the primary ossification center and the periosteum. More 
specifically, in Figure 5.10 I&J magnified images of the left femur are presented, 
where we can see that the majority of mature/pre-hypertrophic, proliferating and 
resting chondrocytes are positive for b-gal, while very few apoptotic chondrocytes 
are stained. Additionally, another example of the shoulder joint is displayed in Figure 
195 
5.10 G&H, where the whole scapula and part of the humerus are included in the 
picture. Here we see the same pattern of expression, where signal is seen only in the 
mature, proliferating and resting chondrocytes but in addition we see that the 
articular cartilage – i.e. the chondrocytes that cover the ends of bones where they 
come together to form joints – is positive for β-gal, as well as some parts of the 
articular capsule and parts of the tendons surrounding the joint (Fig. 5.10H). Finally, 
in Figures 5.10 E&F two different cutting planes of the vertebral column are 
demonstrated showing Lac-Z activity in the proliferating/resting chondrocytes of the 
vertebral discs with few positive cells in the hypertrophic/apoptotic chondrocytes 
(ossifying vertebral bodies) accompanied by some positive cells in the annulus 
fibrosus (pf) and annuls pulposus (ap). Again, we see strong expression in the 
articular chondrocytes and the connecting tissue between each vertebral body, 
indicating PRELP as a component of the skeletal connecting-cartilage tissues (Fig.  
5.10F).     
In order to further analyse the expression of PRELP in the embryonic E17.5 
head, frozen PRELP+/LacZ heads were sectioned coronally from front to back and 
subsequently stained with X-gal. In Figures 5.11 and 5.12 six different section planes 
are presented, where we can see that b-gal expression is overall similar to E15.5 
heads, but has expanded to include some more areas. More specifically, PRELP is 
expressed in chondrocytes of the outer nasal capsule (Fig. 5.11A); in the inner nasal 
capsule the signal is lost (Fig. 5.11B), while chondrocytes of the nasal septum are 
again positive (Fig. 5.11C arrows). Few cells of the vomeronasal organ cartilage are 
b-gal positive, whereas both the right and left Meckel’s cartilages, together with their 
fusion site, are also positive (Fig 5.11 D&E). Furthermore, some b-gal signal can be 
seen in the cartilaginous parts of the developing sphenoid bones that have not yet 
been ossified (Fig 5.11C arrowheads). On the contrary, no signal is present neither in 
the eyes or the olfactory bulbs, nor in the teeth primordia or any ossified mandible 
and maxilla regions.  
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Figure 5.10: PRELP expression in sagittal sections of X-gal stained PRELP+/LacZ E17.5 embryos. (A) Whole-mount stained and cleared E17.5 heterozygote 
embryo demonstrating X-gal staining in all the cartilaginous skeletal elements. Arrows indicate primary ossification centres where staining is absent. (B)-(C) Two 
sagittal sections of the whole body showing X-gal staining in cartilage of long bones, ribs and vertebral bodies. (D) Magnified view of one metacarpal, where β-
gal signal is seen in all the chondrocytes apart from the hypertrophic (hc) ones where ossification starts. (E)-(F) Vertebral bodies (vb) exhibiting Lac-Z activity in 
proliferating, resting and articular chondrocytes but not in the ossified areas. Signal is also seen in the nucleus pulposus (np) and annulus fibrosus (af). (G)-(H) 
Shoulder joint displaying X-gal staining additionally in the articular cartilage (ac), parts of the articular capsule and the tendons surrounding the joint. (I)-(J) 
Section of a femur where strong  β-gal signal is observed in resting and proliferating (pc) chondrocytes, less signal is seen in pre-hypertrophic (phc) which 
declines even more in the hypertrophic chondrocytes (hc) until no staining is present at all in the ossified matrix. Scale bars, 3mm for (A)-(C), 200μm for (F), 140 
μm for (I) and (J), 100μm for (D), (E), (H), 50μm for (J). 
Figure 5.11: PRELP expression in coronal sections of X-gal stained PRELP+/LacZ E17.5 heads. (A)-(C) 
Three different coronal planes showing Lac-Z activity in the chondrocytes of the outer but not the inner 
nasal capsule, as well as in chondrocytes of the nasal septum (arrows) and in cartilage of the sphenoid 
bones (arrowheads). (D) Few cells of the vomeronasal cartilage are β-gal positive, while chondrocytes of 
the left and right Meckel’s cartilages are exhibiting Lac-Z activity (E). No staining can be seen in other 
parts of the head like the developing teeth or eyes. Scale bars, 2mm for (A)-(C), 100μm for (E), 50μm for 
(D). 
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Moving further into the posterior half of the embryo head, Lac-Z activity can be 
seen in all the cartilaginous parts of the developing endochondral cranial bones and 
also in some areas of the brain (Fig. 5.12). In detail, β-gal signal is observed in the 
cartilage primordia of the sphenoid, the temporal, the petrous part of the temporal 
and the basioccipital bones, as well as in the thyroid cartilage and the chondrocytes 
of the greater horn of hyoid bone (Fig. 5.12 A&B). In addition, moderate PRELP 
expression is also seen in the brain, in the dorsal part of the 3rd ventricle wall closure 
and specifically in the future ependymal cells (Fig. 5.12D), as well as in the 
premature choroid plexus of the 4th ventricle (Fig 5.12E). Lastly, X-gal staining can 
be seen in the mature, proliferating and resting chondrocytes surrounding the ossified 
regions of the exoccipital bone (same expression pattern as seen in the long bones), 
accompanied by strong expression in the chondrocytes of the articular cartilage in the 
atlas and the other cervical vertebrae (Fig. 5.12C and in detail 5.12F).  
In conclusion, during this developmental stage PRELP is expressed mainly in 
the developing skeletal elements, including mostly the mature, proliferating and 
resting chondrocytes, as well as in the articular cartilage between bone joints. Also, 
PRELP starts to be expressed in specific areas of the brain.  
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Figure 5.12: PRELP expression in coronal sections of X-gal stained PRELP+/LacZ E17.5 heads 
(continued). (A)-(C) Three different coronal planes showing Lac-Z activity in the cartilaginous parts of the 
developing endochondral cranial bones, i.e. the basioccipital (bo), temporal (tb), petrous parts of the 
temporal (ptb), and exoccipital (eo) bones, and also the thyroid cartilage (tc). B-gal signal is also seen in the 
resting, proliferating and articular chondrocytes of the atlas (at) and the other cervical vertebrae, as shown 
in higher magnification in (F). In addition, X-gal staining is observed in the dorsal 3rd ventricle wall of the 
brain (D) and also in the posterior developing choroid plexus (E). Scale bars, 2mm for (A)-(C), 50μm for 
(D)-(F). 
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5.2.4 PRELP expression in new-born (P0) mice 
Similarly to the OMD analysis, new-born (P0) neonates were collected within 16 
hours of their birth time from   PRELP+/LacZ ♂ x PRELP+/LacZ ♀ crossings, so all the 3 
genotypes would occur within the same litter. The size of the litters varied between 
7-10 pups and the ratio of genotypes followed Mendelian inheritance, while no 
differences were observed in the size or gross anatomy between individual new-
borns. Similarly to before, after euthanization heads and bodies were separated and 
processed for freezing, followed by subsequent sectioning and staining with X-gal. 
Due to the big size of the bodies and the restricted fixation time – in order to avoid 
reduction of the β-gal signal – intact sections were not always easy to achieve, but 
clear results of the staining pattern were obtained. Again, no staining was observed in 
any PRELP+/+ sections, while β-gal signal was very specific in heterozygote 
samples. 
Starting with the head, PRELP expression is confined to the cartilaginous 
tissues, similarly to what was seen previously, and is demonstrated in seven different 
coronal sections in Figures 5.13, 5.14 & 5.15. In detail, PRELP at this stage is 
expressed again at the snout, in chondrocytes of the nasal capsule (Fig. 5.13 A&C), 
of the nasal septum and the cartilaginous part of the vomeronasal organ, as well as in 
some of the chondrocytes at the fusion point of Meckel’s cartilages (Fig. 5.13 B&D). 
Further ahead, the expression signal in the inner nasal septum is reduced (Fig. 5.14 
A&C), while there is no staining at all in the olfactory bulbs or the developing eyes 
and teeth. However, signal is now present in the choroid plexus of the 3rd ventricle, 
as well as in the cells forming the adjacent epithelial lining of the ventricles (Fig. 
5.14 B&D). In addition, faint signal can be seen in chondrocytes of the developing 
temporal bones, and the other cartilaginous formations (arrowheads). Moving 
towards the posterior end of the head, Lac-Z activity is present in the cartilage of the 
sphenoid and temporal bones, as well as in the chondrocytes encompassing the 
ossified region of the basioccipital bone (Fig. 5.15 A&B). Furthermore, β-gal signal 
is again observed in the differentiating ependymal cells of the 3rd ventricle wall, and 
also the 4th ventricle choroid plexus (Fig. 5.15 D&E). Finally, strong staining can be 
seen in the articular chondrocytes surrounding the ossified regions of the exoccipital 
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bones, the atlas and the other cervical vertebrae (very similar pattern to the E17.5 
embryos) (Fig. 5.15 C&E). 
Figure 5.13: PRELP expression in coronal sections of X-gal stained PRELP+/LacZ P0 heads. Lac-Z 
activity is seen in chondrocytes of the nasal capsule (A) & (C), and in the nasal septum (B). (D) Β-gal 
signal is also observed in the cartilaginous part of the vomeronasal organ, while fainter staining is 
present in some chondrocytes of Meckel’s cartilage. No staining is seen in the developing incisors. 
Scale bars, 3mm for (A)-(B), 50μm for (C), 100μm for (D).  
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Figure 5.14: PRELP expression in coronal sections of X-gal stained PRELP+/LacZ P0 heads (continued). 
Lac-Z activity in the nasal septum is reduced, as shown in (A) and (C), while there is faint staining in the 
chondrocytes of the developing sphenoid bones (arrowheads), similarly to the previous stage examined. This 
expression pattern is seen in all the bones that develop by endochondral ossification in the head, also pointed 
by arrowheads in (B). B-gal signal is additionally seen the choroid plexus of the lateral ventricles and the cells 
that line the ventricle walls (D). Scale bars, 3mm for (A)-(B), 150μm for (C), 100μm for (D).  
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Figure 5.15: PRELP expression in coronal sections of X-gal stained PRELP+/LacZ P0 heads (last part). 
In the posterior part of the head X-gal staining is very similar to the E17.5 embryonic heads. Staining is seen 
in the cartilaginous parts of the developing bones, i.e. the basioccipital (bo), temporal (tb), pertrous parts of 
the temporal (ptb), and exoccipital (eo) bones (A)-(B). The signal is more intense in the proliferating and 
articular chondrocytes, while there is no staining in any ossified areas, as also seen in the atlas and the 
cervical vertebrae (C) & (F). Again, similarly to E17.5expression, β-gal signal is also observed in the 3rd 
ventricle wall (D) and the choired plexus of the 4th ventricle (E). Scale bars, 3mm for (A)-(C), 100μm for 
(E), 50μm for (D) & (F). 
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Regarding PRELP expression in the p0 body, sagittal sections of a PRELP+/LacZ 
embryo are displayed in Figure 5.16, where we can see that expression is confined in 
the cartilaginous parts of the long bones and the ribs (Fig 5.16 A&B). More 
specifically, Figure 5.16 C&D shows the ends of the scapula and humerus 
respectively, where β-gal signal is very strong in most chondrocytic populations 
excluding the hypertrophic/apoptotic ones near the ossification front. The different 
maturation stages can be clearly seen in Figure 5.16E, exhibiting intense PRELP 
expression in the proliferating chondrocytes, while the signal is reduced almost 
completely in the pre-hypertrophic and hypertrophic ones, and is non-existent in the 
ossified matrix. In addition, intense signal is also seen in the articular chondrocytes, 
especially in the joint areas (arrowheads). The same expression pattern is visible in 
the elbow joint, where we can see strong signal in the proliferating and some of the 
resting chondrocytes (Fig. 5.16F), while all the articular cells are positive for β-gal 
(Fig. 5.16G). Moreover, some diffuse X-gal staining is noticeable in muscle 
ligaments close to the joints (arrows). In agreement with the previous findings, Lac-Z 
activity in the cervical vertebrae is restricted to the non-ossified and articular 
cartilage (Fig. 5.16H, magnified image of the inset), whereas in the central vertebral 
discs positive are again the proliferating and some resting chondrocytes surrounding 
the ossified bodies, as are some cells in the inner annulus fibrosus and nucleus 
pulposus (Fig. 5.16I).       
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Figure 5.16: PRELP expression in sagittal sections of X-gal stained PRELP+/LacZ P0 bodies. (A)-(B) Sagittal sections of the whole body 
where Lac-Z activity is seen in all the cartilaginous elements of the developing skeleton, including the ribs and the long bones. (C) One end of 
the scapula exhibiting β-gal signal in all the chondrocytes apart from the ones close to the ossification front (pre-hypertrophic/hypertrophic). 
Also strong signal can be seen in the articular chondrocytes (ac) (arrowheads), as also seen in (G). The same expression pattern is seen in the 
humerus (D) and also in the elbow joint (F), where staining is additionally seen in adjacent muscle ligaments (arrows). (E) Enlarged view of the 
humerus ossification front where strong Lac-Z activity is seen in the proliferating chondrocytes (ph), declining in the pre-hypertrophic (phc) and 
hypertrophic chondrocytes (hc) until it is no longer present in the osteoid matrix. (H)-(I) Cervical and central vertebral bodies, where again β-gal 
signal is seen in the proliferating and articular chondrocytes , while less signal can be seen in the annulus fibrosus (af) and nucleus pulposus (np). 
Scale bars, 3mm for (A)-(C), 140μm for (C), (D), (F), 50μm for all the rest.
5.2.5 PRELP expression in adult mice 
Heterozygous and homozygous transgenic mice grew into adulthood, were 
fertile and had a normal life span without any apparent abnormalities and with 
normal reproductive rate. In order to examine PRELP expression during adult life 
various internal organs were isolated from PRELP+/LacZ adult mice and subsequently 
stained for β-galactosidase. The organs that were analysed are brain, eye, bladder and 
bone, and all will be presented and discussed below, each in a separate sub-section. 
Due to the nature of the specimens, X-gal activity in the bone, and specifically in the 
knee joint, covering part of femur and part of tibia, was assessed by whole-mount 
staining, followed by decalcification and subsequent cryo-sectioning, while all the 
other organs where fixed, sectioned and afterwards stained for X-gal. In addition, 
kidney and spleen from heterozygote animals were also examined for β-gal activity, 
but X-gal staining here was non-specific with significant background signal even in 
the control PRELP+/+ samples. Due to this endogenous β-galactosidase activity in 
these organs, in situ hybridization was attempted to explore the expression of mRNA 
PRELP gene transcripts in wild type samples. Unfortunately, this approach failed to 
work twice and no further study of these organs was done, focusing thereafter on the 
other organs analysed (bladder, eye and brain). Also, after confirming the expression 
patterns of PRELP in each of the above organs, immunofluorescence staining was 
performed to identify the specific cell types that were positive for β-gal, and thus 
PRELP.  
5.2.5.1 PRELP expression in the adult mouse bladder  
The structure of the mouse bladder has been previously described in Chapter 4 
and in Figure 4.15 A&B H+E stained sections of a wild type bladder are presented, 
where the three different layers of the urothelium (basal, intermediate and umbrella 
cells) are visible. Similarly to before, in order to investigate if PRELP is expressed in 
the mouse bladder, whole bladders were isolated from adult PRELP+/LacZ and 
PRELP+/+ littermates and after processing and sectioning were subsequently stained 
for Lac-Z activity. X-gal staining of heterozygote bladders revealed β-gal signal at 
the urothelium and particularly in the outer umbrella cell layer (Fig. 5.17 A&B), 
while no staining was seen in any of the wild type samples. Further 
immunofluorescence staining of heterozygote bladders with several markers against 
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the three different layers of the urothelium was performed, confirming expression of 
β-gal in the superficial umbrella cells. In detail, X-gal staining was co-localised with 
uroplakin-3 and CK18 (both are markers for umbrella cells) (Fig. 5.18 C-D), while it 
did not overlap with either CK5 (which is a marker for basal cells) or laminin 
(marker for the basement membrane between stromal and epithelial layers) (Fig. 
5.18). Overall, we can conclude that PRELP is expressed in a sub-population of the 
umbrella epithelial cells, an expression pattern almost identical to OMD.      
208 
Figure 5.17: PRELP expression in adult mouse PRELP+/Lac-Z bladder is localised in the umbrella 
cell layer. (A)-(B) Two different images of a heterozygote X-gal stained bladder demonstrating signal 
in the outer layer of the urothelium. (C)-(D) X-gal staining followed by  immunofluorescence revealed 
co-localisation of the β-gal signal with uroplakin- and CK18-positive areas, confirming PRELP 
expression in the umbrella cell layer. Panels (i) are X-gal staining, (ii) are specific immunostaining 
with the primary antibodies, visualized using alexa-488 (green) as secondary, while in panels (iii) are 
the merged images where X-gal is colored red and DAPI (blue) is used as a nuclei stain. Scale bars, 
100μm for all images. 
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Figure 5.18: PRELP expression in the mouse bladder is confined to the outer layers of the 
urothelium. (A)-(B) X-gal and immunofluorescence staining of PRELP+/LacZ bladders using laminin and 
CK5 antibodies that mark the basement membrane of the lamina propria and the basal cells respectively. 
Β-gal signal was not co-localised with any of these markers, confirming our previous result that PRELP 
is expressed within the umbrella cell layer. Panels (i) are X-gal staining, (ii) are specific immunostaining 
with the primary antibodies, visualized using alexa-488 (green) as secondary, while (iii) are the merged 
images where X-gal is colored red and DAPI (blue) is used as a nuclei stain. Scale bar, 100μm for all 
images. 
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5.2.5.2 PRELP expression in the adult mouse eye 
The mouse eye structure, together with more detailed descriptions of the retina 
and ciliary body, is presented in Figure 4.17.  After sagittaly cryo-sectioning whole 
eyes from PRELP+/LacZ mice, X-gal staining was always observed in the ciliary body, 
and more specifically in the non-pigmented epithelium, and occasionally in the 
trabecular meshwork (Fig. 5.19 A&C), while there was no staining in the retina or 
other areas of the eye (Fig. 5.19 B). Also, staining appeared "spotty" in some cells, 
while it was more diffuse in others. Sections from PRELP+/+ littermates were always 
negative for X-gal staining, as expected. Moreover, X-gal staining followed by 
immunofluorescence with Pax6, a marker for the epithelial stem cells of the CB, 
revealed co-localization of the β-gal signal with Pax6-positive cells of the external 
epithelial layer of the CB, where in most cells the "spotty" signal appeared to be 
outside the cell nuclei (Fig. 5.19 C&D). Thus, we can conclude that PRELP is 
expressed in the majority of the non-pigmented CB epithelial cells.    
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Figure 5.19: PRELP expression in the adult mouse eye is localised in the ciliary body and specifically in 
the non-pigmented epithelial cells. (A) X-gal staining of PRELP+/LacZ eye demonstrating Lac-Z activity in the 
epithelial cells of ciliary body and occasionally in the trabecular meshwork (arrows). (C) Higher magnification 
of an X-gal stained sample where the signal is visible in the non-pigmented cells. Immunofluorescence was 
performed using a Pax6 primary antibody and an alexa-488 (green) as secondary (ii). (C-iii) Merged images of 
(i) and (ii), where X-gal is coloured red and DAPI (blue) is added as nuclei stain. B-gal signal is co-localised 
with some of the Pax6-positive cells, while in others it appears to be located adjacent to the cell bodies. No X-
gal staining is seen in any of the retinal cell layers (B). Scale bars, 200μm for (A), 50μm for all other images. 
RGC, retinal ganglion cells; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; 
ONL, outer nuclear layer; IS, inner segments; OS, outer segments. 
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5.2.5.3 PRELP expression in the adult mouse brain 
Whole brains were isolated from adult PRELP+/LacZ and PRELP+/+ littermates 
and were either whole-mount stained for X-gal, or processed for cryo-sectioning and 
subsequently stained. In the latter case, X-gal staining was performed in serial 
sections covering the whole brain from the olfactory lobes to the end of the 
cerebellum. Starting with Figure 5.20, where a heterozygote whole-mount stained 
brain is presented, strong β-galactosidase activity is observed in all the blood vessels 
covering both the dorsal and ventral part of the brain, as well as around the optic 
nerves, the space between the two hemispheres (superior sagittal sinus) and the 
central canal of the spinal cord (Fig. 5.20 A&B). In addition, there is some diffuse 
staining in the hypothalamic area, while no staining is present in the optic chiasm 
(Fig 5.20C arrow and arrowhead respectively). In figure 5.20D a magnified view of 
the middle cerebral artery is displayed, where it is clear that the X-gal staining is 
very specific to some cells surrounding the surface of the blood vessels, reminding 
pericyte-like cells whose cell bodies are encircling the capillaries. Upon dividing the 
brain into the two hemispheres (Fig. 5.20E), β-gal signal is present in the 
hypothalamic area, the dorsal 3rd ventricle (Fig. 5.20F), the aqueduct and the 4th 
ventricle together with the cerebellar vasculature (Fig. 5.20G). Furthermore, all the 
blood vessels of the cerebral cortex are also positive for X-gal (Fig. 5.20H), whereas 
in Figure 5.20I a closer view of the right olfactory bulb capillaries is shown, 
demonstrating b-gal and thus PRELP expression in the majority of the vessels.   
In parallel, other PRELP+/LacZ brains were frozen, coronally sectioned and 
afterwards stained for X-gal. The results are demonstrated in Figure 5.21, where 
overall the b-gal signal is confined around the ventricle walls, the choroid plexus 
(CP) and the blood vessels (as was expected from the whole-mount staining). In 
detail, around 0.86 mm before the bregma, b-gal staining is seen in the cells 
surrounding the walls of the lateral ventricles (LV), indicating that PRELP is 
probably expressed by ependymal cells (thin epithelium-like cells lining the 
ventricular system of the brain and the spinal cord) (Fig. 5.21 A&D). Moving a little 
bit further after the bregma, very strong X-gal staining is observed in the choroid 
plexus of the dorsal 3rd ventricle (D3V), where some cells have more "spotty"-like 
staining, while others are fully stained (Fig 5.21 B&E). Reaching deeper into the 
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hippocampus area, signal is seen again in the walls of both the lateral ventricles, as 
well as the CP of the LV and D3V, together the lining of the 3rd ventricle (Fig. 5.21 
C, F, G and H). Moreover, towards the posterior end of the brain, b-gal expression is 
seen in the walls of the 4th ventricle and the aqueduct (Aq) (Fig. 5.21I). Finally, the 
majority of the capillaries found in the coronal sections are also positive, as expected 
(Fig. 5.21 arrows), while no expression is seen in any possible neuronal cell types.   
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Figure 5.20: PRELP expression in the adult mouse brain. Brains were isolated from PRELP+/LacZ animals and 
were whole-mount stained for X-gal. (A)-(B) Dorsal and ventral sides of the brain demonstrating Lac-Z activity in 
the blood vessels, the optic nerves and the central canal of the spinal cord. (C) Magnified images showing 
additional X-gal staining in the hypothalamic area (arrow), but not the optic chiasm (arrowhead). (D) Enlarged 
view of the middle cerebral artery exhibiting specific β-gal signal around the capillaries. (E) Cutting the brain 
sagittaly revealed X-gal staining in the dorsal 3rd ventricle (F), the 4th ventricle and the aqueduct (G) and the 
cerebellar vasculature (H). In (I) a view of the olfactory bulb is shown, demonstrating again X-gal staining around 
the capillaries. Scale bars, 2mm for (A), (B) and (E), 1mm for (C), (G), 500μm for (F), (H), (I), 50μm for (D). cr, 
cerebrum; ce, cerebellum; ol, olfactory lobes; sc, spinal cord; co, cortex; t, thalamus; ht, hypothalamus; p, pons; m, medulla; 
D3V, dorsal 3rd ventricle.  
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Figure 5.21: PRELP expression in sections of the adult mouse brain. Brains from PRELP 
heterozygous mice were cryo-sectioned and stained with X-gal. (A)-(C) Three different coronal 
planes demonstrating Lac-Z activity in the linings of ventricles, in choroid plexus and in blood 
vessels (arrows). (D) Enlarged view showing clear X-gal staining in the epithelial lining of the 
lateral ventricle, where ependymal cells reside. (E) Magnified view of the dorsal 3rd ventricle 
choroid plexus, where β-gal staining is very strong in some cells and faint in other. The same 
staining pattern is seen further inwards the brain (F) & (G), while the linings of the 3rd ventricle and 
the aqueduct are also positive for Lac-Z, as shown in (H) and (I). Arrows indicated X-gal stained 
blood vessels. Scale bars, 1mm for (Α)-(C), 140μm for (D), (F), (I), 50μm for (E), (G) and (H). CPu, 
caudate putamen; cc corpus callosum; LV, lateral ventricle; CP, choroid plexus; D3V, dorsal 3rd ventricle; Aq, 
aqueduct; DG, dentate gyrus; CA1/2/3, pyramidal cell populations of the CA1/2/3 fields.
216 
In order to identify the specific cell types where PRELP is expressed (through β-
gal) fluorescence staining with several markers was performed on top of the X-gal 
reaction, and during image processing the X-gal signal was coloured either green or 
red. More specifically, β-gal staining was co-localised with vimentin, which is a 
marker for ependymal cells, in the epithelial-lining of the walls in all the ventricles. 
In Figure 5.22 A-C an image of the 3rd ventricle is shown, where most of the X-gal is 
localised around or inside the vimentin-positive ependymal cells. Furthermore, 
regarding PRELP expression around the brain capillaries, three different markers 
were used, namely NG2, PECAM-1 (or CD31) and anti-alpha smooth muscle actin 
(α-SMA) antibodies, which stain for pericytes, endothelial cells and smooth muscle 
cells respectively. In Figure 5.22 B-C two examples of stained blood vessels are 
presented, where the X-gal signal is expressed in a sub-population of NG2-positive 
pericytes. Particularly, in Figure 5.22 B-iii we can discern the main body of a 
pericyte, which is not positive for PRELP (arrow), whereas in Figure 5.22 C-iii, even 
though only one side of the branched vessel is positive for β-gal, the signal is co-
localised with the pericytes found on that side (arrowheads). As pericytes are 
characterised by a large spherical shape around their nucleus (arrows in Fig. 5.22 
B/C-iii) accompanied by thin extensions surrounding the vessels, it is possible that 
the β-gal signal (and thus PRELP) is localised, apart from the cytoplasm around the 
nucleus (like shown in Fig. 5.22 C), also in the thin extensions, which we cannot 
always pick up with this imaging resolution.  
Continuing with the other markers, X-gal signal does not overlap with PECAM-
1 positive endothelial cells, as shown in Figure 5.23A. In addition, when staining for 
vascular smooth muscle cells (VSMCs) using the α-SMA antibody, we observe that 
most of the signal does not co-localize with the X-gal staining, with the exception of 
few occasions (Fig. 5.23B, arrowheads). Thus, we can conclude that PRELP is 
expressed by a sub-population of pericytes and occasionally from VSMCs. However, 
complete characterization of PRELP expression in the brain vasculature still remains 
obscure, since all these different cells types are positioned in very close proximity 
with each other and higher resolution imaging technique is required to distinguish the 
exact localization of the X-gal signal. Finally, an area close to the 3rd ventricle was 
stained with X-gal and NeuN (a general neuronal marker), confirming that PRELP 
expression is absent from neurons (Fig. 5.23C).    
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Figure 5.22: PRELP is expressed in ependymal cells and pericytes. (A) In the area of the 3rd ventricle X-gal overlaps 
with vimentin staining, suggesting PRELP expression in ependymal cells. (B)-(C) In the blood vessels β-gal signal 
occasionally overlaps with NG2-positive pericytes. Arrows indicate the main bodies of pericytes that do not express Lac-Z, 
while arrowheads show areas of co-localisation with X-gal, which can be seen either close to the pericyte main body or 
further away from it. Panels (i) are X-gal staining, panels (ii) are immunofluorescence using specific primary antibodies and 
alexa-488 (green) as secondary, and panels (iii) are merged images with DAPI (blue) as a nuclei stain. Scale bars, 50μm for 
all images. 
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Figure 5.23: PRELP is occasionally expressed in vascular smooth muscle cells. (A) X-gal staining does not overlap with 
PECAM-1 positive endothelial cells around the blood vessels, while it occasionally overlaps with a-SMA positive vascular 
smooth muscle cells, as indicated by arrows in (B). (C) The area of the 3rd ventricle showing that the β-gal signal seen in the 
lining of the ventricle is not co-localised with any neuronal cells types (NeuN-positive cells). Panels (i) are X-gal staining, 
panels (ii) are immunofluorescence using specific primary antibodies and alexa-488 (green) as secondary for (A)&(B), alexa-
546 (red) for (C), and panels (iii) are merged images with DAPI (blue) as a nuclei stain. Scale bars, 100μm for (A), 50μm for 
(B), (C). 
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5.2.5.4 PRELP expression in the adult mouse bone 
Evaluation of PRELP expression in the adult bone was performed on the knee 
joint including part of the femur and the tibia. As mentioned before, X-gal activity 
was assessed through whole-mount staining of the tissue, followed by decalcification 
and cryo- or paraffin-sectioning.  Sectioning and subsequent X-gal staining, that 
would give more accurate results, was not applicable in this case, as decalcification 
(which is necessary at this stage) would nullify the β-gal enzyme. In Figure 5.24 
A&B two different sections of a PRELP+/LacZ knee joint are presented, where signal 
can be seen in the articular cartilage, the meniscus, the synovial tissue and 
occasionally in some areas around the cortical bone, between the calcified bone and 
the adjacent muscle (probably the periosteum). More specifically, strong staining is 
present in the outmost articular chondrocytes towards the ventral and dorsal sides of 
both femur and tibia, but not in the middle of the joint capsule. In addition, certain 
parts of the synovium are intensely stained, including the areas close to the articular 
cartilage and the meniscus (Fig. 5.24 C&D). Also, in Figure 5.24E a magnified view 
of the femur cortical bone is presented, where diffuse staining is visible in what 
probably is the periosteum. Furthermore, β-gal signal is present in the fat tissue 
surrounding the joint, while it is absent from the growth plate or the bone marrow. 
Finally, a section of a PRELP+/+ sample is included in Figure 5.24 F&G, showing 
minimum background staining in the apoptotic/hypertrophic chondrocytes of the 
growth plate, indicating that the X-gal staining in the heterozygote knee joint is true 
and specific signal for PRELP.      
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Figure 5.24: PRELP expression in the adult bone. (A)-(B) X-gal stained knee joints from PRELP+/LacZ animals demonstrating Lac-Z activity in the 
articular cartilage, the meniscus, the synovial tissue and occasionally around the cortical bone. (C) Magnified view showing strong β-gal signal in the 
articular chondrocytes of the femur and the adjacent synovial tissue. (D) Enlarged view of the meniscus area exhibiting again strong staining in the 
synovial tissue. (E) View of the femur cortical bone, were diffuse X-gal staining can be seen in the periosteum area. (F)-(G) X-gal staining of a wild 
type sample where minimum background staining can be seen in the apoptotic chondrocytes of the growth plate. Scale bars, 500μm for (A), (B), (F), 
100μm for (D), 50μm for (C), (E) and (G). f, femur; t, tibia; m, meniscus; st, synovial tissue; ft, fat tissue; gp, growth plate; ac, articular cartilage; cb, cortical 
bone; bm, bone marrow; mu, muscle.
5.3 Discussion 
Detailed analysis of the murine PRELP gene expression was performed using 
the newly established PRELP knock-out mouse model. In this model, the gene 
transcription domain, located in exons 2 & 3, is replaced with a Lac-Z cassette, 
generating viable and fertile heterozygous (PRELP+/LacZ) and homozygous 
(PRELPLacZ/LacZ) mice, without any obvious gross abnormalities during development 
or postnatal life. Expression of PRELP is widely detected in the cartilaginous 
skeleton during the embryonic stages, but also in the early and late fetal brain. This 
pattern expands to include other organs as well, like the eye and the bladder, in the 
adult animals.  
PRELP expression in developing brain 
Expression was examined in the E12.5, E15.5, and E17.5 embryonic stages, and 
in new-born P0 mice. Intensity of the β-gal signal after X-gal staining was always 
higher in the PRELPLacZ/LacZ than PRELP+/LacZ animals, while no background staining 
was present in wild type embryos, demonstrating specific expression of the Lac-Z 
cassette under the PRELP promoter. In E12.5 embryos expression is located in the 
developing somites and the brain, while signal is also visible in the cartilage 
primordia of the forelimb, the notochord, the neural tube and the 4th ventricle 
roofplate in the hindbrain (Fig. 5.2, 5.3 & 5.4). To our knowledge, this is the first 
time PRELP expression is seen in non-cartilaginous tissues during development. 
Grover and Roughley reported PRELP mRNA expression in 7.5dpc embryos, which 
declined afterwards, to be detected again at 14.5dpc following the onset of 
skeletogenesis (Grover and Roughley, 2001). However, this analysis included RNA 
extracted from whole embryos, so it is inconclusive of the areas of expression.  
Interestingly, the symmetrical β-gal signal observed in the forebrain (Fig. 5.4 
arrows), appears to be located in the cortical hem just above the developing choroid 
plexus (CP). The cortical hem was originally identified as an embryonic structure 
defined by Wnt expression that exhibits hippocampal organizer activity (Grove et al., 
1998; Mangale et al., 2008). More specifically, Lac-Z staining is in the same area 
where Wnt3a and Wnt2b are expressed, marking the cortical neuroepithelium but not 
the CP (Grove et al., 1998; Himmelstein et al., 2010), indicating a possible role of 
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PRELP in early patterning of the telencephalon. In addition, the β-gal signal that is 
seen in the midbrain/hindbrain boundary could be co-localised with the expression 
domains of Wnt1 and Fgf8, where, together with the floor plate, the isthmic organizer  
and the rhombic lip are located (Basson and Wingate, 2013). This could further 
suggest involvement of PRELP in the development of the vermis and cerebellum. 
Unfortunately, due to time restrictions, proper characterization of the Lac-Z positive 
cells could not be performed at this stage, and therefore we can only make 
speculations about PRELP activity in the early mouse brain patterning. Nevertheless, 
this spatiotemporal PRELP expression pattern is compelling, and detailed analysis of 
the expressing areas, as well as analysis of expression in earlier embryonic stages, 
would be very interesting.  
Lac-Z activity in the fetal brain was reduced by stage E15.5, where β-gal signal 
was visible only at the roof plate of the future aqueduct and not in other structures 
like the cortical hem or the choroid plexus (Fig. 5.8). Lac-Z activity is seen again at 
17.5dpc, specifically in the choroid plexus of the 4th ventricle and some cells on the 
lining of the dorsal 3rd ventricle wall closure (Fig. 5.12 D&E). The same staining 
pattern is observed in new-born mice with the additional staining of the 3rd ventricle 
choroid plexus and also the cells lining the ventricles (Fig. 5.14 D, 5.15 D&E). 
Although no staining with specific cell makers was performed, we can assume that 
the positive cells on the ventricle walls are ependymal cells due to their localization 
and epithelial-like shape. 
 Choroid plexuses are formed between E11 and E14 stages in the mouse embryo 
with the 4th ventricular CP differentiating first followed by the lateral ventricles and 
lastly the 3rd ventricle CP (Dziegielewska et al., 2001). The exact roles of the CP in 
brain development together with the factors that regulate CP development are still 
largely unknown. However, Notch and BMP signaling pathways regulated by the 
rhombic lip have been shown to be involved in choroid plexus development during 
the early embryonic stages (Hebert et al., 2002; Hunter and Dymecki, 2007). Also, 
CPs acquire their barrier and secretory functions shortly after formation, thus 
influencing cerebrospinal fluid (CSF) composition and the development of neural 
stem cells in the ventricle linings (Gotz and Huttner, 2005; Johansson et al., 2006; 
Johansson et al., 2005; Millgard et al., 1976). Therefore, expression of PRELP in the 
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CPs by day E17.5 indicates that PRELP probably does not affect choroid plexus 
formation, but becomes a component of the mature epithelial CP cells. Whether 
expression of PRELP in the rhombic lip at stage E12.5 could affect CP formation we 
do not know, but we cannot exclude such possibility.  
  These processes are also linked with ependymal cell differentiation. Most 
ependymal cells are generated between E14 and E16, while maturation and 
formation of the cilia occurs during the first postnatal week (Spassky et al., 2005). 
The ependymal progenitors are thought to be radial glial cells, while it appears that 
continuous contact with the CFS might also affect their differentiation (Spassky et 
al., 2005; Tramontin et al., 2003). Silva-Alvarez et al. showed that ependymal cell 
differentiation coincided with glucose transporter 1 (GLUT1) expression in the 
ventricular walls (Silva-Alvarez et al., 2005). Interestingly, Lac-Z activity in the P0 
PRELP+/LacZ brain shows very similar staining to that of GLUT1, suggesting PRELP 
expression in the differentiating ependymal cells.   
Embryonic brain morphogenesis and patterning is a very complex procedure 
involving many signaling molecules and regulators. Clearly PRELP is somehow 
involved in some stages of this process, but since this was not the primary subject of 
this project no more work was conducted on this field. However, it would be very 
interesting to unravel how PRELP acts during brain formation. 
PRELP expression in the developing skeleton  
At the earliest stage examined (E12.5) the developing skeleton is still very 
premature and X-gal activity was seen only faintly in the cartilage primordia of the 
forelimb (Fig. 5.4 F). However, by stage E15.5 skeletal development has progressed 
considerably and strong X-gal staining is present in all the cartilaginous elements of 
the developing axial and appendicular skeleton, including the forelimb and hindlimb, 
the ribs, the vertebrae, the nasal septum and Meckel’s cartilage in the mandible (Fig. 
5.5., 5.6 and 5.7). The main cell types expressing Lac-Z are chondrocytes, with some 
diffuse staining seen occasionally in mesenchymal cells, such as the borders of the 
nasal septum or Meckel’s cartilage and the dental papilla of the developing molars 
(Fig. 5.7 and 5.8). Again, this mesenchymal-type expression has not been reported 
before and appears to be specific for this stage of development, as during the next 
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analysed stages (E17.5 & P0) β-gal is clearly expressed only in the chondrocytes of 
the respective tissues (Fig. 5.8 vs. 5.11/5.13).  
Looking at the long bones of the forelimb or hindlimb at 15.5dpc (Fig. 5.9), it is 
visible that Lac-Z activity, and thus PRELP, follows a gradient of expression through 
the different chondrocytic populations. More specifically, signal is strong in the 
columnar/proliferating and the pre-hypertrophic chondrocytes, while it is decreased 
in the hypertrophic ones until it is no more present in the primary ossification groove. 
Signal is seen in some resting chondrocytes as well (localised in the opposite end of 
the ossification front) and also in the perichondrium. This pattern is slightly changed 
in E17.5 heterozygote embryos, where signal is still strong in the proliferating 
chondrocytes but has decreased in the pre-hypertrophic ones. Faint staining is still 
present in apoptotic/hypertrophic chondrocytes, marking the start of the 
mineralization front. In addition, staining is no longer present in the perichondrium 
but is now visible in the articular chondrocytes of the joints and in the early synovial 
tissues (Fig. 5.10). Furthermore, resting, proliferating and articular chondrocytes in 
the endochondral bones of the head are also β-gal positive (Fig.5.12 A, B, C, F) 
resembling the expression pattern seen in the long bones.  
The same expression pattern is maintained in P0 new-born embryos. Briefly, X-
gal staining can be seen the nasal septum, the cartilaginous part of the VNO, in part 
of Meckel’s cartilage as well as the chondrocytic parts of the cranial bones that have 
not yet been ossified (Fig. 5.13, 5.14, 5.15). In the long bones β-gal signal is 
observed again in resting and proliferating chondrocytes, while the staining is also 
strong in the articular chondrocytes of the joints and the vertebral bodies (Fig. 5.16). 
All the above findings are in agreement with previous studies demonstrating PRELP 
expression in the skeletal cartilage of the developing mouse, in proliferating 
chondrocytes of rat tibia bones and in human cartilage (Grover et al., 1996; Grover 
and Roughley, 2001; Lui et al., 2010). 
Overall, PRELP appears to be a cartilage-specific SLRP, following a specific 
chondrocytic expression pattern during endochondral osteogenesis. Although we 
have specified the main cell populations that are positive for Χ-gal activity, usage of 
markers to identify chondrocytic differentiation stages (as described in section 4.3) is 
necessary. Apart from the fetal brain, Lac-Z activity was not observed in any other 
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internal organs, indicating that PRELP mainly functions in the brain and 
skeletogenesis during development.  
PRELP is expressed in the adult mouse bladder, eye, brain and bone 
PRELP expression was examined in the adult bladder, eye, brain and knee joint 
through X-gal staining. In the bladder Lac-Z activity was seen in the umbrella cell 
layer, as demonstrated by co-localisation of the β-gal signal with uroplakin and 
CK18, but not laminin and CK5 (Fig. 5.17 & 5.18). This expression pattern is very 
similar to the OMD expression and since this was extensively discussed in the 
previous chapter it will not be reviewed again here. 
 In the adult eye β-gal signal is seen in the ciliary body and occasionally in the 
trabecular meshwork (Fig. 5.19A). Staining with Pax6 demonstrated Lac-Z 
expression in the non-pigmented epithelial cells of the CB, while no expression was 
seen in the retina or other areas of the eye. Also, we cannot exclude expression in the 
pigmented cells of the CB, but in order to test this other technical approaches, like 
removal of the pigment, have to be employed. The mammalian ciliary body 
contributes to lens accommodation and aqueous humor secretion. The epithelial 
layers of the CB are connected at their apical membranes through gap junctions, 
while tight junctions at the apical borders of the non-pigmented cells form the blood–
aqueous barrier, which also affects and determines the intraocular pressure (IOP) 
(Ford et al., 2012; Freddo, 2013; Raviola and Raviola, 1978). Therefore, PRELP 
could have a potential role in IOP modulation through tight junction or gap junction 
regulation. Furthermore, the pigmented cells of the CB have been proposed to act as 
stem cells of the adult mammalian eye (Tropepe et al., 2000; Xu et al., 2007), 
although this has been a matter of controversy over the last decade. Hence, any 
possible involvement of PRELP in stem cell functions would also be an interesting 
proposition to examine.   
In contrast to our findings, high mRNA and protein levels of PRELP, and also 
other SLRPs like decorin and lumican, were previously discovered in the human 
adult sclera (Johnson et al., 2006). Given the fact that sclera is a highly collagenous 
tissue, expression of ECM molecules like SLRPs would not be surprising. However, 
a different study demonstrated strong PRELP expression in the human neurosensory 
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retina and only moderate levels in the choroid and sclera (Keenan et al., 2012). We 
therefore see that findings are quite variable depending on the specificity and the 
efficacy of the method used, even within the same species examined. In the 
PRELP+/LacZ mouse eyes examined here the β-gal signal continuously appeared in the 
same areas, while no signal was seen in any PRELP+/+ wild type mice, indicating the 
specificity of the staining. Thus, the different expression patterns seen in the above 
studies could probably be attributed to the species difference.  
 Amongst the other organs examined, PRELP expression is very intriguing in the 
adult brain as well. Lac-Z activity was observed all around the blood capillaries, the 
optic nerves, the lining of all the ventricles and in the choroid plexus (Fig. 5.20 & 
5.21). Staining with vimentin confirmed β-gal signal in ependymal cells, while 
occasionally β-gal was co-localised with NG2 and a-SMA, demonstrating PRELP 
expression in pericytes and vascular smooth muscle cells (Fig. 5.22 & 5.23). 
Pericytes, ependymal cells and epithelial cells of the choroid plexus, all play 
important roles in forming barrier mechanisms within the brain. CP forms the blood-
CSF barrier, pericytes together with smooth muscle and endothelial cells are part of 
the neurovascular unit (NVU) which forms the blood-brain barrier (BBB), while 
ependymal cells regulate the CSF flow as well as the uptake of molecules from the 
CSF to the brain parenchyma through gap junctions  (Neuwelt et al., 2011; Winkler 
et al., 2011). PRELP expression was only mentioned in the adult brain in one study 
so far where it was localized in pericytes of the rat anterior pituitary (Horiguchi et al., 
2013). Expression in other areas of the brain was not examined or at least was not 
mentioned in the above study. Therefore, PRELP might emerge as an important 
regulator of brain vessel permeability and could be involved in a variety of BBB-
related pathological conditions such as Alzheimer’s disease, Parkinson’s disease or 
multiple sclerosis.  
Finally, similarly to OMD, PRELP expression in the adult bone was assessed in 
the knee joint, where Lac-Z activity was observed mainly in the synovial tissue and 
in articular chondrocytes, and occasionally around the cortical bone (Fig. 5.24). 
These findings are in contrast with a previous study by Grover et al. demonstrating 
PRELP protein and mRNA expression in the growth plates rather than the articular 
cartilage of the joints in the adult mouse (Grover and Roughley, 2001). As our 
227 
 
method of detection involved whole-mount staining prior to sectioning we cannot 
exclude the possibility that staining solutions did not penetrate the sample equally or 
that the staining time was insufficient for the enzymatic reaction to take place in the 
whole tissue. Therefore, optimizing the current staining method but also testing 
alternative detection approaches, like in situ hybridisation, is necessary to determine 
if PRELP is indeed expressed in the growth plates of the adult bone. Also, our results 
indicate a shift of PRELP expression from the majority of chondrocytes (especially 
proliferating) in the developing embryo and new-born to only articular cartilage in 
the adult mouse, which is very similar to the OMD findings.  In general agreement 
with our results, expression of PRELP in articular cartilage of adult human and 
bovine tissues has been shown before (Bengtsson et al., 1995; Grover et al., 1996; 
Grover and Roughley, 2001), confirming the role of PRELP in connecting tissues. 
Lastly, regarding the strong expression of PRELP in the knee synovial tissues, 
Segawa et al. also found high PRELP expression in mesenchymal stem cells isolated 
from human synovial tissues, suggesting a conserved role of PRELP in these cells 
(Segawa et al., 2009). 
In conclusion, PRELP has a very dynamic expression pattern involving skeletal, 
connecting and also neural tissues, indicating the matricellular functions it may have 
throughout different biological systems.  
Comparison of OMD and PRELP expression patterns 
OMD and PRELP both belong to class II of the SLPR family based on their 
close homology, chromosomal organization and the spacing between their N-
terminal Cys-rich clusters (Dellett et al., 2012). However, even though these two 
proteins are structurally similar, their expression patterns and functions may not 
always overlap, as is also seen with other SLRP members that belong to the same 
class. Utilising our novel knock-out mice models, OMD and PRELP expression 
patterns have now been extensively studied and thus we can assess their homology at 
the protein expression level. 
During mouse embryonic development both proteins are strongly expressed in 
the growing skeletal elements. High levels of expression are seen already from E15.5 
embryos, when skeletogenesis has slightly progressed and the first ossification 
228 
 
centres are starting to form. At this stage, OMD is exclusively localised in the 
periosteum/perichondrium and the primary ossification groove of the long bones, 
while very low levels of expression are occasionally seen in apoptotic chondrocytes. 
As skeletal development advances, OMD continues to be expressed in the 
periosteum but is additionally seen in proliferating chondrocytes, at 17.5 dpc. At the 
time of birth expression persists in the periosteum, but is also observed now in the 
osteoid matrix of the forming trabecular bone, while it is still present in the 
proliferating chondrocytes in some of the long bones.  
On the contrary, at E15.5, PRELP expression is very strong in resting and 
proliferating chondrocytes, while it declines in the pre-hypertrophic and hypertrophic 
chondrocytes until it is no longer present in the ossification groove. This expression 
motif continues in E17.5 embryos and new-born mice, where PRELP is additionally 
seen in the articular chondrocytes of the joints. In contrast to OMD, PRELP 
expression is not seen at all in the ossification grooves or in the osteoid matrix.  
We therefore see that during long bone development the two proteins are 
differentially expressed. OMD is mainly seen in areas where most cells will 
differentiate into osteoblasts, while PRELP is entirely seen in cartilage cells. These 
results are in agreement with previous findings on the two SLRPs. OMD binds to 
hydroxyapatite (which is found in mineralised tissues) and was initially isolated from 
the matrix of bovine bone (Sommarin et al., 1998; Wendel et al., 1998), while 
PRELP has been found in cartilaginous tissues of the developing mouse (Grover and 
Roughley, 2001), suggesting that the two proteins have different functions.  
However, there are also some common areas of expression. For example, the 
proliferating chondrocytes of the growth plates, which are always positive for 
PRELP, are occasionally positive for OMD as well (Fig. 4.9J). This could indicate 
that both proteins share common roles in a specific stage of chondrocytic maturation. 
The rate of chondrocytic maturation in the growth plate cartilage is what regulates 
the endochondral bone development, and a complex network of interacting signalling 
pathways is employed to drive this process (reviewed by Kronenberg, 2003). Key 
players are the Indian hedgehog (Ihh) and parathyroid hormone-related peptide 
(PTHrP) protein. Briefly, Ihh is produced by pre-hypertrophic chondrocytes and 
induces the formation of proliferating chondrocytes while is also induces PTHrP 
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expression in the distant resting/periarticular chondrocytes. This secreted PTHrP 
antagonises then both the action of the Ihh and the maturation of the proliferative 
chondrocytes into pre-hypertrophic ones. With this negative-feedback loop the rate 
of chondrocytic maturation is regulated. Additionally to this mechanism, other 
factors likes Wnt5a and Wnt5b also regulate the transitions from resting to 
proliferative and proliferative to pre-hypertrophic chondrocytes, while bone 
morphogenic proteins (BMPs) and fibroblast growth factors (FGFs) also participate 
in this process (Kronenberg, 2003; Yang et al., 2003) (Fig. 5.25).   
 
Figure 5.25: Model of the PTHrP and Ihh signaling in chondrocyte differentiation during long 
bone development. The morphology of a developing long bone is schematically shown, where 
chondrocytes proliferate and differentiate sequentially along the longitudinal axis. Ihh expression is 
shown in red and PTHrP expression is shown in yellow. Ihh acts through PTHrP to inhibit 
chondrocyte hypertrophy. Ihh acts independently of PTHrP to control chondrocyte proliferation, 
periarticular chondrocyte differentiation and osteoblast differentiation. Ihh also promotes chondrocyte 
hypertrophy independently of PTHrP and this function is likely to be mediated by Bmp and Wnt/β-
catenin signalling. (Adopted by Mak et al., 2008).  
Therefore, OMD and PRELP could both play potential roles in the regulation of 
the above signalling pathways and thus affect the rate of bone development. OMD 
has been found to interact with molecules of the Wnt pathway and with BMPs (Rehn 
et al., 2006) so it might somehow be involved in the proliferative to pre-
hypertrophic/hypertrophic transition, while PRELP has already been used in a study 
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as a marker of proliferative chondrocytes during mouse endochondral development 
(Ahrens et al., 2009).  
Apart from the periosteum and the osteoid matrix, OMD is also seen in the 
proliferating chondrocytes of the head endochondral bones, which develop similarly 
to the long bones. In the same area PRELP is also seen in the proliferating but also 
the articular chondrocytes (Fig. 4.13 vs. 5.15). Thus, this pattern of common 
expression in the developing growth plate is maintained even in all the endochondral 
bones, further supporting the notion that both proteins somehow affect the 
chondrocytic maturation process. In addition, chondrocytes of the outer nasal capsule 
and the inner nasal septum are positive for both OMD and PRELP, although OMD 
appears to have a more specific expression towards the marginal chondrocytes 
(and/or the perichondrium) found in these cartilaginous tissues (for example Fig. 
4.11 vs. 5.13), suggesting potential functions in a particular chondrocyte 
maturation/differentiation stage. Finally, another common area of expression is the 
vertebral bodies and discs. In all the developmental stages examined both OMD and 
PRELP are expressed in the chondrocytes around the ossified vertebral bodies. Due 
to time limitations, in the current project specific staining was not performed in order 
to discriminate between the different chondrocytic types, but from cell morphology 
and shape we can hypothesize that these chondrocytes are again proliferating and/or 
resting. Thus, we can conclude that OMD and PRELP not only have their own 
specific roles during bone formation, but they additionally also share possible 
osteogenic functions and might have common signalling targets in the skeletal 
programming. The fact that in later life both proteins are expressed in the articular 
chondrocytes of the knee joint (and probably other joints as well) is quite intriguing, 
and additionally suggests specific roles of both OMD and PRELP for this type of 
chondrocytes.   
Regarding expression in the adult mice, we have shown that OMD and PRELP 
are variably expressed in the different organs examined. Interestingly, both SLRPs 
are expressed in the bladder umbrella cells, indicating their potential common roles 
in these cell types. Taking into account our in vitro findings (Chapter 3) and Dr. 
Hamamoto’s microarray data we can postulate that both OMD and PRELP could 
regulate junctional complexes in the umbrella cells. Since these cells play a critical 
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role as a permeability barrier to urine, proper regulation of their apical tight junctions 
is necessary for normal bladder homeostasis (Birder and Andersson, 2013). 
Moreover, a layer of polysaccharide GAGs and mucin usually covers the superficial 
urothelium and is thought to have variable functions, defending against 
microorganisms, toxic substances and carcinogens in the urine (Parsons et al., 2002; 
Parsons et al., 1990). Thus, SLRPs might constitute newly-discovered potential 
regulators of the bladder homeostasis. 
As discussed in Chapter 4, several SLRPs are variably expressed throughout the 
different eye components and can affect eye formation and function in various ways. 
OMD and PRELP probably act in a similar manner and can potentially regulate 
functions of the mouse eye retina and ciliary body, which are yet to be discovered. 
The same applies to the mouse brain, where we have shown distinct expression 
patterns of the two SLRPs.  
Summary 
In conclusion, PRELP is expressed in specific areas of the early developing 
mouse brain but also in all the cartilaginous skeletal elements during embryonic 
growth. In adult life PRELP expression is confined to specific cell types in multiple 
organs, i.e. umbrella cells of the bladder, in pericytes and ependymal cells of the 
brain, in the epithelial ciliary body cells of the eye, and in articular and synovial 
tissues of the joints, demonstrating its multiple functions and roles in the living 
organism. 
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Chapter 6  
 
Phenotyping of OMD and PRELP knock-out 
mice 
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6.1 Introduction 
SLRPs are extra-cellular matrix components that can bind to many different 
molecules and receptors thereby regulating cell-matrix crosstalk and affecting 
various biological processes. Their spatial and temporal expression patterns are 
variable, and as structural and signaling molecules they play important roles during 
development but also in regulating the homeostasis of mature tissues. Utilizing 
animal models of SLPR deficiencies has revealed their importance in embryonic life 
and disease progression. 
Several SLRP knock-out mice models have been established so far and the 
phenotypes arising are variable. To start with, decorin knock-out mice exhibit skin 
fragility phenotype with loosely packed collagen fibrils resembling the Ehlers-
Danlos syndrome (Danielson et al., 1997), and are characterized by disrupted 
angiogenesis in the cornea (Schonherr et al., 2004) and altered mechanical lung 
morphology (Fust et al., 2005), emphasizing decorin’s importance in regulating 
collagen fibrillogenesis. Most importantly, in the context of this project, one third of 
decorin-deficient mice develop intestinal tumours that further progress to 
adenocarcinomas (Bi et al., 2008), while double-KO mice of decorin and the tumour 
suppressor p53 showed accelerated lymphoma tumorigenesis which lead to earlier 
mortality (mice succumbed very early with a mean survival of ≈ 4 months versus 6 
months for the p53 null mice alone) (Iozzo et al., 1999). As Iozzo and colleagues 
pointed out, these studies represent genetic evidence that lack of decorin is 
“permissive” for tumour development (Goldoni and Iozzo, 2008; Iozzo and 
Sanderson, 2011), strongly supporting the roles of SLRPs in cancer initiation and 
progression. 
Other SLPR-KO models mainly involve biglycan, lumican and fibromodulin and 
again demonstrate several different phenotypes. Biglycan deficient mice have 
collagen fibril abnormalities, reduced bone mass and an osteoporosis-like phenotype 
(Chen et al., 2002; Corsi et al., 2002; Xu et al., 1998), while they also develop 
spontaneous aortic dissection and rupture (Heegaard et al., 2007). Fibromodulin-KO 
mice exhibit collagen fibril abnormalities in the cornea (Chen et al., 2010), impaired 
dental tissue and alveolar bone formation (Goldberg et al., 2009) and delayed wound 
closure (Zheng et al., 2011). Lumican deficient mice have skin fragility and reduced 
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corneal transparency (Chakravarti, 2002; Chakravarti et al., 1998), while keratocan-
KO mice also display alterations in the cornea (Liu et al., 2003), but also decreased 
rates of bone formation and mineral apposition (Igwe et al., 2011). 
SLRP double knock-out mice models have also been established and usually 
display stronger phenotypes that the single-KOs, indicating synergistic activity of the 
SLRPs. For example, biglycan and decorin deficient mice display severe osteopenia 
and increased skin fragility (Corsi et al., 2002; Young et al., 2002) and also severe 
fibril and stromal corneal phenotype (Zhang et al., 2009). Furthermore, biglycan and 
fibromodulin KO mice show severely impaired collagen fibrils in tendons and lead to 
gait differences, ectopic ossification and osteoarthritis (Ameye et al., 2002). In a 
similar context, epiphycan/biglycan deficient mice exhibited shorter femurs that the 
wild types and developed osteoarthritis, which had an earlier age onset compared to 
epiphycan single knock-outs (Nuka et al., 2010).  
We therefore see that phenotypes arising from SLRP deficiencies vary from skin 
fragility to osteopenia, corneal opacity and cancer, further demonstrating the multiple 
functions of these proteins. In collaboration with Takeda Pharmaceutical Company 
we generated the first knock-out models of OMD and PRELP, where a Lac-Z 
cassette has been inserted in the two gene’s coding regions. After defining the 
expression patterns of OMD and PRELP through X-gal staining (Chapters 4 & 5), 
our current aim is to investigate the phenotypes arising due to OMD/PRELP absence. 
Focus will be given mostly on the bladder as the initial in vitro data of this project 
were obtained from a bladder cancer cell line. Since we have already established a 
strong link of the OMD and PRELP genes with cancer in an in vitro experimental 
environment, cancer-related phenotypes constitute our primary interest, while 
preliminary analysis of other organs and other possible phenotypes will be also 
carried out.  
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6.2 Results 
Construction of the OMD and PRELP knock-out mice was explained in 
Chapters 4 & 5, with no apparent severe defects in any of the heterozygote or knock-
out mice, either during embryonic development or adulthood. This allowed us to 
study extensively not only the expression patterns of the two genes but also any 
latent phenotypic effects their deletion could generate. In adults, several organs were 
initially isolated in order to be studied, but due to time limitations primary attention 
was given to the analysis of the bladder, with less focus on the eye and bone. These 
organs were thoroughly investigated between wild types and knock-outs, while 
additional tests were occasionally performed in order to characterize any underlying 
phenotypes. Since both genes appear to be mostly expressed in skeletal development 
during gestation, examination of skeletal elements was performed in embryonic 
litters as well.  
During the last months of the current project, and with the help of our lab 
technician Steven Bolsover, we managed to produce double knock-out animals 
where both the OMD and PRELP genes are disrupted by the Lac-Z cassette. 
OMDLacZ/LacZPRELPLacZ/LacZ double knockout mice were generated by interbreeding 
mice from the OMDLacZ/LacZ colony with mice from the PRELPLacZ/LacZ colony. Due to 
time restraints double KO samples were included only in the bladder analysis, while 
for the other organs single knock-out animals were used.  
6.2.1 OMD/PRELP knock-out phenotypes in adult mice 
6.2.1.1 Effect of OMD and PRELP targeted deletion in the mouse bladder 
In order to analyze how depletion of OMD and PRELP could affect the normal 
function of the mouse bladder, three bladders from each OMD+/+, PRELP+/+, 
OMDLacZ/LacZ, PRELPLacZ/LacZ and OMDLacZ/LacZPRELPLacZ/LacZ (named onwards as 
double KO) mice at 3 months of age, were isolated and studied. Since OMD and 
PRELP transgenic mice were generated using the same strategy and genetic 
background, OMD+/+ and PRELP+/+ mice should be phenotypically and genetically 
similar, and either of them would suffice as wild type.  However, we chose to 
analyze both genotypes as WT controls in case any background alterations had 
occurred due to the extensive breeding and prolonged maintenance of the lines, at the 
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same time increasing our control numbers. As expected, no differences were found 
between OMD+/+ and PRELP+/+ WT bladders, and therefore samples from only one 
of the two genotypes will be presented as wild type in the following figures.   
The first step in this analysis was the morphological and histological comparison 
of the bladders through H+E staining of paraffin sections. Shown in Figure 6.1 are 
panoramic views of all the bladders sectioned from each genotype. Interestingly, clot 
formations were found in three out of the nine knock-out samples tested. More 
specifically, clots were seen in the lumen of one out of the three PRELPLacZ/LacZ 
bladders, and in two out of the three double knock-outs (Fig. 6.1 C-ii & D-ii and 
more moderate in D-iii, arrows). In the PRELP-KO bladder the clot occupies the 
whole lumen, while in the double-KO (Fig. 6.1 D-ii) it covers almost half of the 
space in one case whereas it has slightly formed in the other (Fig. 6.1 D-iii). A more 
detailed analysis of these clots will be presented further below. Regarding the overall 
morphology of the bladders, all the samples appeared of similar size and the 
proportion of the mucosa (urothelium, basement membrane, lamina propria) and 
muscularis propria (surrounding muscle) remained analogous. In addition, the 
mucosal folds appeared to have the same density and length throughout the samples. 
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In order to further analyse the tissue morphology, careful examination of the 
mucosal layer and specifically the urothelium was initially conducted. Figure 6.2 
Figure 6.1: OMD and PRELP depletion leads to the formation of clots in the mouse bladder. Bladders were 
isolated from 3months-old mice, paraffin-sectioned and stained for H&E. Multiple mages were captured under the 
10x magnification lens and were then stitched together to produce panoramic views of the whole organ. Clot 
formations were found in one PRELP KO and two double KO samples (arrows). In (C-ii) the clot is pretty big 
occupying the whole lumen, while in (D-ii) and (D-iii) the clots are smaller. Regarding the general morphology, wild 
type and knock-out samples appeared of similar size and the proportion of muscle and muscularis seems comparable. 
Scale bar, 500mm for all images. 
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shows magnified images of the urothelium from all genotypes. When comparing the 
four different sample groups we found many sites with "disruption" or 
discontinuation of the urothelium apical surface in the knock-out bladders (Fig. 6.2 
B-D, arrows). This disruption is characterized by a burst-like formation of the 
umbrella cell layer, and therefore we named these structures "epithelial bursts". 
Epithelial burst were seen in the wild type samples less frequently compared to the 
knock-outs. Quantification of the bursts was performed in five different sections of 
each sample, in all 15 bladders. The results are presented in Figure 6.3A, where 
interestingly, the mean number of epithelial bursts in all the knockout-samples is 
significantly higher than the wild type controls. In detail, the OMDLacZ/LacZ bladders 
have a mean number of 9.66 ± 2.9, n=3 (p=0.0031 against the control); the 
PRELPLacZ/LacZ bladders have 9.33 ± 1.45, n=3 (p<0.001 against the control); and the 
double KO have 10.67 ± 0.88, n=3 (p<0.001 against the control) versus the wild type 
samples with a mean value of 0.66 ± 0.49, n=6.  
In addition, cells in the epithelial bursts were characterized by big and round 
nuclei, being histologically similar to the umbrella cells. Immunofluorescence 
staining using a uroplakin-III (marker for umbrella cells) antibody indeed confirmed 
that the spread cells of the epithelial bursts originated from umbrella cells. An 
example of an epithelial burst from an OMD KO bladder stained with uroplakin is 
shown in Figure 6.3 B-C. 
These observations indicate that OMD and/or PRELP depletion results in 
occasional defects of the urothelium, leading to a possible epithelial dysplasia or 
early papilloma-like formations initiating from the umbrella cells. 
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Figure 6.2: Knock-out bladders are characterised by disruptions in the urothelium. Panels (i) are panoramic 
views of the whole bladders, one of each genotype, while panels (ii) and (iii) are magnified areas of the urothelium 
seen in (i) but also from other samples. Arrows indicate the epithelial bursts seen in the knock-out samples, which 
are observed much less frequently in the wild type bladders. Scale bars, 500μm for panels (i), 100μm for (ii) & (iii). 
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Figure 6.3: OMD and PRELP depletion results in occasional defects of the umbrella cell layer. 
(A) Number of epithelial bursts per genotype. Quantification was performed on 5 different sections 
from each bladder, where n=6 for the wild type, n=3 for each of the OMD, PRELP and double KOs. 
Data are presented as mean±SEM, multiple t-tests were carried out comparing means of the knock-
outs to the WT control, **equals p<0.01, ***equals p<0.001, against the WT. (B) 
Immunofluorescence staining of an OMDLacZ/LacZ bladder using a uroplakin primary antibody and an 
alexa-488 (green) as secondary, demonstrating that cells of the epithelial bursts are umbrella cells. 
(C) Same as (B) with DAPI added as a nuclei stain. Arrow points to the epithelial burst. Scale bar, 
50μm. 
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After studying the urothelium, a more detailed analysis of the clots was carried 
out. In Figure 6.4A three different H+E planes of the PRELPLacZ/LacZ bladder with the 
clot are shown in addition to the one presented at Fig. 6.1 C(ii), since this was the 
sample with the most abnormal morphology. We can see that around the middle of 
the bladder the clot takes up almost all the space of the lumen (Fig. 6.4 A-i), while 
further towards the anterior side it becomes smaller (A-ii) until it is not present 
anymore (A-iii). In parallel, the mucosa folds are abnormally increased, occupying 
the whole lumen, whereas a kind of "matrix" deposition is observed in the 
intermediate space. Magnified views of the clot are demonstrated in Figure 6.4 B, C 
& D, where it is visible that there are no cells in the main mass and only around the 
periphery some hematoxylin positive nucleuses are present (arrows). From their 
appearance and their close proximity to the urothelium we could speculate that these 
are umbrella cells, and as shown in panel B they either contribute somehow to the 
formation of the clot or they are damaged by it. Furthermore, under H+E staining 2 
different colorations are visible within the clot mass, i.e. a red eosin color mixed with 
gray areas, suggesting different compositions within certain regions of the clot. The 
exact same pattern is seen in the fully formed clot mass found in the double knock-
out sample (Fig. 6.1 D-ii & 6.4 G). On the contrary, the second double-KO affected 
bladder is characterized by a pale grey color with some eosin-positive depositions 
only towards the middle area, possibly suggesting that this clot is still at the first 
stages of formation and that the "hardening" and the progression to a fully formed 
hard mass starts from the center of the clot itself (Fig. 6.1 D-iii & 6.4 H-I). In 
addition, in panels E-F (Fig. 6.4) the abnormal mucosal folds are shown in greater 
detail, where we can observe an eosin-colored matrix in the lumen between the folds, 
which could either be deposited from the urothelial cells and in this way contribute to 
the formation of the clot, or oppositely it could be derived from the clot. Finally, in 
Figure 6.4J a possible point of abnormal cell invasion into the lamina 
propria/muscularis is shown, although examination of the sample by a specialized 
pathologist is needed to confirm such speculation. 
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Figure 6.4: Abnormal mucosal and clot morphology in the PRELP and double KO mice. (A) Three different 
planes of the PRELPLacZ/LacZ bladder showing abnormally increased mucosal folds around the formed clot. (B)-(D) 
Enlarged images of the PRELPLacZ/LacZ  clot displaying differential H+E colouration of the clot, while possible 
umbrella cells can be seen around the edges (arrows). (E)-(F) Magnified views of the mucosa folds and the matrix 
found between them. (G) The fully-formed clot of the double KO bladder, showing the same H+E colouration as the 
one found in the PRELP KO sample. (H)-(I) Half-formed clot from another double KO bladder, demonstrating a 
pale grey H+E staining. (J) Enlarged view of (A-iii) showing possible infiltration of abnormal urothelial cells into 
the muscle layer. Scale bars, 500μm for (A), 100μm for (B), (E), (H), (J), 50μm for all the rest. 
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In order to further identify the composition of these clots, a variety of tinctorial 
stains were utilised, which selectively stain different cellular components. As the 
clots had a really hard texture during paraffin sectioning, von Kossa staining was 
carried out firstly, aiming to identify any calcium deposits that would be in this case 
colored black. However, all the samples were negative for von Kossa, and therefore 
the possibility that these clots were urine or kidney stones was excluded. Next, congo 
red and alcian blue stains were performed, which identify amyloids and mucins 
respectively, and again none of the clots were positive for either stains. 
 Continuing, the trichrome MSB (Martius, Scarlet and Blue) stain was 
employed, which is a reliable technique for fibrin labeling, based on the property of 
the dyes to penetrate porous tissues depending on their molecular size. With this 
method, fibrin is stained red and fresh fibrin yellow, while collagen and connective 
tissue blue, red blood cells yellow, and muscle pale red. Surprisingly, the clots from 
all three affected bladders appeared positive for fibrin (Fig. 6.5A). The coloration of 
the clot mass can be seen in greater detail in Figure 6.5 B&C, where it is visible that 
it is a mix or fresh and older fibrin. Some areas are red (fibrin), while others are 
yellow to orange (fresh fibrin), probably explaining the differential staining of H+E 
as well. In addition, this deposited matrix that is seen in the lumen space between the 
mucosal folds is a mixture of mostly blue and red color, suggesting that it is 
comprised of extracellular matrix components which possibly undergo cleavage and 
then polymerise to form fibrin (Fig 6.5 D&E). The same can be seen in panels F+G 
(Fig. 6.5, high magnification images of A(iii)-PRELPLacZ/LacZ bladder) with a small 
part of fibrin clot surrounded by thick matrix (arrow). In conclusion, we can deduce 
that these clots found in three of the bladders analysed are composed of fibrin. 
Further immunofluorescence staining with an anti-fibrinogen antibody 
additionally confirmed our result. Presented in Figure 6.5 H-I is a section of a 
double-KO bladder, showing positive staining for fibrinogen in certain areas of the 
clot with minimum background in the urothelium.  
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Figure 6.5: Clots found in the PRELP and double knock-out bladders are composed of fibrin. MSB (Martius, 
Scarlet and Blue) staining was performed and clots appeared positive for fibrin (red) and fresh fibrin (yellow). (A) 
Panoramic images of all three clot-containing bladders stained for MSB, where (i)-(ii) are double KO bladders and (iii) 
is the PRELP KO bladder. (B)-(C) Magnified images of the clot demonstrating a mixture of old and fresh fibrin. (D)-(E) 
The matrix seen in the lumen of these bladders is coloured blue and red under MSB staining, indicating the presence of 
extra-cellular matrix components that probably undergo cleavage and polymerisation to form fibrin. The same is also 
seen in panels (F) & (G) (images from the PRELP KO bladder), where the arrow indicates the thick blue matrix around 
the formed fibrin (red). (H)-(I) Immunofluorescence staining of a double KO bladder with an anti-fibrinogen primary 
antibody, visualised with alexa-546 (red) secondary and DAPI used as nuclei stain, further confirming that the clot is 
comprised of fibrinogen material. Scale bars, 500μm for (A), 50μm for (B)-(G), 100μm for (H)-(I). 
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Taking into account these findings we sought to find out if there is any 
hemorrhage or abnormalities in the composition of the urine in the transgenic mice. 
For this purpose, urine samples were collected from 11 wild types, 9 OMDLacZ/LacZ, 
10 PRELPLacZ/LacZ and 15 double-KO mice of variable ages and were subsequently 
tested with specific urine strips to detect blood or protein. No blood traces were 
detected in any of the samples tested, whereas the presence of protein varied slightly 
between the different genotypes (Fig. 6.6). In detail, no difference was seen between 
the wild types and OMD knock-outs with mean values of 0.2227 ± 0.02 and 0.2278 ± 
0.09 g of protein/L respectively. In contrast, an increase of protein was observed in 
the PRELP knock-out mice, which although small was statistically significant (mean 
value 0.4650 ± 0.09, p=0.0410 against the WT), while the double-KOs were mostly 
ranged around the baseline values seen in the WT with a mean of 0.2500 ± 0.06. 
Overall, we can see a trend for increased protein content in the urine of the knock-out 
mice, and especially the PRELP-KOs, which probably is correlated with the matrix 
found in the lumen of some of the bladders and could further lead to the formation of 
the fibrin clots. Additionally, since urine is being produced from the kidneys, we 
cannot exclude the possibility of a defective filtration mechanism from the nephrons, 
resulting in high urine protein content. In order to unravel how the fibrin clots are 
formed and if they are related to the urine composition, further examination of the 
kidneys and the whole renal system is essential. 
Figure 6.6: Protein levels in the urine are slightly elevated in the PRELP knock-out mice. Urine 
samples were collected from n=11 WT, n=9 OMDLacZ/LacZ, n=10 PRELPLacZ/LacZ and n=15 double KO 
mice of variable ages (23-77 weeks old). Protein levels were assessed using specific urine strips, where 
concentration was measured according to the colouration of the strips. A trend for increased protein 
content can be seen in in the PRELP KO mice. Data are
 
presented as mean±SEM, *equals p<0.05 
Apart from the histological analysis described above, we wanted to further study 
the effect of OMD/PRELP depletion in the mouse urothelium, mostly since they 
appeared to be expressed in the umbrella cell layer (Sections 4.2.5.1 & 5.2.5.1). For 
this purpose, immunofluorescence staining was performed using various different 
markers against the mouse urothelium. Initially, uroplakin-III was used to stain the 
umbrella cells, and sections from every sample (15 sections in total) were compared 
between them. Representative images from every genotype are demonstrated in 
Figure 6.7, where we can see strong and specific staining of the outermost umbrella 
cell layer. No significant differences were found in the overall intensity of the 
staining and the thickness of the uroplakin-III positive cell layer between wild types 
and knock-outs (including the double-KOs). 
Next, an anti-laminin antibody was used to stain the basal lamina, a component 
of the basement membrane which connects the urothelium with the lamina propria. 
Similarly to before, staining was conducted on all 15 samples and representative 
images from each genotype are shown in Figure 6.8. The basal lamina can be 
observed as a thin line surrounding the surface of the lamina propria just under the 
basal cells of the urothelium, while the staining seen towards the middle of the 
lamina propria represents blood vessels. Again, we could not detect any differences 
in the staining between WT and KO samples, suggesting that this layer of the 
basement membrane is not affected. 
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Figure 6.7: The umbrella cell layer appears to be normal in knock-out mice. 
Immunofluorescence staining was performed with a uroplakin primary antibody that marks the 
umbrella cells, visualised using alexa-488 (green) as secondary and DAPI as nuclei stain. Sections 
from all bladders (n=6 WT, n=3 for each single and double KOs) were stained and representative 
images are shown. No significant differences can be observed in the overall staining intensity or 
thickness of the umbrella cell layer between the different genotypes. Scale bar, 50μm for all images. 
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Figure 6.8: Laminin expression is similar between wild type and knock-out mice. 
Immunofluorescence staining was performed with a laminin primary antibody which marks the basal 
lamina, one layer of the basement membrane located between the lamina propria and the urothelium, 
visualised using alexa-488 (green) as secondary and DAPI as nuclei stain. Again, sections from all 
bladders (n=6 WT, n=3 for each single and double KOs) were stained and representative images are 
shown here. No significant differences can be observed between wild type and knock-out samples. 
Scale bar, 100μm for all images. 
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Continuing further with our analysis and in search of a cancer-related phenotype, 
we examined all the bladders for E-cadherin expression, since loss of function or 
expression of epithelial cadherin has been correlated with cancer progression and 
metastasis. In addition, adherens junction was also one of the affected pathways after 
altered expression of OMD and PRELP (Dr. Hamamoto’s analysis, Appendix A). 
Again, immunofluorescence staining was carried out for all fifteen samples and 
exemplar images are presented in Figure 6.9. We can see that E-cadherin expression 
is strong in all the epithelial layers of the urothelium, i.e. basal, intermediate and 
umbrella cells. Moreover, it is specifically localised in cell-cell membranes and only 
a minimum cytoplasmic signal is present. Staining between the wild type and the 
OMD/PRELP or double-KO samples appeared similar, with comparable staining 
intensity and pattern. Occasionally a stronger signal was seen in the apical surface of 
the outermost umbrella cells in the knock-out samples, but under the current staining 
conditions we cannot make any definite conclusions about the adherens junction 
status of the knock-out bladders.  
Zonula occludens 1 (ZO-1) is another adhesion protein, specific for tight 
junctions, which is associated with cancer at the point of epithelial-mesenchymal 
transition (EMT). During EMT both E-cadherin and ZO-1 are lost, resulting in 
transformation of the polarized epithelial cells into a more elongated, mesenchymal-
like phenotype (Lamouille et al., 2014). In addition, ZO-1 and several claudins are 
key molecules in the bladder homeostasis, as they form tight junctions in the 
intersections of apical and lateral membranes of the umbrella cells, regulating in this 
way the paracellular transport of molecules (gate and fence functions) (Khandelwal 
et a., 2009). We have shown that OMD and PRELP are selectively expressed in a 
subpopulation of bladder umbrella cells (Chapters 4&5). Also, overexpression of 
OMD and PRELP in human bladder cancer cells led to an increase of TJ formation 
(Chapter 3), while microarray data acquired from Dr. Hamamoto showed that 
OMD/PRELP affect both tight junction and adherens junction pathways (see 
Appendix A). Thus, we wanted to evaluate the TJ status of the urothelium in the 
OMD/PRELP knock-out mice. For this purpose, immunofluorescence staining using 
a ZO-1 antibody was performed in all the mouse bladders (n=6 for WT, n=3 for each 
OMD/PRELP and double KOs). Additionally, ultrastructural analysis was also 
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performed by EM on one bladder from each WT, OMD/PRELP KO and double KO 
animals. 
In Figure 6.10 A-D representative images of the ZO-1 stained bladders are 
shown, where strong staining is seen in the apicolateral borders of the umbrella cells 
in the wild type samples (arrowheads). This staining pattern appeared reduced in the 
single and double knock-outs and we therefore performed quantification of these 
apical ZO-1 positive junctions in relation to the outermost urothelial cell nuclei. 
Quantification was performed in three random viewing planes under the 40x 
magnification lens, where we counted how many times the intense positive ZO-1 
signal was seen in the apicolateral borders of umbrella cells. In addition, the 
outermost DAPI cell nuclei were counted representing the umbrella cells, and the 
total tight junction number is presented as percentage of the apical ZO-1 positive 
junctions in relation to the umbrella cell number.    Shown in Figure 6.10E, are the 
results of the quantification demonstrating reduction in the number of the ZO-1 
positive tight junctions in all the knock-out samples compared to wild type. In detail, 
wild type samples had a mean value of 12.44 ± 1.34 (%) against 4.97 ± 0.69 for the 
OMDLacZ/LacZ (p=0.0004), 6.75 ± 0.68 for the PRELPLacZ/LacZ (p=0.0039) and 4.17 ± 
0.72 for the double KO (p=0.0004) bladders. However, it must be noted that the 
staining pattern was quite variable between the different samples owning to the 
staining conditions (i.e. insufficient antigen retrieval of the paraffin sections and/or 
low specificity of the primary antibody under the current conditions), and therefore it 
is difficult to be sure of any definite conclusions.      
In order to further investigate the TJ status of the bladder urothelium, electron 
microscopy analysis of wild type and knock-out bladders was performed and tight 
junction formation between adjacent umbrella cells was assessed. Shown in Figure 
6.11A is a wide view of wild type bladder urothelium, which includes two umbrella 
cells and an intermediate cell. The apicolateral border of the two umbrella cells is 
strongly sealed by dense tight junctions (indicated by the black arrowheads), while 
another example of this strong connection is shown also in Figure 6.11B. In contrast, 
tight junction formation is much less intense, or junctions might not be properly 
formed, in the knock-out samples, especially in PRELPLacZ/LacZ and double KO 
samples (black arrowheads in D and E), and to a lesser extend in the OMDLacZ/LacZ (as 
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seen in panel C). Moreover, the cell membrane borders were not visible in the WT 
samples, whereas they are easily discernible in the knock-outs, indicating weaker 
connections or junctions. In the knock-out samples we can additionally see 
formations that probably are adherens junctions (white arrows) or desmosomes 
(white arrowheads), which are not visible in the wild type bladders. This may be due 
to the very strong TJ connections in the latter samples or can be an effect of the TJ 
disruption in the knock-outs. 
Lastly, characteristic of the umbrella cells is the scalloped nature of their apical 
plasma membrane, which comprises plagues and intervening hinge regions, 
accompanied by the presence of discoidal or fusiform-shaped vesicles in their 
cytoplasm. No differences were seen in the above structures or the overall shapes of 
the umbrella cells between wild type and knock-out bladders under EM. We 
therefore see that OMD and PRELP depletion causes a decrease in tight junction 
formation between neighboring umbrella cells, agreeing also with our previous in 
vitro findings, and further suggesting that these two SLRPs can somehow regulate TJ 
formation.  
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Figure 6.9: E-cadherin expression in the mouse urothelium of wild type and knock-out mice. 
Immunofluorescence staining was performed with an E-cadherin primary antibody, visualised using 
alexa-488 (green) as secondary and DAPI as nuclei stain. Staining can be seen in the cell membranes 
of the whole urothelium, with comparable staining intensity and pattern between wild type and knock-
outs. Occasionally stronger signal could be observed in the apical surface of the outermost umbrella 
cells in the knock-out samples, but under the current staining circumstances we cannot make any 
definite conclusions about the adherens junction status of the knock-out bladders. Scale bar, 50μm for 
all images. 
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Figure 6.10: ZO-1 expression and tight junction formation in the urothelium of transgenic mice. (A)-(D) 
Immunofluorescence staining was performed with a ZO-1 primary antibody, visualised using alexa-488 (green) as 
secondary and DAPI was used as nuclei stain. Specific staining can be seen in the apical sides of the outermost 
umbrella cells, marked with arrowheads. This signal was reduced in the OMD/PRELP and double knock-outs. Scale 
bars, 20μm for all images. (E) Quantification was performed in 3 random viewing planes under the 40x 
magnification lens in every sample and the results are presented as percentage of the apical ZO-1 positive junctions 
in relation to the outermost urothelial cell nuclei. Data are presented as mean±SEM, **p<0.01, ***p<0.001 against 
the WT. 
E 
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Figure 6.11: Ultrastructural analysis of the umbrella cells in wild type and knock-out bladders. One 
bladder of each WT, OMD/PRELP and double KO mice was processed and analysed under electron 
microscopy. In (A) a wide view of wild type bladder urothelium is shown, which includes two umbrella cells 
and an intermediate cell. The apicolateral border of the two umbrella cells is strongly sealed by dense tight 
junctions (black arrowheads). The same can be seen in (B), while tight junctions are much less intense or are 
not properly formed at all in the knock-out samples (black arrowheads in C, D and E). The effect is more 
pronounced in the PRELP and double KO bladders. Additionally, possible adherens junctions (white arrows) 
or desmosomes (white arrowheads) are visible in the knock-out samples. Also, cell plasma membranes are 
discernible in the knock-outs and not in the wild type, indicating weaker junctions in the former. Scale bar, 
300nm for (A), 200nm for all other images. 
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Finally, since abnormal proliferation is one of the characteristics accompanying 
cancerous tissues and is involved in cancer progression, we sought to look for any 
irregular proliferation patterns in the knock-out bladders and specifically in the 
urothelium. To this end, immunostaining for the proliferation marker Ki-67 was 
conducted in all the different bladders and representative pictures are demonstrated 
in Figure 6.12A. As the proliferative index of the normal mouse bladder epithelium 
is quite low (without injuries, around 0.4-0.5% as previously reported)(Farsund, 
1975) we did not expect to find many Ki-67 positive cells around the urothelium. 
Indeed, as shown in Figure 6.12, only few cells were Ki-67 positive, and these were 
observed to be umbrella, intermediate or basal cells (arrowheads). However, when 
comparing the wild type with the knock-outs we did notice a slight increase of Ki-67 
positive cells in the latter samples, and this can be seen in panels (ii), (iii) & (iv), in 
which samples we often observed more than a single positive cell in the standard 
viewing plane in contrast with the WT (i). Counting all the Ki-67 stained cells in one 
section per bladder (a total of 4 sections for the WT samples and 3 sections for each 
single and double KO), revealed a two-fold increase of proliferative cells in the 
OMDLacZ/LacZ samples (mean value of 6.000 ± 3.0) and an approximate 3-fold 
increase in the double-KOs (mean of 10.33 ± 3.3) compared to the wild type mice 
(3.000 ± 1.4) (Fig. 6.12B). No difference was seen in the homozygous 
PRELPLacZ/LacZ bladders, where the total number of Ki-67 positive cells was almost 
identical to the WT with a mean value of 3.000 ± 2.0. Although these changes were 
not statistically significant, we can see that there is a trend, at least regarding the 
OMD and double knock-out mice, for an increased proliferation index in the 
urothelium, suggesting a potential role of OMD/PRELP in suppressing abnormal cell 
proliferation in the mouse bladder.  
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Figure 6.12:  Proliferation of urothelial cells is slightly increased in OMD and double KO 
bladders. (A) Immunofluorescence staining was performed with a Ki-67 primary antibody 
which marks the proliferating cells, visualised using alexa-488 (green) as secondary and DAPI 
as nuclei stain. More Ki-67 positive urothelial cells were seen in the single and double knock-
out samples, under the standard viewing plane, compared to the wild types (arrowheads). Scale 
bar, 50μm for all images. (B) Quantification of Ki-67 positive cells was performed in one 
section per bladder, with a total of n=4 bladder for the WT and n=3 bladders for each OMD, 
PRELP and double knock-outs. Data are presented as mean±SEM. No significant difference 
was seen between the different genotypes, but there is a trend for increased proliferation in the 
OMDLacZ/LacZ and double KO samples. 
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6.2.1.2 Effect of OMD and PRELP targeted deletion in the mouse eye 
As explained earlier, during phenotyping of the knock-out mice primary 
attention was given to the bladder, while other organs, including the eye, were 
examined in less detail.  As shown in Chapters 4 and 5, OMD and PRELP are both 
expressed in the adult mouse eye, and hence a preliminary analysis was conducted to 
evaluate any noticeable eye-related phenotypes that could arise from OMD & 
PRELP depletion. For this study eyes were collected from three of each WT, 
OMDLacZ/LacZ and PRELPLacZ/LacZ animals, at three months of age, and were 
subsequently processed.  
 Initially, H+E staining was performed and samples from wild type and knock-
outs were compared in order to detect any gross histological differences. In Figure 
6.13 A&B representative pictures of whole WT and OMDLacZ/LacZ eyes are displayed, 
where no noticeable differences can be observed regarding the size and the overall 
structure of the components of the eye (i.e. cornea, lens, retina, CB). Additionally, 
enlarged views of two ciliary bodies can be seen in panels C&D, demonstrating 
normal gross morphology of the pigmented and non-pigmented epithelial cells. 
Further attention was given on the analysis of the retina, where close comparison 
between wild types and knock-outs was performed. Exemplar images of low and 
high magnification views of the central retina are shown in Figure 6.14, where we 
can observe a more "fractured" pattern in the retinal ganglion cell layer of the OMD 
KO samples, with more spaces between the cells and the inner limiting membrane 
(Fig. 6.14D, arrowheads).  The retinal cell layers (RGC, IPL, INL, OPL, ONL, IS, 
OS) appeared to be of the same thickness and density between WT and KOs, 
indicating no abnormal decrease in cell numbers. However, since OMD is normally 
expressed in the RGCs, quantification of the ganglion cells was conducted in order to 
find any possible differences. Quantification was performed in four different areas of 
the retina, in 6 different sections from each sample. Those four areas include two 
parts of the central retina and two parts at the periphery, adjacent to the ciliary 
bodies, and they are noted with the red dotted boxes in Figure 6.13A. After 
quantification the two central retina counts were pooled together, as were the counts 
from the peripheral areas. Presented in Figure 6.14E are the results of the 
quantification, showing no significant differences between the wild type and the 
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OMD knock-out samples both in the central and the peripheral retina. In detail, 
central retina ganglion cells of wild types numbered a mean of 69 ± 4.7 versus 64.8 ± 
3.0 for the knock-outs (p=0.4599), while the in the peripheral retina WTs had a mean 
of 35.7 ± 1.5 vs. 36.7 ± 1.5 for the KO respectively (p=0.6991). On the contrary, 
what we observed in all samples was that ganglion cells towards the periphery of the 
retina tend to decrease and therefore are considerably less than the central areas. 
Finally, since a more "fractured" pattern was seen in the space above the RGCs with 
H+E staining in the OMD knock-out eyes, it was decided to search for any 
disruptions at the inner limiting membrane through immunostaining with an anti-
laminin antibody, and as shown in Figure 6.18 & 6.19, no breaks of the membrane 
were observed in the knock-outs, while their staining pattern was very similar to the 
wild types. 
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Figure 6.13: Comparison of eye morphology in wild type and OMD knock-out samples. (A)-(B) Panoramic 
views of the whole eyes from WT and OMD KO animals stained with H+E, showing no differences in the gross 
morphology or the size of the eyes. The red dotted boxes indicate the areas used for retinal ganglion cell 
counting, where R is central retina and CB the peripheral retina areas. (C)-(D) Magnified views of the ciliary 
bodies from each sample demonstrating normal cell structure in both genotypes. Scale bars, 1mm for (A)-(B), 
100μm for (C)-(D) 
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Figure 6.14: Analysis of the retina between wild type and OMD knock-out samples. (A)-(D) Two 
different magnifications  of the central retina from WT and OMDLacZ/LacZ eyes. In the OMD KO samples a 
more "fractured" pattern of the RGC layer can be seen, with more spaces between the cells and the inner 
limiting membrane (arrowheads). All the other retinal layers appear to be of similar thickness and density as 
seen in the wild type retinas, indicating no abnormal decrease in cell number. Scale bars, 100μm for (A)-(B), 
50μm for (C)-(D). RGC, retinal ganglion cells; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, 
outer plexifrom layer; ONL, outer nuclear layer; IS, inner segments; OS, outer segments. (E) Quantification 
of RGC cells in the central and peripheral retina was performed in 6 different sections from each sample (n=3 
eyes for WT, n=3 eyes for OMD KO), where no significant differences were seen between the control and the 
knock-out samples. Data are present as mean±SEM. ns, non-significant.  
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A similar analysis was performed on the PRELP knock-out eyes, where again 
the first step was to compare the gross histology between different samples with H+E 
staining. Demonstrated in Figure 6.15 A&B are two representative pictures of whole 
eyes from a wild type and a PRELPLacZ/LacZ sample, showing no major abnormalities 
in the overall structure and size of the eye. In addition, magnified views of the retina 
are displayed in panels C&D, showing similar retinal cell layers thickness and 
density. Since PRELP is normally expressed only at the ciliary bodies (Chapter 5), 
we would expect to find any phenotypic effects around the CB areas and therefore 
further attention was given in the analysis of the latter. Close histological 
examination of WT and KO ciliary bodies was performed, but no noticeable 
differences could be observed in the overall morphology or cell density of the ciliary 
body epithelium (Figure 6.16 A-D). Thus, we decided to then measure the area they 
occupy, as marked with the red dotted lines in Figure 6.16, panels C&D. The 
measurements were done on both dorsal and ventral CBs, in 6 different sections for 
each sample and for three samples/genotype, using the Image J analysis software. 
Interestingly, a modest but statistically significant reduction of the CB area was 
observed in the PRELP knock-out eyes compared to the wild types (Figure 6.16 E). 
More specifically, WT ciliary bodies occupied a mean area of 78220 ± 4140, 
measured in pixels, versus a value of 66570 ± 3172 for PRELPLacZ/LacZ samples 
(p=0.0301), suggesting a possible shrinkage of the CB epithelium due to PRELP 
deletion. 
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Figure 6.15: Comparison of eye morphology in wild type and PRELP knock-out samples. (A)-(B) Panoramic 
views of whole eyes from WT and PRELP KO animals stained with H+E, showing no differences in the gross 
morphology or the size of the eyes. (C)-(D) Magnified views of the retinas from each sample demonstrating 
similar thickness and density of the different cell layers. Scale bars, 1mm for (A)-(B), 100μm for (C)-(D). 
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Figure 6.16: Analysis of the ciliary bodies between wild type and PRELP knock-out eyes. (A)-(D) Two 
different magnifications  of H+E stained ciliary bodies from WT and PRELPLacZ/LacZ samples, demonstrating 
similar morphology and cell density of the CB epithelium. Red dotted lines demonstrate the chosen area to be 
measured. Scale bars, 100μm for (A)-(B), 50μm for (C)-(D). (E) Quantification of the CB area was 
performed in 6 different sections of each sample (n=3 eyes for WT, n=3 eyes for PRELP KO) using the 
Image J analysis software. PRELP KO animals had smaller ciliary bodies when compared to wild types. Data 
are presented as mean±SEM, *p<0.05. 
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Following this last finding, immunofluorescence staining was performed using 
an anti-Pax6 antibody, marking the pigmented and non-pigmented cells of the ciliary 
body epithelium. Presented in Figure 6.17 A&B are images of CBs from WT and 
PRELPLacZ/LacZ samples respectively, showing no difference in the intensity of the 
staining or the density of the Pax6 positive cells, indicating no apparent cell decrease 
in the epithelium. Lastly, staining with an anti-Laminin antibody was also carried out 
in all PRELP and OMD samples and representative images of both are exhibited 
together in Figures 6.18 and 6.19. More specifically, as already mentioned, laminin 
staining of the central retina marks the inner limiting membrane, which is localised 
above the ganglion cell layer (arrow), together with the blood capillary walls 
(arrowheads), as seen in Figure 6.18. Comparison of either the OMD or PRELP 
knock-outs with the WT revealed no difference the staining intensity or pattern. The 
same observation can be seen in the ciliary bodies staining, where laminin labels the 
basement membrane of the CB epithelial cells as well as the linings of the blood 
vessels (Fig. 6.19).   
In conclusion, this preliminary analysis revealed a difference in the ciliary body 
size due to PRELP depletion. Other differences in cell viability or number were not 
found, although a more detailed analysis including more samples needs to be done in 
order to have a more conclusive result. 
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Figure 6.17: No decrease in the ciliary body epithelial cells is seen in the PRELP knock-out eyes. 
Immunofluorescence staining was performed with a Pax6 primary antibody and was visualised using alexa-488 
(green) as secondary, and DAPI as nuclei stain. Comparison between wild type and PRELP knock-out samples 
did not reveal any differences in the staining intensity or cell density of the CB cells. Scale bar, 50μm for all 
images. 
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Figure 6.18: No differences were seen in the inner limiting membrane of wild type and knock-out 
retinas. Immunofluorescence staining was performed with a laminin primary antibody and was visualised 
using alexa-488 (green) as secondary, and DAPI as nuclei stain. Arrow indicates the inner limiting membrane 
which is positive for laminin, while arrowheads point to blood vessels walls which are also positive. 
Comparison between wild type and OMD/PRELP knock-out samples did not show any differences in the 
staining pattern or intensity. Scale bar, 50μm for all images. 
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Figure 6.19: No differences were seen in the basement membrane of ciliary bodies between wild type 
and knock-out eyes. Immunofluorescence staining was performed with a laminin primary antibody and was 
visualised using alexa-488 (green) as secondary, and DAPI as nuclei stain. Laminin stains the basement 
membrane of the CB epithelial cells and the blood vessel walls. No obvious differences are seen in the 
staining pattern or intensity between the wild type and knock-out samples. Scale bar, 50μm for all images. 
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6.2.1.3 Effect of OMD and PRELP targeted deletion in the mouse gait 
locomotion and bone content 
Since OMD and PRELP are expressed in both bone and brain, we wanted to 
assess any possible motor-related phenotypes. Gait analysis provides an easy way to 
evaluate neurological disorders as well as skeletal defects like arthritis or knee 
injuries. Therefore, we performed a preliminary gait study employing the footprint 
test, including only wild type and OMD knock-out mice at two months of age.  
Five mice of each WT and OMDLacZ/LacZ genotypes were used in this study and 
representative images of the hindlimb ink-stained walking pattern are shown in 
Figure 6.20A.  The parameters analysed are the stride length between the same feet, 
the sway distance and the stance, as indicated by the dotted lines. Each mouse was 
tested thrice and measurements were calculated using the Image J software. 
Histograms relative to the different elements are shown in Figure 6.20 B-D, 
demonstrating very small differences between the groups of mice. In detail, 
regarding the stride, WTs showed a mean length of 107.9 ± 1.63, measured in pixels, 
versus 109.4 ± 2.01 for the OMD-KO (p=0.5626). For the sway, WTs had a mean 
distance of 52.61 ± 0.69 whereas the knock-outs had 49.77 ± 1.09, a very small but 
significant difference (p=0.0315), while for the stance the values were at 77.43 ± 
1.39 for controls against 80.09 ± 1.87 for transgenics (p=0.2562). Collectively, we 
can conclude that the gait between controls and OMD knock-out animals is similar 
with some minor differences, which however could indicate a possible role of OMD 
in affecting mouse mobility. In order to have a more convincing outcome we need to 
increase the number of the samples and also repeat the test in several different age 
points. 
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Figure 6.20: Gait analysis of OMD transgenic mice. Gait analysis was performed with the 
footprint test, where the front and hind paws are dipped in ink so that the mice leave a trail of 
footprints as they walk along a corridor. Measurements of stride, stance and sway length give an 
indication of gait. Five mice of each genotype were tested thrice. Measurements were calculated 
using the Image J analysis software. (A) Examples of the footprints seen in WT and OMD KO 
mice. (B)-(D) Measurements  of stride length (B), sway distance (C) and stance length (D) between 
wild types and knock-outs. Data are presented as mean±SEM, *p<0.05. ns, non-significant. 
270 
Lastly, automated measurements were obtained for bone and soft-tissue 
composition of transgenic mice using the Lunar PIXImus Densitometer. The 
parameters tested are bone mineral density (BMD) and bone mineral composition 
(BMC), as well as the fat, lean and total fat+lean for the whole body. This study was 
performed on a preliminary basis as well, and thus, only a small number of mice 
were used. More specifically, two OMD+/+ and four OMDLacZ/LacZ at four weeks of 
age were tested regarding the OMD gene, and five of each PRELP+/+ and 
PRELPLacZ/LacZ for the PRELP gene at 8 weeks of age.  The results are presented in 
Figure 6.21, where we can observe small differences between the controls and 
knock-outs, none of which are statistically significant though. The biggest 
differences can be seen in the lean and total measurements for the OMD group, but 
due to the small sample size tested no significant conclusions can be reached.  Also, 
the differences observed between the OMD+/+ and PRELP+/+ mice can be attributed 
to the age difference between the two distinct groups. Therefore, under the current 
findings, we cannot make any significant conclusion concerning the effect of OMD 
or PRELP depletion on bone mineral or body composition of the transgenic mice.   
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Figure 6.21: Piximus analysis of OMD and PRELP transgenic mice. Using the Lunar PIXImus 
Densitometer automated analysis of the bone mineral density (BMD), bone mineral composition (BMC), 
lean, fat and the total of lean+fat was performed. Two OMD+/+ and four OMDLacZ/LacZ mice at four weeks 
of age (A), and five of each PRELP+/+ and PRELPLacZ/LacZ mice at 8 weeks of age (B) were tested. No 
significant differences were seen between wild type and knock-out mice in the above parameters. Data are 
presented as mean±SEM. ns, non-significant. 
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6.2.2 Effect of OMD and PRELP depletion in mouse embryonic development 
The initial step in most skeletal phenotype investigations is the analysis of whole-
mount skeletal preparations. This specialized staining allows evaluation of different 
skeletal elements in their appropriate location and is the main technique used to 
detect changes in skeletal patterning. This method involves differential staining of 
cartilage and ossified bone, using alcian blue and alizarin red respectively, and can 
therefore also be used to assess the pace of skeletal maturation. Alcian blue/alizarin 
red whole-mount staining was performed in E15.5 and E17.5/E18.5 litters arising 
from OMD+/LacZ ♂ x OMD+/LacZ ♀ and PRELP+/LacZ ♂ x PRELP+/LacZ ♀ matings, and 
knock-out embryos were compared to wild types within the same litter. 
Overall we could not detect any differences between wild type and knock-out 
embryos concerning skeletal preparations of E15.5 embryos. During this stage of 
development ossification has not progressed much and the areas that are stained with 
alizarin red are mostly the mandible, small parts of the vertebral discs and the ribs, 
together with the primary ossification centers of all the long bones, while all the 
other skeletal elements are cartilage and therefore stained blue. Starting with OMD 
transgenic E15.5 embryos, in Figure 6.22A representative images are shown of the 
lateral and dorsal sides of an OMD+/+ and an OMDLacZ/LacZ embryo, where it is visible 
that there are no noticeable differences in the overall size of the embryos, the number 
of vertebrae or ribs, the length of the appendicular bones, or the shape of the head. In 
addition, magnified views of the forelimb and hindlimb long bones are presented in 
Figure 6.22B-C (i) and (ii) respectively. The primary ossification centers of radius 
(R), ulna (U) and humerus (H) are discernible, moderately stained with alizarin red, 
where we see no changes in the intensity of staining or the length of the epiphysis 
between wild type and knock-out embryos, suggesting that OMD depletion did not 
affect ossification or chondrocyte maturation rates even though it is expressed in the 
bone collar and in a sub-population of chondrocytes (Fig 6.22 B(i) vs. C(i)). The 
same pattern is seen in the leg bones femur (F), tibia (Ti) and fibula (Fi), where 
alizarin red staining is even less intense around the ossification grooves, and again 
there are no differences between the wild type and knock-outs (Fig. 6.22 B(ii) vs. 
C(ii)).  
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Figure 6.22: Skeletal preparations of E15.5 OMD transgenic embryos. Alizarin red and alcian blue 
staining of E15.5 wild type and OMD knock-out littermates was performed and representative images of the 
dorsal and lateral sides are shown in in (A). (B)-(C) Panels (i) and (ii) show magnified views of the frontlimb 
and hindlimb respectively. No differences were seen in the overall skeleton or in the long bones of the limbs 
between wild types and knock-outs, while ossification appears to be progressing in the same rate in both 
genotypes. Scale bars, 2mm for (A), 1mm for (B)-(C). H, humerus; R, radius; U, ulna; F, femur; Ti, tibia; Fi, 
fibula. 
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Moving on to older OMD transgenic embryos, the second target stage to be 
studied was E17.5, but due to technical difficulties E18.5 embryos were isolated 
instead and were prepared for skeletal staining. By this stage, skeletal development 
has progressed considerably and we can see that most of the osteoid elements of both 
the axial and appendicular skeleton have now been ossified. More specifically, all the 
cranial bones and the osseous parts of the vertebrae are stained with alizarin red, 
together with the dorsal segments of the ribs and most of the length of all the long 
bones in the limbs. In addition, the centers of metacarpals, metatarsals and phalanges 
are now ossified. Similarly to above, representative images of the lateral and dorsal 
sides of OMD+/+ and OMDLacZ/LacZ embryos are presented in Figure 6.23A, where 
again there are no observable differences in the overall size of the embryos, the 
number of vertebrae or ribs, the length of the long bones, or the appearance of the 
head between the two genotypes. In Figure 6.23 B(i)&C(i) enlarged images of the 
forelimb are shown, where we can see that radius and ulna have both been ossified to 
the same extent in the wild type and knock-out embryos. Furthermore, when 
observing the hindlimb and specifically the femur, tibia and fibula, again we see no 
differences in the length of the bones or the ossification progression (Fig. 6.23 B(ii) 
vs. C(ii)). Also, when looking at the sternum the partly ossified sternebrae (St) can be 
identified, as well as the xiphoid bone and cartilage (Xi), both being at the same 
stage of endochondral ossification between OMD+/+ and OMDLacZ/LacZ embryos (Fig. 
6.3 B(iii) vs. C(iii)). Finally, no differences can be seen in the intramembranous 
ossification of the cranial bones when comparing the wild type with the OMD knock-
out embryos. All the cranial elements, including the mandible (Man) and maxilla 
(Max), the frontal (F), parietal (P), intraparietal (I), supraoccipital (So) and 
exoccipital (Eo) bones, together with the first cervical vertebrae the atlas (At) and the 
hyoid bone (Hy) have the same alizarin red staining intensity and thus ossification 
progression (Fig. 6.3 D vs. E). In conclusion, OMD depletion does not have an 
apparent effect on skeletal development even at this more progressed stage of bone 
maturation.  
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 Figure 6.23: Skeletal preparations of E18.5 OMD transgenic embryos. Alizarin red and alcian blue 
staining was performed in E18.5 wild type and OMD knock-out littermate embryos and representative images 
of the dorsal and lateral sides are shown in (A). (B)-(C) Panels (i), (ii) and (iii) show magnified views of the 
frontlimb, hindlimb and sternum respectively. No differences can be seen in the length of the ossified bones 
or the alizarin red intensity between controls and KOs, demonstrating normal skeletal development in 
OMDLacZ/LacZ embryos. (D)-(E) Enlarged images of the head showing comparable pattern of ossification and 
similar head size/structure between wild type and transgenic embryos. Scale bars, 3mm for (A), 1mm for (B-i, 
B-ii) & (C-i, C-ii), 2mm for all the rest. H, humerus; R, radius; U, ulna; F, femur; Ti, tibia; Fi, fibula; St,sternum; Xi, 
xiphoid; Fr, frontal; P, parietal; I, intraparietal; So, supraoccipital; Eo, exoccipital; At, atlas; Hy, hyoid; Max, maxilla; 
Man, mandible.
 
 
The same analysis was performed in PRELP transgenic litters at stages E15.5 
and E17.5 and again no differences were seen between PRELP+/+ and PRELPLacZ/LacZ 
embryos. In Figure 6.24A E15.5 embryos are presented, where the ossification of the 
growing skeleton is still in early stages and most of the alizarin staining is seen in the 
mandible, in a small part of the vertebrae and ribs, and in the primary ossification 
centers of the long bones. More specifically, a magnified view of the humerus is 
shown with part of the radius and ulna, demonstrating the same level of 
endochondral maturation and ossification in the primary groove between wild type 
and knock-out (Fig. 6.24 B(i) vs. C(i)). The same applies for the long bones of the 
hindlimb, i.e. femur, tibia and fibula (Fig. 6.24 B(ii) vs. C(ii)).  
Continuing with older PRELP embryos, stage E17.5 samples were stained for 
bone and cartilage, and in Figure 6.25A the lateral and dorsal views of two 
representative embryos are demonstrated, where we can see that skeletal 
development has progressed considerably, with no overall differences between 
PRELP+/+ and PRELPLacZ/LacZ embryos in either the axial or appendicular skeleton. In 
detail, the biggest parts of the forelimb/hindlimb have now been ossified and alizarin 
red staining of the humerus, radius, ulna, femur, tibia and fibula has the same 
intensity and volume between wild types and knock-outs, suggesting similar 
chondrocytic maturation and ossification levels (Fig. 6.25 B(i-ii) vs. C(i-ii)). 
Moreover, ossification of the sternebrae has progressed at the same rate, while the 
xiphoid bones are still in a more cartilaginous stage (Fig. 6.25 B(iii) vs. C(iii)). 
Furthermore, close comparison between wild type and PRELP knock-out embryonic 
heads reveals no difference in the intramembranous or endochondral ossification of 
the cranial bones, where the mandible and maxilla, the frontal, parietal, intraparietal 
and exoccipital bones, along with the first cervical vertebrae and the hyoid bone have 
the same alizarin red staining intensity and thus ossification progression (Fig. 62.5 D 
vs. E). In comparison to E18.5 OMD embryos, it is visible that ossification has not 
advanced at the same level, which is expected since these PRELP embryos are one 
day younger, and for example, ossification of the supraoccipital bone has still not 
taken place in either PRELP+/+ or PRELPLacZ/LacZ E17.5 embryos, whereas the bone 
is almost fully formed in the OMD E18.5 embryos.  
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Figure 6.24: Skeletal preparations of E15.5 PRELP transgenic embryos. Alizarin red and alcian 
blue staining of E15.5 wild type and PRELP KO littermates was performed and representative 
images of the dorsal and lateral sides are shown  in (A). Due to the prolonged period of handling the 
embryos during the skeletal staining, breaks at the ribs, as seen here, and other fragile parts of the 
embryo often occur. (B)-(C) Panels (i) and (ii) show magnified views of the frontlimb and hindlimb 
respectively. No differences were seen in the overall skeleton or in the staining and size of long 
bones in the limbs between wild types and knock-outs, while ossification appears to be progressing 
in the same rate in both genotypes. Scale bars, 2mm for (A), 1mm for (B)-(C). H, humerus; R, 
radius; U, ulna; F, femur; Ti, tibia; Fi, fibula. 
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 Figure 6.25: Skeletal preparations of E17.5 PRELP transgenic embryos. Similarly to before, lateral and 
dorsal sides of E17.5 wild type and PRELP KO littermate stained embryos are shown in (A), demonstrating no 
apparent differences in the size or the structure of the developing skeleton. (B)-(C) Panels (i), (ii) and (iii) 
show enlarged views of the frontlimb, hindlimb and sternum respectively. Again, no differences can be seen in 
the length of the ossified bones or the alizarin red intensity between controls and KOs, indicating normal 
skeletal development of KO embryos. (D)-(E) Enlarged images of the head showing similar alizarin red 
staining between wild type and transgenic embryos. Scale bars, 3mm for (A), 1mm for (B-i, B-ii) & (C-i, C-ii), 
2mm for all the rest. H, humerus; R, radius; U, ulna; F, femur; Ti, tibia; Fi, fibula; St,sternum; Fr, frontal; P, parietal; I, 
intraparietal; So, supraoccipital; Eo, exoccipital; At, atlas; Hy, hyoid; Max, maxilla; Man, mandible.
 
 
In conclusion, OMD or PRELP depletion did not result in any discernible 
phenotypes during embryonic skeletal development. Even though both proteins are 
found to be largely expressed in skeletal elements (Chapters 4&5), alizarin red/alcian 
blue staining of embryos revealed no apparent differences in chondrocytic 
maturation or ossification rate.  
6.2.3 Micro-CT of OMD E17.5 embryos 
Since OMD and PRELP are strongly expressed during skeletal development it 
was decided to study more closely the embryonic bone formation. For this purpose 
micro computed tomography (micro-CT) was performed, which is X-ray imaging in 
3D similar to the clinical "CAT" scans but on a smaller scale with very high 
resolution. This method basically represents 3D microscopy, where very fine scale 
internal structure of objects can be imaged by creating realistic visual models and in 
addition 3D bone morphometric parameters can be measured. However, due to the 
very high cost of the scanning equipment usage and the extensive time needed to 
complete the scans, this analysis was performed on OMD transgenic E17.5 embryos 
only, while PRELP embryos were not included in the present study.   
Whole-embryo reconstructions were generated from ~3500 individual cross 
sections per sample, optimized for bone analysis, and were artificially colored to 
enhance the signal. Three wild type and five OMD knock-out embryos were included 
in this study. In Figure 6.26 A&B representative images of OMD+/+ and 
OMDLacZ/LacZ embryos are shown respectively. In panels (i) the front/ventral sides of 
the embryos are shown, while in panels (ii) the back/dorsal and in (iii) the 
right/lateral views are displayed. Interestingly, small differences can be seen in the 
mineralization content of some skeletal elements. For example, ossification of the 
intraparietal bone is delayed in the OMD knock-out embryos compared to WT (Fig. 
6.26 A(ii) vs. B(ii), arrows). In addition, the same effect can be observed for the 
metacarpal and metatarsal bones, where the signal in the OMDLacZ/LacZ samples is 
much less compared to OMD+/+ (Fig 6.26 A(iii) vs. B(iii), arrows). All the other 
skeletal elements, including the ribs, frontlimb/hindlimb long bones and vertebrae 
appear to be of comparable ossification levels and size between wild types and 
knock-outs. 
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Figure 6.26: Micro-CT reconstructions of E17.5 OMD transgenic embryos. Three wild type and five 
OMD knock-out embryos were scanned for bone content. Reconstructions were generated with the 
CTvox software and colour was added to the images to enhance the signal. Therefore, orange colour 
represents ossified bone. Panels (i) show the front/ventral sides of the embryos while in panels (ii) the 
back/dorsal and in (iii) the right/lateral views are displayed. Arrows in panels (ii) indicate delayed 
intraparietal bone ossification in the knock-out embryos compared to the controls. Arrows in panels (iii) 
point to metatarsals and metacarpals, which are very faint in the OMD KO, demonstrating decreased 
ossification. All the other skeletal elements appear normal in both genotypes. Scale bar, 3mm for all 
images. 
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Quantitative bone morphometric analysis of the 3D reconstructed micro-CT 
models can be performed through the CTvol software, and can provide quantitative 
data about structural properties of cortical and trabecular bone. For instance, 
properties like tissue volume (TV), bone volume (BV), bone surface (BS), as well as 
bone volume density (BV/TV) and bone surface density (BS/TV) can all be 
measured and give us information about bone morphology. Three OMD+/+ and five 
OMDLacZ/LacZ embryos were scanned and analysed for all the above parameters and 
the most important findings are presented in Figure 6.27. More specifically, the 
percent bone volume density (BV/TS) of the OMD knock-out embryos (0.16 ± 0.03, 
n=5) was lower compared to the wild type (0.21 ± 0.02, n=3), but not significantly 
different (p=0.2644) (Fig. 6.27A). The same was observed for the bone surface, 
where OMDLacZ/LacZ had a mean value of 580.3 ± 101.7 vs. 713.9 ± 54.06 for the 
OMD+/+ (p=0.2983) (Fig. 6.27B), as well as for the bone surface density (BS/TV) 
with values of 0.34 ± 0.05 for OMD-KO against 0.43 ± 0.03 for WT (p=0.2358) (Fig. 
6.27C). Finally, the bone surface/bone volume ratio, which gives information about 
cortical/trabecular proportion, was slightly but not significantly different between the 
two groups, with the knock-outs having a higher mean value of 218.7 ± 12.93 vs. 
200.4 ± 7.2 for the WT (p=0.2734) (Fig. 6.27D). Since at this stage of development 
neither cortical nor trabecular bone has completely form, the latter measurements 
probably do not have any significant value for embryonic bone analysis.  
In conclusion, although not statistically significant, the overall bone content of 
the knock-out embryos is lower compared to the wild types, as demonstrated from 
the bone volume density and bone surface density graphs. Thus, we can say that 
there is a trend towards a delayed or decreased skeletal mineralization rate caused by 
OMD depletion, at least during this stage of development. Since alizarin red/alcian 
blue staining of E18.5 embryos showed no differences between OMD-KOs and WTs, 
we cannot know if this effect is attenuated in later developmental stages, or whether 
it is not visible due to the lower sensitivity of the skeletal preparation against the 
micro-CT imaging.       
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 Figure 6.27: Bone morphometric analysis of E17.5 OMD transgenic embryos. Using the 
CTvol software structural properties of the developing bones were assessed, including: bone 
volume density (BV/TS), shown in (A); bone surface (BS), shown in (B); bone surface density 
(BS/TV), shown in (C); and bone surface/bone volume ratio, which gives information about 
cortical/trabecular proportion, shown in (D). In the first three parameters OMD KO embryos 
had lower, but not significantly different, values compared to the WT. Regarding the BS/BV 
ratio, OMD KO presented slightly higher values that the controls, but that was not significant 
as well. Data are presented as mean±SEM. ns, non-significant. BV, bone volume; BS, bone 
surface; TV, tissue volume. 
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6.3 Discussion 
SLRPs have emerged as important regulators of multiple signaling pathways, thereby 
affecting various biological processes from development to tissue homeostasis. The 
development of knock-out transgenic mice has revealed their multiple roles in 
pathological conditions varying from cancer to osteoarthritis and eye abnormalities. 
Amongst the SLRP members studied extensively so far are decorin, lumican, 
biglycan and fibromodulin, but not OMD or PRELP. In the current study we used the 
novel OMD and PRELP knock-out mice to analyse any cancer-related but also other 
phenotypes that could arise from the targeted deletion of OMD and PRELP, with the 
aim of gaining insight into their functions. 
OMD and PRELP depletion alter the bladder homeostasis and may contribute 
to cancer initiation 
Extensive histological and immunohistochemical analysis of single and double 
OMD/PRELP knock-out bladders revealed three main findings, i.e. fibrin clots in the 
lumen, epithelial bursts formation in the urothelium and reduced tight junction 
formation between umbrella cells. The epithelial bursts have the appearance of 
disorganized masses of umbrella cells and are indeed composed of umbrella-
originated cells, as shown by positive uroplakin staining (Fig. 6.2 & 6.3).    
As we showed in the previous chapters, OMD and PRELP are expressed in a 
subpopulation of the outermost umbrella cells and not in the basal or intermediate 
cells. It has been previously shown that basal cells of the urothelium include 
multipotent stem cells that are capable of cell renewal and differentiation, which if 
triggered can lead to direct carcinoma in situ (CIS) formation, bypassing the non-
invasive tumor stage (Ho et al., 2012; Shin et al., 2011). In contrast, bladder papillary 
non-invasive tumours might originate from umbrella cells, as shown in another study 
where selective overexpression of a mutant H-Ras under a uroplakin promoter 
resulted in low-grade papillary tumour (Castillo-Martin et al., 2010).  Therefore, the 
epithelial bursts we observed in the OMD/PRELP knock-out mice might constitute 
very early stages of umbrella cell-papillary cancer formations. This is also supported 
by the slight increase in proliferating, Ki-67-positive cells in knock-out samples (Fig. 
6.12).  
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Staining with specific cancer-related markers is necessary to confirm the true 
identity of the epithelial bursts cells. However, at the very early stages of tumor or 
papilloma formation cancer cells tend to grow slowly, are well differentiated and 
look quite similar to normal neighboring cells. Therefore, it is technically 
challenging to identify the exact nature of epithelial bursts. 
 Urothelial cell carcinomas can be generally separated into two molecular 
pathways: in one patients present with mutations in the FGFR3, HRAS, PIK3CA 
genes or deletions of candidate tumor suppressor genes mapping to chromosome 9q 
(where OMD is located as well), and they develop only superficial papillary tumours 
with good prognosis; the other tumour subtype have TP53, RB or PTEN gene 
mutations, leading to CIS and invasive cancer (Ahmad et al., 2011; Castillo-Martin et 
al., 2010; Luis et al., 2007; Wu, 2005). Therefore, if epithelial bursts are initiators of 
papilloma formations they would probably belong to the first genetic type and further 
research on the status of the aforementioned genes in the knock-out bladders is 
desirable. Taking into account our findings so far, it might be highly possible that 
OMD is one of the tumor suppressor genes mapped in the 9q locus that contribute to 
bladder cancer initiation.   
Umbrella cells line the mucosal surface of the bladder and are characterised by 
junctional complexes in the intersections of their apical and lateral membranes. 
These complexes include tight junction and adherens junction (both of which form 
continuous belts) and desmosomes. Similarly to other epithelia, umbrella cell TJs 
modulate the paracellular transport of molecules (gate function), while they also 
restrict the movement of lipids and membrane proteins in the exofacial leaflet of the 
apical and basolateral plasma membrane domains (fence function) (Khandelwal et 
al., 2009; Matter and Balda, 2003). Therefore, proper regulation of tight junction 
components and formation is necessary for maintenance of the bladder homeostasis. 
ZO-1 staining and ultrastructural analysis of OMD KO, PRELP KO and double 
knock-out bladders revealed decreased and/or incomplete TJ formation in the 
apicolateral borders of the umbrella cells (Fig. 6.10 and 6.11), indicating regulation 
of tight junction by OMD and PRELP. These findings are in agreement with our in 
vitro data, where tight junction formation was increased in a bladder cancer cell line 
after overexpression of OMD/PRELP.  
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As was discussed in Chapter 3, altered expression of many TJ components has 
been related with cancer cells transformation and metastasis (Runkle and Mu, 2013). 
In addition, during EMT epithelial cells lose their junctions and polarity, and 
reorganize their cytoskeleton. This reorganization is accompanied by changes in gene 
expression of junctional proteins, i.e. downregulation of claudins, occludin, ZO-1 
and E-cadherin, and activation of N-cadherin and vimentin (Lamouille et al., 2014). 
We did not observe any significant changes in E-cadherin expression in knock-out 
bladders under our current staining conditions (Fig 6.9), while staining for vimentin 
was attempted but unfortunately did not work. Thus, at this point we cannot conclude 
that the urothelium undergoes EMT due to OMD/PRELP depletion. But we did 
observe a considerable decrease in tight junction formation, suggesting that knock-
out umbrella cells might be in the initial stages of epithelial cytoskeleton 
reorganization.  
Other components of the tight junction complex, such as occludin, claudin-4 and ZO-
2/ZO-3, were also examined but specific signal could not be seen in any of the wild 
type or knock-out samples, which can probably be attributed to inefficient staining 
conditions. In a previous study, ZO-1 was localised in punctate structures at the 
apicolateral borders of adjacent mouse umbrella cells, while it had a more diffuse 
cytoplasmic distribution in the underlying cell layers, a similar pattern to our staining 
(Acharya et al., 2004). In the same study, occludin also showed an apicolateral 
distribution at the umbrella cells but was additionally expressed in the basolateral 
surface and on the plasma membranes of the underlying cells layers, while claudin-4 
was localised as well in the apicolateral junction of umbrella cells where TJ are 
formed (Acharya et al., 2004). Claudins-4,-8, and -12 are associated with high 
resistance TJ and expression of these claudins in the junctions of umbrella cells is 
consistent with the high-resistance, low-permeability barrier function of latter cells 
(Lewis, 2000). Therefore, further examination of these proteins in the knock-out 
bladders will definitely contribute to our understanding of how OMD and PRELP 
can regulate such complexes.  
In addition, other components of the adherens junction, such as β-catenin, α-catenin 
and p120-catenin should also be investigated, especially since adherens junctions 
became more apparent in knock-out samples under EM examination. Some tight 
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junction components can also interact with proteins that are concentrated at adherens 
junction, for instance ZO-1 can form complexes with α-catenin, coupling the 
assembly of tight junctions to adherens junctions (Maiers et al., 2013; Rajasekaran et 
al., 1996), further demonstrating the importance of investigating both complexes. 
Overall, tight junctions have central roles in processes that regulate epithelial 
proliferation and differentiation and their functions are modulated by multiple 
signalling pathways and mediators including GTP-binding proteins, GTPases, and 
multiple kinases and phosphatases (Matter and Balda, 2003; Matter and Balda, 
2014). Although we have already discovered some of the signalling mediators that 
are affected by OMD and PRELP, further investigation of TJ and AJ-related 
pathways is crucial in order to unravel how these two SLRPs can regulate junction 
assembly. 
Interestingly, fibrin clots were found in the lumen of PRELPLacZ/LacZ and double 
KO bladders, which are the samples that also showed the strongest decrease in 
umbrella TJs under EM examination. Fibrin is a protein involved in blood clotting 
and is produced in response to bleeding. It is formed through fibrinogen 
polymerization by the action of thrombin, which forms a spongy mass that gradually 
hardens to form the clot. We cannot know exactly how or why these fibrin clots were 
formed in the lumen of the bladders. However, it is possible that fibrinogen could 
leak from vasculature if the blood-urine barrier is malfunctioning, or vice versa if the 
blood-urine barrier is not working properly pathogens and other urine substances 
could infiltrate the urothelium and cause scarring (as is the case with intersticial 
cystitis), which could lead to fibrin production. Tight junction formation is one of the 
earliest cellular events during urothelial differentiation, highlighting its importance in 
the blood-urine barrier (Jezernik and Pipan, 1993). In addition, during superficial and 
full-thickness urothelial wound healing restoration of tight junctions is also a primary 
event (Kreft et al., 2010). Therefore, decreased TJs in the knock-out samples due to 
PRELP/OMD depletion could be also involved with the fibrin clots found in the 
bladder lumen of these mice. 
Finally, the presence of fibrin/fibrinogen degradation products has been used as 
a bladder cancer marker in human urine samples (Bassi et al., 2005; Jeong et al., 
2012; Tsihlias and Grossman, 2000), demonstrating another probable link of PRELP 
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and/or combined OMD/PRELP depletion with bladder cancer. In a small preliminary 
analysis we conducted, detection of protein in urine samples was slightly higher in 
the PRELP and double KO mice compared to wild types (Fig. 6.6), and therefore 
further analysis of mouse urine for possible fibrinogen degradation products is very 
compelling. 
Overall, we have shown that OMD and PRELP depletion may potentiate the 
formation of superficial, low-grade papillary formations in the bladder urothelium 
and, consistent with our previous observations, OMD and PRELP can regulate tight 
junction formation in the umbrella cells, where they are expressed.  
Non-cancer related OMD and PRELP knock-out phenotypes 
A preliminary analysis was performed in the eyes of OMD and PRELP knock-out 
mice, where no gross abnormalities in morphology or histology were detected. 
OMDLacZ/LacZ samples occasionally presented with slightly fractured tissue between 
the RGCs and the inner limiting membrane (Fig. 6.14). However, retinal ganglion 
cells quantification (Fig. 6.14) and laminin staining (Fig. 6.18) did not show any 
differences in the RGC number or in the inner limiting membrane structure between 
wild types and knock-outs. Interestingly, PRELPLacZ/LacZ eyes had smaller ciliary 
body area compared to WTs (Fig. 6.16), although CB epithelial cell viability or 
basement membrane structure was not affected, as shown by Pax6 and laminin 
staining (Fig. 6.17 & 6.19.). Tsukushi was also found to be expressed in the epithelial 
cells of the ciliary body mouse eyes and a similar histological analysis showed that 
TSK null animals had expanded dorsal and ventral CB areas (Ohta et al., 2011). In 
addition, depletion of other SLRPs, such as lumican and keratocan, resulted in eye 
abnormalities, mostly in the cornea (Chakravarti et al., 2000; Liu et al., 2003), 
demonstrating the multiple roles of SLRPs in eye homeostasis. Therefore, since we 
have confirmed OMD and PRELP expression in the mouse retina and CB, a more 
thorough analysis of PRELP and OMD knock-out eyes would possibly unravel their 
functions in eye biology.  
Since OMD and PRELP are expressed in the developing skeleton and the adult bone 
and brain, a small-scale analysis was also conducted in search of any bone-related or 
motor-related phenotypes. OMD knock-out mice were tested with the gait ink test, 
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where they had a marginally lower sway distance whereas no differences were seen 
in the stride or stance length compared to wild types (Fig. 6.20). Bone mineral 
density and bone mineral content were also assessed, and although not statistically 
significant, they had lower values in the OMD knock-out mice compared to wild 
type (Fig. 6.21), which might be indicative of potential bone defects or possible 
delay in bone mineralisation. It must be noted that the number of mice included in 
the aforementioned analyses was quite small and more importantly all the mice that 
were tested were very young (4-8 weeks of age). Increasing the sample size and also 
assessing mice at different ages is important to unravel potential phenotypic effects 
related to the above functions. 
SLRPs are involved in all phases of bone formation including cell proliferation, 
matrix deposition, remodelling and mineral deposition and their roles in bone 
pathophysiology are now firmly established (reviewed by Nikitovic et al., 2012). 
Knock-out models of biglycan, keratocan and fibromodulin all display abnormalities 
in bone morphology and mineral matrix content (Gill et al., 2002; Igwe et al., 2011; 
Xu et al., 1998). Furthermore, many SLRP double knock-out mice exhibit 
osteoarthritis (OA)-related phenotypes, demonstrating their importance in joints and 
bony tissues maintenance (reviewed by Ni et al., 2014). Briefly, 
biglycan/fibromodulin, epihycan/biglycan and lumican/fibromodulin double KOs 
present with alterations in joint laxity and integrity, in tendon mechanics, in the gait 
pattern, in bone content, in chondrocyte proliferation and in cartilage maintenance, 
resulting in OA- like phenotypes (Ameye et al., 2002; Jepsen et al., 2002; Kilts et al., 
2009; Nuka et al., 2010). In all the above studies phenotypes were observed in mice 
at 3,6 and 9 months of age and above, while the older the mice the stronger the 
phenotypes they had. Thus, it is crucial to assess bone and joint-related phenotypes in 
OMD/PRELP knock-out mice that are at least 3 months or older.  
Moreover, double SLRP-deficient mice usually display more severe phenotypes 
compared to their single knock-out counterparts, demonstrating that they have either 
overlapping functions, or that they have independent functions and when both are 
deleted result in a stronger phenotype. Therefore, assessment of bone and OA-related 
abnormalities in old OMD/PRELP double-KO animals will be very interesting and is 
highly likely that strong phenotypes can be observed under these circumstances. 
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Finally, in the aforementioned studies it was shown that some SLPRs compensate for 
the loss of others. Hence, it may be possible that the effects of OMD/PRELP 
depletion are attenuated by increased expression of other family members. 
Examining the levels of other SLRPs in our knock-out mice will further contribute to 
our understanding of their functions.    
OMD and PRELP depletion might affect embryonic skeletal development  
Since OMD and PRELP are strongly expressed in bone and cartilage during 
embryonic development, we wanted to assess any possible defects in skeletal 
development arising from OMD and PRELP depletion. For this purpose skeletal 
preparations of alizarin red/alcian blue staining were performed in two different 
embryonic stages of transgenic littermates.  
No differences were seen between wild type and OMD KO embryos regarding 
their overall size, the size of the long bones or the ossification progression in the 
axial and appendicular skeleton during E15.5 and E18.5 stages (Fig. 6.22 & 6.23). 
The same result was observed for wild type and PRELP KO littermate embryos at 
stages 15.5 and 17.5 dpc (Fig. 6.24 & 6.25). It should be noted that occasional 
defects seen in E15.5 embryos, for example the "squashed" dorsal part of the 
cranium in OMD and PRELP embryos in Fig. 6.22A and 6.24A or the broken ribs 
seen in the latter samples, can be attributed to the handling of the embryos during the 
staining. Since at this embryonic stage most of the skeleton is still cartilage and the 
embryos are very fragile, it was very difficult to keep embryonic structures 
completely intact during the very long protocol of alizarin red/alcian blue staining. 
Interestingly, small-scale differences were seen when micro-CT was performed 
in E17.5 OMD WT and KO littermate embryos. These included delayed ossification 
of the metatarsals/metacarpals and the intraparietal bone in the knock-out embryos 
(Fig. 6.26). However, quantification of bone volume/density or bone surface/density 
of the whole embryos did not reveal any significant differences, although OMD 
knock-out embryos had overall lower values in most of the examined parameters 
(Fig. 6.27). Analysis of these parameters in single bones might reveal a possible 
effect of OMD depletion in the ossification rate of different skeletal elements. These 
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differences were not observed with alizarin red/alcian blue staining, probably due to 
the lower sensitivity of the skeletal staining compared to micro-CT scanning. 
The ultimate sizes, structures and growth rates of the endochondral bones 
depend on the coordinated regulation of chondrocyte proliferation, maturation and 
hypertrophy in response to multiple extracellular signals, and the major regulators of 
these processes were mentioned in Chapter 5. Considering that OMD and PRELP 
knock-out embryos grow normally into adulthood and no gross abnormalities are 
seen in skeletal development, in order to observe possible small-scale defects it is 
essential to assess chondrocyte maturation rates in a more detailed level. 
Transcription factors such as hypoxia inducible factor-2 (HIF-2α), runt-related 
transcription factor-2/3 (RUNX2/RUNX3), myocyte enhancer factor-2C (MEF2C) 
and specificity protein-3 (SP3) all regulate chondrocyte maturation and affect bone 
development (Arnold et al., 2007; Komori, 2005; Magee et al., 2005; Saito et al., 
2010). Examining the status of the above factors but also of other genes that are 
differentially expressed in every chondrocyte and osteoblast maturation stage (such 
Col2a1, Col10a1, Bsp, Ihh, Fgfr3 and others-explained in detail in Chapter 4) will 
definitely provide insight on how OMD and PRELP deficiencies can affect bone 
development. Finally, examination of skeletal development in double-KO embryos, 
which was not performed in this project due to time restraints and the late generation 
of the double knock-out mice, is also necessary and will certainly contribute in 
understanding how these two genes function.    
Summary 
To conclude, OMD and PRELP deficiency resulted in epithelial bursts/early 
papilloma formations in the mouse bladder urothelium, fibrin clot formation in the 
lumen of PRELP and double KO bladders, and reduced tight junction formation in 
the umbrella cell layer of the knock-out bladders. All these demonstrate how OMD 
and PRELP, through regulation of TJ formation, can affect bladder homeostasis and 
cancer initiation. In addition, OMD and PRELP depletion appeared to slightly affect 
eye and bone functions, while no definite conclusions could be made about their 
roles in skeletal development.  
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The aims of this study were 1) to determine the roles of OMD and PRELP in 
cellular functions involved in carcinogenesis and specifically in bladder cancer, and 
elucidate their mechanisms of action; 2) to establish the spatial-temporal pattern of 
OMD and PRELP expression in the mouse; and 3) to characterise any cancer-related 
phenotypes, mainly in the bladder, of the OMD and PRELP knock-out mice. Since 
these knock-out mice are novel, preliminary assessment of other, non-cancer 
phenotypes was also conducted.  
OMD and PRELP belong to the SLRP family of proteins, which serve as as 
structural components modulating synthesis, assembly and degradation of collagen 
fibrils (Chen and Birk, 2013). Apart from their regulatory roles in extra-cellular 
matrix assembly, SLRPs can act as modulators of many signalling pathways, thereby 
affecting various biological processes from development to tissue homeostasis 
(Merline et al., 2009). Mutations or aberrant expression of SLRPs can cause a variety 
of diseases ranging from skin fragility to osteoarthritis, corneal opacity and cancer 
(an overview of human disorders caused by SLRP defects is presented in our review, 
by Dellett et al., 2012), highlighting their importance in biological systems.    
Our main interest is the cancer-related functions of SLRPs, and specifically how 
OMD and PRELP are involved in bladder cancer. There is an emerging body of 
evidence demonstrating the roles of multiple other SLRPs in carcinogenesis, 
including mainly decorin, biglycan and lumican. Altered expression patterns of these 
proteins have been found in resected tumours compared to normal tissue, decorin and 
lumican have been used as predictive biomarkers in breast cancer, decorin knock-out 
mice exhibit enhanced susceptibility to cancer, while there many other lines of 
functional evidence from in vitro and in vivo studies (Iozzo and Sanderson, 2011; 
Iozzo and Schaefer, 2010; Schaefer and Iozzo, 2012; Theocharis et al., 2010). 
Regarding OMD and PRELP, there have been some studies mostly demonstrating 
their roles in cartilage, connecting tissues, and differentiating osteoblasts (Heinegard 
et al., 1986; Rehn et al., 2006; Stanford et al., 1995), while there has been almost no 
evidence so far of their involvement in cancer. PRELP was mentioned only once as 
one of a four-gene signature that could be used to discriminate different types of 
brain cancer (Castells et al, 2009).   
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7.1 OMD and PRELP affect cancer-related properties of the EJ28 bladder 
cancer cell line 
The first evidence associating OMD and PRELP with cancer was obtained by 
previous lab members in collaboration with Dr. Ryuji Hamamoto, who performed a 
gene expression analysis in 31 normal and 126 transformed kidney samples, and 16 
normal and 79 bladder cancer samples. Interestingly, he found that expression of 
OMD and PRELP was markedly reduced in urothelial cell carcinoma and renal cell 
carcinoma, compared to normal bladder and kidney tissue respectively (Fig. 1.5 and 
Appendix A). Furthermore, this reduction in expression was an early event in 
carcinogenesis, and it was possible to differentiate between normal and cancer tissue 
with high sensitivity and specificity (Appendix A). Thus, we obtained very strong 
indications that OMD and PRELP are involved in cancer, and that they may 
represent potential tumour-suppressor genes, functioning in a similar way to other 
SLRPs that were discussed previously. A previous lab member, Dr. Julie Watson, 
conducted the initial analysis to prove the above hypothesis, and indeed found that 
they regulate numerous cellular processes important in carcinogenesis, such as cell 
cycle progression and proliferation, migration, apoptosis and drug-mediated 
apoptosis, and cellular morphology. 
I continued this project and together with Dr. Toshiya Tamura we managed to 
further support the hypothesis that OMD and PRELP can act as tumour-suppressor 
genes. Through a series of in vitro experiments we demonstrated that over-
expression of OMD and PRELP in the EJ28 bladder cancer cell line lead to 
inhibition of anchorage independent growth and cell invasion, and also altered the 
morphology of cells in an ECM-mimicking microenvironment (Chapter 3). All these 
processes constitute "hallmark" characteristics of cancer cells (Hanahan and 
Weinberg, 2011), and exhibit that OMD and PRELP can modulate cancer-related 
functions. Most importantly, overexpression of OMD and PRELP resulted in 
inhibition of tumour growth in vivo using mouse xenograft models, strongly 
demonstrating their anti-tumour properties. Similar in vivo findings with other 
SLRPs are not that many and mainly involve decorin, where it was shown that 
overexpression or injection of recombinant decorin protein into mouse xenograft 
models slows the growth of lung, squamous, mammary and colon carcinoma cells 
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(Buraschi et al., 2010; Goldoni et al., 2008; Reed et al., 2002; Reed et al., 2005; 
Tralhao et al., 2003). 
Apart from OMD and PRELP, few other SLRPs have been implicated in the 
development of urological cancers. Overexpression of biglycan resulted in inhibition 
of bladder tumour growth both in vitro and in vivo, whilst high biglycan expression 
in human tumour biopsies was associated with favourable prognosis (Niedworok et 
al., 2013); also decorin was shown to negatively regulate IGF-IR signalling in 
urothelial carcinoma-derived cells, inhibiting their migration and invasion (Iozzo et 
al., 2011). It is also interesting that the pattern we observed is one of down- rather 
than up-regulation, as of the seven SLRPs that have thus far been described as 
differentially expressed in cancer, only two (decorin and opticin) have been 
downregulated in certain types of cancer. 
In addition, together with Dr. Tamura we discovered that OMD and PRELP 
regulate tight junction formation in the EJ28 cells. Dr. Hamamoto had previously 
found that altered expression of OMD and PRELP could affect tight junction and 
adheren’s junction pathways, but no studies were performed towards this direction so 
far. This finding is very compelling as tight junctions have not been mentioned in 
any other SLRP action mechanisms. Modulation of the EFG and TGF-β pathways by 
OMD and PRELP were also confirmed, in agreement with other findings where 
SLRPs can affect the above signaling pathways (Morris et al., 2007; Nikitovic et al., 
2011). Therefore, we have now completed a mainly in-vitro analysis showing for the 
first time that OMD and PRELP can affect cell cancer-related properties and we have 
identified their possible mechanisms of action.   
Limitations of our analysis and potential future extensions  
For this in vitro analysis Dr. Watson’s stably-transfected EJ28 cells were used 
and the overexpression of OMD and PRELP was confirmed at the RNA level. 
However, expression at the RNA level may not always correlate with expression at 
the protein level, because there are numerous mechanisms of post-transcriptional and 
post-translational regulation that can alter the steady state level of protein. Ideally, 
we would like to assess the expression of OMD and PRELP at the protein level by 
immunohistochemistry or western blot. Unfortunately, although we tried various 
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commercially available antibodies for OMD/PRELP, we could not obtain consistent 
and specific detection. Using tagged versions of the proteins was an alternative 
method, which we tried to employ in some of our experimental approaches. 
Occasionally though, we observed slightly different responses from tagged and non-
tagged cells (for example in the anchorage independent growth experiment, section 
3.2.1), which might imply that the tag could affect the functionality of the protein.  
Additionally, as was explained in chapter 3, Dr. Watson had initially isolated 
and tested two different clones of all the transfected cell lines, in order to confirm 
that the obtained results were due to OMD/PRELP overexpression and not because 
of any functional cell changes arising from the insertion site of the plasmids. We also 
tried to use both clones of each transfectant in our in vitro experiments, but 
unfortunately due to time and material limitations, this was not applied in all the 
assays tested. However, when both clones were used they always gave comparable 
results, indicating the validity of our results. Another weak point of this analysis was 
the lack of vector-only transfected cells in some of the performed assays (i.e. Fig. 
3.4; 3.5; 3.6 & 3.11), where EJ28 wild type cells were used instead. However, during 
our whole in vitro experimentation vector only-transfected cells (expressing only 
GFP without OMD or PRELP cDNA) always behaved similarly to the wild type 
cells and therefore we can make valid comparisons of our results. This certainly does 
not ablate the need to have both wild type and mock-transfected cells in the system 
we studied, and both cell types should be certainly included in future experiments. 
Furthermore, some of the in vitro experiments we conducted together with Dr. 
Tamura were only performed twice or included only the OMD and not the other 
transfected cell lines (mtOMD, PRELP and mtPRELP), usually due to time and 
technical restraints, and therefore further repetition of these experiments using all our 
cell lines would be desirable.       
Another possible route would be to apply recombinant or core OMD and PRELP 
proteins directly in the cell media and assess their effects. We have shown that 
secretion of OMD and PRELP in a co-culture assay caused cell death of EJ28 cells 
(section 3.2.4), which implies that they can be distant-mediators of their effects. In a 
similar context, systemic injection of decorin protein core into A431 squamous 
carcinoma tumours induced apoptosis of the tumour cells by antagonizing EFGR 
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activity (Seidler et al., 2006). This was one of the first studies demonstrating that 
decorin can be administered as a therapeutic agent against cancer. The same concept 
could therefore be applied to OMD and PRELP. Also, the application of molecules 
such as OMD and PRELP as anticancer therapeutics is feasible in early-stage bladder 
cancer patients, as chemotherapy during that stage involves perfusing the bladder 
with drugs on a one-off basis, a situation in which OMD or PRELP could easily be 
introduced.  In addition, since OMD and PRELP are thought to mediate their effects 
from the surrounding environment/ECM, internalization into the cell would not 
necessarily be required. 
Additionally, overexpression of OMD and PRELP in other cell lines and 
assessment of their effects in different cancer types is also very compelling. In Dr. 
Hamamoto’s analysis, these two SLRPs were reduced in renal cell carcinoma, so a 
similar approach to our experimental setup using cell lines derived from renal cancer 
would be useful to see if OMD and PRELP can mediate their anti-cancer effects in 
these cells. Additionally since other SLRPs are involved in a variety of cancers likes 
breast, ovarian and lung, it would be interesting to examine if OMD and PRELP can 
negatively affect these cell types as well. 
Finally, one important issue that is not addressed at all during this project is the 
mechanism by which OMD and PRELP expression is reduced in cancer. One 
possible mechanism could be deletion, since OMD’s locus is frequently deleted in 
bladder cancer. Loss of heterozygosity on chromosome 9 is the most frequent genetic 
alteration identified in bladder tumours, with around 60-70% of the tumours showing 
LOH of at least one locus on either arm of the chromosome (Keen and Knowles, 
1994; Simoneau et al., 1996; Stadler et al., 1994). Another common mechanism of 
gene silencing in cancer is methylation (Baylin and Ohm, 2006). Methylation has 
previously been shown to play a role in SLRP expression, where hypomethylation of 
the decorin promoter in colorectal cancer led to its increased expression (Adany et al, 
1991).  We suspect that they converse might be true for OMD and PRELP in bladder 
and kidney cancer, where their promoters could lead to downregulation of expression 
due to hypermethylation. Analysis of the OMD and PRELP loci on a genetic level 
may be necessary to determine the mechanisms of downregulation.   
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7.2 Development of OMD and PRELP knock-out mouse models – analysis of 
expression patterns 
Having collected all these exciting data we wanted to further advance the current 
project towards a more in vivo direction. For this purpose, we aimed to perform 
functional analysis of OMD and PRELP anti-cancer activities in mouse models. 
Based on Dr. Hamamoto’s microarray study, which showed that OMD and PRELP 
were differentially expressed in several different types of cancer (Appendix A), it 
was suspected that OMD and PRELP are involved in many types of epithelial cancer. 
For this reason, it was decided to construct a whole animal knock-out, rather than 
just a urothelium-specific one. Our novel knock-out mice were produced in 
collaboration with Takeda and the strategy utilised involved the insertion of a Lac-Z 
cassette in the transcription domains of the OMD and PRELP genes. This would also 
allow us to follow and identify the expression of the genes by simple X-gal staining.  
Since this was the first time OMD and PRELP knock-out mice were generated 
and the effects of the gene knock-down were unknown, we established our mouse 
colony through heterozygote pairings. It soon became obvious that both heterozygote 
and homozygote knock-out animals were fertile and grew normally into adulthood. 
Although there were some studies in the literature describing expression of OMD 
and PRELP mainly in osteoblasts and cartilage respectively (Heinegard et al., 1986; 
Rehn et al., 2006; Stanford et al., 1995), these were focused on specific adult organs 
or in other organisms rather than mouse. Therefore, before assessing the effects of 
OMD and PRELP depletion, we decided to examine in detail the expression patterns 
of the two genes during embryonic mouse development and in certain adult organs.  
We demonstrated that OMD and PRELP are mostly expressed in the developing 
skeleton during embryonic growth. PRELP is additionally expressed in the early 
developing brain, while during adult life both genes appear to be expressed in 
various organs (Chapters 4 & 5). It is noticeable that expression was not seen in any 
internal organs during gestation, but was present in later life in the bladder, brain and 
eye, demonstrating that SLRP production, turnover and ultimate localisation are 
dynamic processes.      
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Furthermore, we identified for the first time the specific cell types that express 
OMD and PRELP in the adult bladder, eye and brain. Many SLRPs have been 
previously described to be expressed in the eye and some in the brain, but none in the 
mouse bladder (Conrad & Conrad, 2003; Kappler et al., 1998; Ali et al, 2011). Thus, 
we have greatly improved the current knowledge of OMD and PRELP expression 
and localisation in the mouse model organism, demonstrating that SLRPs are indeed 
matricellular molecules which have the potential to affect various biological 
processes. A detailed spatio-temporal analysis of expression constitutes an initial and 
important step to understand how molecules work and can help to identify novel 
functional roles of the proteins we are investigating. 
Technical considerations and further explorations 
 Defining the expression patterns of OMD and PRELP through X-gal staining 
was quite efficient and specific for heterozygote embryos and most of the adult 
organs examined. However, in several cases, such as kidney and spleen (not shown 
in the current thesis), specific OMD and PRELP expression could not be defined due 
to endogenous β-galactosidase activity in the wild type samples. Mammalian beta 
galactosidase (β-D-galactosidase) is localised in the lysosomes of mammalian cells. 
Consistent with is localization in this acidic organelle, this lysosomal β-galactosidase 
displays maximum activity between pH 4.0 and 4.5 but markedly lower activity at 
pH 6.0 (Zhang et al., 1994). In addition, another type of the β-gal enzyme named SA-
β-gal (senescence associated β-gal) is a β-galactosidase activity detectable at pH 6.0 
in cultured cells undergoing replicative or induced senescence, and is considered as 
marker for senescent cells (Dimri et al., 1995). Our detection method for the bacterial 
β-galactosidase of the LacZ-inserted cassette involved X-gal reaction in pH 7.0, so 
theoretically none of the SA-β-gal or β-D-gal should be detected. We cannot know if 
the background signal seen in kidney and spleen represents lysosomal or senescent β-
gal, but performing the reaction at higher pH of 8.0-9.0 might help to increase the 
signal specificity, as also shown by Weiss et al. (Weiss et al., 1999).  
 Additionally to our β-gal mediated detection of OMD and PRELP expression, 
in situ hybridization is an alternative method of detection which should be 
performed. In situ hybridization detects expression at the RNA level, and could 
therefore present a slightly different pattern that the one we observed. Nevertheless, 
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it is a necessary approach to further confirm our current findings, especially since 
there are no efficient antibodies for immunohistochemistry so far. Previous lab 
member Dr. Margaret Dellett managed to successfully detect OMD and PRELP 
expression by in situ hybridization in the bladder urothelium, in agreement with our 
results (Appendix A). During this project in situ hybridization for OMD and PRELP 
was carried out in spleen and kidney sections of wild type mice but unfortunately we 
could not obtain any conclusive results.  
Another point that perhaps should be considered in future work is the cellular 
localisation of the β-gal enzyme. The Lac-Z cassette is transcribed under the OMD 
and PRELP promoters and therefore β-gal is present in the cell types where these 
promoters are active. However, SLRPs are proteoglycans and as such undergo high 
levels of post-translational modifications. After synthesis, PGs are transported from 
the Golgi (where glycosylation takes place) to their specific destinations, which can 
be the ECM, the cell surface or intracellular organelles. Many of the responsible 
mechanisms for this kind of sorting and delivery require determinants that are 
present in the GAG chains and/or in the PG protein cores (Prydz and Dalen, 2000). 
Thus, localisation of the β-gal might be slightly different that the actual OMD or 
PRELP protein localization. Nonetheless, even if such small differences exist, our 
system provided a very efficient method of detection, where identification of the 
specific cell types where the two genes are expressed could be performed.  
Finally, due to time restraints, specific analysis of the Lac-Z-expressing cell 
types was not performed in the embryonic stages. As discussed also in Chapters 4 & 
5, usage of specific markers to identify the particular chondrocyte and osteoblast 
maturation stages where OMD and PRELP are expressed is desirable, and will 
definitely help to understand how these molecules operate during skeletal 
development. 
7.3 Effects of OMD and PRELP depletion in knock-out mice 
Once the expression analysis was completed we sought to find any cancer-
related phenotypes emerging from OMD and PRELP depletion and primary attention 
was given to the bladder. Interestingly, knock-out mice presented with the initial 
symptoms of bladder papillary cancer initiation, where spontaneous formations that 
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we called "epithelial bursts" could be observed in the umbrella cell layer. These 
bursts had the appearance of disorganized masses of umbrella cells (Chapter 6). This 
is the second time that SLPRs are involved in spontaneous tumour growth. Similar 
findings were shown before in a decorin knock-out mouse model, where 30% of 
decorin-deficient mice spontaneously developed intestinal tumours (Bi et al, 2008). 
Tumourigenesis in these mice was associated with disruption of intestinal maturation 
and was also characterised by decreased cell differentiation and increased 
proliferation. In the same context, we did not observe any decrease in the outer 
umbrella cells maturation but we did notice a small increase of proliferating cells in 
the urothelium. Moreover, in decorin knock-out tumours E-cadherin was 
downregulated while β-catenin was upregulated, indicating an EMT-like behavior. In 
turn, we did not observe any E-cadherin changes but we found possible decreased 
tight junction formation, which potentially could be associated with an EMT-like 
condition.   
Other SLRP deficient models, including biglycan, fibromodulin, keratocan, 
epiphycan, osteoglycin and tsukushi knock-out mice have not been described as 
having specific susceptibilities to cancer, although this may be because the scientists 
who generated them were more interested in other aspects of their phenotype.    
Fibrin clots were also found in the PRELP and double-KO mice, which might be 
potentially linked with the papillary formations or with damaged blood-urine barrier 
due to reduced tight junction formation in the umbrella cells. We have shown that 
OMD and PRELP are selectively expressed in the ciliary body of the eye and in 
ependymal cells of the brain, epithelia that have strong tight junctions and help form 
the blood–aqueous barrier and blood-brain barrier respectively. Therefore, our 
overall findings so far indicate that OMD and PRELP have potentially fundamental 
roles in tight junction regulation. 
Regarding other possible phenotypes, preliminary experiments were performed 
including eye histology, gait and bone content assessment, and also examination of 
embryonic skeletal development, demonstrating potential functional roles of OMD 
and PRELP in those systems. Due to time limitations more extensive analyses could 
not be conducted in the above structures. However, we have shown strong expression 
of OMD and PRELP in these systems and taking into account our preliminary 
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findings as well, we are confident that potential abnormal phenotypes might arise 
from OMD/PRELP/double-deficiencies. A more detailed examination of the above 
organs, including brain as well, is already ongoing. 
Technical considerations and future perspectives 
Our analysis so far has been successful in identifying OMD and PRELP as 
potential tumour-suppressor genes, as their absence leads to spontaneous urothelial 
papillary formations.  It has to be noted that these findings were obtained from 
OMD/PRELP knock-out mice at 3 months of age, which can be considered a very 
young age for the occurrence of such malignancies. P53 null mice have an average 
time of tumour development at 4.5 months of age, while half of the heterozygous 
(p53+/-) mice develop tumours by 18 months (Donehower, 1996). Also, the decorin 
knock-out mice were found to have intestinal tumours at 9 months of age (Bi et al, 
2008). Therefore it is essential to study OMD and PRELP knock-out mice at later 
ages, maybe in specified time points, for example at 6, 9, 12 and 15 months. 
Assessment of spontaneous tumorigenesis over a certain time-course will help us 
observe if the epithelial bursts remain as low-grade non-invasive papilloma 
formations or whether they can develop into a more invasive tumour type. Some of 
our mice have already been set under this kind of time-course setup and will be 
examined in the forthcoming months.   
Our understanding so far is that although OMD and PRELP knock-out mice 
initiated bladder papillary-like formations these are unlikely to develop to late stage 
bladder cancer. This is because the majority of urothelial cell carcinomas, which 
have mutations in the FGFR3, HRAS, PIK3CA genes or deletions of candidate tumor 
suppressor genes mapping to chromosome 9q (where OMD is located as well), 
develop only superficial papillary tumours with good prognosis. Subsequent 
mutations of other cancer genes such as TP53 and RB1 are required for progression 
into malignant cancer (Castillo-Martin et al., 2010). 
Furthermore, it was previously found that decorin/p53 double knock-out mice 
develop spontaneous thymic lymphoma, which lead to earlier mortality compared to 
single p53 null mice (Iozzo et al., 1999). Accordingly, it would be very interesting to 
cross our knock-out mice with p53 null mice and study if susceptibility to tumour 
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initiation and progression is affected. To this end, we have already purchased p53-
mutant mice that carry a R270H missense mutation in exon 8 of the Trp53 mouse 
gene. Heterozygous mice develop a broad spectrum of tumours with a mean survival 
time of 16 months, while homozygotes have a mean survival time of 4.5 months. We 
are now in the process of mouse cross-breeding to generate OMD/p53, PRELP/p53, 
but also OMD/PRELP/p53 triple knock-out mice in order to assess if susceptibility to 
tumour initiation and progression is further affected from OMD/PRELP deficiency.  
Another interesting objective would be to examine if OMD and PRELP knock-
out mice have increased susceptibility to chemically-induced cancer formation. The 
use or inorganic arsenic is a possible candidate, as oral administration of this 
substance to rats and mice has already been shown to cause urothelial hyperplasia 
(Arnold et al., 2013). Also, another point to be considered for all the above future 
experiments is the sample size. In the present analysis our sample size was relatively 
small; comprising only 3 knock-out samples of each genotype and 6 wild type 
samples. It would be preferable to increase this number to at least 10 mice/genotype, 
considering that the study with the decorin knock-out mice examined 12 
homozygous mice (Bi et al, 2008), while the earlier study with the decorin/p53 null 
mice examined 58 double and 68 single knock-out mice (Iozzo et al., 1999), numbers 
substantially larger. 
Regarding the mechanisms of action, we have established so far some of the 
possible pathways affected by OMD and PRELP altered expression. Combining the 
microarray and functional data gathered from previous lab members together with 
our in vitro and in vivo analysis we can conclude that: OMD and PRELP could 
potentially regulate tight junction formation; can affect Akt and ERK1/2 
phosphorylation; and can affect the EGF/TGF-β/Wnt pathways, but not the IGF 
pathway. Certainly the data we have gathered so far are not completely conclusive 
and include various limitations that should be addressed. For example, differences 
seen in tight junction formation between wild type and knock-out mice are not very 
clear, judging only from the ZO-1 staining of the different samples (Fig. 6.10), and 
further staining with other TJ markers is also necessary. In addition, when 
performing ultrastructural analysis of the junctions between the umbrella cells only 
one sample of each WT and OMD/PRELP/double KO animals was used, which 
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unfortunately cannot lead to conclusive results. Electron microscopy analysis 
combined with immuno-gold labeling of TJ and also AJ components would certainly 
give us more clear results on how this complexes are affected by OMD and PRELP 
depletion. Moreover, performing freeze-fructure  EM would allow us to examine in 
detail the tight junction structures and functionality, increasing importantly the 
validity of our data. 
Moreover, now that our mouse colony has been established and we have 
identified some of the possible abnormal phenotypes, a more detailed functional 
analysis can be conducted. To this end, we have already collected RNA from several 
tissues, including the bladder urothelium, the eye ciliary body and the brain 
capillaries from OMD/PRELP knock-out and wild type mice, and we are planning to 
conduct microarray analysis in order to identify affected target genes. Additionally, 
in all the above tissues (where tight junctions have important functions and 
OMD/PRELP as also expressed-the brain choroid plexus can also be added here), a 
more detailed examination of tight junction components and TJ-related signaling 
pathways is necessary in order to unravel how OMD and PRELP can specifically 
regulate TJ formation.    
Apart from the bladder, examination of other organs, such as brain and kidneys, 
for spontaneous tumour formation is a desirable objective. Also, it will be very 
intriguing to examine other, non-cancer related abnormalities, arising from OMD and 
PRELP depletion. During this project we performed some preliminary experiments 
on eye and bone functions, which showed that OMD/PRELP have potential roles in 
these systems as well. Given the fact that our OMD and PRELP knock-out mice are 
novel model systems of these genes, it is compelling to perform a full phenotypic 
analysis. This entails a series of  assessments including embryologic evaluation; 
specialised pathologic evaluation; specialised biochemical and genetic analyses; 
physiologic and behavioural assessments; and other possible pathologic effects like 
environmental and housing conditions (Wood, 2000). 
Finally, one missing point of the current study is the examination of expression 
levels of other SLRPs upon deletion of OMD or PRELP. As was already discussed in 
Chapter 6, knock-out models of combined SLRPs often exhibited more severe 
phenotypes that single knock-outs, demonstrating that some SLRPs may be 
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functionally redundant. Also, it has been shown that some SLRPs compensate for the 
loss of others; for example in the epiphycan/biglycan double-deficient mice the 
mRNA levels of asporin, fibromodulin and lumican were increased compared to wild 
type mice (Nuka et al., 2010). Hence, it will be worthwhile to analyse expression 
levels of other SLRPs in our knock-out mice, especially since these alterations might 
also be a potential reason for the lack of aberrant phenotypes. 
7.4 Summary 
We have identified OMD and PRELP as potent regulators of cancer-related cell 
properties, whereby OMD and PRELP overexpression inhibits anchorage 
independent growth and migration of bladder cancer cells in vitro, while it also 
inhibits tumour growth in vivo in EJ28 xenograft mouse models. Similar results were 
previously obtained by overexpressing other SLRPs, such as decorin, biglycan and 
lumican in other cell systems, demonstrating the potential that these extracellular 
molecules have in affecting or regulating the cancer microenvironment and tumour 
growth. Although we have not elucidated the exact mechanisms of action, we have 
concluded that these two molecules mediate their effects by cross-regulating 
different signalling molecules, including Akt and ERK1/2 but also the EGF, TGF-β 
and Wnt pathways. Since these signaling pathways are also affected by other SLRPs, 
they are likely to be key molecules for the actions of this protein family and a more 
detailed examination of OMD/PRELP signaling cascade will certainly help us 
unravel exactly how they work. Furthermore, we have made a correlation of OMD 
and PRELP overexpression with tight junction formation in the EJ28 cells, where we 
noticed that TJ components such as occludin, ZO-1 and cingulin are found increased 
in the cell membrane compartments when these two SLRPs are overexpressed. 
Although these data are preliminary and do not yet demonstrate a complete link, we 
believe that there is a potential, probably indirect, connection between the two 
SLRPs and the junctional complexes of epithelial cells. As extra-cellular proteins are 
recognised as important regulators of cell-matrix crosstalk and can influence a 
variety of biological processes such as cell proliferation, differentiation, adhesion, 
etc., it would not be surprising if SLRPs could somehow modulate cell junctions 
amongst many other components.   
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In addition, we generated novel OMD and PRELP knock-out mouse models, 
which, amidst other findings, presented with spontaneous urothelial papillary-like 
formations, suggesting that lack of OMD and/or PRELP might be permissive for 
cancer initiation. Similar findings were also seen in decorin knock-out mice, 
indicating again the possible roles of these ECM molecules in cancer initiation and 
progression. OMD and PRELP depletion also had small-scale effects in the eye 
ciliary body, the gait, and the skeletal development of the mice, further confirming 
their multiple roles in biological systems and how they can indeed act also as 
matricellular proteins.  
Overall, with our current findings we hope to improve the understanding of 
SLRP biology in carcinogenesis, and we would like to propose OMD and PRELP, or 
OMD/PRELP-regulated pathways, as potential targets for the development of cancer 
therapies. Lastly, we have performed a detailed analysis of the spatial and temporal 
expression patters of OMD and PRELP in the mouse, significantly contributing to 
the current knowledge of SLRP biology. Our results further demonstrate that SLRPs 
are dynamically-synthesized proteins with multiple functions, which have the 
potential to affect many biological processes.   
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Appendix A: OMD and PRELP in cancer 
All the data presented in this section are acquired by former lab members Dr. 
Hamamoto, Dr. Julie, Dr. Tamura and Dr. Dellett 
Former lab members Dr. R. Hamamoto and Dr. T. Tamura, previously 
discovered that expression of OMD and PRELP is reduced in a number of cancers 
through microarray data comparing expression in tumours and normal tissue for 
many different types of cancer.  OMD expression was reduced in bladder cancer and 
non-small cell lung cancer to less than a tenth of its normal level, and in small cell 
lung cancer to less than half of its normal level (Table A.1). PRELP expression was 
reduced in bladder cancer and small cell lung cancer to less than a tenth of its normal 
level, and in breast cancer, cervical cancer, cholangiocellular carcinoma, lymphoma, 
oesophageal cancer, non-small cell lung cancer, prostate cancer and renal cell 
carcinoma to a lesser extent (Table A.2).   
Table A.1: Cancers in which OMD is differentially expressed 
Type of cancer Number of cases 
Ratio (tumour/normal) 
Below 1/2 Below 1/3 Below 1/5 Below 1/10 
Bladder cancer 31  31 (100%) 31 (100%) 31 (100%) 31 (100%) 
Non small-cell 
lung cancer 2 2 (100%) 2 (100%) 2 (100%) 2 (100%) 
Small cell lung 
cancer 6 6 (100%) 4 (66.7%) 3 (50.0%) 1 (16.7%) 
 
Table A.2: Cancers in which PRELP is differentially expressed 
Type of cancer Number of cases 
Ratio (tumour/normal) 
Below 1/2 Below 1/3 Below 1/5 Below 1/10 
Bladder cancer 34  34 (100%) 34 (100%) 34 (100%) 34 (100%) 
Breast cancer 73 70 (96%) 69 (94.5%) 67 (91.8%) 61 (83.6%) 
Cervical cancer 19 15 (78.9%) 13 (68.4%) 7 (36.8%) 2 (10.5%) 
Cholangiocellular 
carcinoma 25 23 (92.0%) 20 (80.0%) 15 (60.0%) 13 (52.0%) 
Oesophageal 
cancer 52 39 (75.0%) 37 (71.2%) 28 (53.8%) 17 (32.7%) 
Gastric cancer 16 11 (68.8%) 9 (56.3%) 7 (43.8%) 6 (37.5%) 
Non-small cell 
lung cancer 37 36 (97.3%) 36 (97.3%) 33 (89.2%) 26 (70.2%) 
Lymphoma 21 18 (85.7%) 15 (71.4%) 12 (66.7%) 9 (42.9%) 
Prostate cancer 40 32 (80.0%) 28 (70.0%) 23 (57.5% 12 (20%) 
Renal cell 
carcinoma 23 16 (70%) 15 (65.2%) 13 (56.5%) 13 (56.5%) 
Small cell lung 
cancer 15 15 (100%) 15 (100%) 15 (100%) 15 (100%) 
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Since the largest differences in expression were seen in bladder cancer, it 
decided to reconfirm the downregulation of OMD and PRELP in urological cancers 
by RT-PCR (performed by Dr. Hamamoto and Dr. Watson). To this end, 126 bladder 
tumours and 31 normal bladder samples were studied, and on average OMD and 
PRELP expression were reduced by 90%.  76 kidney tumours and 16 normal kidney 
tissues were also studied, and on average OMD and PRELP expression were reduced 
by 90% and 80%, respectively (also shown in Fig. 1.5).  Furthermore, expression of 
both OMD and PRELP was greatly reduced even in early stage bladder tumours, but 
was significantly reduced even further between stages pT2 and pT3/4 (i.e. as the 
tumour invaded into muscle tissue and metastasized) (Fig. A.1 and Table A.3).  
Expression of OMD and PRELP in bladder cancer also correlated with grade and 
metastatic potential. In kidney cancer, expression of both OMD and PRELP was 
greatly reduced even in early stage tumours, but no correlations were seen between 
OMD and PRELP expression and stage, grade or metastatic potential (Fig. A.2 and 
Table A.4). In addition, OMD and PRELP expression could be used to differentiate 
cancerous bladder or kidney tissue from normal tissue with high sensitivity and 
specificity.  Looking at both gene’s expression, it was possible to identify normal 
tissue with 100% specificity and bladder tumours 84.1% specificity (Fig. A.1 and 
Table A.5), and normal tissue with 100% specificity and kidney tumours with 78.4% 
sensitivity (Fig. A.2 and Table A.6). 
Table A.3: The expression of OMD and PRELP in urothelial cell carcinoma 
Characteristic OMD PRELP 
n Mean 95% CI n Mean 95% CI 
Normal 31 4.40 3.08 - 5.72 31 1.67 0.32 - 2.03 
Tumour (total) 126 0.42 0.19 - 0.65 126 0.22 0.13 - 0.41 
Tumour stage       
pTa, pT1 90 0.45 0.15 - 0.76 90 0.26 0.12 - 0.40 
pT2 26 0.43 0.12 - 0.75 26 0.12 0.05 - 0.20 
pT3/4 
 
7 0.01 -0.01 - 0.028 7 0.02 -0.01 - 0.05 
Tumour grade       
G1 12 1.13 -0.95 - 3.20 10 0.50 0.06 - 1.05 
G2 63 0.28 0.09 - 0.47 63 0.21 0.05 - 0.37 
G3 
 
50 0.44 0.16 - 0.72 50 0.16 0.07 - 0.24 
Metastasis       
Negative 99 0.48 0.20 - 0.77 99 0.25 0.13 - 0.38 
Positive 27 0.19 0.06 - 0.33 
 
27 0.08 0.01 - 0.14 
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Table A.4: The expression of OMD and PRELP in renal cell carcinoma 
Characteristic OMD PRELP 
n Mean 95% CI n Mean 95% CI 
Normal 16 1.76 1.05 - 2.47 16 0.36 0.24 - 0.47 
Tumour (total) 79 0.22 0.14 - 0.30 79 0.07 0.05 - 0.09 
Tumour stage       
pT1 25 0.20 0.10 - 0.30 25 0.09 0.04 - 0.14 
pT2 20 0.17 0.02 - 0.32 20 0.06 0.02 - 0.10 
pT3/4 
 
19 0.15 0.04 - 0.25 19 0.06 0.01 - 0.12 
Tumour grade       
G1, G2 42 0.24 0.12 - 0.36 42 0.07 0.04 - 0.10 
G3, G4 
 
27 0.18 0.09 - 0.27 27 0.08 0.03 - 0.13 
Metastasis       
Negative 58 0.29 0.12 - 0.27 58 0.08 0.05 - 0.11 
Positive 8 0.23 -0.03 - 0.43 8 0.02 0 - 0.05 
 
Table A.5: The sensitivity and specificity of diagnosing urothelial cell carcinoma solely by OMD 
and PRELP expression 
Characteristic Normal Tumour Tumour  
(early stage: Ta 
& T1) 
Tumour  
(late stage: 
T2, T3 & T4) 
n Specificit
y 
(%) 
n Sensitivit
y 
(%) 
n Sensitivit
y 
(%) 
n Sensitivit
y 
(%) 
OMD (cutoff: 0.897)         
 Below cutoff: 26 83.9 14 88.9 10 88.9 4 88.9  Above cutoff: 5 112 80 32 
PRELP (cutoff: 0.415)         
 Below cutoff: 28 90.3 12 90.5 10 88.9 2 94.4  Above cutoff: 3 114 80 34 
Combined OMD & 
PRELP 
        
 Both above cutoff: 26 83.9 6 95.2 5 94.4 1 97.2  At least 1 below cutoff: 5 120 85 35 
At least 1 above cutoff: 31 100 20 84.1 15 83.3 5 86.1  Both below cutoff: 0 106 75 75 
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Table A.6: The sensitivity and specificity of diagnosing renal cell carcinoma solely by OMD and 
PRELP expression 
Characteristic Normal Tumour Tumour  
(early stage: Ta 
& T1) 
Tumour  
(late stage: 
T2, T3 & T4) 
n Specificit
y 
(%) 
n Sensitivit
y 
(%) 
n Sensitivit
y 
(%) 
n Sensitivit
y 
(%) 
OMD (cutoff: 0.489)         
 Below cutoff: 14 87.5 12 84.8 10 80.0 4 87.0  Above cutoff: 2 67 80 32 
PRELP (cutoff: 0.170)         
 Below cutoff: 12 75.0 10 87.3 10 80.0 2 90.7  Above cutoff: 4 69 80 34 
Combined OMD & 
PRELP 
        
 Both above cutoff: 10 62.5 5 93.6 2 92.0 3 94.4  At least 1 below cutoff: 6 74 23 51 
At least 1 above cutoff: 16 100 17 78.4 8 68.0 9 83.3  Both below cutoff: 0 62 17 45 
 
Figure A.1: Expression of OMD and PRELP in urothelial cell carcinoma. (A) 
Quantitative analysis of OMD expression in different stages of bladder cancer. (B) Box-
whisker plot of (A). (C) Quantitative analysis of PRELP expression in different stages of 
bladder cancer. (D) Box-whisker plot of (C). Graphs are kindly provided by Dr. Hamamoto. 
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Figure A.2: Expression of OMD and PRELP in renal cell carcinoma. (A) Quantitative 
analysis of OMD expression in different stages of kidney cancer. (B) Box-whisker plot of (A). 
(C) Quantitative analysis of PRELP expression in different stages of kidney cancer. (D) Box-
whisker plot of (C). Graphs are kindly provided by Dr. Hamamoto. 
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Finally, Dr. Hamamoto further performed KEGG pathway analysis of OMD and 
PRELP based on the Affymetrix’s microarray data and identified the major pathways 
affected from altered expression of the two genes (Table A.7) 
Table A.7: The KEGG pathway analysis of OMD and PRELP based on the Affymetrix’s 
microarray data 
 Entry ID Name P 
OMD 
hsa04115 p53 signalling pathway 0.012294 
hsa04530 Tight junction 0.014608 
hsa04520 Adherens junction 0.0160148 
hsa04310 Wnt signalling pathway 0.0194646 
hsa04210 Apoptosis 0.0194646 
hsa05222 Small cell lung cancer 0.0237281 
PRELP 
hsa04115 p53 signalling pathway 4.32 x 10-5 
hsa04210 Apoptosis 0.0088029 
hsa04530 Tight junction 0.04122528 
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Expression of OMD and PRELP by in situ hybridisation in the mouse bladder 
(performed by Dr. Dellett) 
 
Figure A.3: OMD and PRELP expression by in situ hybridisation in the mouse bladder. Specific 
signal is seen with both the OMD and PRELP anti-sense probes in the mouse urothelium, while no 
background signal is seen using the sense probes. Magnification is 10x for all panels. Images are 
kindly provided by Dr. Dellett.  
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